<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002768.pub4" GROUP_ID="CF" ID="364700031009592521" MERGED_FROM="" MODIFIED="2017-11-02 10:17:46 +0000" MODIFIED_BY="Nikki Jahnke" REVIEW_NO="0031" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="14.0">
<COVER_SHEET MODIFIED="2017-11-02 10:16:48 +0000" MODIFIED_BY="Nikki Jahnke">
<TITLE MODIFIED="2015-06-15 08:18:42 +0100" MODIFIED_BY="Nikki Jahnke">Physical exercise training for cystic fibrosis</TITLE>
<CONTACT>
<PERSON ID="z1401291426442200328162969580857" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Thomas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Radtke</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>thomas.radtke@uzh.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiology, Biostatistics and Prevention Institute</DEPARTMENT>
<ORGANISATION>University of Zurich</ORGANISATION>
<ADDRESS_1>Hirschengraben 84</ADDRESS_1>
<ADDRESS_2/>
<CITY>Zurich</CITY>
<ZIP>8001</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 44 634 63 82</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-11-02 10:16:24 +0000" MODIFIED_BY="Nikki Jahnke">
<PERSON ID="z1401291426442200328162969580857" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Thomas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Radtke</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>thomas.radtke@uzh.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiology, Biostatistics and Prevention Institute</DEPARTMENT>
<ORGANISATION>University of Zurich</ORGANISATION>
<ADDRESS_1>Hirschengraben 84</ADDRESS_1>
<ADDRESS_2/>
<CITY>Zurich</CITY>
<ZIP>8001</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 44 634 63 82</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="69987482149416066805111004173943" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Sarah</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Nevitt</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>sjn16@liverpool.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Biostatistics</DEPARTMENT>
<ORGANISATION>University of Liverpool</ORGANISATION>
<ADDRESS_1>Block F, Waterhouse Building</ADDRESS_1>
<ADDRESS_2>1-5 Brownlow Hill</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L69 3GL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1401291432518045233044343632078" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Helge</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hebestreit</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Department</POSITION>
<EMAIL_1>Hebestreit_H@ukw.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Paediatric Departement</DEPARTMENT>
<ORGANISATION>Julius-Maximilians University</ORGANISATION>
<ADDRESS_1>Josef-Schneider-Straße 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Würzburg</CITY>
<ZIP>97080</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 931-201-27728</PHONE_1>
<PHONE_2/>
<FAX_1>+49 931-201-27798</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1401291411438751539653633251577" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Susi</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Kriemler</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor in Pediatrics</POSITION>
<EMAIL_1>susi.kriemlerwiget@uzh.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiology, Biostatistics and Prevention Institute</DEPARTMENT>
<ORGANISATION>University of Zurich</ORGANISATION>
<ADDRESS_1>Hirschengraben 84</ADDRESS_1>
<ADDRESS_2/>
<CITY>Zurich</CITY>
<ZIP>8001</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 44 634 63 20</PHONE_1>
<PHONE_2>+41 79 217 19 8741</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2017-11-01 16:03:21 +0000" MODIFIED_BY="Nikki Jahnke">
<UP_TO_DATE>
<DATE DAY="19" MONTH="10" YEAR="2017"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="5" YEAR="2017"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="21" MONTH="10" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-11-02 10:16:48 +0000" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-11-01 16:05:21 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="1" MONTH="11" YEAR="2017"/>
<DESCRIPTION>
<P>Formatting issues resolved</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-11-02 10:16:48 +0000" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-11-02 10:16:48 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="19" MONTH="10" YEAR="2017"/>
<DESCRIPTION>
<P>Despite the inclusion of two new studies our conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-11-02 10:16:44 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="19" MONTH="10" YEAR="2017"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis and Genetic Disorders Review Group's Cystic Fibrosis Trials Register identified 38 new references which were potentially eligible for inclusion in the review. There was one additional reference to an already included study (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>) and six additional references to five already excluded studies (<LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-del-Corral-Nunez_x002d_Flores-2011" TYPE="STUDY">del Corral Nunez-Flores 2011</LINK>; <LINK REF="STD-Kuys-2011" TYPE="STUDY">Kuys 2011</LINK>; <LINK REF="STD-Lima-2014" TYPE="STUDY">Lima 2014</LINK>; <LINK REF="STD-Salonini-2015" TYPE="STUDY">Salonini 2015</LINK>). Six references to two new studies has been included (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>) and seven references to five new studies are listed as 'Awaiting classification' (<LINK REF="STD-Housinger-2015" TYPE="STUDY">Housinger 2015</LINK>; <LINK REF="STD-Johnston-2004" TYPE="STUDY">Johnston 2004</LINK>; <LINK REF="STD-Lorenc-2015" TYPE="STUDY">Lorenc 2015</LINK>; <LINK REF="STD-Mandrusiak-2011" TYPE="STUDY">Mandrusiak 2011</LINK>; <LINK REF="STD-Oliveira-2010" TYPE="STUDY">Oliveira 2010</LINK>). One study with two references is ongoing (<LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>) and a total of 16 references to 13 new studies have been excluded (<LINK REF="STD-Bieli-2017" TYPE="STUDY">Bieli 2017</LINK>; <LINK REF="STD-Bongers-2015" TYPE="STUDY">Bongers 2015</LINK>; <LINK REF="STD-Calik_x002d_Kutukcu-2016" TYPE="STUDY">Calik-Kutukcu 2016</LINK>; <LINK REF="STD-Chang-2015" TYPE="STUDY">Chang 2015</LINK>; <LINK REF="STD-Dwyer-2017" TYPE="STUDY">Dwyer 2017</LINK>; <LINK REF="STD-Giacomodonato-2015" TYPE="STUDY">Giacomodonato 2015</LINK>; <LINK REF="STD-Haynes-2016" TYPE="STUDY">Haynes 2016</LINK>; <LINK REF="STD-Kriemler-2016" TYPE="STUDY">Kriemler 2016</LINK>; <LINK REF="STD-Ozaydin-2010" TYPE="STUDY">Ozaydin 2010</LINK>; <LINK REF="STD-Patterson-2004" TYPE="STUDY">Patterson 2004</LINK>; <LINK REF="STD-Shaw-2016" TYPE="STUDY">Shaw 2016</LINK>; <LINK REF="STD-Vallier-2016" TYPE="STUDY">Vallier 2016</LINK>; <LINK REF="STD-Wheatley-2015" TYPE="STUDY">Wheatley 2015</LINK>).</P>
<P>A search of clinicaltrials.gov identified 11 additional studies. Five studies were added to 'Awaiting classification' (<LINK REF="STD-NCT00609050" TYPE="STUDY">NCT00609050</LINK>; <LINK REF="STD-NCT00792194" TYPE="STUDY">NCT00792194</LINK>; <LINK REF="STD-NCT02552043" TYPE="STUDY">NCT02552043</LINK>; <LINK REF="STD-NCT03100214" TYPE="STUDY">NCT03100214</LINK>; <LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>), one study was added under ongoing studies (<LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>) and five studies were excluded (<LINK REF="STD-NCT02277860" TYPE="STUDY">NCT02277860</LINK>; <LINK REF="STD-NCT02715921" TYPE="STUDY">NCT02715921</LINK>; <LINK REF="STD-NCT02821130" TYPE="STUDY">NCT02821130</LINK>; <LINK REF="STD-NCT03117764" TYPE="STUDY">NCT03117764</LINK>; <LINK REF="STD-NCT02875366" TYPE="STUDY">NCT02875366</LINK>).</P>
<P>A search of the WHO ICTRN identified three additional studies; one is listed as awaiting classification (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>) and two have been added under ongoing studies (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>; <LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>).</P>
<P>From this update we have stated a minimum duration of the intervention as being at least two weeks.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-05-08 10:30:29 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="15" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>Two authors from the original review have stepped down at this update and a new team of authors have taken on the review.</P>
<P>The title of the review has been changed from 'Physical training for cystic fibrosis' to 'Physical exercise training for cystic fibrosis' as the new team felt this better reflected the content of the review.</P>
<P>Despite the inclusion of new studies and data in this update of the review, the conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-05-08 12:06:42 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="15" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Register identified 32 new references which were potentially eligible for inclusion in this review.</P>
<P>Three new studies (one reference each) were included (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). Two studies previously listed as excluded have been reassessed and moved to included studies with two new references each (although one paper referred to both studies) (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). One study has been moved from 'Awaiting classification' to included studies with an additional two references (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>).</P>
<P>One was an additional reference to an already excluded study (<LINK REF="STD-Kuys-2011" TYPE="STUDY">Kuys 2011</LINK>).</P>
<P>A total of 14 new studies (20 references) were excluded (<LINK REF="STD-Alarie-2012" TYPE="STUDY">Alarie 2012</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Asher-1982" TYPE="STUDY">Asher 1982</LINK>; <LINK REF="STD-Balfour-1998" TYPE="STUDY">Balfour 1998</LINK>; <LINK REF="STD-del-Corral-Nunez_x002d_Flores-2011" TYPE="STUDY">del Corral Nunez-Flores 2011</LINK>; <LINK REF="STD-Dwyer-2008" TYPE="STUDY">Dwyer 2008</LINK>; <LINK REF="STD-Gruet-2012" TYPE="STUDY">Gruet 2012</LINK>; <LINK REF="STD-Lima-2014" TYPE="STUDY">Lima 2014</LINK>; <LINK REF="STD-Lowman-2012" TYPE="STUDY">Lowman 2012</LINK>; <LINK REF="STD-Petrovic-2013" TYPE="STUDY">Petrovic 2013</LINK>; <LINK REF="STD-Rand-2012" TYPE="STUDY">Rand 2012</LINK>; <LINK REF="STD-Reix-2012" TYPE="STUDY">Reix 2012</LINK>; <LINK REF="STD-Salonini-2015" TYPE="STUDY">Salonini 2015</LINK>; <LINK REF="STD-Vivodtzev-2013" TYPE="STUDY">Vivodtzev 2013</LINK>).</P>
<P>One study (one reference) has been listed as 'Awaiting classification' until we are able to obtain further information (<LINK REF="STD-Almajan-2011" TYPE="STUDY">Almajan 2011</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-02-28 12:26:41 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="22" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-05-13 11:47:01 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="7" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>A total of two new references were identified in a search of the Group's CF Trials Register. One study was excluded as it compared Nintendo Wii exercise training to an existing exercise programme and hence did not meet the inclusion criteria (<LINK REF="STD-Kuys-2011" TYPE="STUDY">Kuys 2011</LINK>). The other study did meet the inclusion criteria but outlined in its abstract that recruitment was ongoing and for this reason it has been listed as an ongoing study; results will be included in the review once the study has been completed (Phillips 2008a).</P>
<P>In addition some amendments were made to the Background in order to incorporate updated guidelines and a relevant survey.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-30 15:28:02 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="19" MONTH="1" YEAR="2009"/>
<DESCRIPTION>
<P>The fourth primary outcome 'mortality' was moved to Secondary outcomes in line with Cochrane Collaboration guidance to limit the number of primary outcomes to three.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-11-30 15:27:59 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="5" MONTH="1" YEAR="2009"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register did not identify any references to trials which are potentially eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-01-05 10:52:51 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-03 11:53:44 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="14" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>The generic inverse variance method has been used to analyse data which were previously not able to be presented in the 'Statistical Analysis'.<BR/>
<BR/>The 'Synopsis' has been replaced by a new 'Plain Language Summary'.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-03 11:54:16 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="14" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>The search identified 11 new references. Of these, two were additional references to already excluded studies (Albinni 2004; Edlund 1986). The remaining nine studies did not fulfill the inclusion criteria; four of these studies which seemed eligible from the title, have been excluded on the basis of trial design and are listed under 'Excluded studies' (Acquino 2006; Balestri 2004; Orenstein 2004; Stanghelle 1998).<BR/>
<BR/>The study which was previously listed as 'Awaiting assessment' has been moved to the list of excluded studies after correspondence with the study authors (Hebestreit 2003).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="13" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-03 11:51:38 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="25" MONTH="5" YEAR="2005"/>
<DESCRIPTION>
<P>A further article has been included (Klijn 2004).</P>
<P>The full paper of the trial by Moorcroft (Moorcroft 2004) has also been included. Following publication of this paper, the details about the published abstracts of this trial, previously listed in the 'Characteristics of included studies' table, under Dodd 1998 and Moorcroft 2000 have been listed under Moorcroft 2004.</P>
<P>We contacted authors of trials already included in the review regarding confirmation of data and requests for additional data. Their responses have been included in section detailing the search strategy.</P>
<P>One trial has been moved from the 'Studies awaiting assessment' section to the 'Excluded studies' section of the review (Tuzin 1998).</P>
<P>One trial has been added to the section 'Studies awaiting assessment' section (Hebestreit 2003). The authors have been contacted and have indicated that this study is in preparation for publication.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-03 11:50:40 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="31" MONTH="7" YEAR="2003"/>
<DESCRIPTION>
<P>The presentation of the data in MetaView has been re-formatted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-03 11:50:37 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="31" MONTH="7" YEAR="2003"/>
<DESCRIPTION>
<P>The full paper of the Selvadurai trial has now been included, previously only the abstract of this trial was included in the review (Selvadurai 2002).</P>
<P>A further two trials added to the 'Excluded studies' section of the review (Barry 2001; Kriemler 2001).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-06-03 11:31:41 +0100" MODIFIED_BY="Nikki Jahnke">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-06-03 11:31:41 +0100" MODIFIED_BY="Nikki Jahnke">
<SOURCE MODIFIED="2015-06-03 11:31:41 +0100" MODIFIED_BY="Nikki Jahnke">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This systematic review was supported by the National Institute for Health Research, via Cochrane infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-11-02 10:03:44 +0000" MODIFIED_BY="Nikki Jahnke">
<SUMMARY MODIFIED="2017-10-19 15:13:27 +0100" MODIFIED_BY="Tracey Remmington">
<TITLE>Physical training to improve exercise capacity in people with cystic fibrosis</TITLE>
<SUMMARY_BODY MODIFIED="2017-10-19 15:13:27 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence about whether physical exercise training improves low aerobic fitness, improves health-related quality of life and slows the decline in lung function in people with cystic fibrosis (CF). This is an update of a previously published review.</P>
<P>
<B>Background</B>
</P>
<P>CF affects many systems in the body, but mainly the lungs. It causes shortness of breath and limits the amount of exercise people with the condition can tolerate. The progress of lung disease leads to a low ability to exercise and physical inactivity, which in turn affects health and health-related quality of life. We looked for studies where people with CF of any age did aerobic training (continuous activity at a low to moderate intensity, such as jogging, cycling, swimming or walking) or anaerobic training (weight or resistance training or sprinting at a high intensity for a short duration) or a combination of both compared to no training.</P>
<P>
<B>Search date</B>
</P>
<P>The evidence is current to: 04 May 2017.</P>
<P>
<B>Study characteristics</B>
</P>
<P>This review includes 15 studies with a total of 487 people with CF; the numbers in each study ranged from just nine people up to 72 people in the largest study. Two studies were in adults, seven were in children and adolescents and six studies included all age ranges. Four studies lasted less than one month and took place while the participants were in hospital; 11 studies were outpatient-based and lasted from two months up to three years. The studies included people with a wide range of severity of CF lung disease. There were differing levels of supervision in the studies and a mixture of types of training.</P>
<P>The outcome most often reported in the studies was the change in lung function; other commonly reported outcomes included peak oxygen consumption, health-related quality of life, change in muscle strength and change in body composition (e.g. muscle and fat).</P>
<P>
<B>Key results</B>
</P>
<P>Due to different study designs (type of exercise training, duration, etc.), we could not combine results from different studies. The short-term studies did not show differences between treatments. The longer studies showed that physical exercise training can improve aerobic capacity, there were some improvements in lung function and health-related quality of life, but these were not consistent across all studies. No study reported the number of deaths; two studies reported on side effects; one study reported on pulmonary exacerbations and another on diabetic control.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We included a number of small studies and thought the quality of these studies was moderate at best (only for side effects). Overall, there was only low- to very low-quality evidence that aerobic or anaerobic physical exercise training (or a combination of both) has a positive effect on aerobic exercise capacity, pulmonary function and health-related quality of life in people with CF. In four of the studies the participant characteristics at the start of the studies were different between groups, despite being put into the different treatment groups at random. It is not possible for people not to know which treatment group they are in when comparing exercise training to no exercise. However, we do not think the fact that people knew which treatment they were receiving would affect the results for lung function as long as the assessments were done properly. In contrast, there may be bias when the people assessing an individual's cardiopulmonary fitness are not blinded to which group the volunteer is in. In less than half of the included studies, the investigators tried to prevent the outcome assessors from knowing which groups the participants were in; and in only one study was the lead researcher blinded. The studies did not routinely measure health-related quality of life and where it was measured, different measurement tools were used. Selective reporting of results maybe an issue, especially as most of the included studies were not listed in trial registries, which give advance details of the outcomes being measured. We are uncertain about the effects and further better quality studies will likely change these findings.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-10-19 15:10:18 +0100" MODIFIED_BY="Tracey Remmington">
<ABS_BACKGROUND MODIFIED="2017-10-19 15:04:42 +0100" MODIFIED_BY="Tracey Remmington">
<P>Physical exercise training may form an important part of regular care for people with cystic fibrosis. This is an update of a previously published review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-10-19 15:05:27 +0100" MODIFIED_BY="Tracey Remmington">
<P>To assess the effects of physical exercise training on exercise capacity by peak oxygen consumption, pulmonary function by forced expiratory volume in one second, health-related quality of life and further important patient-relevant outcomes in people with cystic fibrosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-10-19 15:06:33 +0100" MODIFIED_BY="Tracey Remmington">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.</P>
<P>Date of the most recent search: 04 May 2017.</P>
<P>We searched ongoing trials registers (clinicaltrials.gov and the WHO ICTRP). Date of most recent search: 10 August 2017.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-09-26 09:33:16 +0100" MODIFIED_BY="Nikki Jahnke">
<P>All randomised and quasi-randomised controlled clinical trials comparing exercise training of any type and a minimum duration of two weeks with conventional care (no training) in people with cystic fibrosis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-09-26 09:05:32 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Two authors independently selected studies for inclusion, assessed methodological quality and extracted data. The quality of the evidence was assessed using the GRADE system.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-10-19 15:09:50 +0100" MODIFIED_BY="Tracey Remmington">
<P>Of the 83 studies identified, 15 studies which included 487 participants, met the inclusion criteria. The numbers in each study ranged from nine up to 72 participants; two studies were in adults, seven were in children and adolescents and six studies included all age ranges. Four studies of hospitalised participants lasted less than one month and 11 studies were outpatient-based, lasting between two months and three years. The studies included participants with a wide range of disease severity and employed differing levels of supervision with a mixture of types of training. There was also wide variation in the quality of the included studies.</P>
<P>This systematic review shows very low- to low-quality evidence from both short- and long-term studies that in people with cystic fibrosis aerobic or anaerobic physical exercise training (or a combination of both) has a positive effect on aerobic exercise capacity, pulmonary function and health-related quality of life. No study reported on mortality; two studies reported on adverse events (moderate-quality evidence); one of each study reported on pulmonary exacerbations (low-quality evidence) and diabetic control (very low-quality evidence). Although improvements were not consistent between studies and ranged from no effects to clearly positive effects, the most consistent effects of the heterogeneous exercise training modalities and durations were found for maximal aerobic exercise capacity (in four out of seven studies) with unclear effects on forced expiratory volume in one second (in two out of 11 studies) and health-related quality of life (in two out of seven studies).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-10-19 15:10:18 +0100" MODIFIED_BY="Tracey Remmington">
<P>Evidence about the efficacy of physical exercise training in cystic fibrosis from 15 small studies with low to moderate methodological quality is limited. Exercise training is already part of regular outpatient care offered to most people with cystic fibrosis, and since there is some evidence for beneficial effects on aerobic fitness and no negative side effects exist, there is no reason to actively discourage this. The benefits from including physical exercise training in an individual's regular care may be influenced by the type and duration of the training programme. High-quality randomised controlled trials are needed to comprehensively assess the benefits of exercise programmes in people with cystic fibrosis and the relative benefits of the addition of aerobic versus anaerobic versus a combination of both types of physical exercise training to the care of people with cystic fibrosis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-11-02 10:03:44 +0000" MODIFIED_BY="Nikki Jahnke">
<BACKGROUND MODIFIED="2017-10-19 15:14:55 +0100" MODIFIED_BY="Tracey Remmington">
<CONDITION MODIFIED="2017-09-27 15:16:00 +0100" MODIFIED_BY="Thomas Radtke">
<P>Cystic fibrosis (CF) is the most common life-limiting autosomal recessively inherited disease in populations of Northern European descent. The incidence of CF has been estimated as 1 in 3500 live births in the USA (<LINK REF="REF-CF-Foundation-2009" TYPE="REFERENCE">CF Foundation 2009</LINK>; <LINK REF="REF-CF-Trust-2010" TYPE="REFERENCE">CF Trust 2010</LINK>). The prevalence in the European countries varies widely and was recently estimated as 0.840 per 10,000 (<LINK REF="REF-Farrell-2008" TYPE="REFERENCE">Farrell 2008</LINK>). Although CF is a multisystem disease, the primary cause of death is respiratory failure (<LINK REF="REF-CF-Trust-2010" TYPE="REFERENCE">CF Trust 2010</LINK>). Progressive respiratory disease results in an abnormal ventilatory response to exercise in CF, which contributes to dyspnoea (shortness of breath) and is a major limiting factor to exercise tolerance in this population (<LINK REF="REF-O_x0027_Neill-1987" TYPE="REFERENCE">O'Neill 1987</LINK>). In addition, a sedentary lifestyle contributes to the progression of physical and functional impairment in CF (<LINK REF="REF-Schneiderman-2014" TYPE="REFERENCE">Schneiderman 2014</LINK>). A consequence of this is low aerobic fitness that is associated with reduced life expectancy (<LINK REF="REF-Nixon-1992" TYPE="REFERENCE">Nixon 1992</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-03-10 14:01:52 +0000" MODIFIED_BY="Thomas Radtke">
<P>Physical exercise training is defined as participation in a programme of regular vigorous physical activity designed to improve physical performance, cardiovascular function, muscle strength or any combination of these three (<LINK REF="REF-Shephard-1994" TYPE="REFERENCE">Shephard 1994</LINK>). There are basically two different types of physical exercise training: aerobic training or anaerobic training, but none can be considered purely 'aerobic' or 'anaerobic' with respect to energy supply. Aerobic training usually involves periods of continuous training (e.g. cycling or running) for a length of time at a target intensity below the anaerobic threshold. Anaerobic training involves training (e.g. weight or resistance training or sprinting) at a high intensity for a short duration above the anaerobic threshold.</P>
</INTERVENTION>
<THEORY MODIFIED="2017-10-19 15:14:55 +0100" MODIFIED_BY="Tracey Remmington">
<P>Physical exercise training has multiple beneficial effects. It contributes to the alleviation of dyspnoea and improves exercise tolerance in people with CF (<LINK REF="REF-Cerny-2013" TYPE="REFERENCE">Cerny 2013</LINK>). Physical exercise training maintains pulmonary function by improving sputum clearance through a combination of hyperventilation, mechanical vibration, coughing and changes in sputum rheology leading to facilitated and increased sputum expectoration (<LINK REF="REF-Dwyer-2011" TYPE="REFERENCE">Dwyer 2011</LINK>; <LINK REF="STD-Dwyer-2017" TYPE="STUDY">Dwyer 2017</LINK>; <LINK REF="REF-Hebestreit-2001" TYPE="REFERENCE">Hebestreit 2001</LINK>) and possibly training of respiratory muscles (<LINK REF="REF-Houston-2013" TYPE="REFERENCE">Houston 2013</LINK>).</P>
<P>Physical exercise training may also be an important part of the management of diabetes in CF, as exercise improves glycaemic control in type 1 diabetes mellitus by improving insulin sensitivity and reducing systemic inflammation (<LINK REF="REF-Galassetti-2013" TYPE="REFERENCE">Galassetti 2013</LINK>). Regular exercise may delay the onset of osteoporosis by preventing a reduction in bone mineral density (<LINK REF="REF-Tejero-Garc_x00ed_a-2011" TYPE="REFERENCE">Tejero García 2011</LINK>). Other postulated benefits of any physical exercise training may be decreased anxiety and depression, enhanced feelings of well-being and health-related quality of life (HRQoL) (<LINK REF="REF-Hebestreit-2014" TYPE="REFERENCE">Hebestreit 2014</LINK>) and enhanced performance at work, recreational and sport activities (<LINK REF="REF-ACSM-2010" TYPE="REFERENCE">ACSM 2010</LINK>). It is not clear how many weeks training are required to achieve these benefits or what combination of aerobic and anaerobic training is required. Non-adherence to prescribed physical training may contribute to worsening signs and symptoms of respiratory disease, more frequent respiratory infections and a reduced ability to perform activities of daily living and thus ultimately have a detrimental effect on the individual's prognosis. Side effects of physical exercise training are extremely rare so that exercise can be considered safe in CF (<LINK REF="REF-Ruf-2010" TYPE="REFERENCE">Ruf 2010</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-05-08 12:17:50 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This review aims to provide evidence for the inclusion of physical exercise training in regular care for people with CF. This version of the review is an update of previous versions (<LINK REF="REF-Bradley-2002" TYPE="REFERENCE">Bradley 2002</LINK>; <LINK REF="REF-Bradley-2008" TYPE="REFERENCE">Bradley 2008</LINK>; <LINK REF="REF-Radtke-2015a" TYPE="REFERENCE">Radtke 2015a</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-11-01 16:17:02 +0000" MODIFIED_BY="Nikki Jahnke">
<P>To assess the effects of physical exercise training on exercise capacity by peak oxygen consumption (VO<SUB>2</SUB> peak), pulmonary function by forced expiratory volume at one second (FEV<SUB>1</SUB>), HRQoL and further important patient-relevant outcomes in people with CF.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-11-02 09:59:23 +0000" MODIFIED_BY="Nikki Jahnke">
<SELECTION_CRITERIA MODIFIED="2017-11-02 09:59:23 +0000" MODIFIED_BY="Nikki Jahnke">
<CRIT_STUDIES MODIFIED="2017-09-26 09:40:13 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised controlled trials (RCT) or quasi-RCTs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-02-04 12:39:34 +0000" MODIFIED_BY="Thomas Radtke">
<P>People with CF, of any age, and any degree of disease severity, diagnosed on the basis of clinical criteria and sweat testing or genotype analysis. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-10-19 15:15:35 +0100" MODIFIED_BY="Tracey Remmington">
<P>Any type of prescribed physical exercise training delivered to people with CF compared to usual care. Studies which involved pure respiratory muscle training were excluded. In a post hoc change it was stipulated that studies must have a duration of at least two weeks.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-11-02 09:59:23 +0000" MODIFIED_BY="Nikki Jahnke">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-11-01 16:06:23 +0000" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Exercise capacity (VO<SUB>2</SUB> peak reported either as L, mL per kg body weight or fat-free mass or as per cent (%) predicted)</LI>
<LI>Pulmonary function (FEV<SUB>1</SUB> reported either as L or % predicted and as absolute values or change from baseline)</LI>
<LI>HRQoL (measured by generic or disease-specific instruments, or both using validated instruments or patient reports)</LI>
</OL>
<P>In a post hoc change, the fourth primary outcome 'mortality' was moved to secondary outcomes in line with Cochrane guidance to limit the number of primary outcomes to three.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-11-02 09:59:23 +0000" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>CF-related mortality</LI>
<LI>Muscle strength and anaerobic exercise capacity, measured by muscle force tests (isokinetic or non-isokinetic tests), a Wingate Anaerobic Test (WaNT) or by a supramaximal sprint test on a cycle ergometer measured by e.g. aerobic capacity as power in absolute values (Watt), adjusted for body weight, fat-mass; fat-free mass, or as % predicted), or muscle strength as kg or Nm or anaerobic capacity as peak power, mean power and fatigue index during a WaNT</LI>
<LI>Additional indices of exercise capacity (such as peak work capacity, peak heart rate, minute ventilation, lactate and functional capacity tests (six-and 12-minute walk tests; shuttle tests; three-minute step test; sit-to-stand test); oxygenation; effort and fatigue)</LI>
<LI>Additional indices of pulmonary function, pulmonary diffusing capacity, ventilation inhomogeneity and respiratory muscle strength (such as forced vital capacity, forced expiratory flows between 25% and 75% of expirated volume, total lung capacity, functional residual capacity, residual volume, pulmonary diffusing capacity for carbon monoxide, pulmonary diffusing capacity for nitric oxide, lung clearance index and maximum inspiratory and expiratory pressures)</LI>
<LI>Physical activity, measured by self report (diary), validated questionnaires or objectively with pedometers (e.g. number of steps) or accelerometers (counts per min; time spent in different exercise intensities, e.g. light, moderate, vigorous physical activity)</LI>
<LI>Body composition, measured by weight (kg), body mass index (kg/m² or z scores), skinfolds (mm), bioelectrical impedance analysis or whole body air-displacement plethysmography or dual-energy X-ray absorptiometry (e.g. fat mass, fat-free mass in kg, % or % predicted)</LI>
<LI>Acute exacerbations</LI>
<OL>
<LI>number of exacerbations</LI>
<LI>time to first exacerbation</LI>
</OL>
<LI>Antibiotic use (including oral, intravenous or inhaled antibiotics)</LI>
<LI>Bone health (measured by dual X-ray energy absorptiometry or peripheral quantitative computed tomography)</LI>
<LI>Diabetic control, measured by fasting blood glucose levels (mmol/L or mg/dL), insulin levels (mmol/L or mg/dL) or homeostasis model assessment (HOMA) or oral glucose tolerance test (blood glucose in mmol/L or mg/dL)</LI>
<LI>Compliance with physical exercise training, assessed by questionnaires, (online) diaries, or with exercise monitoring devices such as heart rate monitors</LI>
<LI>Adverse events related to the exercise intervention or exercise testing as part of intervention</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-10-19 15:20:16 +0100" MODIFIED_BY="Tracey Remmington">
<P>There are no restrictions regarding language or publication status.</P>
<ELECTRONIC_SEARCHES MODIFIED="2017-10-19 15:20:16 +0100" MODIFIED_BY="Tracey Remmington">
<P>Relevant studies were identified from the Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register using the term: exercise.<BR/>
<BR/>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals - <I>Pediatric Pulmonology </I>and the <I>Journal of Cystic Fibrosis</I>. Unpublished work is identified by searching through the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cystic Fibrosis and Genetic Disorders Group <A HREF="http://cfgd.cochrane.org/our-specialised-trials-registers">website</A>. Date of the most recent search of the Group's Cystic Fibrosis Trials Register: 04 May 2017.</P>
<P>We searched the ongoing trials database clinicaltrials.gov (<A HREF="https://clinicaltrials.gov/">https://clinicaltrials.gov/</A>) using the terms: "physical activity" AND "cystic fibrosis". A further search was run using the terms "exercise" AND "physical activity" AND "training" AND "cystic fibrosis". Date of most recent search: 01 June 2017.</P>
<P>We also searched the WHO ICTRP (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>) using the terms: "physical activity and cystic fibrosis". Date of the most recent search: 09 August 2017.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-02-04 12:41:26 +0000" MODIFIED_BY="Thomas Radtke">
<P>The reference lists of each RCT and of review articles were searched for additional publications that may contain RCTs. Authors of studies included in this review and other experts in the field were contacted and asked for information on other published and unpublished studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-10-19 15:23:35 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY_SELECTION MODIFIED="2015-06-26 10:18:29 +0100" MODIFIED_BY="Tracey Remmington">
<P>Two authors (for the original review JB, FM; from the 2015 update onwards SK, TR) independently assessed the titles and abstracts of identified citations and selected the studies to be included in the review. They excluded non-RCTs, those studies involving respiratory muscle training exclusively, those which did not have a programme of exercise training and those that did not meet the inclusion criteria, based on screening the abstracts or full text articles. If disagreement arose on the suitability of a study for inclusion in the review, the authors reached a consensus by discussion. The authors recorded any areas of disagreement. The studies that did not fulfil all of the inclusion criteria were excluded and their details listed with the reason for exclusion. A third review author solved all the discrepancies if disagreement or uncertainty of the two authors persisted.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-10-19 15:20:55 +0100" MODIFIED_BY="Tracey Remmington">
<P>Each author (SK, TR) independently extracted data using standard data acquisition forms containing details about: study design (parallel versus multi-arm; single-centre versus multicentre, participants and trial characteristics for baseline equality between groups, details on the number of participants screened for eligibility, randomised, analysed, excluded, lost to follow up and dropped out, method of randomisation and allocation concealment, blinding of personnel and outcome assessors, use of stratification, incomplete outcome data, selective reporting, use of intention-to-treat analysis); the detailed intervention (aerobic training versus no training; anaerobic training versus no training and a combination of both versus no training; duration of studies, i.e. short term (less than one month) and long term (more than one month) and whether the study was supervised, partially supervised or not supervised); and outcome measures (continuous and dichotomous). If disagreement arose on the quality of a study, the authors reached a consensus by discussion. If disagreement persisted, they contacted a third author. The authors recorded any areas of disagreement. One author (for the original review JB, from the 2015 update onwards TR) entered the data into the Cochrane software Review Manager (<LINK REF="REF-Review-Manager-2014" TYPE="REFERENCE">Review Manager 2014</LINK>) and a second author (from the 2015 update onwards SK) reviewed it. The review authors contacted the authors of the included studies in case of unclear or missing data and information.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-10-19 15:21:26 +0100" MODIFIED_BY="Tracey Remmington">
<P>For the original review two authors judged the methodological quality of the review (JB, FM). From the 2015 update onwards, two authors (SK, TR) independently assessed the risk of bias for each included study according to the Cochrane risk of bias tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). In particular, the authors examined details of the randomisation method with sequence generation, allocation concealment, degree of blinding, inclusion and exclusion criteria, dropouts or withdrawals, intention-to-treat and detailed statistical analysis. Authors also examined for selective reporting and any other potential sources of bias. The authors judged the risk of bias as low, unclear or high. Unexplained dropouts or an unequal number of dropouts across treatment groups was considered as a potential risk of bias. Likewise, a lack of important information, e.g. on adverse effects, missing data, statistical methods etc., was also considered as potential risk of bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-10-19 15:21:56 +0100" MODIFIED_BY="Tracey Remmington">
<P>The authors have currently only been able to report continuous outcome data and have calculated the mean differences (MD) with 95% confidence intervals (CIs) where between-group differences in the mean change from baseline were recorded. When data on the standard deviation (SD) for an individual group were not available, but instead standard error (SE) of the difference was available they used the available calculator within the Review Manager software (<LINK REF="REF-Review-Manager-2014" TYPE="REFERENCE">Review Manager 2014</LINK>)<I>
<B>.</B>
</I> Where possible, the published standard error of the mean (SEM) was used, or alternatively, published CIs were taken to estimate SE. If in future updates of this review, different measurement scales are used for an outcome, e.g. different HRQoL scales, the authors plan to analyse the data using the standardised mean difference (SMD) with 95% CIs.</P>
<P>Also, if in future updates of this review, the authors are able to present data for dichotomous outcomes, e.g. mortality or adverse events, they plan to record the number of participants experiencing an event and the total number of participants by group. They will analyse the data and report the odds ratio (OR) (the odds that an outcome will occur given a particular treatment, compared to the odds of the outcome occurring in the absence of that treatment) with 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-06-26 10:22:00 +0100" MODIFIED_BY="Tracey Remmington">
<P>The authors have not included any cross-over studies in this latest version of the review. If future versions of this review include cross-over studies and if data are presented in published papers from paired statistical analyses or if available information is available to allow us to adjust for within-patient correlation using the methods described by Elbourne (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>), we will use the generic inverse variance method for data analysis. If appropriate data are not presented to allow adjustment for within-patient correlation, we will contact study investigators to request these data. If we are unable to make the necessary adjustments, we will describe data from cross-over studies narratively in the review.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-09-28 09:24:10 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The review authors contacted the investigators of studies included in this review for further study details and data and 12 investigators responded. The investigators of four studies stated that the requested data were not available (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). The investigator of a further study confirmed that the extracted data were correct and that no further data were available (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>). The investigators of the Hebestreit study stated that they were in the process of writing up the abstract for publication - the review authors have now included this study in the updated review (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>). One investigator involved in the Phillips study, currently listed under <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>, confirmed that the study has been completed and the review authors updated the information in the table (<LINK REF="STD-Phillips-2008" TYPE="STUDY">Phillips 2008</LINK>). In both publications by Santana-Sosa, the means and SEs were reported for all variables; the review authors contacted the investigators for additional data (<LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). Finally, investigators of six studies provided additional raw data for this review update (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-05-08 12:40:49 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Due to the low number of included studies and variability of interventions, the authors were unable to combine data for any of the listed outcomes; however, if for future updates of this review the authors are able to combine any data, they will measure heterogeneity between studies using the the Chi² test and the I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The Chi² test measures the deviation of observed effect sizes from the underlying overall effect. A low P value (or a large Chi² statistic relative to its degree of freedom) provides evidence of heterogeneity of intervention effects (variation in effect estimates beyond chance). The authors will use a P value of 0.10, rather than the conventional level of 0.05, to determine statistical significance. The I² statistic, as defined by Higgins (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), measures heterogeneity as a percentage where a value:</P>
<P>&#8226; 0% to 40%: might not be important;<BR/>&#8226; 30% to 60%: may represent moderate heterogeneity;<BR/>&#8226; 50% to 90%: may represent substantial heterogeneity;<BR/>&#8226; 75% to 100%: considerable heterogeneity.<BR/>The importance of the observed value of I² depends on: (i) magnitude and direction of effects; and (ii) strength of evidence for heterogeneity (e.g. P value from the Chi² test, or a CI for I²).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-03-10 13:18:19 +0000" MODIFIED_BY="Thomas Radtke">
<P>The authors assessed relevant bias and selective reporting by comparing the 'Methods' and 'Results' sections from the included papers and trial registries, if available. They have documented this information in the risk of bias tables and figures. If, for future updates of the review, they are able to include and combine a sufficient number of studies (n = 10), the authors will assess publication bias initially by visual inspection of a funnel plot, although they are aware that an asymmetrical funnel plot is not necessarily due to publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-06-26 10:27:10 +0100" MODIFIED_BY="Tracey Remmington">
<P>The review authors used a fixed-effect model for all outcome parameters using the Review Manager software (<LINK REF="REF-Review-Manager-2014" TYPE="REFERENCE">Review Manager 2014</LINK>). The authors were unable to pool studies due to the low number of available studies, the use of different exercise types and different study durations. For future updates, the authors will use a random-effects model if substantial or considerable heterogeneity exists. The random-effects model incorporates any between-study heterogeneity into a meta-analysis if the number of studies is sufficient. The authors will select the MD when combining data and use forest plots to compare results across studies.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-06-26 10:27:31 +0100" MODIFIED_BY="Tracey Remmington">
<P>If the authors are able to include a sufficient number of studies (about n = 10) and they observe at least moderate heterogeneity in the pooled analyses, they will undertake subgroup analyses of children versus adults, supervised versus unsupervised training and disease severity.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-10-19 15:23:35 +0100" MODIFIED_BY="Tracey Remmington">
<P>If the authors are able to include a sufficient number of studies (n = 10) and in order to investigate whether heterogeneity impacted upon the overall pooled effect estimate, the authors plan to apply random-effects modelling, and compare this with a fixed-effect model. They also plan a sensitivity analysis with and without quasi-randomised studies and based on the quality of the studies. The authors will exclude studies with a high risk of bias from the analysis.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings tables and quality of the evidence (GRADE)</HEADING>
<P>In a post hoc change in line with current Cochrane guidance, at the 2017 update we added a summary of findings table for each comparison presented in the review (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). We selected the following seven outcomes to report (chosen based on relevance to clinicians and consumers):</P>
<OL>
<LI>Exercise capacity</LI>
<LI>Pulmonary function</LI>
<LI>HRQoL</LI>
<LI>CF-related mortality</LI>
<LI>Pulmonary exacerbations</LI>
<LI>Diabetic control</LI>
<LI>Adverse events</LI>
</OL>
<P>We determined the quality of the evidence using the GRADE approach; and downgraded evidence in the presence of a high risk of bias in at least one study, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We downgraded evidence by one level if they considered the limitation to be serious and by two levels if very serious.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-11-02 10:03:44 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY_DESCRIPTION MODIFIED="2017-11-01 16:17:21 +0000" MODIFIED_BY="Nikki Jahnke">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification.</LINK>
</P>
<SEARCH_RESULTS MODIFIED="2017-10-10 14:34:03 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Please see the study flow chart for details (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The combined searches to date have identified 123 individual references to 83 unique studies. A total of 15 studies (30 references) are included, 51 studies (73 references) have been excluded (for further details, see <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>),13 studies (15 references) are currently awaiting assessment and four studies (five references) are ongoing.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-11-01 16:17:18 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Of the 83 studies identified, 15 studies with a total of 487 participants met the inclusion criteria (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial characteristics</HEADING>
<P>All included studies were of a randomised parallel group design. The study by Beaudoin was registered as randomised cross-over study (<A HREF="http://clinicaltrials.gov">ClinicalTrials.gov</A>) but results were reported as randomised parallel group design in the final publication (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). Thirteen studies were single-centre studies (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>) and two studies were national multicentre studies conducted in Germany and Switzerland (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). The size of trials varied from a minimum number of nine participants (<LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>) to a maximum of 72 participants (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). In one study the number of participants in each group was not reported and the MD between the treatment and control groups could not be calculated (<LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>).</P>
<P>There was wide heterogeneity in study designs with eight studies using a supervised training approach (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>); six studies a partially-supervised approach (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>) and one an unsupervised training approach (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>).</P>
<P>Four studies were of short duration (less than one month) and were carried out during hospitalisations (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>). In one study the hospital admission was for routine assessment (<LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>); in two further studies, the hospital admission was due to an acute exacerbation requiring intravenous antibiotic treatment (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>); and in the fourth study, the reason for and the duration of admission were not reported (<LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>). The remaining 11 longer-term studies (more than one month) were outpatient-based (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). Both Santana-Sosa studies used a two-month training period including a one-month detraining period, during which the participants did not engage in supervised exercise training (<LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). Three studies were home-based training studies lasting three months (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). The Klijn study was a three-month study with a three-month follow up (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>). The Hebestreit and Kriemler studies were both of six months duration including a six- and 18-month follow-up period (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). The Moorcroft study was a 12-month study (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>), the Douglas study is a 24-month intervention study (<LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>) and the Schneiderman-Walker study lasted three years (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>).</P>
<P>Follow-up studies off training were undertaken in seven studies (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Two studies included adults only (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>); seven studies included children and adolescents only (<LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>) and six studies included both adults and children (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). Overall, the studies included participants with a broad range of disease severity.</P>
<P>The vast majority of studies included participants of both sexes (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>); however, no information was available for two studies (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>, <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>). Eight studies provided detailed information about the proportion of male and female participants at baseline (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>).</P>
<P>In seven of the 11 studies published as full-text articles, FEV<SUB>1</SUB> % predicted values were used as exclusion criteria (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>, <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>); this was also true of the study only available from <A HREF="http://ClinicalTrials.gov">ClinicalTrials.gov</A> (<LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>). The remaining five studies published as full-text articles did not specify disease severity based on FEV<SUB>1</SUB> or other outcomes (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>), but no information was available in the remaining two studies (<LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>).</P>
<P>In four of the studies, the baseline characteristics of the participants were different between groups despite randomisation (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). In the Cerny study, FEV<SUB>1</SUB> and FEF<SUB>25-75</SUB> were significantly lower in the control compared to the training group at admission (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>). In both Santana-Sosa studies, the training groups had a lower aerobic exercise capacity (VO<SUB>2</SUB> peak) and lower muscle strength (most but not all strength measures) (<LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>, <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). In the study by Rovedder, a significantly lower body mass index (BMI) was observed in the intervention group compared to the control group (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>).</P>
<P>In the study by Kriemler, the control group experienced an unusual deterioration of physical health during the study and the results should be interpreted with caution (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>As the aim of this review was to assess the efficacy of physical exercise training, studies which involved respiratory muscle training exclusively were excluded. All 15 studies included a control group which did not receive a prescribed exercise programme. Two studies compared two different types of exercise training programmes (aerobic training or anaerobic training) with a control group (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). One study compared anaerobic training alone to a control group (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>). Five studies compared aerobic training alone to a control group (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>). Five studies compared the effects of a combined training programme (a mixture of aerobic and anaerobic exercise training) to a control group (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>, <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>). One study used a home-based exercise training with aerobic and strengthening exercises without training supervision (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). The later Santana-Sosa study compared a combined programme (aerobic and strength) including additional inspiratory muscle training with a control group (<LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). In a further study, an individualised exercise programme including endurance type or strengthening exercises or a combination of both regimens was compared with a control group (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>). The Santana-Sosa and the Hebestreit studies were added to the section combined aerobic and anaerobic training (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>).</P>
<P>In two studies, all participants additionally received intravenous antibiotic treatment (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The most commonly reported outcome measure was the change in FEV<SUB>1</SUB> which was reported in all studies except one (<LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>). The change in VO<SUB>2</SUB> peak was documented in nine studies (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). The change in HRQoL was also reported in nine studies (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>), the change in muscle strength was reported in eight studies (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). The change in body composition was reported in 11 studies (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). The change in physical activity was reported in six studies (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>) and the change in other indices of exercise capacity (other than cardiopulmonary exercise testing) in four studies (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). Only one study reported on changes in diabetic control after an exercise training intervention (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-11-01 16:17:21 +0000" MODIFIED_BY="Nikki Jahnke">
<P>We excluded 51 studies for the reasons which follow: 16 studies were not RCTs (<LINK REF="STD-Andreasson-1987" TYPE="STUDY">Andreasson 1987</LINK>; <LINK REF="STD-Asher-1982" TYPE="STUDY">Asher 1982</LINK>; <LINK REF="STD-Balfour-1998" TYPE="STUDY">Balfour 1998</LINK>; <LINK REF="STD-Barry-2001" TYPE="STUDY">Barry 2001</LINK>; <LINK REF="STD-Bongers-2015" TYPE="STUDY">Bongers 2015</LINK>; <LINK REF="STD-de-Jong-1994" TYPE="STUDY">de Jong 1994</LINK>; <LINK REF="STD-Edlund-1986" TYPE="STUDY">Edlund 1986</LINK>; <LINK REF="STD-Heijerman-1992" TYPE="STUDY">Heijerman 1992</LINK>; <LINK REF="STD-NCT02277860" TYPE="STUDY">NCT02277860</LINK>; <LINK REF="STD-NCT02715921" TYPE="STUDY">NCT02715921</LINK>; <LINK REF="STD-NCT03117764" TYPE="STUDY">NCT03117764</LINK>; <LINK REF="STD-Orenstein-1981" TYPE="STUDY">Orenstein 1981</LINK>; <LINK REF="STD-Petrovic-2013" TYPE="STUDY">Petrovic 2013</LINK>; <LINK REF="STD-Salh-1989" TYPE="STUDY">Salh 1989</LINK>; <LINK REF="STD-Stanghelle-1998" TYPE="STUDY">Stanghelle 1998</LINK>; <LINK REF="STD-Tuzin-1998" TYPE="STUDY">Tuzin 1998</LINK>); 24 studies did not include a physical training programme as per our protocol (<LINK REF="STD-Alarie-2012" TYPE="STUDY">Alarie 2012</LINK>; <LINK REF="STD-Albinni-2004" TYPE="STUDY">Albinni 2004</LINK>; <LINK REF="STD-Amelina-2006" TYPE="STUDY">Amelina 2006</LINK>; <LINK REF="STD-Aquino-2006" TYPE="STUDY">Aquino 2006</LINK>; <LINK REF="STD-Balestri-2004" TYPE="STUDY">Balestri 2004</LINK>; <LINK REF="STD-Bieli-2017" TYPE="STUDY">Bieli 2017</LINK>; <LINK REF="STD-Bilton-1992" TYPE="STUDY">Bilton 1992</LINK>; <LINK REF="STD-Chang-2015" TYPE="STUDY">Chang 2015</LINK>; <LINK REF="STD-Chatham-1997" TYPE="STUDY">Chatham 1997</LINK>; <LINK REF="STD-Dwyer-2008" TYPE="STUDY">Dwyer 2008</LINK>; <LINK REF="STD-Falk-1988" TYPE="STUDY">Falk 1988</LINK>; <LINK REF="STD-Giacomodonato-2015" TYPE="STUDY">Giacomodonato 2015</LINK>; <LINK REF="STD-Haynes-2016" TYPE="STUDY">Haynes 2016</LINK>; <LINK REF="STD-Irons-2012" TYPE="STUDY">Irons 2012</LINK>; <LINK REF="STD-Lannefors-1992" TYPE="STUDY">Lannefors 1992</LINK>; <LINK REF="STD-NCT02821130" TYPE="STUDY">NCT02821130</LINK>; <LINK REF="STD-NCT02875366" TYPE="STUDY">NCT02875366</LINK>; <LINK REF="STD-Ozaydin-2010" TYPE="STUDY">Ozaydin 2010</LINK>; <LINK REF="STD-Patterson-2004" TYPE="STUDY">Patterson 2004</LINK>; <LINK REF="STD-Rand-2012" TYPE="STUDY">Rand 2012</LINK>; <LINK REF="STD-Reix-2012" TYPE="STUDY">Reix 2012</LINK>; <LINK REF="STD-Salonini-2015" TYPE="STUDY">Salonini 2015</LINK>; <LINK REF="STD-Vallier-2016" TYPE="STUDY">Vallier 2016</LINK>; <LINK REF="STD-Vivodtzev-2013" TYPE="STUDY">Vivodtzev 2013</LINK>); eight studies did not use a control arm with 'no physical training' (<LINK REF="STD-Calik_x002d_Kutukcu-2016" TYPE="STUDY">Calik-Kutukcu 2016</LINK>; <LINK REF="STD-del-Corral-Nunez_x002d_Flores-2011" TYPE="STUDY">del Corral Nunez-Flores 2011</LINK>; <LINK REF="STD-Gruet-2012" TYPE="STUDY">Gruet 2012</LINK>; <LINK REF="STD-Kuys-2011" TYPE="STUDY">Kuys 2011</LINK>; <LINK REF="STD-Lima-2014" TYPE="STUDY">Lima 2014</LINK>; <LINK REF="STD-Lowman-2012" TYPE="STUDY">Lowman 2012</LINK>; <LINK REF="STD-Orenstein-2004" TYPE="STUDY">Orenstein 2004</LINK>; <LINK REF="STD-Shaw-2016" TYPE="STUDY">Shaw 2016</LINK>); and three studies were acute exercise studies and of insufficient duration (less than 14 days) to be included in this review (<LINK REF="STD-Dwyer-2017" TYPE="STUDY">Dwyer 2017</LINK>; <LINK REF="STD-Kriemler-2016" TYPE="STUDY">Kriemler 2016</LINK>; <LINK REF="STD-Wheatley-2015" TYPE="STUDY">Wheatley 2015</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting classification</HEADING>
<P>There are 13 studies awaiting classification (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>; <LINK REF="STD-Almajan-2011" TYPE="STUDY">Almajan 2011</LINK>; <LINK REF="STD-Housinger-2015" TYPE="STUDY">Housinger 2015</LINK>; <LINK REF="STD-Johnston-2004" TYPE="STUDY">Johnston 2004</LINK>; <LINK REF="STD-Lorenc-2015" TYPE="STUDY">Lorenc 2015</LINK>; <LINK REF="STD-Mandrusiak-2011" TYPE="STUDY">Mandrusiak 2011</LINK>; <LINK REF="STD-NCT00609050" TYPE="STUDY">NCT00609050</LINK>; <LINK REF="STD-NCT00792194" TYPE="STUDY">NCT00792194</LINK>; <LINK REF="STD-NCT02552043" TYPE="STUDY">NCT02552043</LINK>; <LINK REF="STD-NCT03100214" TYPE="STUDY">NCT03100214</LINK>; <LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>; <LINK REF="STD-Oliveira-2010" TYPE="STUDY">Oliveira 2010</LINK>; <LINK REF="STD-Phillips-2008" TYPE="STUDY">Phillips 2008</LINK>). One author of the study informed us that the trial has been terminated prematurely due to recruitment problems and that no paper will be published from this study (<LINK REF="STD-NCT00792194" TYPE="STUDY">NCT00792194</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial characteristics</HEADING>
<P>Nine of the 13 studies awaiting classification were of a randomised parallel group design (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>; <LINK REF="STD-Almajan-2011" TYPE="STUDY">Almajan 2011</LINK>; <LINK REF="STD-Johnston-2004" TYPE="STUDY">Johnston 2004</LINK>; <LINK REF="STD-Lorenc-2015" TYPE="STUDY">Lorenc 2015</LINK>; <LINK REF="STD-Mandrusiak-2011" TYPE="STUDY">Mandrusiak 2011</LINK>; <LINK REF="STD-NCT00792194" TYPE="STUDY">NCT00792194</LINK>; <LINK REF="STD-NCT02552043" TYPE="STUDY">NCT02552043</LINK>; <LINK REF="STD-NCT03100214" TYPE="STUDY">NCT03100214</LINK>; <LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>; <LINK REF="STD-Phillips-2008" TYPE="STUDY">Phillips 2008</LINK>). One study was described as a modified RCT (<LINK REF="STD-Housinger-2015" TYPE="STUDY">Housinger 2015</LINK>) and one study used a cross-over design (<LINK REF="STD-NCT00609050" TYPE="STUDY">NCT00609050</LINK>). The study by Phillips (published as abstract only) was described as controlled, prospective clinical trial (<LINK REF="STD-Phillips-2008" TYPE="STUDY">Phillips 2008</LINK>), but is it not clear from the abstract whether the two study groups were randomly allocated. We contacted one author of this study, but we did not receive an answer. All studies were single-centre studies and the study size ranged from 12 to 150 participants (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>; <LINK REF="STD-Almajan-2011" TYPE="STUDY">Almajan 2011</LINK>; <LINK REF="STD-Housinger-2015" TYPE="STUDY">Housinger 2015</LINK>; <LINK REF="STD-Johnston-2004" TYPE="STUDY">Johnston 2004</LINK>; <LINK REF="STD-Lorenc-2015" TYPE="STUDY">Lorenc 2015</LINK>; <LINK REF="STD-Mandrusiak-2011" TYPE="STUDY">Mandrusiak 2011</LINK>; <LINK REF="STD-NCT00609050" TYPE="STUDY">NCT00609050</LINK>; <LINK REF="STD-NCT00792194" TYPE="STUDY">NCT00792194</LINK>; <LINK REF="STD-NCT02552043" TYPE="STUDY">NCT02552043</LINK>; <LINK REF="STD-NCT03100214" TYPE="STUDY">NCT03100214</LINK>; <LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>; <LINK REF="STD-Oliveira-2010" TYPE="STUDY">Oliveira 2010</LINK>; <LINK REF="STD-Phillips-2008" TYPE="STUDY">Phillips 2008</LINK>).</P>
<P>Inclusion and exclusion criteria were reported in five studies (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>; <LINK REF="STD-NCT00792194" TYPE="STUDY">NCT00792194</LINK>; <LINK REF="STD-NCT02552043" TYPE="STUDY">NCT02552043</LINK>; <LINK REF="STD-NCT03100214" TYPE="STUDY">NCT03100214</LINK>; <LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>). Six studies included children (<LINK REF="STD-Almajan-2011" TYPE="STUDY">Almajan 2011</LINK>; <LINK REF="STD-Johnston-2004" TYPE="STUDY">Johnston 2004</LINK>; <LINK REF="STD-Mandrusiak-2011" TYPE="STUDY">Mandrusiak 2011</LINK>; <LINK REF="STD-NCT00609050" TYPE="STUDY">NCT00609050</LINK>; <LINK REF="STD-NCT02552043" TYPE="STUDY">NCT02552043</LINK>; <LINK REF="STD-Oliveira-2010" TYPE="STUDY">Oliveira 2010</LINK>); seven studies included children, adolescents and adults (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>; <LINK REF="STD-Housinger-2015" TYPE="STUDY">Housinger 2015</LINK>; <LINK REF="STD-Lorenc-2015" TYPE="STUDY">Lorenc 2015</LINK>; <LINK REF="STD-NCT00792194" TYPE="STUDY">NCT00792194</LINK>; <LINK REF="STD-NCT03100214" TYPE="STUDY">NCT03100214</LINK>; <LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>; <LINK REF="STD-Phillips-2008" TYPE="STUDY">Phillips 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>There was a great variety between studies with respect to exercise training modalities and approaches. Three studies were of a combined aerobic and anaerobic home-based exercise training (<LINK REF="STD-NCT00792194" TYPE="STUDY">NCT00792194</LINK>; <LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>; <LINK REF="STD-NCT00609050" TYPE="STUDY">NCT00609050</LINK>). One study focused on aerobic type exercises during a six-week supervised programme followed by a 16-week home-based programme (<LINK REF="STD-Johnston-2004" TYPE="STUDY">Johnston 2004</LINK>). Four exercise training studies were conducted with participants hospitalised for treatment of a pulmonary exacerbation (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>; <LINK REF="STD-Housinger-2015" TYPE="STUDY">Housinger 2015</LINK>; <LINK REF="STD-NCT03100214" TYPE="STUDY">NCT03100214</LINK>; <LINK REF="STD-Phillips-2008" TYPE="STUDY">Phillips 2008</LINK>); one of these was a web-based intervention to promote physical activity participation (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>). One study was conducted in hospital followed by a 8- to 12-week home-based exercise training programme (<LINK REF="STD-Mandrusiak-2011" TYPE="STUDY">Mandrusiak 2011</LINK>). One study investigated the effects of active video games during a six-week domiciliary pulmonary rehabilitation programme (<LINK REF="STD-NCT02552043" TYPE="STUDY">NCT02552043</LINK>) and another study investigated the feasibility and effectiveness of Tai Chi as exercise intervention (<LINK REF="STD-Lorenc-2015" TYPE="STUDY">Lorenc 2015</LINK>). Two studies did not report on the type of exercises included in their training study (<LINK REF="STD-Almajan-2011" TYPE="STUDY">Almajan 2011</LINK>; <LINK REF="STD-Oliveira-2010" TYPE="STUDY">Oliveira 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Five studies reported on changes in FEV<SUB>1</SUB> after exercise training (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>; <LINK REF="STD-Almajan-2011" TYPE="STUDY">Almajan 2011</LINK>; <LINK REF="STD-NCT00609050" TYPE="STUDY">NCT00609050</LINK>; <LINK REF="STD-NCT03100214" TYPE="STUDY">NCT03100214</LINK>; <LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>); in one of these it was a secondary outcome (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>). Eight studies report on changes in exercise capacity measured with cardiopulmonary exercise testing (VO<SUB>2</SUB> peak) (<LINK REF="STD-NCT00609050" TYPE="STUDY">NCT00609050</LINK>; <LINK REF="STD-NCT00792194" TYPE="STUDY">NCT00792194</LINK>) or exercise capacity measured by field exercise tests such as the six-minute walk test (<LINK REF="STD-Housinger-2015" TYPE="STUDY">Housinger 2015</LINK>; <LINK REF="STD-NCT03100214" TYPE="STUDY">NCT03100214</LINK>; <LINK REF="STD-NCT02552043" TYPE="STUDY">NCT02552043</LINK>); shuttle test (<LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>; <LINK REF="STD-Phillips-2008" TYPE="STUDY">Phillips 2008</LINK>) or three-minute step test (<LINK REF="STD-Oliveira-2010" TYPE="STUDY">Oliveira 2010</LINK>). One study did not specify the exercise test to measure aerobic capacity (<LINK REF="STD-Johnston-2004" TYPE="STUDY">Johnston 2004</LINK>). Eight studies report on changes in HRQoL (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>; <LINK REF="STD-Housinger-2015" TYPE="STUDY">Housinger 2015</LINK>; <LINK REF="STD-Lorenc-2015" TYPE="STUDY">Lorenc 2015</LINK>; <LINK REF="STD-NCT00609050" TYPE="STUDY">NCT00609050</LINK>; <LINK REF="STD-NCT02552043" TYPE="STUDY">NCT02552043</LINK>; <LINK REF="STD-NCT03100214" TYPE="STUDY">NCT03100214</LINK>; <LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>; <LINK REF="STD-Oliveira-2010" TYPE="STUDY">Oliveira 2010</LINK>) and three studies on changes in muscle strength after exercise training (<LINK REF="STD-Housinger-2015" TYPE="STUDY">Housinger 2015</LINK>; <LINK REF="STD-NCT02552043" TYPE="STUDY">NCT02552043</LINK>; <LINK REF="STD-Phillips-2008" TYPE="STUDY">Phillips 2008</LINK>). Four studies also report on changes in physical activity (<LINK REF="STD-ACTRN12617001009303" TYPE="STUDY">ACTRN12617001009303</LINK>; <LINK REF="STD-Almajan-2011" TYPE="STUDY">Almajan 2011</LINK>; <LINK REF="STD-Johnston-2004" TYPE="STUDY">Johnston 2004</LINK>; <LINK REF="STD-NCT03109912" TYPE="STUDY">NCT03109912</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>Four studies are listed as ongoing (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>; <LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>; <LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>; <LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial characteristics</HEADING>
<P>All four studies are of a randomised parallel group design (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>; <LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>; <LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>; <LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>) and registered with clinicaltrials.gov (<A HREF="https://clinicaltrials.gov/">https://clinicaltrials.gov/</A>) or WHO ICTRP (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>). Three studies are single-centre studies (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>; <LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>; <LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>) and one study in an international, multi-centre study (<LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>). The studies range in duration, from three months (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>), over one year (<LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>; <LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>) to two years (<LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>). Inclusion and exclusion criteria are specified for all studies (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>; <LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>; <LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>; <LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>). All four studies include both genders and focus on either children and adults (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>; <LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>), only children and adolescents (<LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>) or only adults (over 18 years) (<LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>). In two studies, participation in the exercise trial is restricted to participants with an FEV<SUB>1</SUB> &#8805; 20% predicted (<LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>) and &#8805; 35% predicted (<LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>) and in one of these participants must additionally have access to the Internet (<LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>). The target sample size in the studies ranges from a minimum of 30 to a maximum of 292 study participants (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>; <LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>; <LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>; <LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>There is a great variety in interventions with respect to the study designs. One study provides participants with a written manual with instructions regarding physical activity and investigates the effects of the programme on posture and balance (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>). In the study by Gupta, study participants take part in a one-year resistance exercise and plyometric jumping exercise training programme to improve bone mineral density (<LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>). In the third study, participants take part in a partially supervised exercise training intervention using step counters and online diaries as motivational elements over a period of six months; in the second part of the study (also six months), supervision by exercise experts is withdrawn (<LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>). The remaining study aims to evaluate whether the use of a fitness tracker (Fitbit<SUP>®</SUP>) and an exercise prescription is associated with increased daily physical activity and exercise tolerance in young adults with CF over a period of two years (<LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The primary outcome measures of the studies are: changes in posture (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>); bone mineral density (<LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>); FEV<SUB>1</SUB>, % predicted (<LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>) and submaximal exercise capacity (<LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>). All studies included HRQoL (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>; <LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>; <LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>; <LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>) as secondary outcome and three studies included changes in FEV<SUB>1</SUB> as secondary outcomes (<LINK REF="STD-Donadio-2017" TYPE="STUDY">Donadio 2017</LINK>; <LINK REF="STD-Gupta-2017" TYPE="STUDY">Gupta 2017</LINK>; <LINK REF="STD-NCT02700243" TYPE="STUDY">NCT02700243</LINK>). Several other secondary endpoints will be considered, listed under characteristics of ongoing studies.</P>
</SUBSECTION>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-11-01 16:17:24 +0000" MODIFIED_BY="Nikki Jahnke">
<P>A risk of bias of each study was assessed according to the Cochrane risk of bias tool, which categorises studies into low, high or unclear risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The results are displayed graphically in the figures (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2017-10-19 15:32:01 +0100" MODIFIED_BY="Tracey Remmington">
<SUBSECTION>
<HEADING LEVEL="4">Sequence generation</HEADING>
<P>Three studies described the methods used for generation of the randomisation sequence and were judged to have a low risk of bias (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). A total of 10 studies were described as randomised, but did not give details of the methods used; these were deemed to have an unclear risk of bias (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>). In two studies, information on the generation of the random sequence was provided, but the method used in the studies can potentially introduce selection bias and lacks reproducibility; these were judged as having a high risk of bias (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Only four studies described how allocation was adequately concealed. Two of these studies were judged to have a low risk of bias (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). The other two studies were judged as high risk of bias because allocation concealment is no longer given when the investigator is aware of the number of lots in the bag and if for one group all available lots have already been drawn out (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). A total of 11 studies did not give any details of the method of allocation concealment (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2017-10-19 15:33:09 +0100" MODIFIED_BY="Tracey Remmington">
<P>None of the studies was obviously blinded for group assignment, as it is impossible to blind exercise training compared to no exercise training.</P>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants and personnel (performance bias)</HEADING>
<P>In two of the 13 included studies, one researcher of the study team was blinded to the participants group allocation (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>). Klijn reported that the primary researcher was blinded to group allocation, but their role in the study is not clear (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>). In the Rovedder study , one researcher was blinded for randomisation, the intervention and was responsible for database entries (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). We judged all included studies to have an unclear risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of outcome assessment (detection bias)</HEADING>
<P>In five of 15 studies, outcome assessors were blinded to group allocation (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). These studies were deemed to have a low risk of bias. It is unclear whether outcome measures were assessed by blinded investigators in nine of the studies (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>) and one study reported that the primary researcher was blinded but is is not clear whether this person was responsible for outcome assessment (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>).</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-10-19 15:36:10 +0100" MODIFIED_BY="Tracey Remmington">
<P>We evaluated risk of bias for incomplete outcome data with respect to:</P>
<OL>
<LI>the use of an intention-to-treat analysis including appropriate methods for imputing data;</LI>
<LI>the dropout rate (balanced or unbalanced between groups) including a description of reasons for dropouts; and</LI>
<LI>the differentiation of the dropout rate between short-term (less than one month) and long-term studies (over one month).</LI>
</OL>
<P>Information about dropouts was provided in 12 studies (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Three studies were published only in abstract form and did not give any details about dropouts (<LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>).</P>
<P>Six studies were rated as having a low risk of bias for incomplete outcome data (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>, <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Two short-term studies (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>) and one long-term study (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>) reported no dropouts. In three long-term studies the dropout rate was balanced among groups and reasons for dropout were clearly reported (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>, <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). Additionally, Rovedder used multiple imputation to account for missing data in the statistical analysis (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>).</P>
<P>Three long-term studies were rated as having a high risk of bias (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). In two studies, dropout rates were high and not balanced between groups. The use of intention-to-treat was reported in both studies, while in one study the last value carried forward method was applied (<LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>); in the second study, the method used for data imputation was not reported (<LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). In the study by Beaudoin, the dropout rate (post-randomisation) was 18% (n = 3) and the group allocation of two study participants was not reported (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). This study was registered as randomised cross-over study (<A HREF="http://clinicaltrials.gov">ClinicalTrials.gov</A>), but the results were only reported for the first phase and the original publication described it as a parallel design study (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
<P>The remaining studies were rated as having an unclear risk of bias for incomplete outcome data (<LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>). Three of these studies were published only in abstract form and did not give any details about dropouts (<LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>). In one long-term study, dropouts were reported and balanced between groups, but reasons for dropouts were not described and intention-to-treat was not used (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>). One study reported the reasons for participants dropping out and that an intention-to-treat analysis produced similar results for pulmonary function outcomes; however, data were only reported for 65 participants excluding dropouts (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). Another study reported the use of an intention-to-treat analysis, but missing data were treated by omission rather than imputation and reasons for dropout were not clearly described (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>).<BR/>
</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-11-01 16:09:11 +0000" MODIFIED_BY="Nikki Jahnke">
<P>We judged seven studies to have a low risk of bias since they reported all outcomes detailed in the 'Methods' sections for all time points in the 'Results' section (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>, <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). One of these studies mentioned in the original publication that data for HRQoL would be addressed separately (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). Data from this study were published together with data from another study which used similar methods (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>); the combined data are presented in a separate paper (<LINK REF="REF-Hebestreit-2014" TYPE="REFERENCE">Hebestreit 2014</LINK>).</P>
<P>Six studies did not report all outcomes and were deemed to have an unclear risk of bias (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>). Three of these studies were in abstract format and selective reporting could not be assessed (<LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>); even so, we would expect the most common measure of lung function (FEV<SUB>1</SUB>) to be mentioned which it is not in one of these studies (<LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>). Three studies did not report all outcomes for HRQoL (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>) and anaerobic exercise capacity (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>). Two studies did not report all variables for cardiopulmonary exercise testing as mentioned in the methods section (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>The study by Beaudoin was judged as high risk of bias for selective reporting, because the study was registered as randomised cross-over study, but reported as a parallel-design study. The second part of the study was not reported in the original publication. Moreover, oxygen saturation and heart rate were measured during cardiopulmonary exercise testing, but results were not reported in the full-text publication (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-11-01 16:17:24 +0000" MODIFIED_BY="Nikki Jahnke">
<SUBSECTION>
<HEADING LEVEL="4">Description of inclusion or exclusion criteria</HEADING>
<P>Three studies are only available in abstract format and do not state inclusion or exclusion criteria, nor do they describe the methods of statistical analysis used which could be a source of bias (<LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>). Six studies clearly stated inclusion and exclusion criteria which limits the potential for bias (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Three studies described the inclusion criteria but not the exclusion criteria, which could be a potential source of bias (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Statistical analysis</HEADING>
<P>A total of 11 studies clearly described the methods of statistical analysis, thus eliminating a potential source of bias (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>In one study, the MD between the treatment and control groups could not be calculated, as the number of participants in each group was not reported (<LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>).</P>
<P>In one study, information on sample size and recruitment goals differ between the information provided on the trial registry and the final publication (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). The study aimed to recruit 24 participants (12 in each group) but the recruitment goal was not achieved (18 were recruited and only 17 randomised), but according to the power calculation provided in the original publication, 18 participants (nine per group) were required for the analysis. Only 14 participants actually completed the study (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Group characteristics</HEADING>
<P>In five studies, significant between-group differences existed at baseline despite randomisation (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). In one study, FEV<SUB>1</SUB> and FEF<SUB>25-75</SUB> were significantly lower in the control compared to the training group at admission (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>). In a second study, differences in exercise capacity (peak power was higher in the strength training group compared to the control group) and in vigorous physical activity (lower in the aerobic training group compared to controls) were evident at baseline (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). In both Santana-Sosa studies, the training groups had a lower aerobic exercise capacity (VO<SUB>2</SUB> peak) and lower muscle strength (most but not all strength measures) (<LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). In the fifth study, BMI was significantly lower in the intervention group compared to the control group (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). It is uncertain whether these factors could be a potential source of bias so we judged the risk to be unclear for significant between-group differences at baseline.</P>
<P>In six of the 12 studies published as full-text articles, FEV<SUB>1</SUB> % predicted values were used as exclusion criteria (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>, <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). We accept that studies which exclude participants on the basis of one of our outcomes may cause a risk of bias to the review. However, the risk of exercise-induced adverse effects is likely to be higher in people with severe CF lung disease and many researchers tend to exclude those people because of this. In one study, financial support was provided to the training group participants to foster the activity plan; this study was judged as having an unclear risk of bias (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>In the original publication, no information was provided on the control intervention. We noticed discrepancies between the registered (clinicaltrials.gov) and published trial design (cross-over versus parallel-group design) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Data discrepancies</HEADING>
<P>Three studies were rated as having a high risk of bias (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). Two studies for which we received some raw data from the authors were rated as high risk of bias, due to inconsistencies between the raw data files and the data reported in the original publications (<LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). Furthermore, Beaudoin reported within-group changes from baseline and not between-group differences, as would be appropriate for a RCT (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). We calculated between-group differences using raw data provided by the authors and our results suggest no between-group differences for the primary endpoint. When considered alongside the fact that the stated power calculation requiring 18 participants to demonstrate a difference was not achieved (see above), there is a high risk of bias that the reported effects are not sound.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-11-02 10:03:44 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Where primary studies reported differences between groups but did not provide adequate data (means and SD) that could be presented in the Review Manager software (<LINK REF="REF-Review-Manager-2014" TYPE="REFERENCE">Review Manager 2014</LINK>), the information from the primary (original) study has been included in the results. It was not possible to pool data for any outcomes due to variations in the type and duration of studies, the times at which outcomes were measured, the different methods of reporting outcomes, the omission of data relating to either mean change from baseline for each group and the SD or SE.</P>
<P>We present the effects of the interventions according to training modalities, i.e. aerobic training, anaerobic training and combined aerobic and anaerobic training, these are further differentiated by length of training. There are four short-term (less than one month) aerobic studies (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>); three longer-term aerobic studies ranging from six months to three years (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>); one short-term anaerobic study (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>); two longer-term anaerobic studies ranging from three (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>) to 24 months (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>); and five longer-term combined aerobic and anaerobic training studies ranging from three to 24 months (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>, <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>).</P>
<P>In the two studies by Santana-Sosa, means and SE were reported for baseline, post-training and detraining and we were not able to calculate the MD (<LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). We received incomplete raw data files from the authors and due to inconsistencies in the provided data sets, we were unable to reproduce all data. Due to the review authors' concerns about data quality, both studies were excluded from the formal analysis in the review and data are provided in two additional tables at the end of the review (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Two studies comparing aerobic exercise training with no training were published as abstracts (<LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Turchetta-1991" TYPE="STUDY">Turchetta 1991</LINK>) and no information on relevant outcomes for this review was available.</P>
<SUBSECTION>
<HEADING LEVEL="3">Aerobic training versus no physical training</HEADING>
<P>Five studies with 197 participants are included in this comparison (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). In the study by Kriemler, the control group experienced an unusual deterioration of physical health during the study and the results should be interpreted with caution (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Exercise capacity by VO<SUB>2</SUB> peak</HEADING>
<P>This outcome was reported in four studies (n = 180) (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Results are presented in the analysis (very low-quality evidence) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>In the short-term study by Selvadurai, exercise capacity was measured by VO<SUB>2</SUB> peak during a treadmill exercise test (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Improvements in exercise tolerance during aerobic training were significantly greater than with no specific training after hospital discharge, MD 8.53 mL/min per kg body weight (95% CI 4.85 to 12.21). One month after hospital discharge VO<SUB>2</SUB> peak remained significantly higher in the aerobic training group compared to the control group, MD 4.91 mL/min per kg body weight (95% CI 1.13 to 8.69) (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>Two studies reported on this outcome after three months (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). In the study by Hommerding, exercise capacity was measured during cycle ergometry. No between-group differences in VO<SUB>2</SUB> peak (mL/min per kg body weight) were observed after three months, MD -1.20 mL/min per kg body weight (95% CI -7.26 to 4.86) (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>). In the study by Kriemler, VO<SUB>2</SUB> peak (mL/min per kg body weight) was measured during cycle ergometry (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). After three months, a significant difference in VO<SUB>2</SUB> peak between the aerobic training group and the control group was observed, MD 9.71 mL/min per kg body weight (95% CI 0.86 to 18.56). When combined, the data from both studies showed no difference in VO<SUB>2</SUB> peak between the exercise and control groups, pooled MD 2.29 (95% CI -2.71 to 7.29). Heterogeneity between these studies was high (I² = 75%); most likely due to the unusual deterioration of the control group.</P>
<P>In the Kriemler study, VO<SUB>2</SUB> peak was significantly higher in the training compared to the control group after six months, MD 18.33 mL/min per kg body weight (95% CI 8.95 to 27.71). No differences between groups were observed at six and 18 months off training, MD 9.51 mL/min per kg body weight (95% CI -1.32 to 20.34) and 2.86 mL/min per kg body weight (95% CI -9.70 to 15.42), respectively.</P>
<P>In the study by Schneiderman-Walker, VO<SUB>2</SUB> peak was measured during cycle ergometry (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). No significant difference between groups was found in the annual rate of decline in VO<SUB>2</SUB> peak, MD 0.05 mL/min per kg body weight (95% CI -1.15 to 1.25) (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Pulmonary function (FEV<SUB>1</SUB>)</HEADING>
<P>This outcome was reported in five studies (n = 197) (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Results are presented in the analysis (low-quality evidence) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Two short-term aerobic training studies reported on change in FEV<SUB>1</SUB> (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). In the study by Cerny, there was no difference in the change in FEV<SUB>1</SUB> % predicted (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>). In the study by Selvadurai there was no significant difference between the groups in FEV<SUB>1</SUB> % predicted at hospital discharge, MD 2.03% (95% CI -2.31 to 6.37) and one month after discharge, MD 1.53% (95% CI -2.93 to 5.99) (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>Three long-term studies reported on changes in FEV<SUB>1</SUB> after aerobic training compared to no exercise training (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). In the study by Hommerding, no between-group differences were observed in FEV<SUB>1</SUB> % predicted after three months, MD -2.80% (95% CI -10.69 to 5.09). In the Kriemler study, the aerobic training group had significantly higher values for FEV<SUB>1</SUB> % predicted compared to control group after three months, MD 12.81% (95% CI 6.91 to 18.71). When combined, the data from both studies showed a significant increase in favour of the exercise group, pooled MD 7.21% (95% CI 2.49 to 11.94). Heterogeneity between these studies was high (I² = 90%); most likely due to the unusual deterioration of the control group.</P>
<P>Also after six months, FEV<SUB>1</SUB> % predicted was higher in the exercise compared to the control group, MD 17.17% (95% CI 8.59 to 25.75) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). At the six and 18 months off-training period, a difference was found between the training and control group for FEV<SUB>1</SUB>, MD 16.92% (95% CI 6.07 to 27.77) and MD 12.45% (95% CI 1.27 to 23.63).</P>
<P>Schneiderman-Walker reported on the effects of aerobic physical training on lung function at three years (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). The control group was not significantly different from the intervention group in annual decline in FEV<SUB>1</SUB> % predicted, MD 2.01% (95% CI -0.06 to 4.08) (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Health-related quality of life</HEADING>
<P>This outcome was reported in three studies (n = 143) (low-quality evidence) (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). No detailed results were presented for HRQoL scales in the study by Hommerding (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>).</P>
<P>Hommerding assessed HRQoL with the Cystic Fibrosis Questionnaire (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>). No effects of physical exercise training were found for HRQoL scales after the intervention. Selvadurai assessed HRQoL using the generic 'Quality of Well-being Scale'. Since this scale was validated in an outpatient setting, assessment was undertaken on the participants' admission to hospital and during the follow-up one month after their discharge, at which time there was a significant difference between the groups in favour of the intervention group for the change in HRQoL, MD 0.10 (95% CI 0.03 to 0.17) (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Schneiderman-Walker reported on attitudes toward physical activity and perceived feasibility of a regular aerobic exercise programme (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). Positive effects, reported by 43 out of 49 participants, included generally feeling better about themselves, having more energy and less chest congestion. A small number of participants reported no differences. Both groups stated it would be feasible to meet aerobic exercise targets, if requested to do so by doctors (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. CF-related mortality</HEADING>
<P>No data were reported from any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Muscle strength and anaerobic exercise capacity</HEADING>
<P>This outcome was reported in two studies (n = 71) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>In the Kriemler study, no significant differences in muscle strength measured by a leg Wingate anaerobic test (WAnT) (change in mean power in watt (W) per kg body weight) were observed between the study groups after three months, MD 0.28 W/kg body weight (95% CI -0.53 to 1.09) and six months, MD -0.09 (95%CI -0.92 to 0.74) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). No significant differences in leg muscle strength between the training and control group were found at the six months off-training time point, MD 0.23 W/kg body weight (95% CI -0.65 to 1.11) and 18 months off training period, MD 0.28 W/kg body weight (95% CI -0.72 to 1.28) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
<P>In the study by Selvadurai, the aerobic training group had a significantly greater increase in lower limb muscle strength than the control group at hospital discharge, MD 8.13 Newton metres (Nm) (95% CI 4.49 to 11.77). This increase remained significant one month after discharge, MD 6.13 Nm (95% CI 2.47 to 9.79) (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Additional indices of exercise capacity</HEADING>
<P>These outcomes were reported in five studies (n = 187) (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>Three studies reported on peak exercise capacity (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). In the study by Cerny, results were presented in figures but raw data were not available for this study. Cerny reported no differences between groups in peak work capacity (Watt (W) per kg body weight) (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>). In the Kriemler study, a significant difference between the training and control group was observed for peak work capacity after three months, MD 0.52 W/kg body weight (95% CI 0.17 to 0.87) and after six months, MD 0.81 W/kg body weight (95% CI 0.52 to 1.10) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). No between-group differences existed after the six months off-training period, MD 0.25 W/kg body weight (95% CI -0.11 to 0.61) and 18 months off-training period, MD 0.13 W/kg body weight (95% CI -0.46 to 0.72).</P>
<P>Schneiderman-Walker reported on the annual rate of decline in peak work capacity (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>); no significant difference was found between groups, MD 0.82% (95% CI -1.91 to 3.55) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
<P>One study reported on treadmill speed (km/h) and treadmill exercise time (min) after three months (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>). In this study, no differences between groups were found in treadmill speed, MD -0.60 km/h (95% CI -2.03 to 0.83) or treadmill exercise time, MD -0.50 min (95% CI -2.06 to 1.06) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
<P>Three studies reported on heart rate (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). In the study by Hommerding, no differences between groups were found for resting heart rate, MD 7.00 beats per min (bpm) (95% CI -5.35 to 19.35) or peak exercise heart rate, MD 4.00 bpm (95% CI -17.03 to 25.03) after three months (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>). The study by Schneiderman-Walker reported that there was no significant difference in the annual rate of decline in peak heart rate between groups, MD 1.10 bpm (95% CI -0.85 to 3.05) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). Cerny did not present any data that we could analyse, but reported that there was no significant difference between control and treatment arms in change in peak heart rate or the ratio of peak heart rate to peak load (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>).</P>
<P>One study measured oxygen saturation at rest (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>) and two studies reported on oxygenation during exercise (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). In the study by Hommerding, no differences between the training and control groups were found in either resting oxygen saturation, MD -0.70% (95% CI -2.53 to 1.13) or peak oxygen saturation during maximal exercise, MD 9.60% (95% CI -5.20 to 24.40). The reasons for the large changes in peak oxygen saturation in the control group (about 10% change in peak oxygen saturation) are unclear to the authors of this review. In the study by Selvadurai, the aerobic training group demonstrated less desaturation following training compared to control, MD 0.62% (95% CI 0.32 to 0.92) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). These differences did not reach statistical significance in the original study (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>Two studies reported on minute ventilation at peak exercise (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). In the study by Schneiderman-Walker, there was no significant difference in the annual rate of decline in maximum minute ventilation between groups, MD 2.09 L/min (95% CI -1.60 to 5.78) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). The study by Cerny again did not present any data we were able to analyse, but stated that there were no differences between groups in the ratio change of peak minute ventilation to peak load (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>).</P>
<P>Finally, in the study by Hommerding breathlessness and fatigue was measured with a 0 to 10 Borg scale. Data were presented as medians (interquartile range) in the original publication and could not be analysed in this review. Hommerding reported no differences in either variable between groups after the three-month intervention (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Additional indices of pulmonary function and respiratory muscle strength</HEADING>
<P>Changes in pulmonary function in addition to FEV<SUB>1</SUB> were reported in five studies (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). No study reported on respiratory muscle strength.</P>
<P>All five studies reported on FVC % predicted (n = 187) (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). In the short-term study by Selvadurai, there was no significant difference between the groups in change of FVC % predicted at hospital discharge, MD 0.06% (95% CI -2.55 to 2.67) and one month after discharge, MD -0.11% (95% CI -2.64 to 2.42) (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). In the second short-term study (by Cerny), there was no difference reported in the change in FVC % predicted among groups (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>). In the longer-term study by Hommerding, there was no difference between the study groups in FVC % predicted after the three-month intervention, MD -1.60% (95% CI -8.22 to 5.02) (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>). In the Kriemler study, significant differences were observed in the training group compared to the control group for FVC % predicted at three and six months, MD 9.24% (95% CI 3.82 to 14.66) and MD 12.51% (95% CI 5.90 to 19.12), respectively (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). When combined, the data from both studies showed a significant difference in FVC % predicted between the exercise and control groups at three months, pooled MD 4.89% (95% CI 0.69 to 9.08) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). Heterogeneity between these studies was high (I² = 84%); most likely due to the unusual deterioration of the control group. Further, differences between groups were found in favour for the exercise group after six months off-training, MD 15.09% (95% CI 6.01 to 24.17). No differences between groups were observed after 18 months off-training, MD 9.10% (95% CI -0.94 to 19.14) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
<P>Schneiderman-Walker reported on the effects of aerobic physical training on lung function at three years (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). The control group demonstrated a significantly greater mean rate of annual decline in FVC % predicted than the exercise group, MD 2.17% (95% CI 0.47 to 3.87) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
<P>Two longer-term studies reported on changes in FEF<SUB>25-75</SUB> % predicted (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). No between-group differences in FEF<SUB>25-75</SUB> % predicted were found in the study by Hommerding after three months, MD -9.00% (95% CI -23.29 to 5.29) (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>). Schneiderman-Walker also reported that the control group demonstrated a significantly greater mean rate of annual decline in FEF<SUB>25-75</SUB> % predicted, MD 0.80% (95% CI -2.20 to 3.80), although this was not statistically significant (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
<P>The Kriemler study additionally reported on the ratio of residual volume to total lung capacity (RV/TLC) in % predicted (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). Compared to the control group, no differences were observed for this outcome at either three, MD -3.93 (95% CI -9.53 to 1.67) or six months, MD -0.73 (95% CI -7.60 to 6.14) (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). Results remained non-significant after six, MD 3.19 (95% CI -4.02 to 10.40) and 18 months off-training, MD -1.98 (95% CI -8.82 to 4.86).</P>
<P>Hommerding also reported on FEV<SUB>1</SUB>/FVC as % predicted (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>). They found no differences in FEV<SUB>1</SUB>/FVC between the training and control group after the intervention, MD -1.40% (95% CI -8.66 to 5.86) (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>) (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Physical activity</HEADING>
<P>Physical activity was reported in three studies (n = 105) (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>, <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>Hommerding assessed physical activity levels by self-report (diary) and reported an increase in self-reported physical activity in the intervention compared to the control group after three months. However, in the original publication, data were presented as N (%) and could not be included in our analysis (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>).</P>
<P>Kriemler measured physical activity levels using accelerometry (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). At three months, total physical activity (counts per min) was higher in the aerobic training group compared to the control group, MD 121.00 counts per min (95% CI 29.90 to 212.10) (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>). There were no differences in this outcome at six months, MD -86.00 counts per min (95% CI -375.51 to 203.51); after six months off-training, MD -20.00 counts per min (95% CI -309.67 to 269.67) and after 18 months off-training, MD -13.00 counts per min (95% CI -362.46 to 336.46) (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
<P>Kriemler also reported on moderate to vigorous physical activity (hours per week) but found no differences between the aerobic training group and the control group at any time point reported during the study: at three months, MD -0.50 hours per week (95% CI -2.30 to 1.30); at six months, MD -0.20 hours per week (95% CI -2.28 to 1.88); after six months off-training, MD 0.55 hours per week (95% CI -1.09 to 2.19); and after 18 months off-training, MD 1.20 hours per week (95% CI -1.05 to 3.45) (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>Selvadurai measured physical activity levels with a combination of accelerometry and activity diaries in a sub-sample of study participants (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). No between-group differences in physical activity levels were reported at hospital discharge, MD 1.20 mega joules (MJ) per day (95% CI -0.20 to 2.60) (<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Body composition</HEADING>
<P>Changes in body composition were reported in five studies (n = 187) (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>Selvadurai reported on change in weight (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). There was no difference between groups at hospital discharge, MD -0.23 kg (95% CI -0.59 to 0.13) and one month after discharge, MD 0.10 kg (95% CI -0.33 to 0.53) (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>). Michel also reported on weight at one-month follow up, the mean (SD) increase in weight in the aerobic exercise group, 6.4 (4.8) lb was greater than in the non-exercise group 3.8 (3.4) lb (<LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>). These data cannot be entered into the data tables, as the number of participants assigned to each treatment group was not reported. We have contacted the authors for further information, but there is none available.</P>
<P>In the study by Kriemler, no changes were observed in BMI after three and six months, MD 0.30 kg/m² (95% CI -0.13 to 0.73) and MD 0.40 kg/m² (95% CI -0.00 to 0.80), respectively (<LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>). At six months off-training, BMI was significantly higher in the training compared to the control group, MD 0.50 kg/m² (95% CI 0.01 to 0.99), but at 18 months off-training no significant difference was observed between groups, MD 0.40 kg/m² (95% CI -0.37 to 1.17). Hommerding reported BMI z scores and found no differences between the training and the control group at three months, MD 0.10 (95% CI -0.16 to 0.36) (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>) (<LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>).</P>
<P>Selvadurai reported no difference in fat-free mass between the the aerobic training group and the control group at hospital discharge, MD 0.01 kg (95% CI -0.19 to 0.21) and one month after discharge MD 0.04 kg (95% CI -0.19 to 0.27) (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>) (<LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>). Kriemler also reported on fat-free mass, for which there were no significant differences between the aerobic training and the control groups at three months MD -0.30 kg (95% CI -1.05 to 0.45) and six months MD 0.30 kg (95% CI -0.95 to 1.55) (<LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>). This was also the case at six and 18 months off-training, MD 0.90 kg (95% CI -0.39 to 2.19) and MD 0.50 kg (95% CI -0.75 to 1.75).</P>
<P>The change in % of body fat reported in the study by Kriemler was higher in the training compared to the control group after three months, MD 1.60 % (95% CI 0.36 to 2.84) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). No between group differences were observed after six months, MD 1.40 % (95% CI -0.40 to 3.20) and at six and 18 months off-training, MD 1.00% (95% CI -1.66 to 3.66) and MD 1.20% (95% CI -1.64 to 4.04), respectively (<LINK REF="CMP-001.24" TYPE="ANALYSIS">Analysis 1.24</LINK>).</P>
<P>The study by Schneiderman-Walker reported on the annual rate of decline in % of ideal weight for height (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). There was there was no significant difference between groups at after 36 months, MD 0.52% (95% CI -0.76 to 1.80) (<LINK REF="CMP-001.25" TYPE="ANALYSIS">Analysis 1.25</LINK>).</P>
<P>Hommerding measured triceps skinfold thickness and arm muscle circumference (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>). No between-group differences were observed in either triceps skinfold thickness, MD 0.39 mm (95% CI -0.39 to 1.17) or arm muscle circumference, MD 0.16 cm (95% CI -0.05 to 0.37) (<LINK REF="CMP-001.26" TYPE="ANALYSIS">Analysis 1.26</LINK>; <LINK REF="CMP-001.27" TYPE="ANALYSIS">Analysis 1.27</LINK>). Michel also reported skinfold thickness and stated that there was a trend towards a greater increase in the sum of four skin folds in the exercise group and mid-arm muscle circumference than the non-exercise group (<LINK REF="STD-Michel-1989" TYPE="STUDY">Michel 1989</LINK>).</P>
<P>
<B>7. Acute exacerbations</B>
</P>
<P>One study reported on this outcome (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>). There were no between-group differences reported for the mean number of hospitalisations or mean number of days in hospital at year one, two and three (low-quality evidence) (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Antibiotic use</HEADING>
<P>No data were reported in any of the studies.</P>
<P>
<B>9. Bone health</B>
</P>
<P>No data were reported in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10. Diabetic control</HEADING>
<P>No data were reported in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11. Compliance with physical exercise training</HEADING>
<P>Two studies reported on this outcome (n = 92) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>).</P>
<P>The Kriemler study reported on training compliance for the overall study groups, but not separately for the different training groups. Altogether, the training groups fulfilled at least 65% of all training sessions (i.e. two out of three sessions per week) and 80% of all participants performed the requested three training sessions per week (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
<P>In the Schneiderman-Walker study, mean (SD) scores for compliance with exercise were reported, where the possible scores ranged from zero to two indicating poor, partial or full compliance, respectively. These scores within the exercise group for year 1 (1.51), year 2 (1.51) and year 3 (1.49) were not significantly different, but they were always higher than the scores for compliance with airway clearance techniques. Compliance with airway clearance was not statistically different between the groups (<LINK REF="STD-Schneiderman_x002d_Walker-2000" TYPE="STUDY">Schneiderman-Walker 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12. Adverse events</HEADING>
<P>Two studies specifically reported on adverse events (n = 71) (moderate-quality evidence) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). The Kriemler study reported that no adverse effects (e.g. injuries, pneumothorax, asthma attacks, hypoglycaemia) occurred during the study (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). In the study by Selvadurai, one participant in the aerobic training group injured her ankle and missed two days of aerobic training. One participant from the control group developed haemoptysis and withdrew from the study (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). No other study reported on adverse events.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Anaerobic training versus no physical training</HEADING>
<P>Three studies with 86 participants are included in this comparison (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). In the study by Kriemler, the control group experienced an unusual deterioration of physical health during the study and the results should be interpreted with caution (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Exercise capacity by VO<SUB>2</SUB> peak</HEADING>
<P>This outcome was reported in three studies (n = 86) (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Results are presented in the analysis (low-quality evidence) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>Selvadurai reported that anaerobic training was not associated with improvements in VO<SUB>2</SUB> peak compared with control at hospital discharge, MD 1.95 mL/min per kg BW (95% CI -1.61 to 5.51) and one month after hospital discharge, MD -0.40 mL/min per kg BW (95% CI -4.03 to 3.23). Two studies reported on this outcome at three months (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). In the study by Klijn, the change in VO<SUB>2</SUB> peak was not significantly greater in the anaerobic training versus control group, MD 3.95 mL/min per kg body weight (95% CI -2.95 to 10.85). Kriemler also reported there was no difference in VO<SUB>2</SUB> peak in the training group compared to the control group after three months, MD 9.34 mL/min per kg body weight (95% CI -1.31 to 19.99). When combined, the data from both studies showed no between group differences, pooled MD 5.54 (95% CI -0.25 to 11.34). Klijn reported no significant changes in VO<SUB>2</SUB> peak in the training group after three months off training, while VO<SUB>2</SUB> peak significantly decreased in the control group by -1.5 (1.7) mL/min per kg body weight. No data were available in the original paper to calculate the mean difference (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>). Kriemler reported significant differences in VO<SUB>2</SUB> peak in the training group compared to the control group after six months, MD 17.70 mL/min per kg body weight (95% CI 5.98 to 29.42). No significant differences between the groups was found at six and 18 months off training, MD 11.59 mL/min per kg body weight (95% CI -1.02 to 24.20) and MD 9.26 mL/min per kg body weight (95% CI -4.26 to 22.78), respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Pulmonary function by FEV<SUB>1</SUB>
</HEADING>
<P>This outcome was reported in three studies (n = 86) (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Results are presented in the analysis (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>In the study by Selvadurai, the anaerobic training group showed a significantly greater mean increase in FEV<SUB>1</SUB> % predicted at hospital discharge, MD of 5.58% (95% CI 1.34 to 9.82) (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). This increase was maintained one month after hospital discharge, MD 5.08% (95% CI 0.66 to 9.50). In the study by Kriemler, significant differences in FEV<SUB>1</SUB> % predicted in favour for the anaerobic training group were seen for all study time points: at three months, MD 11.11% (95% CI 5.16 to 17.06); at six months, MD 19.51% (95% CI 10.57 to 28.45); at six months off-training, MD 16.09% (95% CI 4.95 to 27.23) and at 18 months off-training, MD 17.01% (95% CI 6.27 to 27.75) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). The Klijn study reported that there were no significant between group differences in lung function parameters, but no data were reported which could be entered into the analysis (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Health-related quality of life</HEADING>
<P>This outcome was reported in two studies (n = 64) (low-quality evidence) (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>Selvadurai assessed HRQoL with the 'Quality of Well-being Scale' (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Since this scale was previously only validated in an outpatient setting, assessment was undertaken on the participants' admission to hospital and one month after their discharge. There was no significant difference between the groups in the change in HRQoL, MD 0.03 (95% CI -0.04 to 0.10) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>In the Klijn study no significant difference in the HRQoL scale physical function between the groups was found at the end of the anaerobic training period, MD 1.30 (95% CI -11.55 to 14.15) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). No other difference was found in any other HRQoL domain (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>). Klijn reported that there were significantly higher values for the domain of physical functioning in the training group after the follow-up period (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>). No data were available in the paper to calculate the MD.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. CF-related mortality</HEADING>
<P>No data were reported from any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Muscle strength and anaerobic exercise capacity</HEADING>
<P>These outcomes were reported in three studies (n = 86) (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>In two studies (n = 42), a WAnT was performed, but due to differences in outcome measures, we are not able to combine any data (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). The Klijn study reported a significantly greater change in peak power and mean power during WAnT in the anaerobic training versus control group: peak power, MD 70.30 W (95% CI 32.50 to 108.10) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>); and mean power, MD 43.30 W (95% CI 22.56 to 64.04) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). Klijn reported a higher peak power and mean power in the training groups after three months off training; however, no data were available for analysis from the original publication. The Kriemler study reported no significant differences in mean power among the groups after three and six months of anaerobic training, MD -0.63 W/kg body weight (95% CI -1.30 to 0.04) and MD 0.30 W/kg body weight (95% CI -0.34 to 0.94), respectively (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>). This remained the case at six and 18 months off training, MD -0.15 W/kg body weight (95% CI -0.97 to 0.67) and 0.10 kg body weight (95% CI -0.94 to 1.14), respectively (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>).</P>
<P>In the study by Selvadurai, the anaerobic training group had a significantly greater increase in lower limb strength than the control group at discharge, MD 24.62 Nm (95% CI 20.73 to 28.51). The increase remained significant between groups one month after hospital discharge, MD 19.23 Nm (95% CI 15.24 to 23.22) (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>) (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Additional indices of exercise capacity</HEADING>
<P>This outcome was reported in three studies (n = 86) (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>In the study by Klijn, peak work capacity was significantly higher in the anaerobic training versus control group, MD 13.00 W (95% CI 4.11 to 21.89) (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>). In the study by Kriemler, peak work capacity was significantly lower in the training compared to the control group after three months, MD -0.50 W/kg body weight (95% CI -0.84 to -0.16) (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>). However, in the original study by Kriemler, no between-group difference in peak work capacity was reported after three months training (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). Our analysis showed significant between-group differences in favour for the training group in peak work capacity after six months of training, MD 0.31 W/kg body weight (95% CI 0.01 to 0.61). However, the differences were not significant at six months and 18 months off-training, MD 0.10 W/kg body weight (95% CI -0.26 to 0.46) and MD, 0.00 W/kg body weight (95% CI -0.79 to 0.79), respectively (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
<P>Klijn also reported on lactate levels (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>). At three months the anaerobic training group showed significant improvements in serum lactate levels compared to the control group, MD 3.40 mmol/L (95% CI 1.33 to 5.47) (<LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>).</P>
<P>One study reported on desaturation during exercise (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). The anaerobic training group demonstrated significantly less desaturation following training compared to the control group at hospital discharge, MD 0.33% (95% CI 0.04 to 0.62) (<LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>). These differences did not reach statistical significance in the original study for an unknown reason (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Additional indices of pulmonary function and respiratory muscle strength</HEADING>
<P>Changes in pulmonary function measures were reported in three studies (n = 86) (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). No study reported on respiratory muscle strength.</P>
<P>Two studies reported on FVC % predicted (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). In the study by Selvadurai, there was no significant difference in FVC % predicted in the anaerobic training group compared to control at hospital discharge, MD 0.17% (95% CI -2.31 to 2.65) and one month after discharge, MD 0.06% (95% CI -2.42 to 2.54) (<LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>). Kriemler reported significant differences between the training and control group at all study time points: at three months, MD 7.37% (95% CI 1.89 to 12.85); at after six months, MD 14.05% (95% CI 7.16 to 20.94); at six months off-training, MD 13.66% (95% CI 4.38 to 22.94) and 18 months off-training, MD 13.63% (95% CI 4.13 to 23.13) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>) (<LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>).</P>
<P>Kriemler also reported RV/TLC % predicted (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). The results show significant differences between the anaerobic training and the control group at three months, MD -6.42% (95% CI -10.87 to -1.97); six months, MD -14.86% (95% CI -21.36 to -8.36); six month off-training, MD -6.86% (95% CI -13.47 to -0.25), but not at 18 months off-training, MD -4.77% (95% CI -10.61 to 1.07) (<LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>).</P>
<P>In the Klijn study there were no significant differences reported between groups in lung function parameters, but no data were available for analysis (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Physical activity</HEADING>
<P>This outcome was reported in three studies (n = 86) (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>One study assessed physical activity levels using accelerometry (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>); a second study used a combination of accelerometry and activity diary (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>); and the third study used the habitual activity estimation scale to assess physical activity levels (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>).</P>
<P>Kriemler observed no between-group differences in total physical activity after three or six months of training, MD 17.00 counts per min (95% CI -81.59 to 115.59) and MD 17.00 counts per min (95% CI &#8211;58.95 to 92.95), respectively (<LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>). This was also true at six months off-training, MD 10.00 counts per min (95% CI -98.04 to 118.04) and at 18 months off-training, MD 105.00 (95% CI -34.90 to 244.90) (<LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
<P>Kriemler also reported on moderate to vigorous physical activity (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). No differences existed in the hours of moderate to vigorous physical activity undertaken per week for the anaerobic training and the control groups after three and six months, MD -1.40 hours per week (95% CI -2.93 to 0.13) and MD 0.20 hours per week (95% CI -1.58 to 1.98), respectively (<LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>). No differences were observed at six months off-training, MD -1.10 hours per week (95% CI -2.56 to 0.36) and at 18 months off-training, MD 1.10 hours per week (95% CI -0.85 to 3.05) (<LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>).</P>
<P>Selvadurai measured physical activity levels in a subgroup of 18 participants in the anaerobic training group and 16 participants in the control group (<LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). No differences in physical activity levels (MJ per day) were observed between the intervention and control group at hospital discharge, MD 0.65 MJ per day (95% CI -0.86 to 2.16) (<LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>).</P>
<P>Klijn reported no differences between the anaerobic training and control group in habitual physical activity levels after 12 weeks (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>). A subgroup of participants (anaerobic n = 18; control n = 16) who completed an activity diary and wore an activity accelerometer showed no significant differences for between group comparisons in habitual activity at follow-up (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Body composition</HEADING>
<P>Outcomes related to changes in body composition were reported in three studies (n = 86) (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>).</P>
<P>Selvadurai reported a significantly greater change in weight at hospital discharge in the training group compared to the control group, MD 1.73 kg (95% CI 1.35 to 2.11) and one month after discharge, MD 1.65 kg (95% CI 1.24 to 2.06) (<LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
<P>Kriemler reported had lower values for BMI in the control group at all time points during the study: at three months, MD 0.50 kg/m² (95% CI 0.07 to 0.93); after six months, MD 0.70 kg/m² (95% CI 0.27 to 1.13); after six months off-training, MD 1.10 kg/m² (95% CI 0.45 to 1.75); and after 18 months off-training, MD 1.30 kg/m² (95% CI 0.34 to 2.26) (<LINK REF="CMP-002.19" TYPE="ANALYSIS">Analysis 2.19</LINK>).</P>
<P>Kriemler and Selvadurai both reported fat-free mass (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Selvadurai reported a significant difference favouring the training group at hospital discharge, MD 1.80 kg (95% CI 1.57 to 2.03) and again one month after discharge MD 1.71 kg (95% CI 1.46 to 1.96). Kriemler observed no significant differences in fat-free mass between groups after three months, MD 0.70 kg (95% CI -0.34 to 1.74). However, significantly higher values for fat-free mass favouring the exercise group were found after six months, MD 1.50 kg (95% CI 0.08 to 2.92); after six months off-training, MD 2.00 kg (95% CI 0.14 to 3.86) and after 18 months off-training, MD 3.20 kg (95% CI 1.02 to 5.38) (<LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>).</P>
<P>Only one study reported on body fat as a % of the whole (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). No differences between groups in % body fat were reported after three and six months, MD 1.20% (95% CI -0.26 to 2.66) and MD 0.80% (95% CI -0.85 to 2.45), respectively. This was also true after six months off-training, MD 1.70% (95% CI -0.14 to 3.54) and 18 months off-training, MD 1.10% (95% CI -1.65 to 3.85), respectively (<LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>).</P>
<P>Klijn reported that there was no significant difference in change in body composition between the groups at end of the training period, but no data were available for analysis (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Acute exacerbations</HEADING>
<P>No data were reported for this outcome in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Antibiotic use</HEADING>
<P>No data were reported for this outcome in any of the studies.</P>
<P>
<B>9. Bone health </B>
</P>
<P>No data were reported for this outcome in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10. Diabetic control</HEADING>
<P>No data were reported for this outcome in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11. Compliance with physical exercise training</HEADING>
<P>Two studies reported on compliance (n = 42) (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>). In the study by Klijn, the mean (SD) attendance rate at exercise sessions was 98.1% (4.3) with reasons for absence being holidays or sickness (<LINK REF="STD-Klijn-2004" TYPE="STUDY">Klijn 2004</LINK>).</P>
<P>The Kriemler study reported on overall training compliance for the study groups, but not separately for the different groups. Overall, the training groups fulfilled at least 65% of all training sessions (i.e. two out of three sessions per week) and 80% of all participants performed the requested three training sessions per week (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12. Adverse events</HEADING>
<P>The Kriemler study (n = 22) reported that no adverse effects (e.g. injuries, pneumothorax, asthma attacks, hypoglycaemia) occurred during the study (moderate-quality evidence) (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Combined aerobic and anaerobic training versus no training</HEADING>
<P>Seven studies with 257 participants are included in this comparison (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>).</P>
<P>Additional data were provided by the authors of the two Santana-Sosa studies, which included 42 participants (<LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>; <LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). However, due to inconsistencies between the data provided and the published results, the results for these studies are not formally included in this review. Published results of the two studies are summarised in the additional tables (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). These results showed significant group x time interactions for VO<SUB>2</SUB> peak and muscle strength in the training compared to the control group after eight weeks of training. In one study, during a four-week detraining period, when no exercise training was performed, VO<SUB>2</SUB> peak decreased to pre-training values but muscle strength was maintained (<LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>). In the second study, which combined aerobic and anaerobic training with respiratory muscle training, the improvements in VO<SUB>2</SUB> peak and muscle strength were largely preserved during the four-week detraining period (<LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). In this later study, respiratory muscle strength (PI<SUB>max</SUB>) improved in the intervention group after eight weeks (<LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>), while the earlier study without respiratory muscle training did not show any effects on PI<SUB>max</SUB> (<LINK REF="STD-Santana_x002d_Sosa-2012" TYPE="STUDY">Santana-Sosa 2012</LINK>). One of the studies showed a group x time interaction effect for fat mass and fat-free mass (% of total) (<LINK REF="STD-Santana_x002d_Sosa-2014" TYPE="STUDY">Santana-Sosa 2014</LINK>). In both studies, exercise training did not have any effect on pulmonary function or HRQoL.</P>
<P>The study by Beaudoin published within-group changes for the exercise and control group from baseline to 12 weeks (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). The investigators provided us with participant-level data allowing us to calculate values for the change from baseline measurements for all relevant outcomes by intervention group. We note that, for this reason, the results presented in the review are different from the results presented in the published report (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). There were several methodological inadequacies in this study (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for further details), including that the study was originally designed as a cross-over study but the authors present only the first period as if it was a parallel study. The study also did not reach the target sample size so is likely to be underpowered. For these reasons, we have not combined results from the Beaudoin study with any other results and we encourage that the results from this study should be interpreted with caution (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Exercise capacity by VO<SUB>2</SUB> peak</HEADING>
<P>These outcomes were reported in two studies (n = 52) using a maximal cardiopulmonary exercise test on a cycle ergometer (low-quality evidence) (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
<P>Hebestreit reported the change from baseline to the three-month to six-month assessment period and observed significantly higher values for VO<SUB>2</SUB> peak, in the training compared to the control group, MD 2.04 mL/min per kg body weight (95% CI 0.08 to 4.00). During the follow-up period, no differences between groups were observed six months off-training, MD 0.70 mL/min per kg body weight (95% CI -1.61 to 3.01), but a significantly higher VO<SUB>2</SUB> peak was found in the training compared to the control group after 12 to 18 months off-training, MD 3.73 mL/min per kg body weight (95% CI 1.32 to 6.14) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>).</P>
<P>In the Beaudoin study, no between group differences were found for VO<SUB>2</SUB> peak after 12-weeks, MD -2.13 mL/min per kg body weight (95% CI -4.93 to 0.67) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Pulmonary function (FEV<SUB>1</SUB>)</HEADING>
<P>This outcome was reported in four studies (n = 144) (low-quality evidence) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). Results on FEV<SUB>1</SUB> were not reported in detail in the original paper by Hebestreit (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>).</P>
<P>Three studies (n = 100) reported FEV<SUB>1</SUB> % predicted (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). At three months, Rovedder observed no between-group differences after three months, MD -4.00% (95% CI -11.86 to 3.86) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). Our calculations using the data from the Beaudoin study, also showed no differences between groups for FEV<SUB>1</SUB> % predicted at this time point, MD -0.75% (95% CI -5.62 to 4.12) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). After three to six months, Hebestreit also reported no between-group differences in FEV<SUB>1</SUB> % predicted, MD 2.00% (95% CI -5.31 to 9.31). Hebestreit also found no differences in FEV<SUB>1</SUB> % predicted at six months and 12 to 18 months off-training, MD -1.10% (95% CI -8.69 to 6.49) and MD 3.60 (95% CI -4.37 to 11.57), respectively (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>) (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>).</P>
<P>Moorcroft reported the annual change in FEV<SUB>1</SUB> (mL) (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>). This study showed no significant change in FEV<SUB>1</SUB> after one year of training compared to the control group, MD 107.00 mL (95% CI -73.98 to 287.98) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Health-related quality of life</HEADING>
<P>This outcome was reported in three studies (n = 93) (very low-quality evidence). All studies used the disease-specific questionnaire the Cystic Fibrosis Questionnaire (CFQ) to assess HRQoL (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>); the Rovedder study applied an additional questionnaire (Medical Outcomes Study-36 Item Short-Form Health Survey, SF-36) (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>).</P>
<P>In the Beaudoin study, no differences were observed in any single HRQoL scale between the training and control group after 12 weeks (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>): physical functioning, MD -0.04 (95% CI -4.35 to 4.27); vitality, MD 0.38 (95% CI -0.78 to 1.53); emotional state, MD -1.17 (95% CI -2.78 to 0.45); treatment burden, MD -0.50 (95% CI -2.17 to 1.17); health perception, MD -0.50 (95% CI -1.93 to 0.93); social limitations, MD -1.38 (95% CI -3.28 to 0.53); body image, MD -0.54 (-1.88 to 0.80); role limitations, MD 0.54 (95% CI -1.13 to 2.21); respiratory symptoms, MD -0.58 (95% CI -3.51 to 2.35); digestion symptoms, MD 1.33 (95% CI -0.49 to 3.16) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). Effect estimates (MD and 95% CIs) are not estimable for the scales eating disturbances and weight problems as mean (SD) change values for all participants in the control group were zero.</P>
<P>In the study by Hebestreit, the HRQoL subscale of "subjective health perception" was higher in the training compared to the control group after three to six months, MD 9.91 (95% CI 0.89 to 18.93) (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>). No differences between groups were found six months off-training, MD -2.31 (95% CI -15.46 to 10.84), while there were significant between group differences at 12 to 18 months off-training, MD 9.89 (95 % CI 0.64 to 19.14). No other HRQoL scales were significantly different between groups (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). Results for the other HRQoL scales were reported as non-significant for all time points in the original paper (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>).</P>
<P>In the study by Rovedder, no differences were found in any single HRQoL scale between the training and control group in either the CFQ-R or the SF-36 questionnaire after three months (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). Data for each single HRQoL scale were reported for both questionnaires in the original publication. The data were presented as medians (interquartile range) in the publication and could not be analysed in the review. Data are presented in additional tables (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. CF-related mortality</HEADING>
<P>No data were reported for this outcome in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Muscle strength and anaerobic exercise capacity</HEADING>
<P>These outcomes were reported in the publications of two studies (n = 55) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>); Data on anaerobic capacity were not reported in detail in the original paper by Hebestreit (n = 32), but additional data have been made available by the study investigators (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>).</P>
<P>Beaudoin measured muscle strength (leg press, chest press, latpull down and biceps curl) using the 1RM test; muscle endurance was assessed using different exercises (push-up, sit-up, flexibility and handgrip-strength) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). After 12 weeks, there were no between-group differences in leg press, MD 19.26 kg (95% CI -7.33 to 45.85) (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>); chest press, MD 3.14 (95% CI -5.64 to 11.91) (<LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>); latpull down, MD 1.95 kg (95% CI -2.80 to 6.70) (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>) and biceps curl, MD -1.09 kg (95% CI -3.20 to 1.03) (<LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>). Moreover, no between-group differences were found for the number of push ups, MD 7.18 (95% CI -13.7 to 15.73) (<LINK REF="CMP-003.13" TYPE="ANALYSIS">Analysis 3.13</LINK>); the number of sit-ups, MD 6.07 (95% CI -2.26 to 14.41) (<LINK REF="CMP-003.14" TYPE="ANALYSIS">Analysis 3.14</LINK>); flexibility, MD -1.96 cm (95% CI -15.64 to 11.71) (<LINK REF="CMP-003.15" TYPE="ANALYSIS">Analysis 3.15</LINK>) and handgrip strength, MD -5.92 kg (95% CI -18.48 to 6.63) (<LINK REF="CMP-003.16" TYPE="ANALYSIS">Analysis 3.16</LINK>). In the original study, Beaudoin reported significantly higher values for leg press, chest press and the number of push-ups in the exercise group after 12 weeks of training (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
<P>Hebestreit measured anaerobic capacity measured by a WAnT (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>). After three to six months, no differences were observed for peak power, MD -0.44 W per kg body weight (95% CI -0.98 to 0.10); there were also no differences between groups found during the follow-up period at six months and 12 to 18 months off-training, MD -0.43 W per kg body weight (95% CI -2.23 to 1.37) and MD 0.37 W per kg body weight (95% CI -0.66 to 1.40), respectively (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>). The results reported for mean power were also not significant between the training and control group at three to six months, MD -0.22 W per kg body weight (95% CI -0.58 to 0.14); six months off-training, MD -0.08 W per kg body weight (95% CI -0.94 to 0.78) and 12 to 18 months off-training, MD 0.17 W per kg body weight (95% CI -0.34 to 0.68) (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</P>
<P>Rovedder measured muscle strength of elbow flexors and knee extensors using the one repetition maximum (1RM) strength test (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). After three months, the training group had significantly higher values compared to the control group for right upper limb muscle strength, MD 1.00 kg (95% CI 0.15 to 1.85) and left upper limb muscle strength, MD 1.40 kg (95% CI 0.33 to 2.47) (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>). A significant difference between groups was also observed for left lower limb muscle strength, MD 1.60 kg (95% CI 0.15 to 3.05), but not for right lower limb muscle strength, MD 1.10 kg (95% CI -0.51 to 2.71) (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>). In the original paper by Rovedder, differences of left lower limb muscle strength among groups did not reach statistical significance (P value &gt; 0.05) (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Additional indices of exercise capacity</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Peak work capacity</HEADING>
<P>One study reported changes in peak work capacity (n = 38) (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>). This study found significantly higher values for peak work capacity in the training compared to the control group after three to six months, MD 0.25 W/kg body weight (95% CI 0.03 to 0.47) (<LINK REF="CMP-003.17" TYPE="ANALYSIS">Analysis 3.17</LINK>). During the follow-up period, no differences were found six months off-training, MD 0.19 W/kg body weight (95% CI -0.03 to 0.41), but significantly higher values in favour for the exercise training group were observed between 12 and 18 months off-training, MD 0.37 W/kg body weight (95% CI 0.15 to 0.59) (<LINK REF="CMP-003.17" TYPE="ANALYSIS">Analysis 3.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Functional exercise capacity</HEADING>
<P>Rovedder (n = 41) assessed changes in functional exercise capacity after physical training using a six-minute walk test (6MWT) (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). After three months of combined aerobic and strength training no differences were observed in walk distance, MD -0.80 m (95% CI -24.59 to 22.99) or the change in % predicted walking distance, MD 1.90% (95% CI -3.01 to 6.81) (<LINK REF="CMP-003.18" TYPE="ANALYSIS">Analysis 3.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Heart rate</HEADING>
<P>Two studies (n = 92) reported on heart rate (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). Rovedder did not observe any between group differences in peak heart rate at the end of the 6MWT, MD 4.70 bpm (95% CI -9.17 to 18.57) (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>) (<LINK REF="CMP-003.19" TYPE="ANALYSIS">Analysis 3.19</LINK>). Moorcroft reported on the heart rate response which was measured at the end of an identical constant work rate of 55% of participants' maximal workload at baseline on an incremental arm and bicycle ergometry (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>). The study showed a significant reduction in heart rate in favour of the training group at the pre-defined cycling intensity, MD -8.20 bpm (95% CI -15.61 to -0.79), but not during arm ergometry, MD -1.40 bpm (95% CI -10.20 to 7.40) (<LINK REF="CMP-003.20" TYPE="ANALYSIS">Analysis 3.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Ventilation</HEADING>
<P>Moorcroft (n = 51) also reported the annual change in peak ventilation (VE) (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>). There was no significant reduction in VE in the training group compared to the control group during during whole body cycle ergometry, MD -2.50 L/min (95% CI -6.11 to 1.11), but a significant reduction during arm ergometry, MD -3.30 L/min (95% CI -6.40 to -0.20) (<LINK REF="CMP-003.21" TYPE="ANALYSIS">Analysis 3.21</LINK>).</P>
<P>Beaudoin reported VE during maximal cardiopulmonary exercise testing (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). After 12 weeks, there were no between-group differences in VE, MD -6.74 L/min (95% CI -17.35 to 3.87) (<LINK REF="CMP-003.22" TYPE="ANALYSIS">Analysis 3.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Lactate levels</HEADING>
<P>Only Moorcroft (n = 51) reported on lactate levels (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>). Lactate levels decreased significantly during whole body ergometry, MD -0.83 mmol/L (95% CI -1.54 to -0.12), but not during arm ergometry, MD -0.32 mmol/L (95% CI -1.14 to 0.50) (<LINK REF="CMP-003.23" TYPE="ANALYSIS">Analysis 3.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Respiratory rate and respiratory exchange ratio</HEADING>
<P>Two studies (n = 92) reported on respiratory rate (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). At three months Rovedder reported no significant difference in respiratory rate during the 6MWT, MD -1.00 (95% CI -5.56 to 3.56) (<LINK REF="CMP-003.24" TYPE="ANALYSIS">Analysis 3.24</LINK>). Moorcroft also reported no significant changes in respiratory rate at one year either for whole body bicycle ergometry, MD -0.80 (95% CI -4.90 to 3.30), or arm ergometry, MD 1.50 (95% CI -3.11 to 6.11) (<LINK REF="CMP-003.25" TYPE="ANALYSIS">Analysis 3.25</LINK>).</P>
<P>Only Moorcroft presented data for the annual change in respiratory exchange ratio (RER) (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>). No significant differences were identified for either testing modalities; whole body, MD 0.02 (95% CI -0.02 to 0.06) and arm ergometry, MD 0.00 (95% CI -0.04 to 0.04) (<LINK REF="CMP-003.26" TYPE="ANALYSIS">Analysis 3.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Oxygen saturation</HEADING>
<P>One study measuring oxygenation at rest and at the end of a 6MWT report on oxygen saturation by ear or finger oximetry (n = 41) (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). After the three-month intervention no differences in resting oxygen saturations (SaO<SUB>2</SUB>) were found between the exercise and control group, MD 0.90 % (95% CI -0.15 to 1.95); or at the end of the 6MWT, MD 2.60 % (95% CI -0.11 to 5.31) (<LINK REF="CMP-003.27" TYPE="ANALYSIS">Analysis 3.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Breathlessness and fatigue</HEADING>
<P>Two studies reported on breathlessness and fatigue using the Borg scales (n = 92) (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>).</P>
<P>Rovedder reported on breathlessness and fatigue after a three-month intervention (<LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). No differences between the exercise and control groups were observed either at rest, MD 0.00 (95% CI -0.38 to 0.38) and during the 6MWT, MD -0.10 (95% CI -1.31 to 1.11) (<LINK REF="CMP-003.28" TYPE="ANALYSIS">Analysis 3.28</LINK>). Moorcroft reported on the annual change in breathlessness score (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>). No significant reduction was shown by the Moorcroft study data for Borg scale scores between the training compared to the control groups either during bicycle ergometry, MD 0.00 (95% CI -1.00 to 1.00) or during arm ergometry, MD -0.90 (95% CI -1.90 to 0.10) (<LINK REF="CMP-003.29" TYPE="ANALYSIS">Analysis 3.29</LINK>).</P>
<P>Furthermore, Rovedder found no differences between groups in Borg fatigue scale either at rest, MD 0.02 (95% CI -0.50 to 0.54) or during the 6MWT, MD -0.60 (95% CI -1.87 to 0.67) (<LINK REF="CMP-003.30" TYPE="ANALYSIS">Analysis 3.30</LINK>). Moorcroft also found no difference between the training group compared to the control group in the change scores for muscle fatigue during bicycle ergometry, MD -0.30 (95% CI -1.50 to 0.90) or during arm ergometry, MD 0.30 (95% CI -0.99 to 1.59) (<LINK REF="CMP-003.31" TYPE="ANALYSIS">Analysis 3.31</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Additional indices of pulmonary function and respiratory muscle strength</HEADING>
<P>This outcome was reported in four studies (n = 144) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>);. Data for RV/TLC were not reported in detail in the original paper by Hebestreit, but the data were made available by the investigators (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>).</P>
<P>Three studies reported FVC % predicted (n = 93) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Rovedder-2014" TYPE="STUDY">Rovedder 2014</LINK>). In the study by Beaudoin, there were no differences in FVC % predicted between the exercise and control group after 12 weeks, MD 3.29 % (95% CI -4.36 to 10.94) (<LINK REF="CMP-003.32" TYPE="ANALYSIS">Analysis 3.32</LINK>); for the reasons already stated above, we have not combined the data from this study with other studies. In the study by Rovedder, no between-group differences were observed after three months, MD -3.30 (95% CI -11.73 to 5.13) (<LINK REF="CMP-003.32" TYPE="ANALYSIS">Analysis 3.32</LINK>) Hebestreit, too, found no difference between training and control group after three to six months, MD 0.50% (95% CI -4.30 to 5.30); and six months off-training, MD 2.71 (95% CI -4.37 to 9.79). However, the difference between groups was significant at 12 to 18 months off-training, MD 6.06 (95% CI 0.43 to 11.69) (<LINK REF="CMP-003.32" TYPE="ANALYSIS">Analysis 3.32</LINK>).</P>
<P>The study by Moorcroft showed a significant improvement in the annual change in FVC (mL) in the training group compared to the control group, MD 213.00 mL (95% CI 3.01 to 422.99) (<LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>) (<LINK REF="CMP-003.33" TYPE="ANALYSIS">Analysis 3.33</LINK>).</P>
<P>Additionally, Hebestreit measured RV/TLC; there was no observed difference between groups after three to six months, MD -0.90% (95% CI -6.73 to 4.93), six months off-training, MD -2.20% (95% CI -11.33 to 6.93) and 12 to 18 months off-training, MD -4.90% (95% CI -13.68 to 3.88) (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>) (<LINK REF="CMP-003.34" TYPE="ANALYSIS">Analysis 3.34</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Physical activity</HEADING>
<P>This outcome was reported in one study using accelerometry (n = 38) (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>) and in another study using a combination of a physical activity monitor (SenseWear armband) and a physical activity questionnaire (n = 14) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). The instrument used by Beaudoin is available at <A HREF="http://www.ircm.qc.ca/CLINIQUE/educoeur/Documents/questionnaire.pdf">www.ircm.qc.ca/CLINIQUE/educoeur/Documents/questionnaire.pdf</A>; however, the authors of this review are not aware of any study that has validated this physical activity questionnaire in the CF population.</P>
<P>No differences between groups were found in total energy expenditure in the Beaudoin study, MD -108.92 k/cal (95% CI -360.20 to 142.37) (<LINK REF="CMP-003.35" TYPE="ANALYSIS">Analysis 3.35</LINK>); the same was true for the number of daily steps, MD -110.58 (95% CI -2260.72 to 2039.56) (<LINK REF="CMP-003.36" TYPE="ANALYSIS">Analysis 3.36</LINK>). However, after 12 weeks questionnaire-assessed physical activity was significantly higher in the training group compared to the control group, MD 19.85 % (1.92 to 37.80) (<LINK REF="CMP-003.37" TYPE="ANALYSIS">Analysis 3.37</LINK>) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
<P>In the study by Hebestreit, after three to six months, no differences were observed in vigorous physical activity (hours per week) between the training and control group, MD 1.05 hours per week (95% CI -0.66 to 2.76) or after six months off training, MD 2.08 (95% CI -1.84 to 6.00); however, a significant difference favouring the training group was seen after 12 to 18 months off training, MD 1.63 (95% CI 0.02 to 3.24) (<LINK REF="CMP-003.38" TYPE="ANALYSIS">Analysis 3.38</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Body composition</HEADING>
<P>Changes in body composition were reported in three studies (n = 103) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>). Data on body weight, BMI, body fat and fat-free mass were not reported in detail in the original paper by Hebestreit, but were additionally provided and analysed for this review (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>).</P>
<P>Beaudoin reported on body weight and found no differences between groups after 12 weeks, MD -0.27 kg (95% CI -1.76 to 1.22) (<LINK REF="CMP-003.39" TYPE="ANALYSIS">Analysis 3.39</LINK>) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). Hebestreit also reported on total body weight and found no differences between the groups at three to six months, MD 1.10 kg (95% CI -0.42 to 2.62); after six months off training, MD 0.20 (95% CI -2.52 to 2.92); and after 12 to 18 months off training, MD 0.00 (95% CI -3.78 to 3.78) (<LINK REF="CMP-003.39" TYPE="ANALYSIS">Analysis 3.39</LINK>) (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>).</P>
<P>Three studies reported on the change in BMI, but none of the results were significant (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Moorcroft-2004" TYPE="STUDY">Moorcroft 2004</LINK>). In the study by Beaudoin no between group differences were found after 12 weeks, MD 0.10 kg/m² (95% CI -0.61 to 0.80) (<LINK REF="CMP-003.40" TYPE="ANALYSIS">Analysis 3.40</LINK>). Hebestreit reported at three to six months, MD 0.40 kg/m² (95% CI -0.17 to 0.97); after six months off-training, MD 0.00 kg/m² (95% CI -0.78 to 0.78); and after 12 to 18 months off-training, MD -0.10 kg/m² (95% CI -1.12 to 0.92); Moorcroft reported the change at one year, MD 0.54 kg/m² (95% CI -0.09 to 1.17) (<LINK REF="CMP-003.40" TYPE="ANALYSIS">Analysis 3.40</LINK>).</P>
<P>Hebestreit additionally reported on the sum of four skin folds, which was not significantly different between groups at three to six months, MD -1.19 mm (95% CI -4.95 to 2.57); however, there were significant differences favouring the control group both after six months off-training, MD -5.68 mm (95% CI -10.83 to -0.53) and after 12 to 18 months off-training, MD -7.10 mm (95% CI -13.37 to -0.83) (<LINK REF="CMP-003.41" TYPE="ANALYSIS">Analysis 3.41</LINK>).</P>
<P>Hebestreit and Beaudoin further analysed the changes in body fat and fat-free mass (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>). In the study by Beaudoin, after 12 weeks significantly lower values for body fat (%) and fat mass (kg) were found in the exercise group compared to the control group, MD -1.21% (95% CI -2.38 to -0.05) (<LINK REF="CMP-003.42" TYPE="ANALYSIS">Analysis 3.42</LINK>) and 1.09 kg (95% CI -1.80 to -0.39), respectively (<LINK REF="CMP-003.43" TYPE="ANALYSIS">Analysis 3.43</LINK>); however, no difference was found between the two groups for fat-free mass, MD -0.15 kg (95% CI -1.55 to 1.26) (<LINK REF="CMP-003.44" TYPE="ANALYSIS">Analysis 3.44</LINK>) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
<P>In the study by Hebestreit, there were no significant differences at any time point in % body fat: at three to six months, MD 1.30% (95% CI -2.35 to 4.95); after six months off-training, MD -0.50% (95% CI -4.77 to 3.77); and after 12 to 18 months off-training, MD 2.20% (95% CI -3.90 to 8.30) (<LINK REF="CMP-003.42" TYPE="ANALYSIS">Analysis 3.42</LINK>). Likewise, there were no differences between groups in fat-free mass: at three to six months, MD 0.90 kg (95% CI -4.76 to 6.56); after six months off-training, MD 0.70 kg (95% CI -2.08 to 3.48); or after 12 to 18 months off-training, MD -1.40 kg (95% CI -6.86 to 4.06) (<LINK REF="CMP-003.44" TYPE="ANALYSIS">Analysis 3.44</LINK>).</P>
<P>
<B>7. Acute exacerbations</B>
</P>
<P>No data were reported for this outcome in any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Antibiotic use</HEADING>
<P>No data were reported for this outcome in any of the studies.</P>
<P>
<B>9. Bone health</B>
</P>
<P>No data were reported for this outcome in any of the studies.</P>
<P>
<B>10. Diabetic control</B>
</P>
<P>Only Beaudoin reported on this outcome and the investigators have provided additional raw data from the study (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). The outcomes measured were HbA1c and the plasma glucose and insulin response to a two-hour oral glucose tolerance test before and after 12 weeks (very low-quality evidence) (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
<P>No differences in the change in HbA1c were observed between the exercise and control groups, MD -0.00 % (95% CI -0.01 to 0.00) (<LINK REF="CMP-003.45" TYPE="ANALYSIS">Analysis 3.45</LINK>). In our analysis, this was also true for area under the curve for plasma glucose, MD -5.59 (95% CI -13.51 to 2.33) (<LINK REF="CMP-003.46" TYPE="ANALYSIS">Analysis 3.46</LINK>) (in the original publication the authors reported a significant improvement in this outcome for the training group) and area under the curve for plasma insulin, MD -20.02 (95% CI -52.90 to 12.85) (<LINK REF="CMP-003.47" TYPE="ANALYSIS">Analysis 3.47</LINK>). However, after 12 weeks the insulin sensitivity index was significantly higher in the exercise compared to the control group, MD 0.02 (95% CI 0.00 to 0.04) (<LINK REF="CMP-003.48" TYPE="ANALYSIS">Analysis 3.48</LINK>).</P>
<P>The authors of this review further analysed data for plasma glucose and plasma insulin at different time points during the oral glucose tolerance test (time point 0 and 30, 60, 90 and 120 minutes after the oral glucose load). The authors presented these data in figures in the original publication (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>).</P>
<P>Plasma glucose values were not different between groups at time points 0 minutes, MD 0.44 mmol/L (95% CI -0.41 to 1.28); 60 minutes, MD -1.86 mmol/L (95% CI -4.11 to 0.40); and 90 minutes, MD -1.69 mmol/L (95% CI -5.09 to 1.71). Significant differences in favour of the intervention group were noted for the time points 30 minutes after ingestion of the glucose solution, MD -1.96 mmol/L (95% CI -3.58 to -0.33) and at 120 minutes after ingestion of the glucose solution, MD -3.24 mmol/L (95% CI -6.41 to -0.06) (<LINK REF="CMP-003.49" TYPE="ANALYSIS">Analysis 3.49</LINK>). Plasma insulin values were not different between groups at 0 minutes, MD -2.10 µU/mL (95% CI -5.46 to 1.26); at 90 minutes, MD 6.20 µU/mL (95% CI -17.05 to 29.45); and at 120 minutes, MD 2.23 µU/mL (95% CI -13.98 to 18.45). Significant differences in favour for the intervention group were noted for the time points 30 and 60 minutes after the ingestion of the glucose solution, MD -13.90 µU/mL (95% CI -19.47 to -8.33) and MD -12.39 µU/mL (95% CI -22.14 to -2.65), respectively (<LINK REF="CMP-003.50" TYPE="ANALYSIS">Analysis 3.50</LINK>).</P>
<P>The results presented herein are different to the results reported in the original publication by Beaudoin (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). Beaudoin reported within-group changes for plasma glucose and plasma insulin at different time points (Figure 1 A-D in the original publication) during the oral glucose tolerance test for the exercise and control group separately (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). The results presented herein should be interpreted with caution due to the low sample size and high chance for type II error.</P>
<P>
<B>11. Compliance with physical exercise training</B>
</P>
<P>This outcome was reported in two studies (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>; <LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>).</P>
<P>Beaudoin reported that over 80% (n = 8) were compliant to the exercise programme; this information was available from the study diary (<LINK REF="STD-Beaudoin-2017" TYPE="STUDY">Beaudoin 2017</LINK>). Beaudoin excluded one participant from the exercise group due to non-compliance based on self-report and information derived from the study diary; but a definition of "compliance" and "non-compliance" was not provided in the original publication.</P>
<P>In an interim analysis of the INSPIRE-CF study, Douglas reported on participation and attendance and non-attendance (%) in the physical exercise programme (<LINK REF="STD-Douglas-2015" TYPE="STUDY">Douglas 2015</LINK>). Results were only reported for intervention group participants (n = 34) and between-group differences can not be computed for this outcome. Narrative results from the abstract state that overall the mean (SD) attendance was 53.5 (23)% of 52 potential weeks in the first 12 months. Individual attendance ranged between 0% and 92% of sessions. Boys attended more often than girls (58% versus 49%). Major reasons for non-attendance were: no membership with a fitness centre in place (6.4%), family (5.8%) or trainer holidays (6.3%) and unexplained non-attendance (4.5%). Minor reasons were recorded as child illness (3%), hospital admissions or clinic appointments (2.8%), public holidays (2.5%), school events (1.9%), family events (1.7%), staff training (2.3%), with other reasons less than 1% accounting for the remaining missed sessions (3.5%).</P>
<P>
<B>12. Adverse events </B>
</P>
<P>No data were reported for this outcome in any of the studies.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-11-01 16:19:07 +0000" MODIFIED_BY="Nikki Jahnke">
<SUMMARY_OF_RESULTS MODIFIED="2017-11-01 16:18:51 +0000" MODIFIED_BY="Nikki Jahnke">
<P>This systematic review shows limited evidence from both short- and long-term studies that in people with CF aerobic or anaerobic physical exercise training or a combination of both has a positive effect on exercise capacity, pulmonary function and HRQoL. Although improvements are not consistent between studies and ranged from no effects to clearly positive effects the most consistent effects of the heterogeneous exercise training modalities and durations were found for maximal aerobic exercise capacity measured by VO<SUB>2</SUB> peak (in four out of seven studies) with unclear effects on FEV<SUB>1</SUB> (in two out of 11 studies) and HRQoL (in two out of seven studies).</P>
<P>Also, the length of training required to obtain any physiological benefits in CF cannot be defined based on this review, but it is unlikely that training for short periods of less than one month would achieve physiological benefit (<LINK REF="REF-Casaburi-1992" TYPE="REFERENCE">Casaburi 1992</LINK>). Lung function as measured by FEV<SUB>1</SUB> was not responsive of change, except in two studies (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Whether this finding is an indication of true non-responsiveness or rather explained by poor exercise adherence, insufficient exercise training (sub-optimal modality, insufficient frequency, intensity, duration) or by the inappropriate methodology of the current literature (i.e. insufficient power) has to be determined.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-11-01 16:18:57 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The improvement of VO<SUB>2</SUB> peak is of clinical relevance as exercise training addresses low exercise capacity as an important risk factor and strong predictor of mortality in CF (<LINK REF="REF-Nixon-1992" TYPE="REFERENCE">Nixon 1992</LINK>). In order to have any measurable beneficial effect on exercise capacity, exercise training should be performed for at least six weeks, with exercises for an initially tolerable time, but progressing to at least 20 to 30 minutes of exercise at an intensity of 55% to 64% of maximum heart rate, for three to five days a week (<LINK REF="REF-ACSM-2010" TYPE="REFERENCE">ACSM 2010</LINK>). Although many of the included studies were sufficient to achieve a training effect, this condition was not always fulfilled. Yet, no data are available on the minimal important difference of VO<SUB>2</SUB> peak in CF that would provide us with some information about the clinical relevance of improvement in aerobic capacity.</P>
<P>Nevertheless, as the studies in this review recruited mixed populations with regard to age, gender, disease severity and stability, the results have some applicability to the general CF population. Due to the small number and heterogeneity of included studies, we were unable to tease out effects of different length, types (aerobic versus anaerobic versus a combination of both), level of supervision of training, and whether effects were different for subgroups by age, gender, genetical constellation, or severity of disease<B>
<I>.</I>
</B>
</P>
<P>It is possible that more sophisticated functional measures such as pulmonary diffusing capacity and multiple-breath washout may be more sensitive to document subtle, but clinically relevant effects of exercise training on pulmonary function than FEV<SUB>1</SUB>. Furthermore, in the included studies, HRQoL was rarely assessed and if so, mostly by non-validated or generic questionnaires.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-11-01 16:19:01 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Overall, there is very low- to low-quality of evidence that aerobic or anaerobic physical exercise training or a combination of both has positive effects on VO<SUB>2</SUB> peak, FEV<SUB>1</SUB> and HRQoL. We are uncertain about the estimates and further research will very likely have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</P>
<P>It should be highlighted that considerable caution is indicated when interpreting the results of this review. The training modalities and durations were heterogenous, sometimes of very short duration and combined with additional treatments such as intensive physiotherapy, nutritional rehabilitation and intravenous antibiotic treatment in the short-term in-hospital studies (<LINK REF="STD-Cerny-1989" TYPE="STUDY">Cerny 1989</LINK>; <LINK REF="STD-Selvadurai-2002" TYPE="STUDY">Selvadurai 2002</LINK>). Further, most studies showed considerable methodological shortcomings based on the Cochrane risk of bias tool that was used (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>); this may also reflect the inappropriate methodology of the current literature (i.e. insufficient power) in general. All studies had small sample sizes, which puts them at risk of imprecision and lack of power which can work in two ways, i.e. under- or overestimation of intervention effects (<LINK REF="REF-Ellis-2010" TYPE="REFERENCE">Ellis 2010</LINK>).This phenomenon can at least in part be explained by a publication bias, as small studies are unlikely be published if they present negative results (<LINK REF="REF-Hopewell-2009" TYPE="REFERENCE">Hopewell 2009</LINK>).</P>
<P>A lack of effectiveness does not necessarily mean that the treatment was ineffective; especially in longer-term studies, poor adherence to training, which requires precise monitoring, could be a reason for lack of treatment effects. Although standard outcome measures were used in the included studies to assess efficacy of physical exercise training, estimates for the minimal clinically important differences of these outcome measures were not available. Although the effect sizes for some of the outcome measures in this review were statistically significant, the clinical significance of these results remains open to interpretation.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-11-01 16:19:07 +0000" MODIFIED_BY="Nikki Jahnke">
<P>There are some potential biases in the review process that need to be addressed. One important issue is participant selection bias which limits external validity. In 64% of the included full-text articles (where inclusion and exclusion criteria were reported) participants were excluded based on disease severity expressed by FEV<SUB>1</SUB>, which is one of our primary outcome measures. We acknowledge that study investigators are ethically bound to keep potential exercise-induced adverse reactions at a minimum; however, this limits the generalisability of findings to people with mild to moderate CF lung disease and may not be representative to the overall population of people with CF. We have chosen FEV<SUB>1</SUB> and VO<SUB>2</SUB> peak as primary outcomes measures because both are clinically relevant and predictive for mortality in people with CF. Moreover, HRQoL was chosen as important patient-reported outcome. Overall, FEV<SUB>1</SUB> was measured in all and VO<SUB>2</SUB> peak and HRQoL in about half of the included studies, but results were mostly inconclusive. Despite extensive searches it is theoretically possible that we failed to identify studies. However, since the field of researchers publishing on physical exercise training in CF is relatively small and close-knit, we are quite confident that we did not miss any potentially relevant study. In summary, this review includes a limited number of mostly small studies with low to moderate quality and predominantly unclear risk of bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-10-26 11:29:25 +0100" MODIFIED_BY="Tracey Remmington">
<P>To the best of the authors' knowledge, there are no other published systematic reviews on physical exercise training in people with CF. Due to the low number of included studies and the inability to pool study results in this review update, the overall conclusions have not substantially changed compared to the previously published versions of this Cochrane physical training review despite a larger number of included studies (<LINK REF="REF-Bradley-2002" TYPE="REFERENCE">Bradley 2002</LINK>; <LINK REF="REF-Bradley-2008" TYPE="REFERENCE">Bradley 2008</LINK>; <LINK REF="REF-Radtke-2015a" TYPE="REFERENCE">Radtke 2015a</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-11-01 16:19:10 +0000" MODIFIED_BY="Nikki Jahnke">
<IMPLICATIONS_PRACTICE MODIFIED="2017-11-01 16:19:10 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Conclusions about the efficacy of physical exercise training in cystic fibrosis (CF) are limited by the small size, duration and incomplete reporting of most of the studies included in this review. However, there is limited evidence that physical exercise training is beneficial.</P>
<P>The benefits obtained from including physical exercise training in a package of care may be influenced by the type of training programme and the inclusion of aerobic and anaerobic training. Physical exercise training is already part of the regular care offered to most people with CF and there is no evidence to actively discourage this.</P>
<P>In conclusion, the limited number of available studies with low to moderate quality does not allow us to make firm conclusions about the efficacy of physical exercise training on peak oxygen consumption (VO<SUB>2</SUB> peak), forced expiratory volume in one second (FEV<SUB>1</SUB>) and health-related quality of life (HRQoL) (primary outcomes) and other (secondary) outcomes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-10-26 11:30:40 +0100" MODIFIED_BY="Tracey Remmington">
<P>Further research is needed to comprehensively assess the benefits of exercise programmes in people with CF and the relative benefits of the addition of aerobic versus anaerobic versus a combination of both types of physical training to the care of people with CF. There is a need for high-quality randomised controlled studies with sufficient numbers of study participants and well-chosen, objectively measurable, reproducible and sensitive primary outcome measures. Physical exercise training components (type, intensity, duration, and frequency) should be sufficient to elicit beneficial adaptations and should be clearly reported and monitored. There is a lack of studies investigating the effects of physical exercise training on important and clinically relevant outcomes such as bone health, diabetic control and exacerbations, which could be a focus of future work. Investigators should also consider adherence to the training regimens. Moreover, the use of more sophisticated diagnostic techniques such as multiple-breath washout and the measurement of pulmonary diffusing capacity during exercise may improve our understanding about the effects of physical exercise training on pulmonary function in CF. For all outcomes, meaningful and patient-relevant changes of the outcomes need to be determined.</P>
<P>To draw firm conclusions, larger high-quality studies are clearly needed to assess whether exercise training is safe, effective and well-tolerated by people with CF. While exercise training appears to be safe in CF (<LINK REF="REF-Ruf-2010" TYPE="REFERENCE">Ruf 2010</LINK>), safety measures should be implemented in exercise training studies and include the documentation of any (exercise-related) adverse events, pulmonary function, exacerbations and oxygen saturation. Other important outcomes which should be used to measure effectiveness are improved (functional) exercise capacity and HRQoL.</P>
<P>The optimal training components (e.g. type, frequency, intensity, duration) need to be determined in the future by large high-quality studies. Study investigators should carefully select the number and type of study endpoints as a high number of outcomes requiring time-consuming assessments may decrease participants' compliance and on the other hand increase the risk of false-positive results by chance. Besides selecting the clinically relevant and participant-oriented outcomes, testing of the interrelationship of the outcome measures would ascertain whether, for instance, changes in HRQoL correlate with changes in exercise capacity (<LINK REF="REF-Hebestreit-2014" TYPE="REFERENCE">Hebestreit 2014</LINK>).<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-09-15 10:24:54 +0100" MODIFIED_BY="Thomas Radtke">
<P>We would like to thank Dr Judy Bradley and Dr Fidelma Moran, who have stepped down at the 2015 update, for their previous contributions to the review which are detailed below.</P>
<P>We would like to kindly thank Nikki Jahnke from the Cochrane Cystic Fibrosis and Genetics Disorders Group for her guidance and support during the process of writing this review.</P>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-09-15 10:25:53 +0100" MODIFIED_BY="Thomas Radtke">
<P>HH has received financial compensation for travel and accomodation or free meeting participation (or both) at the European Cystic Fibrosis Society conference and the North American Cystic Fibrosis Conference for chairing or presenting at sessions focusing on exercise in cystic fibrosis. For writing an educational booklet on exercise in cystic fibrosis, HH has received money from Novartis. HH is also the lead investigator on one of the studies included in the review (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>). As he is the lead investigator of the international multicentre trial ACTIVATE-CF (<LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>), his institution has received grants from the Mukoviszidose e.V. and a Vertex Innovation Award.</P>
<P>TR belongs to the core study team of the ACTIVATE-CF trial (<LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>). TR has also received financial compensation for chairing and presenting at exercise sessions at the European Cystic Fibrosis Society conference. He has also received financial support (travel, accomodation) from Vifor Pharma Switzerland to participate at the European Cystic Fibrosis Society and European Respiratory Society conference.</P>
<P>SK is the lead investigator on one of the studies included in the review (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>) and also belongs to the core study team of the ACTIVATE-CF trial (<LINK REF="STD-Hebestreit-2016" TYPE="STUDY">Hebestreit 2016</LINK>)</P>
<P>SJN declares no known potential conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-06-03 11:29:36 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The title for the protocol was conceived by the Cochrane Cystic Fibrosis and Genetic Disorders Group.</P>
<P>Both Judy Bradley and Fidelma Moran designed and assisted in writing the protocol and produced the earlier versions of the full review. For updates from 2015, Thomas Radtke and Susi Kriemler were responsible for acquisition of data, analysis and interpretation of data, drafting and critical revision of the manuscript. Sarah Nolan provided statistical support for the 2015 update. All authors provided intellectual input, critically reviewed the manuscript and approved the final version of this updated review.</P>
<P>Thomas Radtke acts as guarantor for this review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-11-01 16:19:17 +0000" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Post hoc changes for the 2017 update</B>
</P>
<P>Summary of findings tables have been added in line with Cochrane guidance.</P>
<P>It was stipulated that the duration of each included study duration should be at least two weeks, which is the typical length of (drug) treatment for pulmonary exacerbations where people with CF may also take part in in-hospital exercise training. Moreover, from an exercise physiology perspective, less than two weeks of structured exercise are unlikely to elicit meaningful changes in the chosen outcomes measures.</P>
<P>We added the lung clearance index (LCI) derived from multiple-breath washout to secondary outcomes "4. Additional indices of pulmonary function and respiratory muscle strength". The LCI is a relatively new and much examined pulmonary function outcome measure and included in many clinical studies including exercise training interventions.</P>
<P>We also added the diffusing capacity for carbon monoxide (DLCO) and the diffusing capacity for nitric oxide (DLNO) to secondary outcomes "4. Additional indices of pulmonary function and respiratory muscle strength". Non-invasive measurement of the pulmonary diffusing capacity can provide novel physiological insights into the exercise training effects on pulmonary function beyond the much examined FEV<SUB>1</SUB>, derived from spirometry.</P>
<P>
<B>Post hoc changes for the 2015 update</B>
</P>
<P>The title of the review has been changed from 'Physical training for cystic fibrosis' to 'Physical exercise training for cystic fibrosis' as the new team felt this better reflected the content of the review.</P>
<P>The fourth primary outcome 'mortality' was moved to secondary outcomes in line with Cochrane guidance to limit the number of primary outcomes to three. For this update, primary and secondary outcome measures were changed as follows:</P>
<P>
<B>Primary outcomes</B>
</P>
<P>We limited the primary outcome measures to:</P>
<OL>
<LI>Exercise capacity by peak oxygen uptake (VO<SUB>2</SUB> peak)</LI>
<LI>Pulmonary function by forced expiratory volume in one second (FEV<SUB>1</SUB>)</LI>
<LI>Health-related quality of life (HRQoL).</LI>
</OL>
<P>In CF, VO<SUB>2</SUB> peak and FEV<SUB>1</SUB> are strong predictors of mortality, objectively measurable and are often used as primary outcomes in studies of physical exercise training. The outcome measure HRQoL is important participant-reported outcome measure and is related to physical fitness in people with CF. None of the other primary outcomes from previous reviews has been shown to be of predictive value in CF and they should be considered explorative endpoints. All previous primary outcomes for pulmonary function are now integrated under the secondary outcome number 4 "Additional indices of pulmonary function and respiratory muscle strength" and exercise capacity variables including effort, oxygenation and fatigue are integrated into the secondary outcome number 3 " Additional indices of exercise capacity".</P>
<P>
<B>Secondary outcomes</B>
<BR/>We removed the secondary outcomes "Symptom scores", "Compliance with other treatment, such as chest physiotherapy, nutritional regimens" and "Cost evaluation". These outcomes are of unclear relevance, difficult to measure reliably and are rarely reported in physical training studies. We added the secondary outcome "Physical activity" because it is an important outcome in exercise training studies. The outcome "Measures of bone mineral density and diabetic control" was separated into "Bone health" and "Diabetic control" because these outcomes are unrelated and should be studied and reported separately. The outcome "Weight" was removed as a separate outcome and is now integrated within the outcome "Body composition" which comprises all measures of nutrition including body weight, body fat and fat-free mass. The secondary outcome "Number of acute exacerbations, intravenous antibiotic courses and time off work or school" was separated as "Acute exacerbations (a) number of exacerbations; (b) time to first exacerbation" and "Antibiotic use (including oral, intravenous or inhaled antibiotics)".</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-09-03 13:17:17 +0100" MODIFIED_BY="Nikki Jahnke"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-11-02 10:17:46 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDIES MODIFIED="2017-08-29 16:06:21 +0100" MODIFIED_BY="Nikki Jahnke">
<INCLUDED_STUDIES MODIFIED="2017-08-09 09:53:04 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Beaudoin-2017" MODIFIED="2017-05-31 16:19:26 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Beaudoin 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-05-31 16:19:18 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beaudoin N, Bouvet GF, Coriati A, Rabasa-Lhoret R, Berthiaume Y</AU>
<TI>Combined exercise training improves glycemic control in adults with cystic fibrosis</TI>
<SO>Medicine and Science in Sports and Exercise</SO>
<YR>2016</YR>
<PG>Supplemental digital content</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="CO62c"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001618"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948883"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-31 16:19:26 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beaudoin N, Bouvet GF, Coriati A, Rabasa-Lhoret R, Berthiaume Y</AU>
<TI>Combined exercise training improves glycemic control in adults with cystic fibrosis</TI>
<SO>Medicine and Science in Sports and Exercise</SO>
<YR>2017</YR>
<VL>49</VL>
<NO>2</NO>
<PG>231-7</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1199954"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="CO62b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001617"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948884"/><IDENTIFIER TYPE="PUBMED" VALUE="27669451"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-31 16:19:18 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beaudoin N, Bouvet GF, Rabasa-Lhoret R, Berthiaume Y</AU>
<TI>Effects of a partially supervised combined exercise program on glycemic control in cystic fibrosis: pilot study</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2015</YR>
<VL>50 Suppl 41</VL>
<PG>367</PG>
<PB>John Wiley and Sons Inc</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="466"/><IDENTIFIER TYPE="CENTRAL" VALUE="1092169"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="CO62a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001365"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948885"/><IDENTIFIER TYPE="EMBASE" VALUE="72081745"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948882"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cerny-1989" MODIFIED="2015-05-13 09:37:05 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Cerny 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-05-13 09:37:05 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerny FJ</AU>
<TI>Relative effects of bronchial drainage and exercise for in-hospital care of patients with cystic fibrosis</TI>
<SO>Physical Therapy</SO>
<YR>1989</YR>
<VL>69</VL>
<NO>8</NO>
<PG>633-9</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:37:05 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:37:05 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE13"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647921"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647920"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Douglas-2015" MODIFIED="2017-05-31 16:23:52 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Douglas 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-05-31 16:23:38 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Douglas H, Ledger S, Main E, Sarria Jaramillo L, Rayner P, Goldman A, et al</AU>
<TI>INSPIRE-CF: An interim review of participation of children with cystic fibrosis randomised to a weekly supervised exercise intervention</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2015</YR>
<VL>14 Suppl 1</VL>
<PG>S97</PG>
<PB>Elsevier</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="152"/><IDENTIFIER TYPE="CENTRAL" VALUE="1081484"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE218a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000000025"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948887"/><IDENTIFIER TYPE="EMBASE" VALUE="71951805"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-31 16:23:52 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ledger SJ, Douglas H, Sarria Jaramillo L, Rayner P, Aurora P, Main E</AU>
<TI>INSPIRE-CF: levels of participation of children with cystic fibrosis randomised to a 24-month weekly supervised exercise intervention</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2016</YR>
<VL>15 Suppl 1</VL>
<PG>S44</PG>
<PB>Elsevier</PB>
<CY>Netherlands</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="ePS04.5"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE218b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001550"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948888"/><IDENTIFIER TYPE="EMBASE" VALUE="614323554"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-31 16:23:52 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ledger SJ, Wade A, Douglas H, Sarria Jaramillo L, Rayner P, Goldman A, et al</AU>
<TI>Interim results for INSPIRE-CF: A 24-month randomised trial evaluating effects of a weekly exercise intervention for children with cystic fibrosis</TI>
<SO>Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society</SO>
<YR>2016</YR>
<VL>15 Suppl 1</VL>
<PG>S88</PG>
<PB>Elsevier</PB>
<CY>Netherlands</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="144"/><IDENTIFIER TYPE="CENTRAL" VALUE="1171475"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE218c"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001590"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948889"/><IDENTIFIER TYPE="EMBASE" VALUE="614323655"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948886"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hebestreit-2010" MODIFIED="2015-05-13 09:51:23 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Hebestreit 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-13 09:38:24 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hebestreit A, Kriemler S, Kieser S, Junge S, Heilmann M, Ballmann M, et al</AU>
<TI>Effects of different conditioning programmes on aerobic capacity in CF [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>Suppl 25</NO>
<PG>329</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:38:24 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:38:24 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE145a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647923"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 09:40:47 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hebestreit H, Kieser S, Junge S, Ballmann M, Hebestreit A, Schindler C, et al</AU>
<TI>Long-term effects of a partially supervised conditioning programme in cystic fibrosis</TI>
<SO>European Respiratory Journal</SO>
<YR>2010</YR>
<VL>35</VL>
<NO>3</NO>
<PG>578-83</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:40:47 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:40:47 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE145b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647924"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 09:51:23 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hebestreit H, Schmid K, Kieser S, Junge S, Ballmann M, Roth K et al</AU>
<TI>Quality of life is associated with physical activity and fitness in cystic fibrosis</TI>
<SO>BMC Pulmonary Medicine</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>26</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:51:23 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:51:23 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE145c//PE120c"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647925"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647922"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hommerding-2015" MODIFIED="2015-05-13 09:59:53 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Hommerding 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-05-12 16:27:38 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hommerding PX, Baptista RR, Makarewicz GT, Schindel CS, Donadio MVF, Pinto LA et al</AU>
<TI>Effects of an educational intervention of physical activity for children and adolescents with cystic fibrosis: a randomized controlled study</TI>
<SO>Respiratory Care</SO>
<YR>2015</YR>
<VL>60</VL>
<NO>1</NO>
<PG>81-7</PG>
<IDENTIFIERS MODIFIED="2015-05-12 16:27:38 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-12 16:27:38 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE194b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647927"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-12 16:26:46 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marostica PJ, Hommerding P, Makarewicz G, Baptista R, Donadio MV</AU>
<TI>Efficacy of an educational intervention of physical activity for children and adolescents with cystic fibrosis [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2012</YR>
<VL>11 Suppl 1</VL>
<PG>S36, Abstract no: WS16.6</PG>
<IDENTIFIERS MODIFIED="2015-05-12 16:26:46 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-12 16:26:46 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE194a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647928"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 09:59:53 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schindel CS, Hommerding PX, Melo DAS, Baptista RR, Marostica PJC, Donadio MVF</AU>
<TI>Physical exercise recommendations improve postural changes found in children and adolescents with cystic fibrosis: a randomized controlled trial</TI>
<SO>Journal of Pediatrics</SO>
<YR>2015</YR>
<VL>166</VL>
<NO>3</NO>
<PG>710-6</PG>
<IDENTIFIERS MODIFIED="2015-05-12 16:27:29 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-12 16:27:29 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE194c"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647929"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647926"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klijn-2004" MODIFIED="2015-05-13 09:43:56 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Klijn 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-05-13 09:43:56 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klijn PH, Oudshoorn A, van der Ent CK, ann der Net J, Helders PJ</AU>
<TI>Effects of anaerobic training in children with cystic fibrosis: a randomised controlled study</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>125</VL>
<NO>4</NO>
<PG>1299-305</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:43:56 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:43:56 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE147"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647931"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647930"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kriemler-2013" MODIFIED="2015-05-13 09:52:22 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Kriemler 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-05-13 09:51:45 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hebestreit H, Schmid K, Kieser S, Junge S, Ballmann M, Roth K et al</AU>
<TI>Quality of life is associated with physical activity and fitness in cystic fibrosis</TI>
<SO>BMC Pulmonary Medicine</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>26</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:51:45 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:51:45 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE145c//PE120c"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647933"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 09:52:14 +0100" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Kriemler S, Hebestreit A, Kieser S, Bachmann M, Hebestreit H. Six months of training improves lung function and aerobic performance in CF [abstract]. Abstracts of the 24th European Cystic Fibrosis Conference 6-9 June 2001; Vienna, Austria 2001; P62.CCT&lt;/p&gt;" NOTES_MODIFIED="2015-05-13 09:52:14 +0100" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kriemler S, Hebestreit A, Kieser S, Bachmann M, Hebestreit H</AU>
<TI>Six months of training improves lung function and aerobic performance in CF [abstract]</TI>
<SO>Abstracts of the 24th European Cystic Fibrosis Conference 6-9 June 2001; Vienna</SO>
<YR>2001</YR>
<PG>P62</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:52:14 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:52:14 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE120a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647934"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 09:52:22 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kriemler S, Kieser S, Junge S, Ballmann M, Hebestreit A, Schindler C, et al</AU>
<TI>Effect of supervised training on FEV<SUB>1</SUB> in cystic fibrosis: A randomised controlled trial</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2013</YR>
<VL>12</VL>
<NO>6</NO>
<PG>714-20</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:52:22 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:52:22 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE120b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647935"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-02-04 14:17:16 +0000" MODIFIED_BY="Thomas Radtke"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647932"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michel-1989" MODIFIED="2015-05-13 09:59:10 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Michel 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-05-13 09:59:10 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michel SH, Darbee JC, Pequignot E</AU>
<TI>Exercise, body composition and strength in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1989</YR>
<VL>Suppl 4</VL>
<PG>116</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:59:10 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:59:10 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE40"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647937"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647936"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moorcroft-2004" MODIFIED="2015-05-13 09:58:47 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Moorcroft 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-05-13 09:58:47 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dodd ME, Moorcroft AJ, Webb AK</AU>
<TI>Improved fitness and decreased symptoms of muscle fatigue for upper and lower body following an individualised unsupervised home exercise training programme in adults with cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1998</YR>
<VL>Suppl 17</VL>
<PG>347</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:58:47 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:58:45 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE97a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647939"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 09:58:26 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moorcroft AJ, Dodd ME, Morris J, Webb AK</AU>
<TI>Individualised unsupervised exercise training in adults with cystic fibrosis: a 1 year randomised controlled trial</TI>
<SO>Thorax</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>12</NO>
<PG>1074-80</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:58:26 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:58:26 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE97c"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647940"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 09:58:11 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Moorcroft AJ, Dodd ME, Webb AK</AU>
<TI>Individualised home exercise training in CF - a one-year trial [abstract]</TI>
<SO>Proceedings of the XIIIth International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden</SO>
<YR>2000</YR>
<PG>153</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:58:11 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:58:11 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE97b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647941"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647938"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rovedder-2014" MODIFIED="2015-05-13 09:57:28 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Rovedder 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-05-13 09:57:28 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rovedder PM, Flores J, Ziegler B, Casarotto F, Jaques P, Baretto SS, et al</AU>
<TI>Exercise programme in patients with cystic fibrosis: A randomized controlled trial</TI>
<SO>Respiratory Medicine</SO>
<YR>2014</YR>
<VL>108</VL>
<NO>8</NO>
<PG>1134-40</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:57:28 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:57:28 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE214"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647943"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647942"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santana_x002d_Sosa-2012" MODIFIED="2015-05-13 09:54:00 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Santana-Sosa 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-05-13 09:54:00 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santana-Sosa E, Groeneveld IF, Gonzalez-Saiz L, Lopez-Mojares LM, Villa-Asensi JR, Barrio Gonzalez MI, et al</AU>
<TI>Intrahospital weight and aerobic training in children with cystic fibrosis: a randomized controlled trial</TI>
<SO>Medicine and Science in Sports and Exercise</SO>
<YR>2012</YR>
<VL>44</VL>
<NO>1</NO>
<PG>2-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE191"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647945"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647944"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santana_x002d_Sosa-2014" MODIFIED="2015-05-13 09:05:14 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Santana-Sosa 2014" YEAR="2013">
<REFERENCE MODIFIED="2015-05-13 09:04:46 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santana-Sosa E, Gonzalez-Saiz L, Groeneveld IF, Villa-Asensi JR, Barrio Gomez de Aguero MI, Fleck SJ, et al</AU>
<TI>Benefits of combining inspiratory muscle with 'whole muscle' training in children with cystic fibrosis: a randomised controlled trial</TI>
<SO>British Journal of Sports Medicine</SO>
<YR>2014</YR>
<VL>48</VL>
<NO>20</NO>
<PG>1513-7</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="874806"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE201"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000097"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647947"/><IDENTIFIER TYPE="PUBMED" VALUE="23681502"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647946"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneiderman_x002d_Walker-2000" MODIFIED="2017-05-08 11:56:56 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Schneiderman-Walker 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-05-08 11:56:56 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papaioannou M</AU>
<TI>A randomized controlled trial of a 3-year home exercise program in cystic fibrosis</TI>
<SO>Pediatric Physical Therapy</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>2</NO>
<PG>94-5</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1343880"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE58c"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001603"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948890"/><IDENTIFIER TYPE="PUBMED" VALUE="17053664"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-31 11:34:27 +0100" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Judy Bradley [01/08/2000][04/03/2003][]; Lisa Morrison [07/09/2007][][]; Cees van der Schans [10/03/2009][][]; Narelle Cox [22/11/2011][][]&lt;/p&gt;" NOTES_MODIFIED="2014-03-31 11:34:27 +0100" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reisman JJ, Schneiderman-Walker J, Corey M, Wilkes D, Pedder L, Levison H, et al</AU>
<TI>The role of an organized exercise program in cystic fibrosis - A three year study [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1995</YR>
<VL>Suppl 12</VL>
<PG>261</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="291537"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE58a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000001555"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647949"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 09:54:43 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schneiderman-Walker J, Pollock SL, Corey M, Wilkes DD, Canny G, Pedder L, et al</AU>
<TI>A randomised controlled trial of a 3-year home exercise program in cystic fibrosis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>136</VL>
<NO>3</NO>
<PG>304-10</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:54:43 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:54:43 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE58b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647950"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647948"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Selvadurai-2002" MODIFIED="2015-05-13 09:56:30 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Selvadurai 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-05-13 09:56:30 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Selvadurai HC, Blimkie CJ, Meyers N, MellisCM, Cooper PJ, Van Asperen PP</AU>
<TI>Randomized controlled study of in-hospital exercise training programs in children with cystic fibrosis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2002</YR>
<VL>33</VL>
<NO>3</NO>
<PG>194-200</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:56:30 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:56:30 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE107b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647952"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 09:56:06 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selvadurai HC, Van Asperen PP, Cooper PJ, Mellis CM, Blimkie CJ</AU>
<TI>A randomised controlled study of in-hospital exercise training programs in children with cystic fibrosis (CF) [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1999</YR>
<VL>Suppl 19</VL>
<PG>287-8</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:56:06 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:56:06 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE107a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647953"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647951"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turchetta-1991" MODIFIED="2015-05-13 09:55:33 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Turchetta 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-05-13 09:55:33 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Turchetta A, Bella S, Calzolari A, Castro M, Ciuffetti C, Drago F, et al</AU>
<TI>Effect of controlled physical activity on lung function test of cystic fibrosis children [abstract]</TI>
<SO>Proceedings of the 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen</SO>
<YR>1991</YR>
<PG>134</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:55:33 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:55:33 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE45"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647955"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647954"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-06-01 12:32:57 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Alarie-2012" MODIFIED="2014-08-08 09:03:04 +0100" MODIFIED_BY="[Empty name]" NAME="Alarie 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-08 09:03:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alarie N, Chan R, Thomas L, Marasco J, Amelie P, Nan W, et al</AU>
<TI>Cardiorespiratory responses to Nintendo Wii in children with cystic fibrosis: a pilot study [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2012</YR>
<VL>47</VL>
<NO>S35</NO>
<PG>367, Abstract no: 399</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE196"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647957"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647956"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albinni-2004" MODIFIED="2008-09-04 12:01:25 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Albinni 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-04 12:01:25 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albinni S, Rath R, Renner S, Eichler I</AU>
<TI>Additional inspiratory muscle training intensifies the beneficial effects of cycle ergometer training in patients with cystic fibrosis [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647959"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eichler I, Renner S, Albinni S, Nachbaur E, Rath R</AU>
<TI>Inspiratory muscle training adds beneficial effects to cycle ergometer training in patients with cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>Suppl 28</NO>
<PG>320</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647960"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647958"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amelina-2006" MODIFIED="2017-05-08 11:54:04 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Amelina 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-05-08 11:54:04 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Amelina E, Cherniak A, Chikina S, Krasovsky S, Appaeva A</AU>
<TI>Inspiratory muscle training (IMT) in cystic fibrosis adults [abstract]</TI>
<SO>Proceedings of European Respiratory Society Annual Congress; 2006 Sep 2-6; Munich, Germany</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2017-05-08 11:54:01 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2017-05-08 11:54:01 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="P4112"/><IDENTIFIER MODIFIED="2017-05-08 11:53:42 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE177a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948891"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-08 11:53:30 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cherniak A, Amelina E, Krasovsky S, Nekludova G, Chikina S</AU>
<TI>The effect of high intensity inspiratory muscle training in adults with cystic fibrosis (CF)</TI>
<SO>European Respiratory Journal</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>Suppl 51</NO>
<PG>767s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="E4514"/><IDENTIFIER TYPE="CENTRAL" VALUE="645383"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE177b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000531"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948892"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647961"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andreasson-1987" NAME="Andreasson 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andreasson B, Jonson B, Kornfalt R, Nordmark E, Sandstrom S</AU>
<TI>Long-term effects of physical exercise on working capacity and pulmonary function in cystic fibrosis</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1987</YR>
<VL>76</VL>
<NO>1</NO>
<PG>70-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647964"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647963"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aquino-2006" MODIFIED="2015-01-22 11:13:12 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Aquino 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-01-22 11:13:12 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aquino A, Balestri E, Dall Ara S, Lami I, Gobb F, Ambroni M, Miano A</AU>
<TI>Efficacy of physical exercise playing a video game for mucus clearance in patients with CF [abstract]</TI>
<SO>Jounal of Cystic Fibrosis</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>Suppl</NO>
<PG>S83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647966"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647965"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asher-1982" MODIFIED="2015-05-13 10:40:02 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Asher 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-05-13 10:40:02 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asher M, Pardy R, Coates A, Thomas E, Macklem PT</AU>
<TI>The effects of inspiratory muscle training in patients with cystic fibrosis [abstract]</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1983</YR>
<VL>13</VL>
<PG>204</PG>
<IDENTIFIERS MODIFIED="2015-05-13 09:17:13 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 09:17:13 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE127a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647968"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-12 16:24:56 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Asher MI, Pardy RL, Coates AL, Thomas E, Macklem PT</AU>
<TI>The effects of inspiratory muscle training in patients with cystic fibrosis</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1982</YR>
<VL>126</VL>
<NO>5</NO>
<PG>855-9</PG>
<IDENTIFIERS MODIFIED="2015-05-12 16:24:54 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-12 16:24:54 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE127b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647969"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647967"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balestri-2004" MODIFIED="2015-01-22 11:16:46 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Balestri 2004" YEAR="">
<REFERENCE MODIFIED="2015-01-22 11:16:46 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Balestri E, Ambroni M, dall'Ara S, Miano A</AU>
<TI>Efficacy of physical exercise for mucus clearance in patients with cystic fibrosis (CF) [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>S27</NO>
<PG>316</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647971"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647970"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balfour-1998" MODIFIED="2015-05-13 11:37:34 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Balfour 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-04-08 14:44:23 +0100" MODIFIED_BY="Thomas Radtke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balfour Lynn IM, Prasad SA, Laverty A, Whitehead BF, Dinwiddie R</AU>
<TI>A step in the right direction: assessing exercise tolerance in cystic fibrosis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>4</NO>
<PG>278-84</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="462732"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE69b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000002462"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647973"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 11:37:34 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balfour-Lynn IM, Prasad SA, Laverty A, Whitehead BF, Dinwiddie R</AU>
<TI>Step-test vs 6-minute walk: Assessing exercise tolerance in children with cystic fibrosis [abstract]</TI>
<SO>Pediatric pulmonology</SO>
<YR>1996</YR>
<VL>Suppl 13</VL>
<PG>305</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:37:34 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:37:34 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE69a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647974"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647972"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barry-2001" MODIFIED="2014-04-09 10:54:15 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Barry 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-04-09 10:54:15 +0100" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Barry S, Dodd J, Jensma M, Gallagher C. Benefits of high intensity strength training in adults with cystic fibrosis [abstract]. American Journal of Respiratory and Critical Care Medicine 2001; 163(5 Suppl):A968&lt;/p&gt;" NOTES_MODIFIED="2014-04-09 10:54:15 +0100" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barry S, Dodd J, Jensma M, Gallagher C</AU>
<TI>Benefits of high intensity strength training in adults with cystic fibrosis [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>5 Suppl</NO>
<PG>A968</PG>
<IDENTIFIERS MODIFIED="2014-04-09 10:54:15 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-09 10:54:15 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE133b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647976"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-09 10:54:01 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barry S, Dodd J, Jensma M, Gallagher C</AU>
<TI>High intensity strength training improves fitness levels in adults with cystic fibrosis [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>8 Suppl</NO>
<PG>A507</PG>
<IDENTIFIERS MODIFIED="2014-04-09 10:54:01 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-09 10:54:01 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE133a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647977"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647975"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bieli-2017" MODIFIED="2017-05-31 16:07:15 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Bieli 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-05-31 16:07:02 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bieli C, Selina S, Demet I, Andreas J, Alexander M</AU>
<TI>Respiratory muscle endurance training in cystic fibrosis</TI>
<SO>European Respiratory Journal</SO>
<YR>2014</YR>
<VL>44</VL>
<NO>Suppl 58</NO>
<PG>P1972</PG>
<PB>European Respiratory Society</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE237b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001917"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948894"/><IDENTIFIER TYPE="EMBASE" VALUE="71851116"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-31 16:07:15 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bieli C, Summermatter S, Boutellier U, Moeller A</AU>
<TI>Respiratory muscle training improves respiratory muscle endurance but not exercise tolerance in children with cystic fibrosis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2017</YR>
<VL>52</VL>
<NO>3</NO>
<PG>331-6</PG>
<PB>John Wiley and Sons Inc. (P.O.Box 18667, Newark NJ 07191-8667, United States)</PB>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1262285"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE237a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001736"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948895"/><IDENTIFIER TYPE="EMBASE" VALUE="614244451"/><IDENTIFIER TYPE="PUBMED" VALUE="28114723"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948893"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bilton-1992" MODIFIED="2015-05-13 11:39:33 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Bilton 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-05-13 11:39:22 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilton D, Dodd M, Webb AK</AU>
<TI>The benefits of exercise combined with physiotherapy in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>Suppl 5</NO>
<PG>238</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:39:22 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:39:22 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE41a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647979"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 11:39:33 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bilton D, Dodd ME, Abbot JV, Webb AK</AU>
<TI>The benefits of exercise combined with physiotherapy in the treatment of adults with cystic fibrosis</TI>
<SO>Respiratory Medicine</SO>
<YR>1992</YR>
<VL>86</VL>
<NO>6</NO>
<PG>507-11</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:39:33 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:39:33 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE41b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647980"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647978"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bongers-2015" MODIFIED="2017-05-31 16:09:11 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Bongers 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-05-31 16:09:11 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bongers BC, Werkman MS, Arets HG, Takken T, Hulzebos HJ</AU>
<TI>A possible alternative exercise test for youths with cystic fibrosis: the steep ramp test</TI>
<SO>Medicine and Science in Sports and Exercise</SO>
<YR>2015</YR>
<VL>47</VL>
<NO>3</NO>
<PG>485-92</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1096730"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE232"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001620"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948897"/><IDENTIFIER TYPE="PUBMED" VALUE="25010405"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948896"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calik_x002d_Kutukcu-2016" MODIFIED="2017-05-31 16:37:09 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Calik-Kutukcu 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-05-31 16:37:09 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calik-Kutukcu E, Saglam M, Vardar-Yagli N, Cakmak A, Inal-Ince D, Bozdemir-Ozel C, et al</AU>
<TI>Listening to motivational music while walking elicits more positive affective response in patients with cystic fibrosis</TI>
<SO>Complementary Therapies in Clinical Practice</SO>
<YR>2016</YR>
<VL>23</VL>
<PG>52-8</PG>
<CY>England</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1199953"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE234"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001601"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948899"/><IDENTIFIER TYPE="PUBMED" VALUE="27157959"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948898"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2015" MODIFIED="2017-05-31 16:21:48 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Chang 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-05-31 16:21:48 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang K, Cotton J, Gashgarian S, Sheppard E, Slack D, Stephenson A, et al</AU>
<TI>Vaildation of clinical assessment tools for leg muscle strength and power in adults with cystic fibrosis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2015</YR>
<VL>50 Suppl 41</VL>
<PG>368</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="469"/><IDENTIFIER TYPE="CENTRAL" VALUE="1092168"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE223"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001364"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948901"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948900"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chatham-1997" MODIFIED="2015-05-13 11:40:54 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Chatham 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-05-13 11:40:54 +0100" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;Chatham, K.//Ionescu, A.//Davies, C.//Baldwin, J.//Enright, S.//Shale, D.J.//&lt;/p&gt;" NOTES_MODIFIED="2015-05-13 11:40:54 +0100" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chatham K, Ionescu A, Davis C, Baldwin J, Enright S, Shale DJ</AU>
<TI>Through range computer generated inspiratory muscle training in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>Suppl 14</NO>
<PG>299</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:40:54 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:40:54 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE90"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647982"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647981"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Jong-1994" NAME="de Jong 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Jong W, Grevink RG, Roorda RJ, Kaptein AA, van der Schans CP</AU>
<TI>Effect of a home exercise training program in patients with cystic fibrosis</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>105</VL>
<NO>2</NO>
<PG>463-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647984"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647983"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-del-Corral-Nunez_x002d_Flores-2011" MODIFIED="2017-05-08 11:51:06 +0100" MODIFIED_BY="Nikki Jahnke" NAME="del Corral Nunez-Flores 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-10-17 10:13:37 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>del Corral Nunez-Flores T, Percegona J, Seborga M, Trujillo N, Hernandez L, Rejas A, et al</AU>
<TI>Exercise physiologic response during three different video games in cystic fibrosis [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2011</YR>
<VL>10 Suppl 1</VL>
<PG>S64, Abstract no: 253</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE190a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647986"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-17 10:13:44 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>del Corral Nunez-Flores T, Percegona J, Seborga M, Trujillo N, Hernandez L, Rejas A, et al</AU>
<TI>Exercise physiologic response during three different video games in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2011</YR>
<VL>46</VL>
<NO>S34</NO>
<PG>353, Abstract no: 389</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE190b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647987"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 11:43:31 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>del Corral T, Percegona J, Seborga M, Rabinovich RA, Vilaro J</AU>
<TI>Physiological response during activity programs using Wii-based video games in patients with cystic fibrosis</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2014</YR>
<VL>13</VL>
<NO>6</NO>
<PG>706-711</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:43:31 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:43:31 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE190c"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948902"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-08 11:51:06 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>del Corral T, Percegona J, Seborga M, Trujillo N, Hernandez L, Rejas A, et al</AU>
<TI>Exercise physiologic response during three different video games in cystic fibrosis patients</TI>
<SO>European Respiratory Journal</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>55</NO>
<PG>878s, Abstract no: P4802</PG>
<PB>European Respiratory Society</PB>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1081933"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE190d"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000474"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948903"/><IDENTIFIER TYPE="EMBASE" VALUE="72122296"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647985"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dwyer-2008" MODIFIED="2015-01-22 11:19:01 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Dwyer 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-01-22 11:19:01 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dwyer T, Alison J, McKeough Z, Daviskas E, Bye P</AU>
<TI>Exercise aids airway clearance by increasing respiratory flow rates and decreasing mucus viscoelasticity in CF [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2008</YR>
<VL>43 Suppl 31</VL>
<PG>386, Abstract no: 513</PG>
<IDENTIFIERS MODIFIED="2015-01-22 09:56:39 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-01-22 09:56:39 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE188"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647990"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647989"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dwyer-2017" MODIFIED="2017-05-31 16:39:51 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Dwyer 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-05-31 16:39:51 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dwyer TJ, Zainuldin R, Daviskas E, Bye PT, Alison JA</AU>
<TI>Effects of treadmill exercise versus Flutter(R) on respiratory flow and sputum properties in adults with cystic fibrosis: a randomised, controlled, cross-over trial</TI>
<SO>BMC Pulmonary Medicine</SO>
<YR>2017</YR>
<VL>17</VL>
<NO>1</NO>
<PG>14</PG>
<CY>England</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE239"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001880"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948905"/><IDENTIFIER TYPE="PUBMED" VALUE="28077104"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948904"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edlund-1986" MODIFIED="2015-05-13 11:45:14 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Edlund 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-05-13 11:45:14 +0100" MODIFIED_BY="Nikki Jahnke" NOTES="&lt;p&gt;No issue number&lt;/p&gt;" NOTES_MODIFIED="2015-05-13 11:45:14 +0100" NOTES_MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adams TD, Edland LL, French RW, Herbst JJ, Ruttenberg HD, Ruhling RO</AU>
<TI>Effects of a swimming program on children with cystic fibrosis [abstract]</TI>
<SO>International Journal of Sports Medicine</SO>
<YR>1984</YR>
<VL>5</VL>
<PG>156</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:45:14 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:45:14 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE154a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647992"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 11:44:32 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Edlund LD, French RW, Herbst JJ, Ruttenburg HD, Ruhling RO, Adams TD</AU>
<TI>Effects of a swimming program on children with cystic fibrosis</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1986</YR>
<VL>140</VL>
<NO>1</NO>
<PG>80-3</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:44:32 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:44:32 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE154b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647993"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647991"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falk-1988" MODIFIED="2015-05-13 11:46:03 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Falk 1988" YEAR="1988">
<REFERENCE MODIFIED="2015-05-13 11:46:03 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falk M, Kelstrup M, Andersen JB, Pedersen SS, Rossing I, Dirksen H</AU>
<TI>PEP treatment or physical exercise - Effects on secretions expectorated and indices of central and peripheral airway function. A controlled study [abstract]</TI>
<SO>Excerpta Medica, Asia Pacific Congress Series</SO>
<YR>1988</YR>
<VL>74</VL>
<PG>35</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:46:03 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:46:03 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE36"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647995"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647994"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giacomodonato-2015" MODIFIED="2017-05-31 16:28:30 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Giacomodonato 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-05-31 16:28:30 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giacomodonato B, Graziano L, Curzi M, Perelli T, De Sanctis S, Varchetta M, et al</AU>
<TI>Respiratory muscle endurance training with normocapnic hyperpnea in patients with cystic fibrosis. A randomized controlled study</TI>
<SO>Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society</SO>
<YR>2015</YR>
<VL>14 Suppl 1</VL>
<PG>S41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="WS21.10"/><IDENTIFIER TYPE="CENTRAL" VALUE="1077187"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE217"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000000016"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948907"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948906"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruet-2012" MODIFIED="2013-10-17 10:15:36 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Gruet 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-10-17 10:15:36 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gruet M, Mely L, Brisswalter J, Vallier J-M</AU>
<TI>Neuromuscular electrical stimulation in cystic fibrosis [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2012</YR>
<VL>11 Suppl 1</VL>
<PG>S109, Abstract no: 208</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE195"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647997"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647996"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haynes-2016" MODIFIED="2017-05-31 16:38:37 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Haynes 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-05-31 16:38:37 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haynes F, Maddison L, Millward S, Hughes T, Dewar J</AU>
<TI>Evaluation of the incremental step test with adult CF patients</TI>
<SO>Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society</SO>
<YR>2016</YR>
<VL>15 Suppl</VL>
<PG>S88</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="146"/><IDENTIFIER TYPE="CENTRAL" VALUE="1171474"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE233"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001589"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948909"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948908"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heijerman-1992" NAME="Heijerman 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heijerman HGM, Bakker W, Sterk PJ, Dijkman JH</AU>
<TI>Long-term effects of exercise training and hyperlimentation in adult cystic fibrosis patients with severe pulmonary dysfunction</TI>
<SO>International Journal of Rehabilitation Research</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>3</NO>
<PG>252-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2647999"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2647998"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Irons-2012" MODIFIED="2015-05-13 11:49:53 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Irons 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-05-13 11:49:53 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>Irons JY, Kenny D, Chang AB</AU>
<TI>Let's sing out!: The effect of singing on quality of life and lung function of children and adolescents with cystic fibrosis</TI>
<SO>www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ID=83944</SO>
<YR>(accessed 10 September 2009)</YR>
<IDENTIFIERS MODIFIED="2015-05-13 11:49:53 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:49:53 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE185a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648001"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-04-08 14:39:38 +0100" MODIFIED_BY="Thomas Radtke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Irons JY, Kenny DT, McElrea M, Chang AB</AU>
<TI>Singing therapy for young people with cystic fibrosis : a randomized controlled pilot study</TI>
<SO>Music and Medicine</SO>
<YR>2012</YR>
<VL>4</VL>
<NO>3</NO>
<PG>136-45</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="861294"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE185b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000007892"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648002"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648000"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kriemler-2016" MODIFIED="2017-05-31 16:26:43 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Kriemler 2016" YEAR="2015">
<REFERENCE MODIFIED="2017-05-31 16:26:16 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kriemler S, Radtke T, Christen G, Kerstan-Huber M, Hebestreit H</AU>
<TI>Short-term effect of different physical exercises and physiotherapy combinations on sputum expectoration, oxygen saturation, and lung function in young patients with cystic fibrosis</TI>
<SO>Lung</SO>
<YR>2016</YR>
<VL>194</VL>
<NO>4</NO>
<PG>659-64</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE219b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001602"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948911"/><IDENTIFIER TYPE="PUBMED" VALUE="27147223"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-31 16:25:37 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radtke T, Christen G, Kerstan Huber M, Hebestreit H, Kriemler S</AU>
<TI>Short-term effect of different physical exercise-physiotherapy combinations on sputum production, oxygen saturation and lung function in young patients with cystic fibrosis</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2015</YR>
<VL>14 Suppl 1</VL>
<PG>S27</PG>
<PB>Elsevier</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="WS14.2"/><IDENTIFIER TYPE="CENTRAL" VALUE="1081483"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE219a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000000019"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948912"/><IDENTIFIER TYPE="EMBASE" VALUE="71951559"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948910"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuys-2011" MODIFIED="2017-05-08 11:46:05 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Kuys 2011" YEAR="2010">
<REFERENCE MODIFIED="2017-05-08 11:46:05 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall K, Peasey M, Wood M, Cobb R, Bell S, Kuys S</AU>
<TI>The effects of nintendo-wii exercise training in adults with cystic fibrosis</TI>
<SO>Physiotherapy (United Kingdom)</SO>
<YR>2011</YR>
<VL>97 Suppl 1</VL>
<PG>eS648</PG>
<PB>Elsevier Ltd</PB>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1089274"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE184c"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000475"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948913"/><IDENTIFIER TYPE="EMBASE" VALUE="71883056"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-22 11:03:42 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall K, Peasey M, Wood M, Cobb R, Bell SC, Kuys S</AU>
<TI>The effects of Nintendo Wii exercise training in adults with cystic fibrosis [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>A275</PG>
<IDENTIFIERS MODIFIED="2013-03-04 09:43:41 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-03-04 09:43:41 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE184a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948914"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-08 11:46:05 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall K, Peasey M, Wood M, Cobb R, Bell SC, Kuys S</AU>
<TI>The effects of nintendo-wii® exercise training in adults with cystic fibrosis</TI>
<SO>Respirology (Carlton, Vic.)</SO>
<YR>2011</YR>
<VL>16</VL>
<NO>Suppl 1</NO>
<PG>P56</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="TP 077"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE184d"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001908"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948915"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 11:46:41 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kuys SS, Hall K, Peasey M, Wood M, Cobb R//Bell SC</AU>
<TI>Gaming console exercise and cycle or treadmill exercise provide similar cardiovascular demand in adults with cystic fibrosis: a randomised cross-over trial</TI>
<SO>Journal of Physiotherapy</SO>
<YR>2011</YR>
<VL>57</VL>
<NO>1</NO>
<PG>35-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE184b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648005"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648003"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lannefors-1992" MODIFIED="2015-05-13 11:51:56 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Lannefors 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-05-13 11:51:47 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lannefors L, Wollmer P</AU>
<TI>Mucus clearance in cystic fibrosis (CF) - a comparison between postural drainage, PEP-mask and physical exercise [abstract]</TI>
<SO>Proceedings of the 11th International Cystic Fibrosis Congress</SO>
<YR>1992</YR>
<PG>AHP31</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:51:47 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:51:47 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE46a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648007"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 11:51:56 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lannefors L, Wollmerr P</AU>
<TI>Mucus clearance with three chest physiotherapy regimes in CF: a comparison between postural drainage, PEP and physical exercise</TI>
<SO>European Respiratory Journal</SO>
<YR>1992</YR>
<VL>5</VL>
<NO>6</NO>
<PG>748-53</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:51:56 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:51:56 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE46b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648008"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648006"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lima-2014" MODIFIED="2017-05-08 12:00:13 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Lima 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-05-08 11:59:58 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lima C, De Andrade AD, Rattes C, Campos S, Brandao D, Aliverti A, et al</AU>
<TI>Effect of noninvasive ventilation on functional exercise capacity, lung function and compartmental chest wall volume in children with cystic fibrosis</TI>
<SO>European Respiratory Journal</SO>
<YR>2013</YR>
<VL>42</VL>
<PG>1075s</PG>
<PB>European Respiratory Society</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="P5065"/><IDENTIFIER TYPE="CENTRAL" VALUE="1099891"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE216b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000267"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948916"/><IDENTIFIER TYPE="EMBASE" VALUE="71843506"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-08 12:00:13 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lima CA, De Andrade ADFD, Campos SL, Brandao DC, Fregonezi, Mourato IP et al</AU>
<TI>Effects of noninvasive ventilation on treadmill 6-min walking distance and regional chest wall volumes in cystic fibrosis: randomized controlled trial</TI>
<SO>Respiratory Medicine</SO>
<YR>2014</YR>
<VL>108</VL>
<NO>10</NO>
<PG>1460-8</PG>
<IDENTIFIERS MODIFIED="2017-05-08 11:59:39 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2017-05-08 11:59:39 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE216a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648010"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648009"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lowman-2012" MODIFIED="2013-10-17 10:14:51 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Lowman 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-10-17 10:14:51 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lowman JD, Britton LJ, Lee LS, Phillips AL, Hoover WC</AU>
<TI>Comprehensive exercise training during hospitalization for an acute CF exacerbation : a randomized controlled trial [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2012</YR>
<VL>11 Suppl 1</VL>
<PG>S23, Abstract no: WS10.5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE192"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648012"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648011"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02277860" MODIFIED="2017-06-01 10:01:57 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT02277860" YEAR="2014">
<REFERENCE MODIFIED="2017-06-01 10:01:54 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02277860</AU>
<TI>Gaming console home-based exercise for adults with cystic fibrosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02277860</SO>
<YR>(first received 27 October 2014)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948918"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948917"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02715921" MODIFIED="2017-06-01 09:52:35 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT02715921" YEAR="2016">
<REFERENCE MODIFIED="2017-06-01 09:52:31 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02715921</AU>
<TI>Impact of telerehabilitation training on pediatric cystic fibrosis patients: an exploratory study</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02715921</SO>
<YR>(first received 12 January 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948920"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948919"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02821130" MODIFIED="2017-06-01 11:00:01 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT02821130" YEAR="2016">
<REFERENCE MODIFIED="2017-06-01 11:00:01 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02821130</AU>
<TI>Orkambi exercise study (Orkambi)</TI>
<TO>Effects of Orkambi on exertional dyspnea, exercise performance, and ventilatory responses in adults with cystic fibrosis</TO>
<SO>clinicaltrials.gov/ct2/show/NCT02821130</SO>
<YR>(first received 06 June 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948922"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948921"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02875366" MODIFIED="2017-06-01 10:35:51 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT02875366" YEAR="2016">
<REFERENCE MODIFIED="2017-06-01 10:35:49 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02875366</AU>
<TI>A study of the effects of lumacaftor/ivacaftor on exercise tolerance in subjects with cystic fibrosis, homozygous for the F508del-CFTR mutation</TI>
<TO>A phase 4, randomized, double-blind, placebo-controlled, parallel-design study of the effect of lumacaftor/ivacaftor combination therapy on exercise tolerance in subjects aged 12 years and older with cystic fibrosis, homozygous for the F508del-CFTR mutation</TO>
<SO>clinicaltrials.gov/ct2/show/NCT02875366</SO>
<YR>(first received 15 August 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948924"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948923"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT03117764" MODIFIED="2017-06-01 12:32:57 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT03117764" YEAR="2017">
<REFERENCE MODIFIED="2017-06-01 12:32:55 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT03117764</AU>
<TI>Evaluation of the impact of intravenous antibiotics on muscular strength in patients with cystic fibrosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT03117764</SO>
<YR>(first received 31 March 2017)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948926"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948925"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orenstein-1981" MODIFIED="2015-05-13 11:58:29 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Orenstein 1981" YEAR="1981">
<REFERENCE MODIFIED="2015-05-13 11:58:29 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orenstein DM, Franklin BA, Doershuk CF, Hellerstein HK, Germann KJ, Horowitz JG, et al</AU>
<TI>Exercise conditioning and cardiopulmonary fitness in CF. The effects of a three-month supervised running program</TI>
<SO>Chest</SO>
<YR>1981</YR>
<VL>80</VL>
<NO>4</NO>
<PG>392-8</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:58:29 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:58:29 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE92"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648014"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648013"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orenstein-2004" MODIFIED="2015-05-13 11:58:57 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Orenstein 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-05-13 11:58:57 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Orenstein DM, Hovell MF, Mulvihill M, Keating KK, Hofstetter CR, Kelsey S, et al</AU>
<TI>Strength vs aerobic training in children with cystic fibrosis: a randomised controlled trial</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>4</NO>
<PG>1204-14</PG>
<IDENTIFIERS MODIFIED="2015-05-13 11:58:57 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 11:58:57 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE165"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648016"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648015"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozaydin-2010" MODIFIED="2017-05-31 16:02:08 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Ozaydin 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-05-31 16:02:08 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ozaydin Z, Savci S, Saglam M, Arikan H, Inal-Ince D, Vardar-Yagli N, et al</AU>
<TI>Effects of inspiratory muscle training on functional capacity and muscle strength in patients with mild cystic fibrosis</TI>
<SO>European Respiratory Society Annual Congress; 2010 Sep 18-22; Barcelona, Spain</SO>
<YR>2010</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="5134"/><IDENTIFIER TYPE="CENTRAL" VALUE="777297"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE235"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000532"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948928"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948927"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-2004" MODIFIED="2017-05-31 16:41:21 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Patterson 2004" YEAR="2004">
<REFERENCE MODIFIED="2017-05-31 16:41:21 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson JE, Bradley JM</AU>
<TI>Inspiratory muscle training in adult patients with cystic fibrosis: a randomised controlled trial to evaluate the efficacy of the test of incremental respiratory endurance (TIRE)</TI>
<SO>Thorax</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>Suppl II</NO>
<PG>ii13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="S36"/><IDENTIFIER TYPE="CENTRAL" VALUE="518434"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE236"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000533"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948930"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948929"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrovic-2013" MODIFIED="2015-05-12 16:27:57 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Petrovic 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-05-12 16:27:57 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrovic M, Kaluza I, Pohl W</AU>
<TI>Effects of individualised aerobic exercise training in adults with cystic fibrosis: A 4 year controlled trial [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2013</YR>
<VL>12 Suppl 1</VL>
<PG>S28, Abstract no: WS14.4</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="875002"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE204"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000011658"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648018"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648017"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rand-2012" MODIFIED="2015-01-22 09:54:12 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Rand 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-01-22 09:54:12 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rand S, Hill L, Prasad SA, Main E</AU>
<TI>Development of an incremental field exercise test for children with cystic fibrosis [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2012</YR>
<VL>11 Suppl 1</VL>
<PG>S36, Abstract no: WS16.7</PG>
<IDENTIFIERS MODIFIED="2015-01-22 09:54:12 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-01-22 09:54:12 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE193"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648020"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648019"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reix-2012" MODIFIED="2015-05-13 12:01:54 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Reix 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-05-13 12:01:54 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reix P, Aubert F, Kassai B, Bige V, Bellon G</AU>
<TI>Better satisfaction of cystic fibrosis paediatric patients with autogenic drainage associated to exercise compared to conventional chest physiotherapy [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2009</YR>
<VL>8 suppl 2</VL>
<PG>S73, Abstract no: 293</PG>
<IDENTIFIERS MODIFIED="2015-05-13 12:01:54 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 12:01:54 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE183a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648022"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-04-08 14:39:52 +0100" MODIFIED_BY="Thomas Radtke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reix P, Aubert F, Werck-Gallois MC, Toutain A, Mazzocchi C, Moreux N, et al</AU>
<TI>Exercise with incorporated expiratory manoeuvres was as effective as breathing techniques for airway clearance in children with cystic fibrosis: a randomised crossover trial</TI>
<SO>Journal of Physiotherapy</SO>
<YR>2012</YR>
<VL>58</VL>
<NO>4</NO>
<PG>241-7</PG>
<CY>Australia</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="841658"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE183b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000095"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648023"/><IDENTIFIER TYPE="PUBMED" VALUE="23177226"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648021"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salh-1989" MODIFIED="2015-05-13 12:02:50 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Salh 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-05-13 12:02:50 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salh W, Bilton D, Dodd M, Webb AK</AU>
<TI>Effect of exercise and physiotherapy in aiding sputum expectoration in adults with cystic fibrosis</TI>
<SO>Thorax</SO>
<YR>1989</YR>
<VL>44</VL>
<NO>12</NO>
<PG>1006-8</PG>
<IDENTIFIERS MODIFIED="2015-05-13 12:02:50 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-05-13 12:02:50 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE63"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648025"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648024"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salonini-2015" MODIFIED="2017-05-08 12:06:42 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Salonini 2015" YEAR="2013">
<REFERENCE MODIFIED="2017-05-08 12:06:32 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Salonini E, Gambazza S, Meneghelli I, Tridello G, Sanguanini M, Cazzarolli C, et al</AU>
<TI>Active video game playing in children and adolescents with cystic fibrosis: Exercise or just fun?</TI>
<SO>Respiratory Care</SO>
<YR>2015</YR>
<VL>60</VL>
<NO>8</NO>
<PG>1172-9</PG>
<PB>American Association for Respiratory Care</PB>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1161387"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE207b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000473"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948932"/><IDENTIFIER TYPE="EMBASE" VALUE="2015465751"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-04-08 14:42:42 +0100" MODIFIED_BY="Thomas Radtke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salonini E, Gambazza S, Tridello G, Sanguanini M, Cazzarolli C</AU>
<TI>Kinect active video game in cystic fibrosis: Exercise or fun? [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2013</YR>
<VL>12 Suppl 1</VL>
<PG>S108, Abstract no: 233</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="875196"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE207"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000011679"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948933"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948931"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-2016" MODIFIED="2017-05-31 16:36:02 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Shaw 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-05-31 16:36:02 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaw I, Kinsey JE, Richards R, Shaw BS</AU>
<TI>Individualized supervised resistance training during nebulization in adults with cystic fibrosis</TI>
<SO>Pakistan Journal of Medical Sciences</SO>
<YR>2016</YR>
<VL>32</VL>
<NO>5</NO>
<PG>1152-7</PG>
<CY>Pakistan</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1343881"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE242"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001737"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948935"/><IDENTIFIER TYPE="PUBMED" VALUE="27882012"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948934"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stanghelle-1998" MODIFIED="2014-03-31 12:52:22 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Stanghelle 1998" YEAR="1988">
<REFERENCE MODIFIED="2014-03-31 12:51:57 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stanghelle JK, Hjeltnes N, Bangstad HJ, Michalsen H</AU>
<TI>Effect of daily short bouts of trampoline exercise during 8 weeks on the pulmonary function and the maximal oxygen uptake of children with cystic fibrosis</TI>
<SO>International Journal of Sports Medicine</SO>
<YR>1988</YR>
<VL>9 Suppl 1</VL>
<PG>32-6</PG>
<IDENTIFIERS MODIFIED="2014-03-31 12:51:57 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="568629"/><IDENTIFIER MODIFIED="2014-03-31 12:51:57 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE155"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000002860"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648029"/><IDENTIFIER TYPE="PUBMED" VALUE="3360541"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648028"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuzin-1998" MODIFIED="2014-04-09 11:28:01 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Tuzin 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-04-09 11:28:01 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuzin BJ, Mulvihill MM, Kilbourn KM, Bertran DA, Buono M, Hovell MF, et al</AU>
<TI>Increasing physical activity of children with cystic fibrosis: A home based family intervention</TI>
<SO>Pediatric Exercise Science</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>1</NO>
<PG>57-68</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648031"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648030"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vallier-2016" MODIFIED="2017-05-31 16:34:02 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Vallier 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-05-31 16:34:02 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vallier JM, Rouissi M, Mely L, Gruet M</AU>
<TI>Physiological Responses of the Modified Shuttle Test in Adults With Cystic Fibrosis</TI>
<SO>Journal of Cardiopulmonary Rehabilitation and Prevention</SO>
<YR>2016</YR>
<VL>36</VL>
<NO>4</NO>
<PG>288-92</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1343882"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE241"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001903"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948937"/><IDENTIFIER TYPE="PUBMED" VALUE="27182761"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948936"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vivodtzev-2013" MODIFIED="2015-05-13 09:00:58 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Vivodtzev 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-04-08 14:40:02 +0100" MODIFIED_BY="Thomas Radtke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vivodtzev I, Decorte N, Wuyam B, Gonnet N, Durieu I, Levy P, et al</AU>
<TI>Benefits of neuromuscular electrical stimulation prior to endurance training in patients with cystic fibrosis and severe pulmonary dysfunction</TI>
<SO>Chest</SO>
<YR>2013</YR>
<VL>143</VL>
<NO>2</NO>
<PG>485-93</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="906021"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE201a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000005"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648033"/><IDENTIFIER TYPE="EMBASE" VALUE="22911373"/><IDENTIFIER TYPE="PUBMED" VALUE="22911373"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-13 09:00:58 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vivodtzev I, Decorte N, Wuyam B, Gonnet N, Durieu I, Levy P, et al</AU>
<TI>Online supplement to "Benefits of neuromuscular electrical stimulation prior to endurance training in patients with cystic fibrosis and severe pulmonary dysfunction" [online]</TI>
<SO>Chest</SO>
<YR>2013</YR>
<VL>143</VL>
<NO>2</NO>
<PG>485-93 online</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="980643"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE201b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000610"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648034"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648032"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wheatley-2015" MODIFIED="2017-05-31 16:13:21 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Wheatley 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-05-31 16:13:21 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wheatley CM, Baker SE, Morgan MA, Martinez MG, Liu B, Rowe SM, et al</AU>
<TI>Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis</TI>
<SO>Respiratory Medicine</SO>
<YR>2015</YR>
<VL>109</VL>
<NO>8</NO>
<PG>1001-11</PG>
<PB>W.B. Saunders Ltd</PB>
<CY>United Kingdom</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1107333"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE225b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000335"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948939"/><IDENTIFIER TYPE="EMBASE" VALUE="2015118578"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-31 16:13:05 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wheatley CM, Baker SE, Morgan MA, Martinez MG, Morgan WJ, Wong EC, et al</AU>
<TI>Effects of exercise intensity compared to albuterol in individuals with cystic fibrosis</TI>
<SO>Respiratory Medicine</SO>
<YR>2015</YR>
<VL>109</VL>
<NO>4</NO>
<PG>463-74</PG>
<CY>England</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1110247"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE225a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001490"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948940"/><IDENTIFIER TYPE="PUBMED" VALUE="25749641"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948938"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-08-29 16:06:21 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12617001009303" MODIFIED="2017-08-28 14:56:42 +0100" MODIFIED_BY="Nikki Jahnke" NAME="ACTRN12617001009303" YEAR="2017">
<REFERENCE MODIFIED="2017-08-28 14:56:42 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12617001009303</AU>
<TI>Action: PACT. Be Active. Online. A trial to promote physical activity in young people with cystic fibrosis.</TI>
<SO>www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617001009303</SO>
<YR>(first received 06 July 2017)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948942"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="ACTRN Clinical Trials Registry" TYPE="OTHER" VALUE="ACTRN12617001009303"/><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948941"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Almajan-2011" MODIFIED="2014-08-19 09:39:37 +0100" MODIFIED_BY="Thomas Radtke" NAME="Almajan 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-19 09:39:37 +0100" MODIFIED_BY="Thomas Radtke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Almajan-Guta B, Avram C, Almajan-Guta V, Rusu A, Ciuca I, Cluci O, et al</AU>
<TI>High motivation for playing sports in cystic fibrosis - what we play is life [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2011</YR>
<VL>10 Suppl 1</VL>
<PG>S64, Abstract no: 254</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE189"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648036"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648035"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Housinger-2015" MODIFIED="2017-05-31 16:16:20 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Housinger 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-05-31 16:16:20 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Housinger E, Sullivan M, Ruiz FE</AU>
<TI>Effects of an interdisciplinary motivational incentive-based walking program in pediatric pulmonary patients during hospitalization</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2015</YR>
<VL>50 Suppl 41</VL>
<PG>369</PG>
<PB>John Wiley and Sons Inc</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="471"/><IDENTIFIER TYPE="CENTRAL" VALUE="1092214"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE222"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001403"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948944"/><IDENTIFIER TYPE="EMBASE" VALUE="72081750"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948943"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnston-2004" MODIFIED="2017-05-31 15:58:42 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Johnston 2004" YEAR="2004">
<REFERENCE MODIFIED="2017-05-31 15:58:42 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnston K, Jenkins, Roberts C, Stick S</AU>
<TI>Improved attitude to exercise in overweight children with lung conditions after an exercise intervention</TI>
<SO>Respirology (Carlton, Vic.)</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>2 Suppl</NO>
<PG>A60</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="475664"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE231"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000476"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948946"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948945"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lorenc-2015" MODIFIED="2017-08-29 15:37:09 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Lorenc 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-05-31 16:30:32 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carr SB, Ronan P, Robinson N, Agent P, Mian A, Madge S</AU>
<TI>A randomised controlled trial of Tai Chi in cystic fibrosis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2016</YR>
<VL>51</VL>
<PG>376</PG>
<PB>John Wiley and Sons Inc</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="480"/><IDENTIFIER TYPE="CENTRAL" VALUE="1212611"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE243c"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001919"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948948"/><IDENTIFIER TYPE="EMBASE" VALUE="612358588"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-08-29 15:37:09 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>Lorenc A, Ronan P, Mian A, Madge S, Carr SB, Agent P, et al</AU>
<TI>Cystic fibrosis-Children and adults Tai Chi study (CF CATS2): Can Tai Chi improve symptoms and quality of life for people with cystic fibrosis? Second phase study protocol</TI>
<SO>Chinese Journal of Integrative Medicine</SO>
<YR>2015 May 26 [Epub ahead of print]</YR>
<CY>China</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1343883"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE243a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001904"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948949"/><IDENTIFIER TYPE="PUBMED" VALUE="26015075"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-31 16:30:32 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madge S, Ronan P, Robinson N, Agent P, Mian A, Carr SB</AU>
<TI>Assessing the benefits of tai chi in people with CF and the feasibility of delivering Tai Chi over the internet (Skype®)</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2016</YR>
<VL>51 Suppl 45</VL>
<PG>370</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="465"/><IDENTIFIER TYPE="CENTRAL" VALUE="1343884"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE243b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001922"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948950"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948947"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandrusiak-2011" MODIFIED="2017-08-29 16:06:21 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Mandrusiak 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-08-29 16:06:21 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandrusiak A, MacDonald J, Paratz J, Wilson C, Watter P</AU>
<TI>A novel exercise program for young people with cystic fibrosis: Moving physiotherapy forward through targeted design</TI>
<SO>Physiotherapy (United Kingdom)</SO>
<YR>2011</YR>
<VL>97</VL>
<PG>eS1550</PG>
<PB>Elsevier Ltd</PB>
<IDENTIFIERS MODIFIED="2017-08-29 16:06:21 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="1076180"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE229"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000415"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948952"/><IDENTIFIER TYPE="EMBASE" VALUE="71884245"/><IDENTIFIER MODIFIED="2017-08-29 16:06:21 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="Poster no." TYPE="OTHER" VALUE="SI-PO-210-22-Thu"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948951"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00609050" MODIFIED="2017-06-01 10:25:53 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT00609050" YEAR="2008">
<REFERENCE MODIFIED="2017-06-01 10:25:53 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00609050</AU>
<TI>Exercise training study for patients with cystic fibrosis</TI>
<TO>Self-regulated exercise in CF: a randomized trial</TO>
<SO>clinicaltrials.gov/ct2/show/NCT00609050</SO>
<YR>(first received 31 January 2008)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948954"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948953"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00792194" MODIFIED="2017-06-01 09:57:20 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT00792194" YEAR="2008">
<REFERENCE MODIFIED="2017-06-01 09:57:17 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00792194</AU>
<TI>Improvement of aerobic capacity in cystic fibrosis patients with a one-year home training period</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00792194</SO>
<YR>(first received 14 November 2008)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948956"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948955"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02552043" MODIFIED="2017-06-01 10:12:52 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT02552043" YEAR="2015">
<REFERENCE MODIFIED="2017-06-01 10:12:47 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02552043</AU>
<TI>Video game exercise effectiveness of a domiciliary pulmonary rehabilitation program in cystic fibrosis patients</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02552043</SO>
<YR>(first received 15 September 2015)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948958"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948957"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT03100214" MODIFIED="2017-06-01 12:40:01 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT03100214" YEAR="2017">
<REFERENCE MODIFIED="2017-06-01 12:39:59 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT03100214</AU>
<TI>Effects of an early rehabilitation program during hospitalization in patients with cystic fibrosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT03100214</SO>
<YR>(first received 31 January 2017)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948960"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948959"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT03109912" MODIFIED="2017-06-01 09:43:36 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT03109912" YEAR="2017">
<REFERENCE MODIFIED="2017-06-01 09:43:36 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT03109912</AU>
<TI>Do More, B'More, Live Fit</TI>
<TO>Do More, B'More, Live Fit: an outpatient fitness-training pilot program designed to optimize the habit of exercise in adolescents and young adults with cystic fibrosis</TO>
<SO>clinicaltrials.gov/ct2/show/NCT03109912</SO>
<YR>(first received 22 February 2017)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948962"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948961"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliveira-2010" MODIFIED="2017-05-31 16:00:45 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Oliveira 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-05-31 16:00:45 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliveira ACN, de Jesus TA, Mesquita- Ferrari RA, Oliveira JC, de Oliveira LVF, Sampaio LM</AU>
<TI>Aerobic training and quality of life in cystic fibrosis</TI>
<SO>European Respiratory Journal</SO>
<YR>2010</YR>
<VL>36 Suppl 54</VL>
<PG>P2651</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE245"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001906"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948964"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948963"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phillips-2008" MODIFIED="2014-08-12 09:55:34 +0100" MODIFIED_BY="Thomas Radtke" NAME="Phillips 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-08-12 09:55:34 +0100" MODIFIED_BY="Thomas Radtke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillips AL, Lee L, Britton LJ, Hoover W, Lowman JD</AU>
<TI>Efficacy of a standardised exercise protocol in inpatient care of patients with cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>Suppl 31</NO>
<PG>385, Abstract 510</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE182"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2648038"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2648037"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2017-08-28 14:56:42 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Donadio-2017" MODIFIED="2017-08-10 14:35:17 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Donadio 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-08-10 14:35:16 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>Donadio M</AU>
<TI>Effect of exercise orientations in the posture and plantar pressure distribution in children and adolescents with cystic fibrosis</TI>
<SO>apps.who.int/trialsearch/Trial2.aspx?TrialID=RBR-3r4h5s</SO>
<YR>(first received 09 July 2014)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948966"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-08-10 14:31:32 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948965"/><IDENTIFIER MODIFIED="2017-08-10 14:31:32 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="REBEC" TYPE="OTHER" VALUE="RBR-3r4h5s"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-2017" MODIFIED="2017-08-10 15:04:52 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Gupta 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-08-10 15:04:51 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>Gupta S</AU>
<TI>Effects of exercise intervention program on bone mineral accretion in children and adolescents with cystic fibrosis</TI>
<SO>apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2013/04/003531</SO>
<YR>(first received 04 April 2013)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948968"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-08-10 14:58:47 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948967"/><IDENTIFIER MODIFIED="2017-08-10 14:58:47 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CTRI" TYPE="OTHER" VALUE="CTRI/2013/04/003531"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hebestreit-2016" MODIFIED="2017-06-01 12:27:22 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Hebestreit 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-06-01 12:27:22 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hebestreit H</AU>
<TI>How to counsel patients regarding exercise and habitual physical activity?</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2016</YR>
<VL>51 Suppl 45</VL>
<PG>188</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="Abstract no" TYPE="OTHER" VALUE="S20.4"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE244a"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001920"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948970"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-01 12:27:22 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01744561</AU>
<TI>Effects of a partially supervised conditioning program in CF (ACTIVATE-CF)</TI>
<TO>Effects of a partially supervised conditioning program in CF: an international multi-centre, randomized controlled trial</TO>
<SO>clinicaltrials.gov/show/NCT01744561</SO>
<YR>(first received 05 December 2012)</YR>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1343886"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PE244b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001724"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948971"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948969"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02700243" MODIFIED="2017-06-01 10:50:52 +0100" MODIFIED_BY="Nikki Jahnke" NAME="NCT02700243" YEAR="2016">
<REFERENCE MODIFIED="2017-06-01 10:50:46 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02700243</AU>
<TI>Increase tolerance for exercise and raise activity through connectedness trial (INTERACT)</TI>
<TO>Pilot RCT study using a Fitbit device to improve exercise tolerance in 80 patients with cystic fibrosis</TO>
<SO>clinicaltrials.gov/ct2/show/NCT02700243</SO>
<YR>(first received 21 February 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6948973"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6948972"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-05-31 16:41:21 +0100" MODIFIED_BY="Nikki Jahnke">
<ADDITIONAL_REFERENCES MODIFIED="2015-06-26 13:40:12 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-ACSM-2010" MODIFIED="2011-03-07 14:33:32 +0000" MODIFIED_BY="Nikki Jahnke" NAME="ACSM 2010" TYPE="BOOK">
<AU>American College of Sports Medicine</AU>
<SO>ACSM's guidelines for exercise testing prescription</SO>
<YR>2010</YR>
<EN>8th</EN>
<PB>Lippincott Williams and Williams</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casaburi-1992" NAME="Casaburi 1992" TYPE="JOURNAL_ARTICLE">
<AU>Casaburi R</AU>
<TI>Principles of exercise training</TI>
<SO>Chest</SO>
<YR>1992</YR>
<VL>101</VL>
<NO>Suppl 5</NO>
<PG>263S-7S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cerny-2013" MODIFIED="2015-02-04 17:10:48 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Cerny 2013" TYPE="JOURNAL_ARTICLE">
<AU>Cerny F</AU>
<TI>Exercise and cystic fibrosis (CF) 2.0</TI>
<SO>Pediatric Exercise Science</SO>
<YR>2013</YR>
<VL>25</VL>
<NO>4</NO>
<PG>616-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CF-Foundation-2009" MODIFIED="2011-03-03 12:50:32 +0000" MODIFIED_BY="[Empty name]" NAME="CF Foundation 2009" TYPE="BOOK">
<AU>Cystic Fibrosis Foundation</AU>
<TI>Patient Registry: Annual Data Report</TI>
<SO>Patient Registry: Annual Data Report</SO>
<YR>2002</YR>
<PB>[Bethesda, Maryland]</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CF-Trust-2010" MODIFIED="2011-03-07 14:32:36 +0000" MODIFIED_BY="Nikki Jahnke" NAME="CF Trust 2010" TYPE="BOOK">
<AU>Cystic Fibrosis Trust</AU>
<SO>Living with Cystic Fibrosis: Annual Review</SO>
<YR>2010</YR>
<PB>Cystic Fibrosis Trust</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dwyer-2011" MODIFIED="2015-02-04 17:11:50 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Dwyer 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dwyer TJ, Alison JA, McKeough ZJ, Daviskas E, Bye PT</AU>
<TI>Effects of exercise on respiratory flow and sputum properties in patients with cystic fibrosis</TI>
<SO>Chest</SO>
<YR>2011</YR>
<VL>139</VL>
<NO>4</NO>
<PG>870-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2015-03-16 13:58:15 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellis-2010" MODIFIED="2015-06-26 13:40:12 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Ellis 2010" TYPE="BOOK">
<AU>Ellis, PD</AU>
<SO>The Essential Guide to Effect Sizes: An Introduction to Statistical Power, Meta-Analysis and the Interpretation of Research Results</SO>
<YR>2010</YR>
<PB>Cambridge University Press</PB>
<CY>United Kingdom</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farrell-2008" MODIFIED="2015-02-04 17:12:29 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Farrell 2008" TYPE="JOURNAL_ARTICLE">
<AU>Farrell PM</AU>
<TI>The prevalence of cystic fibrosis in the European Union</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>5</NO>
<PG>450-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galassetti-2013" MODIFIED="2015-02-04 17:14:46 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Galassetti 2013" TYPE="JOURNAL_ARTICLE">
<AU>Galassetti P, Riddell MC</AU>
<TI>Exercise and type 1 diabetes (T1DM)</TI>
<SO>Comprehensive Physiology</SO>
<YR>2013</YR>
<VL>3</VL>
<NO>3</NO>
<PG>1309-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebestreit-2001" MODIFIED="2015-02-04 17:15:47 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Hebestreit 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hebestreit A, Kersting U, Basler B, Jeschke R, Hebestreit H</AU>
<TI>Exercise inhibits epithelial sodium channels in patients with cystic fibrosis</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>164</VL>
<NO>3</NO>
<PG>443-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebestreit-2014" MODIFIED="2015-02-11 13:48:20 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Hebestreit 2014" TYPE="JOURNAL_ARTICLE">
<AU>Hebestreit H, Schmid K, Kieser S, Junge S, Ballmann M, Roth K, et al</AU>
<TI>Quality of life is associated with physical activity and fitness in cystic fibrosis</TI>
<SO>BMC Pulmonary Medicine</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-10-17 10:53:03 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hopewell-2009" MODIFIED="2015-02-09 18:33:38 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Hopewell 2009" TYPE="COCHRANE_REVIEW">
<AU>Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K</AU>
<TI>Publication bias in clinical trials due to statistical significance or direction of trial results</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-02-09 18:33:38 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-02-09 18:33:38 +0000" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.MR000006.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Houston-2013" MODIFIED="2015-02-04 17:18:34 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Houston 2013" TYPE="COCHRANE_REVIEW">
<AU>Houston BW, Mills N, Solis-Moya A</AU>
<TI>Inspiratory muscle training for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2015-02-04 17:18:00 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-02-04 17:18:00 +0000" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD006112.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nixon-1992" NAME="Nixon 1992" TYPE="JOURNAL_ARTICLE">
<AU>Nixon PA, Orenstein DM, Kelsey SF, Doerschuk CF</AU>
<TI>The prognostic value of exercise testing in patients with cystic fibrosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<NO>25</NO>
<PG>1785-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Neill-1987" NAME="O'Neill 1987" TYPE="JOURNAL_ARTICLE">
<AU>O'Neill PA, Dodds M, Phillips B, Poole J, Webb AK</AU>
<TI>Regular exercise and reduction of breathlessness in patients with cystic fibrosis</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1987</YR>
<VL>81</VL>
<NO>1</NO>
<PG>62-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-2014" MODIFIED="2015-01-22 16:19:36 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Review Manager 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruf-2010" MODIFIED="2015-02-04 17:22:24 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Ruf 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ruf K, Winkler B, Hebestreit A, Gruber W, Hebestreit H</AU>
<TI>Risks associated with exercise testing and sports participation in cystic fibrosis</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>5</NO>
<PG>339-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneiderman-2014" MODIFIED="2015-02-04 17:23:16 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Schneiderman 2014" TYPE="JOURNAL_ARTICLE">
<AU>Schneiderman JE, Wilkes DL, Atenafu EG, Nguyen T, Wells GD, Alarie N, et al</AU>
<TI>Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis</TI>
<SO>European Respiratory Journal</SO>
<YR>2014</YR>
<VL>43</VL>
<NO>3</NO>
<PG>817-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shephard-1994" NAME="Shephard 1994" TYPE="BOOK">
<AU>Shephard RJ</AU>
<SO>Aerobic Fitness and Health</SO>
<YR>1994</YR>
<PB>Human Kinetic Publishers</PB>
<CY>Leeds, England</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tejero-Garc_x00ed_a-2011" MODIFIED="2015-02-04 17:03:32 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Tejero García 2011" TYPE="JOURNAL_ARTICLE">
<AU>Tejero García S, Giráldez Sánchez MA, Cejudo P, Quintana Gallego E, Dapena J, García Jiménez R, et al</AU>
<TI>Bone health, daily physical activity, and exercise tolerance in patients with cystic fibrosis</TI>
<SO>Chest</SO>
<YR>2011</YR>
<VL>140</VL>
<NO>2</NO>
<PG>475-81</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-05-08 12:17:12 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Bradley-2002" MODIFIED="2015-02-11 14:58:07 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Bradley 2002" TYPE="COCHRANE_REVIEW">
<AU>Bradley JM, Moran F</AU>
<TI>Physical training for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-02-11 14:57:58 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2015-02-11 14:57:58 +0000" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002768"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bradley-2008" MODIFIED="2013-03-04 09:55:22 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Bradley 2008" TYPE="COCHRANE_REVIEW">
<AU>Bradley JM, Moran F</AU>
<TI>Physical training for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-03-04 09:55:22 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-03-04 09:55:22 +0000" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002768.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Radtke-2015a" MODIFIED="2017-05-08 12:17:12 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Radtke 2015a" TYPE="COCHRANE_REVIEW">
<AU>Radtke T, Nolan SJ, Hebestreit H, Kriemler S</AU>
<TI>Physical exercise training for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2017-05-08 12:17:12 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2017-05-08 12:17:12 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002768.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2017-05-31 16:41:21 +0100" MODIFIED_BY="Nikki Jahnke"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-11-02 10:13:17 +0000" MODIFIED_BY="Nikki Jahnke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-11-02 10:10:31 +0000" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-11-01 16:24:02 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Beaudoin-2017">
<CHAR_METHODS MODIFIED="2017-11-01 16:24:02 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre, open-label, parallel RCT (the record on clinicaltrials.gov states cross-over design, but this is not evident from published paper).</P>
<P>Inclusion criteria: participants with CF; age &gt; 18 years; sedentary (less than 100 min/week of structured exercise assessed by physical activity questionnaire and phone interview; FEV<SUB>1</SUB> &gt; 40 % predicted; clinically stable for the last 6 weeks; IGT; CFRD without pharmacological treatment or elevated 1-h plasma glucose concentration during an oral glucose tolerance test (indeterminate 1-h glucose concentration of &gt; 11.0 but 2-h plasma glucose concentration &lt; 7.8 mmol/L<SUP>-1</SUP>).<BR/>Exclusion criteria: current pulmonary exacerbation; use of oral or intravenous corticosteroids; low SaO<SUB>2</SUB> during exercise; history of haemoptysis in the last 6 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-08 15:58:45 +0100" MODIFIED_BY="Nikki Jahnke">
<P>14 participants with CF.</P>
<P>
<I>Group demographics</I>
</P>
<P>Exercise group (n = 8): mean (range) age 31.9 (24; 41) years.</P>
<P>Control groups (n = 6): mean (range) age 35.5 (22; 57) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-01 16:19:24 +0000" MODIFIED_BY="Nikki Jahnke">
<P>12-week combined aerobic and resistance training study.</P>
<P>Exercise group: aerobic and resistance training exercises 3x per week for about 20 - 40 minutes with a day off between the training sessions (in total 36 training sessions). Exercise intensity and volume were progressively increased. Participants recorded their training sessions in a diary. Once every 4 weeks, participants received a supervised training session and a phone call on a weekly basis.</P>
<UL>
<LI>Aerobic training consisted of walking, jogging, cycling and elliptic trainer. Training intensity progressively increased throughout the study, starting at 60% of VO<SUB>2</SUB> peak during the first 4 weeks. Thereafter, intensity was increased to 70% (week 5 - 8) and 80% (week 9 - 12) of VO<SUB>2</SUB> peak.</LI>
<LI>Resistance training consisted of 5 - 7 exercises for large muscle groups using the own body weight, free weights and elastic bands (goal 8 - 12 repetitions with a weight of 30% - 50% of one repetition maximum). Exercise intensity and volume were progressively increased.</LI>
</UL>
<P>Control group: no information was reported in the original publication. Detailed information on control intervention is available on clinicaltrials.gov.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:19:30 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: pulmonary function (FVC, FEV<SUB>1</SUB>); metabolic parameters (HbA1c, plasma glucose area under the curve, insulin sensitivity index, plasma insulin area under the curve (0 - 120 min); exercise capacity measured by a cycle cardiopulmonary exercise test (VO<SUB>2</SUB> peak and VE at VO<SUB>2</SUB> peak); muscle strength (leg press, chest press, latpull down, biceps curl) and endurance (push-up, sit-up, flexibility, handgrip strength); body composition (bodyweight, BMI, body fat and fat-free mass); HRQoL and objectively measured physical activity (steps per days; energy expenditure) and assessed by questionnaire.</P>
<P>Further, inflammatory markers were measured in this study (e.g., IL-1; IL-6; IL-8; YKL-40 and CRP-hs) but inflammatory biomarkers are not outcomes relevant for this review.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-29 12:56:54 +0100" MODIFIED_BY="Nikki Jahnke">
<P>
<I>Study registration:</I>
</P>
<P>The study was registered as cross-over trial (Clinicaltrials.gov NCT02127957) but results were reported as parallel-design study. The authors confirmed that they had to stop the study due to recruitment problems. The authors presented only results from the first study phase (12 weeks).</P>
<P>
<I>Information provided on clinicaltrials.gov</I>
</P>
<P>"Intervention Model: Crossover Assignment"</P>
<P>"Following the visit #6, patients in the control group will be invited to participate in a second study phase to participate in supervised exercise program. This participation will involve an additional 12 weeks of follow-up, which included the same visit as Group 1 with exercises. In this case, to simplify participation and reduce the volume of blood collected, the final visit (#5) of the project will also be the first visit of exercises phase. This part of study, involves 2 supervised training sessions and 8 follow up phone call. The exercises program will be performed three times per week for about one hour."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:24:16 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Cerny-1989">
<CHAR_METHODS MODIFIED="2015-05-13 14:08:45 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre, parallel RCT during hospital admission for acute exacerbation.</P>
<P>Inclusion criteria: participants with CF who were admitted to the hospital for treatment of an acute exacerbation. Those who were able to perform a pulmonary function test and provided written informed consent (assumed patient or parental depending on age) were included.</P>
<P>Exclusion criteria: not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-09 18:45:30 +0000" MODIFIED_BY="Nikki Jahnke">
<P>17 participants with CF.<BR/>
<I>Group demographics</I>
</P>
<P>Exercise group (n = 9): mean (SD) age 15.4 (4.9) years.</P>
<P>Bronchial hygiene group (n = 8): mean (SD) age 15.9 (4.9) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-09 18:41:20 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Short-term aerobic study.<BR/>Group 1: 2 cycle ergometer sessions and 1 bronchial hygiene session per day during admission: mean (SD) 13 (3) days.</P>
<P>Group 2: 3 bronchial hygiene sessions per day during admission: mean (SD) 13 days (2.6 days).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:24:16 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: pulmonary function (FVC, ERV, IC, FEV<SUB>1</SUB>, FEF<SUB>25-75</SUB>,RV, FRC, TLC, Raw, SGAW, SaO<SUB>2</SUB>, and PFS); exercise performance during cycle ergometry with load increased by 0.3 W/kg every 2 minutes until participant could continue no longer (SaO<SUB>2</SUB>, peak load, EMG activity, peak HR, peak VE to peak load ratio, peak HR to peak load ratio); cough (15 min post treatment session); sputum (wet and dry weight, volume).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-12 13:10:53 +0000" MODIFIED_BY="Thomas Radtke"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:24:39 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Douglas-2015">
<CHAR_METHODS MODIFIED="2017-11-01 16:12:16 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre RCT (INSPIRE-CF) in the UK; duration 24 months. Powered to show changes in primary outcome measure of FEV<SUB>1</SUB> z score after 24 months (66 participants needed).</P>
<P>Inclusion criteria: not described in abstract.</P>
<P>Exclusion criteria: not described in abstract.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 16:12:19 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Recruited 71 participants with CF; age 6 to 15.5 years; mean (SD) FEV<SUB>1</SUB> 89 (16) % predicted.</P>
<P>
<I>Group demographics</I>
</P>
<P>Intervention group (n = 37).</P>
<P>Control group (n = 34).</P>
<P>67 children completed the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-09-26 12:45:57 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Intervention group: standard specialist care including weekly exercise training.</P>
<P>Control group: standard specialist care without weekly exercise training.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:24:39 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: average and individual exercise training attendance rates (%); reason for non-attendance to the exercise training programme.</P>
<P>At baseline,12 and 24 months the following outcomes were measured: multiple-breath washout (lung clearance index); spirometry (FEV<SUB>1</SUB>, FVC, FEV<SUB>1</SUB>/FVC (measured in litres and converted to z scores)); growth parameters (height; weight; BMI (measured in cm²; kg; and converted to z scores); cardiopulmonary exercise test (Bruce protocol): at peak and anaerobic threshold (VO<SUB>2</SUB> peak; work rate (power); V<SUB>E</SUB>/VCO<SUB>2</SUB>; RER; HRmax; SaO<SUB>2</SUB>; 10m modified shuttle walk test (25-level version) (distance in meters; level achieved); HRmax; SaO<SUB>2</SUB>; Cystic Fibrosis Questionnaire (CFQ UK version)<B>.</B>
</P>
<P>At 6 months only spirometry and the 10 m modified shuttle walk test were repeated.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 16:12:33 +0000" MODIFIED_BY="Nikki Jahnke">
<P>INSPIRE-CF is an 24-month exercise training study that investigates the effects of an individually tailored and supervised exercise training programme on lung function, exercise capacity and HRQoL for children with CF.</P>
<P>This abstract evaluates the participation in the intervention group in the first year of the study (study has been completed, but not yet published in full).</P>
<P>Study was powered to show changes after 24 months in primary outcome measure of FEV<SUB>1</SUB> z score; Required 66 participants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:19:37 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Hebestreit-2010">
<CHAR_METHODS MODIFIED="2017-11-01 16:12:36 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: multicentre parallel RCT; duration 24 months (6-month intervention and long-term, open follow-up period).</P>
<P>Inclusion criteria: participants with CF; age <U>&gt;</U> 12 years; FEV<SUB>1</SUB> <U>&gt;</U> 35 % predicted; ability to perform physical activities.</P>
<P>Exclusion criteria: non CF-related chronic diseases and CF-related conditions posing an increased risk to the participant when exercising. These were specifically oesophageal varicosis, pulmonary bullae, a &lt; 80% drop in arterial oxygen saturation with exercise and signs of pulmonary hypertension on electrocardiogram and/or echocardiogram.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-10 09:01:51 +0000" MODIFIED_BY="Nikki Jahnke">
<P>38 participants with CF.</P>
<P>
<I>Group demographics</I>
</P>
<P>Exercise group (n = 23): mean (SD) age 19.5 (6.4) years.</P>
<P>Control group (n = 15): mean (SD) age 19.4 (5.3) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-26 13:08:07 +0100" MODIFIED_BY="Tracey Remmington">
<P>Long-term partially supervised conditioning programme.</P>
<P>Group 1 (intervention): exercise intervention with endurance-type and strengthening exercises. Participants agreed to increase their vigorous physical activities by a minimum of 3x 60 min per week in the first 6 months of the study. An individual exercise plan was devised for participants; activity counselling was stopped after the first 6 months and participants were encouraged to maintain or further increase their physical activity level.</P>
<P>Group 2 (control): participants told to keep their activity level constant during the first 12 months of the study. During the second year (period from 12 - 24 months) they were free to change their activity behaviour.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:19:37 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: VO<SUB>2</SUB> peak; peak workload; Wingate Anaerobic Test (PP, MP); FVC; FEV<SUB>1</SUB>; RV/TLC; vigorous physical activity; skinfold thickness; body fat; fat-free mass and HRQoL.</P>
<P>Outcomes were measured at baseline and after 3, 6, 12, 18 and 24 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-14 12:59:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This study is a full text article of the Hebestreit 2003 abstract. The author provided additional raw data for this review were not reported in detail in the original paper (e.g. data for RV/TLC, bodyweight, BMI, body fat and fat-free mass).</P>
<P>The control group in this study is also used in the Kriemler study (<LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:24:44 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Hommerding-2015">
<CHAR_METHODS MODIFIED="2015-05-14 16:25:43 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Design: Single-centre parallel RCT; 3-month duration</P>
<P>Inclusion criteria: participants with CF aged 7 - 20 years; stable disease, no signs of exacerbation of respiratory symptoms in last 15 days.</P>
<P>Exclusion criteria: cognitive impairment, non CF-related bone and muscle abnormalities, heart disease with haemodynamic instability.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-11 09:09:09 +0000" MODIFIED_BY="Thomas Radtke">
<P>34 participants with CF (20 boys, 14 girls).</P>
<P>
<I>Group demographics</I>
</P>
<P>Exercise group (n = 17): mean (SD) age 13.4 (2.8) years.</P>
<P>Control group (n = 17): mean (SD) age 12.7 (3.3) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-14 16:26:54 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Aerobic exercise program based on verbal and written guidelines.</P>
<P>Exercise group: participants took part in a 3-month aerobic exercise training program based on verbal and written guidelines. The program included exercises such as jogging, swimming, walking, ball games and stretching exercises. Participants were told to practice the exercises at least twice a week for at least 20 min. No recommendations were provided regarding exercise intensity. Participants received telephone calls every 2 weeks and instructions were provided by one of the authors.</P>
<P>Control group: Participants were instructed about aerobic exercises once at baseline according to the CF center routine.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:24:44 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: VO<SUB>2</SUB> peak; FVC; FEV<SUB>1</SUB>; FEV<SUB>1</SUB>/FVC; FEF<SUB>25-75</SUB>; HRQoL; self-reported physical activity; body weight; BMI z score; triceps skinfold thickness; arm muscle circumference; SaO<SUB>2</SUB> at rest and peak exercise, treadmill time; treadmill speed; peak HR; Borg breathlessness and fatigue.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-11-01 16:12:52 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The sample size was estimated based on a mean (SD) change of 18.1 (13.8) points in the physical score of the HRQoL questionnaire. The estimated sample size was 15 participants in each group (95% power at a 5% level of significance). 2 more participants were included in each group to account for potential dropouts. Another study from the same group using the same aerobic exercise program was published recently (Schindel 2015). The responsible author of this publication confirmed that the vast majority of included participants were the same as in the Hommerding study (<LINK REF="STD-Hommerding-2015" TYPE="STUDY">Hommerding 2015</LINK>). There were only marginal differences in lung function (FEV<SUB>1</SUB>, FVC and FEF<SUB>25-75</SUB>) compared to the Hommerding study for which reasons we decided not to include lung function data in this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-02 10:09:13 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Klijn-2004">
<CHAR_METHODS MODIFIED="2017-11-01 16:12:55 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: Single-centre, parallel RCT, 3-month duration.</P>
<P>Inclusion criteria: Participants with CF aged 9 - 18 years; a stable clinical condition (i.e., no need for oral or IV antibiotic treatment in the 3 months prior to testing); the absence of musculoskeletal disorders; and an FEV<SUB>1</SUB> &gt; 30 % predicted.</P>
<P>Exclusion criteria: not specified.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-17 10:51:47 +0000" MODIFIED_BY="Thomas Radtke">
<P>20 participants with CF (stable disease) completed the study.<BR/>
<I>Group demographics</I>
</P>
<P>Group 1 (training) (n = 11): mean (SD) age 13.6 (1.3) years.</P>
<P>Group 2 (control) (n = 9): mean (SD) age 14.2 (2.1) years.<BR/>3 participants dropped out; 1 withdrew from the training group for practical reasons (training group) and 2 from the control group as they did not complete assessments due to pulmonary exacerbations.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-26 13:08:12 +0100" MODIFIED_BY="Tracey Remmington">
<P>Long-term anaerobic study (12 weeks).</P>
<P>Group 1: anaerobic exercise (2 days per week for 30 - 45 min).</P>
<P>Group 2: normal daily activities.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-02 10:09:13 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: BMI; FEV<SUB>1</SUB>; FVC; FEF<SUB>25-75</SUB>; RV/TLC; Wingate Anerobic Test (PP, MP); VO<SUB>2 </SUB>peak; peak working capacity; VCO<SUB>2</SUB>; VE; RER; lactate; habitual activity estimation scale; HRQoL; fat-free mass.</P>
<P>Outcomes measured again at 12 weeks follow up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-10 10:00:30 +0000" MODIFIED_BY="Nikki Jahnke">
<P>To achieve a difference in PP per kg body weight of 10% with an SD of 0.8 W/kg and a statistical power of 80%, it was calculated that 8 participants had to be included in each study group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:19:55 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Kriemler-2013">
<CHAR_METHODS MODIFIED="2017-11-01 16:13:02 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: multi-centre, parallel RCT with 3 arms; 24 months (6-month intervention and long-term, open follow-up period).</P>
<P>Inclusion criteria: diagnosis of CF; aged 12 years and over; a FEV<SUB>1</SUB> % predicted &#8805; 35%; ability to perform physical activity without harm.</P>
<P>Exclusion criteria: non-CF related chronic diseases and conditions posing an increased risk to the participant when exercising.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-17 14:13:17 +0000" MODIFIED_BY="Thomas Radtke">
<P>39 participants with CF split into 3 groups.</P>
<P>
<I>Group demographics</I>
</P>
<P>Group 1 (aerobic training) (n = 17): mean (95% CI) age 23.8 (21.5 to 26.5) years.</P>
<P>Group 2 (strength training) (n = 12): mean (95% CI) age 19.0 (16.0 to 22.0) years.</P>
<P>Group 3 (control) (n = 10): mean (95% CI) age 20.3 (17.0 to 23.6) years.</P>
<P>A separate control group from a parallel study (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>) was added due to an unusual deterioration of physical health in the control group in this study (n = 15), mean (95% CI) age 19.5 (16.8 to 22.2) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-26 13:00:52 +0100" MODIFIED_BY="Tracey Remmington">
<P>Long-term exercise study.</P>
<P>Group 1: participants consented to perform 3 aerobic training sessions per week of 30 - 45 min duration for the first 6 months and received support which was stopped thereafter.</P>
<P>Group 2: participants consented to perform 3 strength training sessions per week of 30 - 45 min duration for the first 6 months and received support which was stopped thereafter.</P>
<P>Group 3: participants in the control group were told to keep their activity level constant. Free access to a fitness centre for 1 year was offered after the first study year.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:19:55 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: FEV<SUB>1</SUB>; FVC; RV/TLC; VO<SUB>2</SUB> peak; peak workload; Wingate anaerobic test (PP, MP); physical activity; body fat; fat-free mass.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-15 13:53:01 +0100" MODIFIED_BY="Thomas Radtke">
<P>This study is a full text article of the Kriemler 2001 and Hebestreit 2003 abstracts.</P>
<P>The control group experienced a deterioration of physical health during the study. In the original paper, a second control group from a German study with similar design and methods (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>) was used for comparisons.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-09 15:10:49 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Michel-1989">
<CHAR_METHODS MODIFIED="2015-02-10 09:06:41 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre, parallel RCT during hospital admission.</P>
<P>Inclusion criteria: not specified.</P>
<P>Exclusion criteria: not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-09 15:10:24 +0000" MODIFIED_BY="Nikki Jahnke">
<P>9 participants with CF, not stated how many allocated to each group.<BR/>
<I>Group demographics</I>
</P>
<P>Exercise group: mean (SD) age 25.5 (10.5) years.</P>
<P>Non-exercise group: mean (SD) age 21.5 (3.2) years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-17 10:54:39 +0000" MODIFIED_BY="Thomas Radtke">
<P>Short-term aerobic study.<BR/>Group 1: exercise and standardised CF protocol.</P>
<P>Group 2: standardised CF protocol. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-17 10:54:44 +0000" MODIFIED_BY="Thomas Radtke">
<P>Included in this study were: skin folds; mid-arm circumference; grip strength; respiratory muscle strength; ideal body weight.</P>
<P>Measured at 1 month post-discharge.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-09 15:10:49 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Limited information as published as abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:13:16 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Moorcroft-2004">
<CHAR_METHODS MODIFIED="2015-02-10 09:07:29 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre, parallel RCT; 1-year duration.</P>
<P>Inclusion criteria: participants with CF who were willing to participate were recruited from a population of 150 attending the adult CF centre in Manchester at the time of the study. All participants had documented CF on the basis of clinical history plus either an increased sweat chloride or abnormal genetic testing.</P>
<P>Exclusion criteria: participation in another clinical trial; pregnancy; transplant listing, or clinical cor pulmonale.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-09 15:11:07 +0000" MODIFIED_BY="Nikki Jahnke">
<P>51 participants with CF were randomised; 42 completed the study.<BR/>
<I>Group demographics</I>
</P>
<P>Exercise group (n = 30): mean (SD) age 23.5 (6.4) years.</P>
<P>Control group (n = 18): 23.6 (5.5) years.<BR/>3 participants dropped out at the start of programme: 1 from training group due to failure to attend on initial assessment; and 2 in the control group were withdrawn due to ill health. A further 6 participants dropped out during the 1-year period.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-10 08:50:01 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Long-term aerobic and anaerobic study over 1 year.<BR/>Group 1: unsupervised exercise (based on individual preferences general aerobic exercises for lower body and weight training for upper body) 3 times per week.</P>
<P>Group 2: control (continue with usual activities).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:13:16 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: FEV<SUB>1</SUB>; FVC; whole blood lactate; RER; heart rate; Borg breathlessness and muscle effort; VE, RR peak for arm and bicycle ergometry at 55% maximal workload; BMI and weight.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>This study is a full text article of Dodd 1998 and Moorcroft 2000 abstracts.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:24:52 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Rovedder-2014">
<CHAR_METHODS MODIFIED="2015-02-10 09:09:53 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre, parallel RCT; 3-months home-based exercise programme.</P>
<P>Inclusion criteria: participants diagnosed with CF in accordance with the criteria of the consensus;aged &#8805;16 years; &#8805; 30 days of clinical respiratory disease stability.</P>
<P>Exclusion criteria: participants who refused to take part in the study; pregnant ladies; individuals with heart disease, orthopaedic or traumatological problems.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-10 09:11:38 +0000" MODIFIED_BY="Nikki Jahnke">
<P>41 participants with CF.</P>
<P>Group demographics</P>
<P>Exercise group (n = 22): mean (SD) age 23.8 (8.3) years.</P>
<P>Control group (n = 19): mean (SD) age 25.4 (6.9) years.</P>
<P>2 study participants in the exercise group could not be assessed at the 3-months follow up due to lung transplant assessment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-10 09:13:22 +0000" MODIFIED_BY="Nikki Jahnke">
<P>3-month home-based exercise programme.</P>
<P>Group 1: participants received printed guidance for aerobic and muscle strengthening exercises and were advised to perform the programme on a daily basis. Weekly telephone contacts were performed during the 3-month period. </P>
<P>Group 2: control group participants received standard programme without any specific exercise instructions.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:24:52 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: HRQoL; FEV<SUB>1</SUB>; FVC; walking distance (6MWT); SaO<SUB>2</SUB> at peak exercise; RR at peak exercise; peak exercise HR; dyspnoea and fatigue scores; upper and lower body muscle strength.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-26 13:31:00 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:32:42 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Santana_x002d_Sosa-2012">
<CHAR_METHODS MODIFIED="2017-11-01 16:32:42 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre, parallel RCT; 3-month duration (8 weeks training, 4 weeks detraining).</P>
<P>Inclusion criteria: potential participants included 111 children previously diagnosed using a genetic test for CF and treated at the Children&#8217;s Hospital Nino Jesus in Madrid. Males or females aged 5 to 15 years and living in the Madrid area (able to attend training sessions).</P>
<P>Exclusion criteria: severe lung deterioration, as defined by an FEV<SUB>1</SUB> &lt; 50% predicted; unstable clinical condition (i.e. hospitalisation within the previous 3 months); <I>Burkholderia cepacia</I> infection; musculoskeletal disease or any other disorder impairing exercise.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-14 16:31:35 +0100" MODIFIED_BY="Nikki Jahnke">
<P>22 participants with CF.</P>
<P>Group demographics.</P>
<P>Training group (n = 11): mean (SEM, range) age 11 years (3 years, 5 - 15 years).</P>
<P>Control group (n = 11): mean (SEM, range) age 10.0 years (2 years, 6 - 14 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-10 09:20:21 +0000" MODIFIED_BY="Nikki Jahnke">
<P>8-week intrahospital programme followed by a 4-week detraining period. All participants received the same chest physiotherapy during the entire study period.</P>
<P>Group 1: endurance and strengthening exercises, 3 times per week.</P>
<P>Group 2: control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:24:57 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: VO<SUB>2</SUB> peak; upper and lower body strength (bench press, leg press, seated row); FEV<SUB>1</SUB>; FVC; PI<SUB>max</SUB>; SaO<SUB>2</SUB> at peak exercise; body weight; BMI; fat-free mass; body fat; HRQoL; Timed Up and Go test (TUG); Timed Up and Down Stairs test (TUDS).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-16 09:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>Additional raw data for all included outcomes provided by the authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:20:19 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Santana_x002d_Sosa-2014">
<CHAR_METHODS MODIFIED="2017-11-01 16:13:31 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre, parallel RCT; 3-month study (8 weeks training, 4 weeks detraining).</P>
<P>Inclusion criteria: potential participants included 95 outpatient children previously diagnosed with CF by genetic testing and treated at the Children&#8217;s Hospital Nino Jesus in Madrid. Males or females aged 6 &#8211; 17 years and living in the Madrid area (able to attend training sessions).</P>
<P>Exclusion criteria: severe lung deterioration (FEV<SUB>1</SUB> &lt; 50% predicted); unstable clinical condition (i.e., hospitalisation within the previous 3 months); <I>Burkholderia cepacia</I> infection or any disorder (e.g., musculoskeletal) impairing exercise.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-10 09:33:19 +0000" MODIFIED_BY="Nikki Jahnke">
<P>20 participants with CF.</P>
<P>
<I>Group demographics</I>
</P>
<P>Training group (n = 10): mean (SEM) age 11.1 (1.1) years.</P>
<P>Control group (n = 10): mean (SEM) age 10.1 (1.1) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-10 09:40:43 +0000" MODIFIED_BY="Nikki Jahnke">
<P>8-week programme followed by a 4-week detraining period. All participants received the same standard chest physiotherapy.</P>
<P>Group 1: whole body aerobic and weight training 3 times per week, plus two daily inspiratory muscle training sessions</P>
<P>Group 2: control group performed inspiratory muscle training only at a low intensity.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:20:19 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: VO<SUB>2</SUB> peak; FVC; FEV<SUB>1;</SUB> PI<SUB>max;</SUB> SaO<SUB>2</SUB> at peak exercise, muscle strength; body weight; body fat; fat-free mass; and HRQoL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-16 09:53:52 +0100" MODIFIED_BY="[Empty name]">
<P>Additional raw data for all included outcomes provided by the authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:20:35 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Schneiderman_x002d_Walker-2000">
<CHAR_METHODS MODIFIED="2017-11-01 16:13:37 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre, parallel RCT, 3-year duration.</P>
<P>Inclusion criteria: participants with CF aged 7 - 19 years with an FEV<SUB>1</SUB> &gt; 40% predicted.</P>
<P>Exclusion criteria: not specified.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-10 09:44:14 +0000" MODIFIED_BY="Nikki Jahnke">
<P>65 participants with CF; 2 groups similar at baseline. 7 dropouts.<BR/>Group demographics</P>
<P>Exercise group (n = 30): mean (SD) age 13.4 (3.9 years).</P>
<P>Control group (n = 35): mean (SD) age 13.3 (3.6) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-26 13:08:15 +0100" MODIFIED_BY="Tracey Remmington">
<P>Long-term aerobic study.<BR/>Group 1: minimum of 20 min aerobic activity plus 5 min warm up and cool down 3 times per week.</P>
<P>Group 2: maintained regular activity (control).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:20:35 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: FVC; FEV<SUB>1</SUB>; FEF<SUB>25-75</SUB>; PEFR; TV; VO<SUB>2 </SUB>peak; VCO&#8322;; peak exercise heart rate; peak exercise VE; VE peak/MVV; RER; blood pressure; % of ideal weight for height; compliance and sense of well-being; feasibility of exercise; hospital stays and number of days in hospital; chest X-ray; and Schwachman scores.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-29 10:08:59 +0100" MODIFIED_BY="Thomas Radtke"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:20:39 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Selvadurai-2002">
<CHAR_METHODS MODIFIED="2015-02-10 09:46:22 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre, parallel RCT; hospital admission for recurrent chest infections.</P>
<P>Inclusion criteria: children with CF, aged 8 - 16 years who were admitted the the Royal Alexandria Hospital for Children for the treatment of an infectious pulmonary exacerbation.</P>
<P>Exclusion criteria: children with known pulmonary hypertension, or who required daytime oxygen prior to the pulmonary exacerbation which led to the hospital admission.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-10 09:50:59 +0000" MODIFIED_BY="Nikki Jahnke">
<P>66 children with CF (28 males, 38 females). No dropouts.<BR/>
<I>Group demographics</I>
</P>
<P>Aerobic training group (n = 22): mean (SD) age 13.2 (2.0) years), 9 males and 13 females.</P>
<P>Resistance training group (n = 22): mean (SD) age 13.1 (2.1) years, 10 males and 12 females.</P>
<P>Control group (n = 22): mean (SD) age 13.2 (2.0) years, 9 male and 1 females.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-26 13:08:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>Short-term aerobic and anaerobic/strength training study during hospital admission (mean duration 18.7 days, range 14 - 36 days).<BR/>Group 1: 30 min supervised aerobic exercise training 5 times per week.</P>
<P>Group 2: 30 min supervised resistance training 5 times per week.</P>
<P>Group 3: no specific training.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:20:39 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: VO<SUB>2</SUB> peak; peak VE; VCO&#8322;; peak HR; HRQoL; FEV<SUB>1</SUB>; FVC; weight; lower limb strength; and fat-free mass.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-26 13:34:04 +0100" MODIFIED_BY="Thomas Radtke"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-11-01 16:13:47 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Turchetta-1991">
<CHAR_METHODS MODIFIED="2015-02-10 09:53:43 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Design: single-centre, parallel RCT; hospital admission for routine assessment of clinical condition.</P>
<P>Inclusion criteria: not specified.</P>
<P>Exclusion criteria: not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 children with CF, 8 males, mean age 12.3 years.<BR/>No group demographics available.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-26 13:08:45 +0100" MODIFIED_BY="Tracey Remmington">
<P>Short-term aerobic study.<BR/>Group 1: 20 min running or treadmill per day for 2 weeks.</P>
<P>Group 2: normal hospital treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:13:47 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: FEV<SUB>1</SUB> and FVC.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-10 10:10:41 +0000" MODIFIED_BY="Nikki Jahnke">
<P>This study has only been reported in a single abstract and therefore the information is limited.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BMI: body mass index<BR/>CF: cystic fibrosis<BR/>CFRD: cystic fibrosis-related diabetes<BR/>FEF<SUB>25-75</SUB>: forced expiratory flow 25-75%<BR/>FEV<SUB>1</SUB>: forced expiratory volume at one second<BR/>FRC: functional residual capacity<BR/>FVC: forced vital capacity<BR/>HRQoL: health-related quality of life<BR/>IGT: impaired glucose tolerance<BR/>MP: mean power<BR/>MVV: maximal voluntary ventilation<BR/>PFS: progression-free survival<BR/>PI<SUB>max</SUB>: maximum inspiratory mouth pressure<BR/>PP: peak power<BR/>Raw: airways resistance<BR/>RCT: randomised controlled trial<BR/>RER: respiratory exchange ratio<BR/>RR: respiratory rate<BR/>RV: residual volume<BR/>SaO<SUB>2</SUB>: oxygen saturation<BR/>SD: standard deviation<BR/>SEM: standard error of the mean<BR/>SGAW: specific airways conductance<BR/>TLC: total lung capacity<BR/>VE: minute ventilation<BR/>VO<SUB>2</SUB> peak: peak oxygen consumption<BR/>VCO<SUB>2</SUB>: carbon dioxide production<BR/>VO<SUB>2</SUB>: oxygen uptake<BR/>W: watt<BR/>WAnT: Wingate Anaerobic Test<BR/>6MWT: six-minute walk test<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-08-11 16:33:11 +0100" MODIFIED_BY="Thomas Radtke" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-08-29 12:44:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alarie-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-29 12:44:39 +0100" MODIFIED_BY="[Empty name]">
<P>This study compared the acute cardiovascular response in participants playing different active video games. No control group included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-11 08:49:20 +0000" MODIFIED_BY="Thomas Radtke" STUDY_ID="STD-Albinni-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-11 08:49:20 +0000" MODIFIED_BY="Thomas Radtke">
<P>This study was designed with the exercise group as the control group, therefore we could not compare data with baseline, no physical exercise training as per our protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-11 08:49:29 +0000" MODIFIED_BY="Thomas Radtke" STUDY_ID="STD-Amelina-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-11 08:49:29 +0000" MODIFIED_BY="Thomas Radtke">
<P>IMT training and not physical exercise training as per our protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Andreasson-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aquino-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was designed with the aim of comparing the effectiveness of a single treatment sessions of exercise and PEP on sputum clearance. Participants in this study did not undertake a programme of physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-11 08:49:35 +0000" MODIFIED_BY="Thomas Radtke" STUDY_ID="STD-Asher-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-11 08:49:35 +0000" MODIFIED_BY="Thomas Radtke">
<P>IMT training and not physical exercise training as per our protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-10 10:01:47 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Balestri-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-10 10:01:47 +0000" MODIFIED_BY="Nikki Jahnke">
<P>This study was designed with the aim of comparing the effectiveness of a single treatment session of exercise and PEP on sputum clearance. Participants in this study did not undertake a programme of physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 11:03:48 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Balfour-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 11:03:48 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a physical exercise training study, comparison of different tests for assessing exercise capacity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barry-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:08:01 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Bieli-2017">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:08:01 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study of respiratory muscle endurance training, not a physical exercise training study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-10 10:02:02 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Bilton-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-10 10:02:02 +0000" MODIFIED_BY="Nikki Jahnke">
<P>This study was designed with the aim of comparing the effectiveness of a single treatment session of exercise or physiotherapy or exercise and physiotherapy on sputum clearance and lung function. Participants in this study did not undertake a programme of physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:09:46 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Bongers-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:09:46 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study evaluating the clinical usefulness of the steep ramp test and not a physical training study. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:37:27 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Calik_x002d_Kutukcu-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:37:27 +0100" MODIFIED_BY="Nikki Jahnke">
<P>No control group with no physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:22:16 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Chang-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:22:16 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study of methods for evaluating muscle function and not a physical training study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chatham-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study involved respiratory muscle training exclusively. This intervention does not constitute physical training as defined within our protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Jong-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 10:29:37 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-del-Corral-Nunez_x002d_Flores-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 10:29:37 +0100" MODIFIED_BY="Nikki Jahnke">
<P>No control group with no physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:40:16 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Dwyer-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:40:16 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study duration insufficient,</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:40:18 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Dwyer-2017">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:40:18 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study duration insufficient,</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Edlund-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Falk-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was designed with the aim of comparing the effectiveness of a single treatment session of exercise or positive expiratory pressure on lung function. Participants in this study did not undertake a programme of physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:28:58 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Giacomodonato-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:28:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study of respiratory muscle endurance training and not a physical training study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 10:30:19 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Gruet-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 10:30:19 +0100" MODIFIED_BY="Nikki Jahnke">
<P>No control group with no physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:39:02 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Haynes-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:39:02 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Evaluation of the incremental step test not a study of physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heijerman-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 10:07:36 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Irons-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 10:07:36 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a physical exercise training study, examines effect of a singing program compared to no singing.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:27:36 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Kriemler-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:27:36 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study duration insufficient, only 3 single day interventions on non-consecutive days of a week.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-03 11:59:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuys-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-03 11:59:06 +0000" MODIFIED_BY="[Empty name]">
<P>Compares Nintendo Wii exercise training to an existing exercise programme, no control group with no physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lannefors-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was designed with the aim of comparing the effectiveness of a single treatment session of exercise and FET or positive expiratory pressure and FET or postural drainage, thoracic expansion exercises and FET on mucous clearance. Participants in this study did not undertake programme of physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 10:08:38 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Lima-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 10:08:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>No physical exercise training study, study looks at effect of non-invasive ventilation on exercise capacity and lung function.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-17 10:30:02 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Lowman-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-17 10:30:02 +0100" MODIFIED_BY="Nikki Jahnke">
<P>No control group with no physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-01 10:02:14 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-NCT02277860">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-01 10:02:14 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a randomised controlled study, single arm trial of physical exercise,</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-01 09:53:25 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-NCT02715921">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-01 09:53:25 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a randomised controlled study, single arm trial of physical exercise,</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-11 16:32:58 +0100" MODIFIED_BY="Thomas Radtke" STUDY_ID="STD-NCT02821130">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-11 16:32:58 +0100" MODIFIED_BY="Thomas Radtke">
<P>A study of CFTR potentiator therapy and effects on exercise capacity. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-11 16:33:11 +0100" MODIFIED_BY="Thomas Radtke" STUDY_ID="STD-NCT02875366">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-11 16:33:11 +0100" MODIFIED_BY="Thomas Radtke">
<P>A study of CFTR potentiator therapy and effects on exercise capacity. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-01 12:34:19 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-NCT03117764">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-01 12:34:19 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a randomised controlled study, study of the effect of antibiotics on muscular strength and not physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Orenstein-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Orenstein-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compares aerobic training to upper-body strength training, no control group with no physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:02:23 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Ozaydin-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:02:23 +0100" MODIFIED_BY="Nikki Jahnke">
<P>IMT training and not physical exercise training as per our protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:41:46 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Patterson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:41:46 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study to evaluate the efficacy of the test of incremental respiratory endurance, not a physical training study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-04-09 09:28:11 +0100" MODIFIED_BY="Thomas Radtke" STUDY_ID="STD-Petrovic-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-04-09 09:28:11 +0100" MODIFIED_BY="Thomas Radtke">
<P>Not a randomised controlled study. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-08 13:05:20 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Rand-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-08 13:05:20 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a physical exercise training study. This study was designed to develop an incremental field exercise test for children with CF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-26 13:04:50 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Reix-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-26 13:04:50 +0100" MODIFIED_BY="Tracey Remmington">
<P>Acute study comparing exercise with expiratory breathing manoeuvres to breathing techniques for airway clearance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salh-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 10:06:19 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Salonini-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 10:06:19 +0100" MODIFIED_BY="Nikki Jahnke">
<P>A comparison of two exercise interventions (Xbox Kinect versus stationary cycle). No control group with no physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:36:23 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Shaw-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:36:23 +0100" MODIFIED_BY="Nikki Jahnke">
<P>No control group with no physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stanghelle-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tuzin-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:34:39 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Vallier-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:34:39 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study to evaluate modified shuttle test and not a study of physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 10:06:03 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Vivodtzev-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 10:06:03 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This study evaluated neuromuscular electrical stimulation prior to endurance training in people with CF. No control group with no physical training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-31 16:15:38 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Wheatley-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-31 16:15:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Intervention only given on 3 single days, comparison of physical training and albuterol for airway clearance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CF: cystic fibrosis<BR/>FET: forced expiration technique<BR/>IMT: inspiratory muscle training<BR/>PEP: positive expiratory pressure</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-11-02 10:11:59 +0000" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2017-11-02 10:11:03 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-ACTRN12617001009303">
<CHAR_METHODS MODIFIED="2017-10-26 11:52:54 +0100" MODIFIED_BY="Tracey Remmington">
<P>RCT.</P>
<P>Parallel design.</P>
<P>Duration: 12 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-02 10:10:52 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Target sample size: 150.</P>
<P>
<B>Inclusion criteria</B>: confirmed diagnosis of CF, hospital inpatient admission (including hospital in the home) for IV antibiotic therapy for a respiratory cause, informed consent, access to the Internet via computer or mobile device.</P>
<P>
<B>Exclusion criteria</B>: presence of severe co-morbidity limiting mobilisation or physical activity participation, previous lung transplantation, pregnancy.</P>
<P>Age minimum: 12 Years</P>
<P>Age maximum: 24 Years</P>
<P>Gender: Both males and females</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-02 10:11:03 +0000" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Intervention group</B>: use of the ActivOnline program, via the Internet, as well as usual care. ActivOnline was developed in accordance of the principles of motivational interviewing and has been used to promote physical activity participation in older adults with chronic respiratory disease. Those allocated to the ActivOnline group will be provided with a unique logon and password to access the ActivOnline program and will be asked to record their daily physical activity and exercise using the secure portal. When logging onto ActivOnline they will be prompted to set goals, will record their PA or exercise using a pedometer or other device of their choice and will regularly enter data about that will be displayed graphically so they can see their progress.</P>
<P>
<B>Control group</B>: usual care.</P>
<P>Usual care provides details for an online resource regarding physical activity participation and physical activity targets for children and young adults (www.nhs.uk/Livewell/fitness/Pages/physical-activity-guidelines-for-young-people.aspx) as well as activity and exercise guidance, as indicated, as part of their routine clinical care on hospital discharge.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:13:55 +0000" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Primary outcome</B>
</P>
<P>Change in physical activity participation objectively measured via accelerometry<BR/>
</P>
<P>
<B>Secondary outcomes</B>
</P>
<P>Change in exercise capacity as measured by the MST<BR/>Change in health related quality of life as assessed by the CFQ-R<BR/>Change in HADS<BR/>Change in lung function as measured by FEV<SUB>1</SUB>
<BR/>Change in physical activity participation objectively measured via accelerometry<BR/>Change in physical activity participation self reported by the HAES<BR/>Change in the CES-D scale<BR/>Change in the PSQI<BR/>Number of hospital inpatient days by medical record review<BR/>Time to first hospital admission, by medical record review</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-28 14:59:37 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Supported by UK CF Trust.</P>
<P>Email confirmation from lead investigator (17 August 2017) that trial has been completed and they are currently analysing data. We hope to obtain data for the CF participants once the trial has been published.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-01 16:13:57 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Almajan-2011">
<CHAR_METHODS MODIFIED="2017-10-26 11:53:09 +0100" MODIFIED_BY="Tracey Remmington">
<P>Parallel design RCT.</P>
<P>6-month intervention.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-10-26 11:53:11 +0100" MODIFIED_BY="Tracey Remmington">
<P>38 participants with CF aged 7 - 13 years.</P>
<P>No group demographics available.</P>
<P>
<B>Inclusion criteria</B>: not specified.</P>
<P>
<B>Exclusion criteria</B>: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-10 10:04:39 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Group 1 (n = 19): classical physiotherapy plus sport activities 3 times per week.</P>
<P>Group 2 (n = 19): classical physiotherapy alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:13:57 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Eligible for inclusion are: FEV<SUB>1;</SUB> FVC; FEF<SUB>25-75</SUB>; number of hospitalisations; participation at school; and activities of daily living.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-20 14:57:14 +0000" MODIFIED_BY="Thomas Radtke">
<P>No information were available in the abstract about types of exercises, intensity, frequency and duration of exercise training. </P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-10-26 11:54:02 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Housinger-2015">
<CHAR_METHODS MODIFIED="2017-10-26 11:53:33 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: Modified RCT; motivational incentive-based walking program for patients hospitalised with pulmonary exacerbation.</P>
<P>Series of 2-week intervals with 1-week wash-out periods were created and randomized as either treatment or control.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-10-26 11:53:44 +0100" MODIFIED_BY="Tracey Remmington">
<P>29 participants with CF (11 males; 18 females).</P>
<P>
<I>Group demographics:</I>
</P>
<P>Intervention group (n = 18)</P>
<P>Control group (n = 11)</P>
<P>
<B>Inclusion criteria</B>: not specified.</P>
<P>
<B>Exclusion criteria</B>: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 11:54:02 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Intervention group</B> (n = 18): incentive-based walking program plus standard care including daily (Monday to Friday) physical therapy.</P>
<P>
<B>Control group</B> (n = 11): standard care including daily (Monday to Friday) physical therapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-09-27 15:19:13 +0100" MODIFIED_BY="Thomas Radtke">
<P>Included in this study were: 6MWT distance; vital signs; Bruininks-Oseretsky Test of Motor Proficiency; strengths assessment score and HRQoL (CFQ-R).</P>
<P>Data were collected within 72 hours of hospital admission and within 48 hours of hospital discharge.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-09-27 15:20:36 +0100" MODIFIED_BY="Thomas Radtke"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-10-26 11:54:37 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Johnston-2004">
<CHAR_METHODS MODIFIED="2017-10-26 11:54:13 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: parallel RCT; 6-week exercise programme followed by a 16-week home-based programme.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-10-26 11:54:25 +0100" MODIFIED_BY="Tracey Remmington">
<P>89 participants aged 7 - 11 years old and with different lung conditions: asthma (n = 60), CF (n = 12), a history of chronic neonatal lung disease (n = 17).</P>
<P>
<I>Group demographics</I> are not available. No information on dropouts.</P>
<P>
<B>Inclusion criteria</B>: not specified.</P>
<P>
<B>Exclusion criteria</B>: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 11:54:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>6-week exercise programme with weekly exercise sessions followed by a home-based programme using behaviour change strategies to promote aerobic exercise. Participants were evaluated at baseline, 7 weeks and 24 weeks.</P>
<P>
<B>Intervention group</B>: n = 45.</P>
<P>
<B>Control group</B>: n = 44.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-29 15:32:42 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: aerobic fitness (exercise test not specified); vigorous physical activity; self perception of athletic competence and physical appearance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-29 15:34:56 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We plan to contact the authors to obtain the CF-specific data.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-10-26 11:54:59 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Lorenc-2015">
<CHAR_METHODS MODIFIED="2017-10-26 11:54:48 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: parallel RCT; single centre comparative effectiveness trial at the Royal Brompton Hospital, London, UK. Phase 2 study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-10-26 11:54:50 +0100" MODIFIED_BY="Tracey Remmington">
<P>72 participants with CF aged over 6 years from the Royal Brompton Hospital, London.</P>
<P>
<I>Group demographics</I> are not available.</P>
<P>
<B>Inclusion criteria</B>: not specified.</P>
<P>
<B>Exclusion criteria</B>: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 11:54:59 +0100" MODIFIED_BY="Tracey Remmington">
<P>Phase 2 study.</P>
<P>
<B>Group 1</B>: 8x one-on-one Tai Chi sessions then given a DVD and a handout to use at home for 9 months and encouraged to practice up to 5 times per week.</P>
<P>
<B>Group 2</B>: no treatment (standard care) for the first 3 months (<I>this is the control</I>), then 8x online Tai Chi sessions (e.g. via Skype) and given a DVD and a handout to use at home for 6 months and again encouraged to practice up to 5 times per week.</P>
<P>The programme was evaluated at baseline and after 3, 6 and 9 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-29 15:36:34 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: HRQoL; mindfulness, sleep (not specified); medical data (not specified) and respiratory function (not specified); participants' experience; Tai Chi feasibility; perceived health impact and study participation. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-09-27 15:21:28 +0100" MODIFIED_BY="Thomas Radtke">
<P>We plan to contact the authors to obtain more information on study design and results.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-01 16:14:00 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Mandrusiak-2011">
<CHAR_METHODS MODIFIED="2017-10-26 11:55:05 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: parallel RCT, 10 - 14 day inpatient period at a tertiary hospital followed by a 8 - 12 week home-based program. Blinded assessor.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 16:14:00 +0000" MODIFIED_BY="Nikki Jahnke">
<P>31 participants with CF aged 8.5 to 17.6 years and with a mean FEV<SUB>1</SUB> of 66.74 %.</P>
<P>
<I>Group demographics</I>
</P>
<P>
<B>Group 1</B>: exercise program (n = 15).</P>
<P>
<B>Group 2</B>: standard physiotherapy exercise (n = 16).</P>
<P>
<B>Inclusion criteria</B>: not specified.</P>
<P>
<B>Exclusion criteria</B>: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 11:55:22 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Group 1 </B>(n = 15): a novel exercise program including a portable exercise package (FitKit&#8482; - exercise in a bag including instruction cards, exercise equipment and daily exercise log).</P>
<P>
<B>Group 2</B> (n = 16): standard physiotherapy exercise practice.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-10-26 12:48:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Performance on study measures (scoped within the framework of the International Classification of Functioning, Disability and Health model) - details not reported.</P>
<P>Assessment at 3 time points:</P>
<UL>
<LI>admission to the inpatient period;</LI>
<LI>at discharge from the 10 - 14 day inpatient period; and</LI>
<LI>at conclusion of the 8 - 12 week home program.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-29 16:17:33 +0100" MODIFIED_BY="Nikki Jahnke">
<P>No data available currently, but will be added when study published in full.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-01 16:21:32 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-NCT00609050">
<CHAR_METHODS MODIFIED="2017-10-26 11:55:43 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: cross-over RCT; single blind (outcome assessor); 6 months duration; single-centre study at Children's Hospital of Pittsburgh, USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-10-26 11:55:54 +0100" MODIFIED_BY="Tracey Remmington">
<P>Enrolment goal: 38 participants with CF.</P>
<P>
<B>Inclusion criteria</B>: CF diagnosis; males and females; age 10 - 18 years; reliable pulmonary function test; living at home; able to read; able to ride a stationary bike; able to walk and/pr run on a treadmill.</P>
<P>
<B>Exclusion criteria</B>: enrolled in another intervention study; participation in structured aerobic exercise for 30 continuous minutes 3 times per week; sibling enrolled in study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 11:56:06 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Intervention group</B>: home-based exercise programme at least 3 times per week for 6 months with telephone reinforcement. After the first 6 months, participants receive instructions to maintain their self-regulated exercise activity for another 6 months without receiving telephone calls.</P>
<P>
<B>Control group</B>: standard recommendations for exercise activity during the first 6 months. Thereafter, the control group will cross over to the self-regulated exercise without telephone reinforcement.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:21:32 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: VO<SUB>2</SUB> peak; peak workload; VO<SUB>2</SUB> 150 (VO<SUB>2</SUB> at a heart rate of 150 bpm per minute during an exercise test); FEV<SUB>1</SUB>; sustained phonation time; HRQoL (CF questionnaire and well-being scale) and exercise experiences of children and parents assessed with interviews.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-29 16:19:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>A 6-month program of self-regulated, home-based exercise programme with telephone reinforcement on cardiorespiratory fitness, pulmonary function and HRQoL of children with CF, compared to controls. A secondary aim is to exploring the exercise experiences of the children and parents.</P>
<P>The principal investigator confirmed that the trial is completed and data are currently being analyzed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-01 16:21:39 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-NCT00792194">
<CHAR_METHODS MODIFIED="2017-10-26 11:56:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: parallel RCT; open-label; duration 24 months; partially-supervised; single-centre study at University Hospital, Strasbourg, France.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 16:14:06 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Enrolment goal: 50 participants with CF.</P>
<P>
<B>Inclusion criteria</B>: males and females aged 15 - 65 years with CF diagnosed by clinical history and positive genetic or sweat testing; signed informed consent (or by parents for paediatric participants); participant covered by social security; participant has no indication of cardiac issues; stable disease (FEV<SUB>1</SUB> &gt; 1000 mL); in the case of insulin-dependent diabetes, it must be stable; participant had been informed of the results of the medical examination; women of childbearing age confirmed not to be pregnant by urine test.</P>
<P>
<B>Exclusion criteria</B>: participant with unstable diabetes or known cardiac issues; participant on transplant list.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 11:56:49 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Intervention</B> <B>group</B>: partially-supervised exercise training programme with the aim of exercising 3x per week over 24 months; exercise intensity controlled with heart rate monitors and supported by exercise coaches.</P>
<P>
<B>Control</B> <B>group</B>: normal daily activities and physiotherapy regimen.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:21:39 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: VO<SUB>2</SUB> peak; HRQoL (CFQ-14+ and SF 36).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-09-27 15:22:17 +0100" MODIFIED_BY="Thomas Radtke">
<P>The principal investigator of this study responded on our request and confirmed that the study has been closed prematurely due to local organisational and recruitment problems. No publication is planned for this study.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-02 10:11:59 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-NCT02552043">
<CHAR_METHODS MODIFIED="2017-10-26 11:57:11 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: parallel RCT; duration 6 weeks; open-label; single-centre study at Universidad Autonoma de Madrid, Spain.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-10-26 11:57:13 +0100" MODIFIED_BY="Tracey Remmington">
<P>Enrolment goal: 41 participants with CF.</P>
<P>
<B>Inclusion</B> <B>criteria</B>: males and females aged 7-18 years diagnosed with CF; clinically stable with no exacerbations of the disease in the previous 6 weeks to the inclusion date.</P>
<P>
<B>Exclusion</B> <B>criteria</B>: clinical evidence of cardiovascular, neuromuscular or osteo-articular co-morbidities that limit the participation in exercise programmes; lung transplant candidates and participants that followed any kind of rehabilitation programme 12 months before the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-11-02 10:11:59 +0000" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Intervention</B> <B>group</B>: 30 - 60 min exercise using a Nintendo Wii platform with the game EA SPORTS ACTIVE 2, 5 days/week for 6 weeks. The exercise activities are loaded into each participant's console during the clinical interview and the exercises adjusted according to their age: &lt;12 years and &gt;13 years. The program consists of 6 different workouts (1st and 2nd weeks: legs exercises; 3rd week: upper limb exercises; 4th week: thorax exercises; 5th and 6th weeks: cardio exercises) with gradually increasing intensities reaching the maximum load at the end of the training.</P>
<P>
<B>Control</B> <B>group</B>: routine clinical management.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-29 17:31:46 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: exercise capacity (6MWT; modified shuttle walk test); muscular strength (horizontal jump test, medicine ball throw, handgrip strength); HRQoL using 3 versions of the CFQ-R (CFQ-R 6-11, CFQ-R 14+, CFQ-R Parents).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-29 16:40:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The aim of this study is to evaluate the efficacy of a long-term domiciliary exercise program using the Wii video game platform as a training modality in people with CF.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-01 16:14:09 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-NCT03100214">
<CHAR_METHODS MODIFIED="2017-10-26 11:57:42 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: parallel RCT; outcome assessor (exercise supervisor) blinded; single-centre study at Hospital de Clínicas de Porto Alegre, Brazil.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-10-26 11:57:44 +0100" MODIFIED_BY="Tracey Remmington">
<P>Estimated enrolment: 68 participants with CF.</P>
<P>
<B>Inclusion</B> <B>criteria</B>: males and females age 16 - 50 years, diagnosed with CF according to consensus criteria and regularly followed up in the Hospital de Clinicas de Porto Alegre Programme for Adolescents and Adults with CF; admitted to hospital (for at least 24 hours) due to exacerbation of lung disease.</P>
<P>
<B>Exclusion</B> <B>criteria</B>: participants with cardiac, orthopedic or trauma complications that make it impossible to perform the proposed exercises; pregnancy; participants with haemodynamic instability, massive haemoptysis, pneumothorax, and continuous use of non-invasive ventilation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 11:57:52 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Intervention</B> <B>group</B>: aerobic and anaerobic exercise 5 times a week during the hospitalisation period, with sessions lasting about an hour, programme beginning within 48 hours of admission.</P>
<P>
<B>Control</B> <B>group</B>: physiotherapeutic follow-up (including respiratory physiotherapy, inhalation therapy and techniques for removal of secretions) performed by the physiotherapist of the programme for adults with CF during the hospitalisation period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:14:09 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: primary outcome: 6MWT distance; secondary outcomes: FEV<SUB>1</SUB>; HRQoL (CFQ-R); C-reactive protein; interleukin-6; interleukin-8 and tumor necrosis factor.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-29 16:49:04 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This study study aims to evaluate the effects of an early rehabilitation programme based on aerobic training and muscle strength training in adolescent and adult participants with CF hospitalised at Hospital de Clinicas de Porto Alegre for exacerbation of lung disease.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-01 16:14:15 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-NCT03109912">
<CHAR_METHODS MODIFIED="2017-10-26 11:58:03 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: parallel RCT ("Do More, B'More, Live Fit"), duration 6 months; single-centre study at Johns Hopkins University, Baltimore, US.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 16:14:12 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Enrollment goal: 60 participants with CF.</P>
<P>
<B>Inclusion</B> <B>criteria</B>: males and females aged 12 - 21 years old with CF and cared for at Johns Hopkins; participants must have a smartphone and/or computer with universal serial bus (USB) to set-up FitBit Flex.</P>
<P>
<B>Exclusion</B> <B>criteria</B>: FEV<SUB>1</SUB> &lt; 40% predicted; individuals already participating in vigorous physical activity (as assessed by the study team) in year-round organised sports and/or aerobic exercise for longer than 30 minutes more than 5x per weeks may or may not be included in this study at the discretion of the principal investigator and study team.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 11:58:24 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Intervention</B> <B>group</B>: at baseline assessment participants given individualised exercise prescriptions with the aim of achieving 30-minutes of an endurance-style exercise (team sports, walking, jump roping, stair climbing or more complex Tabata-style workouts) 5 times/week for 6 months. At 4-6 weeks and 8-10 weeks post-enrolment, participants attend a follow-up 30-minute session which will vary based on initial assessment and previous exercise prescription success, but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques with additional individualised recommendations. Participants will also receive motivational messages starting 14 days after enrolment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period. Participants also given access to "Do More, B'More, Live Fit" web page which includes spotlighted exercises, instructional exercise photos and videos; also invited to join the "Do More, B'More, Live Fit" Activity Group via the FitBit Dashboard and to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.</P>
<P>
<B>Control</B> <B>group</B>: at baseline assessment, the FitBit daily step goal is set at the manufacturer standard 10,000 steps. At routine clinic visits, baseline and follow-up assessments (3 and 6 month clinic visits) participants given generic, non-personalised encouragement and recommendations (if requested by the participant) for physical activity. At the 3- and 6-month visits, exercise is reinforced with generic encouragement, export FitBit data and review any missing data concerning for equipment failure or user error.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:14:15 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were:</P>
<P>
<B>Primary</B> <B>outcomes</B>: LCI (LCI 2.5 and LCI 5.0); daily activity via FitBit step count and daily step count (mean, median and highest daily) recorded through participant FitBit flex.</P>
<P>
<B>Secondary</B> <B>outcomes</B>: FEV<SUB>1</SUB> % predicted; self-reported physical activity (Habitual Activity estimation Scale); HRQoL (CFQ-R); exercise capacity (modified shuttle walk test); acceptability and feasibility of the programme using semi-structured interviews.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-29 17:11:07 +0100" MODIFIED_BY="Nikki Jahnke">
<P>This study evaluates the "Do More, B'More, Live Fit", a 6-month fitness programme designed to optimise exercise habits of participants with CF through structured exercises with personalised coaching, exercise equipment including the FitBit Flex, online support and motivational messages delivered electronically. The intervention incorporates fitness preferences and encompasses endurance, strength and flexibility exercises while adjusting to physical fitness needs. The hypothesis is that intervention participants will have increased and sustained engagement and better health outcomes compared to control group participants.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-10-26 11:58:57 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Oliveira-2010">
<CHAR_METHODS MODIFIED="2017-10-26 11:58:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: parallel, prospective controlled clinical study; single-centre study; not clear from the abstract whether participants were randomly allocated to different interventions.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-10-26 11:58:50 +0100" MODIFIED_BY="Tracey Remmington">
<P>20 participants with CF, mean age 13.21 years.</P>
<P>
<B>Intervention group</B>: n = 10.</P>
<P>
<B>Control group</B>: n = 10.</P>
<P>
<B>Inclusion criteria</B>: not specified</P>
<P>
<B>Exclusion criteria</B>: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 11:58:57 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Group 1</B>: physical training at a private clinic and physiotherapy clinic.</P>
<P>
<B>Group 2</B>: no physical training.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-29 17:27:44 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were: lung function (not specified), 3-minute step test, maximum exertion test (not specified), collection of blood samples and a quality of life questionnaire.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-29 17:28:54 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Unclear whether this is a RCT. We contacted one author of the abstract, but have not received a reply to date. No information available in the abstract about types of exercises, intensity, frequency and duration of exercise training.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2017-11-01 16:14:18 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Phillips-2008">
<CHAR_METHODS MODIFIED="2017-10-26 11:59:02 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: parallel RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 16:14:18 +0000" MODIFIED_BY="Nikki Jahnke">
<P>35 participants aged 8 - 21 years with an FEV<SUB>1</SUB> &lt; 60%, who were admitted for a &#8805; 10 day hospitalisation for a CF exacerbation.</P>
<P>29 participants, mean (SD) age 15 (3.5) years, completed the study; 4 dropouts were recorded.</P>
<P>
<B>Inclusion criteria</B>: not specified.</P>
<P>
<B>Exclusion criteria</B>: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 11:59:19 +0100" MODIFIED_BY="Tracey Remmington">
<P>Training for PT management of a CF exacerbation during an inpatient hospital stay.</P>
<P>
<B>Group 1</B>: standardized moderate-to-high intensity resistance and aerobic training consisting of 1 hour of resistance training and flexibility training 3 days per week and 20 - 30 min of aerobic and balance training 2 days per week.</P>
<P>
<B>Group 2</B>: current standard of care which included 20 - 30 min of variable intensity aerobic training 5 days per week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-15 16:01:53 +0100" MODIFIED_BY="Thomas Radtke">
<P>MST and multiple measures of peripheral muscle performance at admission and discharge. Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-13 14:15:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study completed in 2008.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>CF: cystic fibrosis<BR/>CFQ-R: cystic fibrosis questionnaire - revised<BR/>FEF<SUB>25-75</SUB>: mid forced expiratory flow<BR/>FEV<SUB>1</SUB>: forced expiratory volume<BR/>FVC: forced vital capacity<BR/>HRQoL: health-related quality of life<BR/>MST: modified shuttle test<BR/>PT: physical therapy<BR/>RCT: randomised controlled trial<BR/>SD: standard deviation<BR/>VO<SUB>2</SUB> max: maximum oxygen consumption<BR/>6MWT: 6-minute walk test<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-11-02 10:13:17 +0000" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2017-11-01 16:14:26 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Donadio-2017">
<CHAR_STUDY_NAME MODIFIED="2017-08-29 17:32:01 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Effect of exercise orientations in the posture and plantar pressure distribution in children and adolescents with cystic fibrosis.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-08-29 17:32:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>RCT (open-label).</P>
<P>Design: parallel (2 arms).</P>
<P>Duration: 3 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-10 14:39:39 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Target sample size: 34</P>
<P>
<B>Inclusion criteria</B>: diagnosis of CF, clinically stable disease and regular follow-up at the CF outpatient clinic.</P>
<P>
<B>Exclusion criteria</B>: children and adolescents with comprehension deficits and/or who present arms/legs problems that would make it impossible to perform the tests.</P>
<P>Age minimum: 6 years.</P>
<P>Age maximum: 20 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-10 14:44:54 +0100" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Intervention group</B> (n = 17): participants will receive a written manual with orientations regarding physical activity, including weekly frequency. The manual contains physical activities and stretching orientations and participants are advised to perform their favourite exercise modality with a minimal frequency of 3 times per week, during 40 minutes. The manual also contains a calendar where the participant will mark the days when activities were performed.</P>
<P>
<B>Control group</B> (n = 17): participants will keep with their regular routine care orientations.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:14:26 +0000" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Primary outcome</B>
</P>
<P>General posture improvement: measured by the number of degrees obtained for kyphosis, lordosis, head position and chest size, using a specific software.</P>
<P>
<B>Secondary outcomes</B>
</P>
<P>Change in balance (measured using a baropodometer).</P>
<P>Lung function using spirometry (FEV<SUB>1</SUB>).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-08-10 14:37:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Date of first enrolment; 01 November 2013.</P>
<P>Recruitment completed.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-08-10 14:49:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Márcio Vinícius Fagundes Donadio (mdonadio@pucrs.br) - União Brasileira de Educação e Assistência - Porto Alegre, RS, Brazil</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-08-10 14:45:04 +0100" MODIFIED_BY="Nikki Jahnke"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-11-01 16:14:36 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Gupta-2017">
<CHAR_STUDY_NAME MODIFIED="2017-08-29 17:32:34 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Effects of exercise intervention program on bone mineral accretion in children and adolescents with cystic fibrosis.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-08-10 15:28:47 +0100" MODIFIED_BY="Nikki Jahnke">
<P>RCT (stratified block randomization, allocation concealed using sequentially numbered, sealed, opaque envelopes, open label).</P>
<P>Design: parallel.</P>
<P>Single centre.</P>
<P>Duration: 1 year.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 16:14:30 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Total sample size: 30.</P>
<P>
<B>Inclusion criteria</B>: children with confirmed diagnosis of CF (sweat chloride &#8805; 60 mEq/l on 2 or more occasions in a child with clinical features suggestive of CF), stable medical condition (not required IV antibiotics for last 1 month prior to enrolment), FEV<SUB>1</SUB> &#8805; 20%.</P>
<P>
<B>Exclusion criteria</B>: children unwilling to participate in the study; presence of any prior diagnosed musculoskeletal disorder such as rheumatoid arthritis, muscular dystrophy, chronic renal failure.</P>
<P>Age minimum: 6 years.</P>
<P>Age maximum: 18 years.</P>
<P>Gender: both.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-08-10 15:11:56 +0100" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Intervention group</B>: exercise program - resistance exercise and plyometric jumping exercise, 1x daily, 3x a week for 1 year.<BR/>
<B>Control group</B>: no exercise program, continue with regular physical activity for 1 year.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:14:36 +0000" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Primary outcome</B>
</P>
<P>Mean bone mineral density at 1 year.</P>
<P>
<B>Secondary outcomes</B>
</P>
<P>Lung function (FEV<SUB>1</SUB> and FVC) at baseline, 3 months, 6 months, 9 months and at the end of 1 year.<BR/>Exercise capacity at baseline and at the end of 1 year.<BR/>CFQ-R at baseline and at the end of year.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-08-10 15:33:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Date of first enrolment: 08 September 2012.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-10-26 11:48:53 +0100" MODIFIED_BY="Tracey Remmington">
<P>Sumita Gupta (Physiotherapist)<BR/>All India Institute of Medical Sciences, Department of Pediatrics, AIIMS, Ansari Nagar,New Delhi, DELHI 110029, India.<BR/>Email sumitabisoi@gmail.com<BR/>
<BR/>Professor SK Kabra<BR/>Department of Pediatrics, AIIMS, Ansari Nagar,New Delhi, DELHI 110029, India.<BR/>Email: skkabra@hotmail.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-08-10 15:10:01 +0100" MODIFIED_BY="Nikki Jahnke"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-11-02 10:13:17 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Hebestreit-2016">
<CHAR_STUDY_NAME MODIFIED="2017-08-29 17:32:53 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Effects of a Partially Supervised Conditioning Program in CF (ACTIVATE-CF, NCT01744561)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-10-26 11:59:43 +0100" MODIFIED_BY="Tracey Remmington">
<P>Design: parallel RCT; duration 12 months; international, multicentre study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-11-01 16:14:39 +0000" MODIFIED_BY="Nikki Jahnke">
<P>A total of 292 participants will be recruited.</P>
<P>
<B>Inclusion</B> <B>criteria</B>: males and females aged 12 years and older with a confirmed diagnosis of CF; FEV<SUB>1</SUB> &#8805; 35% predicted and access to Internet.</P>
<P>
<B>Exclusion</B> <B>criteria</B>: participation in another clinical trial up to 4 weeks prior to the first baseline visit; pregnancy or breast feeding; inability to exercise; more than 4 hours of reported strenuous physical activities per week currently or up to 3 months prior to baseline measurements and not already planned within the coming 6 months; unstable condition precluding exercise (major haemoptysis or pneumothorax within the last 3 months, acute exacerbation and IV antibiotics during the last 4 weeks, planned surgery, listed for lung transplantation, major musculoskeletal injuries such as fractures or sprains during the last 2 months, others according to the impression of the doctor); cardiac arrhythmias with exercise; requiring additional oxygen with exercise; recent diagnosis of diabetes 3 months prior to screening or at screening; recent changes in medication 1 month or less prior to screening (systemic steroids, ibuprofen, inhaled antibiotics, mannitol, DNAse, hypertonic saline); at least one G551D mutation and not on ivacaftor (VX770) yet but planned start or planned stop of ivacaftor during the trial and colonization with <I>Burkholderia cenocepacia</I>.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 12:00:02 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Intervention</B> <B>group</B>: addition of 3 hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 min of strength building activities and at least 2 hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time. Participants are given exercise counselling to boost motivation towards an active lifestyle, strategies include face-to-face information, motivational interviewing, clear goal settings, a written "activity contract" with specific information on which activities are scheduled for which day and for how long, a pedometer, a web-based activity diary (<A HREF="http://www.activate-cf.org">www.activate-cf.org</A>) providing feedback on missing time in intense activities to reach the weekly goal, and repeated counselling via telephone contacts and during clinic visits. A full manual describing the intervention and all intervention materials including the website are available in four languages: Dutch, English, French, and German.</P>
<P>
<B>Control</B> <B>group</B>: the control group is requested to their keep activity level constant.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-02 10:13:17 +0000" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Primary outcome</B>: FEV<SUB>1</SUB> % predicted (change from baseline to 6 months)</P>
<P>
<B>Secondary outcomes</B>: VO<SUB>2</SUB> peak (% predicted change from baseline to 6 months and baseline to 12 months); maximal aerobic power (% predicted change from baseline to 6 months and baseline to 12 months); steps per day (change from baseline to 6 months and baseline to 12 months); exercise steps per day (change from baseline to 6 months and baseline to 12 months); self-reported physical activity (baseline to 6 months and baseline to 12 months); FEV<SUB>1</SUB> (% predicted, change from 6 months to 12 months and baseline to 12 months); FVC (% predicted, change from baseline to 6 months and baseline to 12 months); residual volume in % of total lung capacity (change from baseline to 6 months and baseline to 12 months); time to first exacerbation (baseline to 6 months and baseline to 12 months); number of upper respiratory tract infections from diary (baseline to 6 months and baseline to 12 months); days on additional oral or IV antibiotics from questionnaire (baseline to 6 months and baseline to 12 months); body mass index (baseline to 6 months and baseline to 12 months); muscle mass (baseline to 6 estimated from skinfold thickness (baseline to 6 months and baseline to 12 months); body fat estimated from skinfold thickness (baseline to 6 months and baseline to 12 months); HRQoL (CFQ-R, baseline to 6 months and baseline to 12 months); depression, anxiety and stress scores from Depression Anxiety Stress Scales (baseline to 6 months and baseline to 12 months); plasma glucose concentrations 1 and 2 hours after a standardised glucose load (standardised oral glucose tolerance test only for participants without CF-related diabetes mellitus (baseline to 9 months); adverse events possibly or likely related to exercise (causality as judged by investigator, baseline to 6 months and baseline to 12 months); severe adverse events and serious adverse events (baseline to 6 months and baseline to 12 months).</P>
<P>
<B>Other outcome measures</B>: compliance with the exercise goal based on questionnaire and diary (baseline to 6 months and baseline to 12 months); lung clearance index based on nitrogen multiple breath washout, in selected centres only (baseline to 6 months and baseline to 12 months); time spent in moderate-and-vigorous physical activity based on accelerometry, in selected centres only (baseline to 6 months and baseline to 12 months); bone mineral density and body composition based on dual energy x-ray absorptiometry, in selected centres only (baseline to 6 months and baseline to 12 months); mucociliary clearance with exercise based on nuclear medicine scans, US centres only (baseline to 6 months).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-08-29 17:41:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>July 2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-08-29 17:41:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Prof. Dr. Helge U Hebestreit</P>
<P>Telephone: +49 931 201 22 728</P>
<P>E-mail: hebstreit@uni-wuerzburg.de</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-11-01 16:14:48 +0000" MODIFIED_BY="Nikki Jahnke">
<P>ACTIVATE-CF is an international, multicentre, randomised controlled trial to assess the effects of additional intense physical activity on a variety of outcomes. A combination of several strategies is used to boost motivation towards an active lifestyle. The primary objective of this study is to evaluate the effects of a 12-months partially supervised exercise intervention along with regular motivation on FEV<SUB>1</SUB> in a large international group of people with CF.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-11-01 16:14:54 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-NCT02700243">
<CHAR_STUDY_NAME MODIFIED="2017-08-29 17:45:57 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Increase Tolerance for Exercise and Raise Activity Through Connectedness Trial (INTERACT)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-08-29 17:46:10 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Design: parallel RCT, single-centre study at Boston Children&#8217;s Hospital, USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-10-26 12:00:19 +0100" MODIFIED_BY="Tracey Remmington">
<P>Enrolment goal: 80 participants with CF.</P>
<P>
<B>Inclusion</B> <B>criteria</B>: males and females aged 18 years and older with a confirmed diagnosis of CF; able to complete at least level 1 of the baseline exercise fitness test; participants must not have required IV antibiotics for a CF exacerbation within 30 days of starting the study.</P>
<P>
<B>Exclusion</B> <B>criteria</B>: pregnancy at enrolment; a history of CF exacerbation requiring IV antibiotics with the last month; use of a fitness tracker or similar product with 6 months of enrolment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-10-26 12:00:24 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Intervention</B> <B>group</B>: given a Fitbit and followed for 1 year, completing surveys and exercise tests.</P>
<P>
<B>Control</B> <B>group</B>: usual care for 1 year, then offered a Fitbit in the 2nd year. Followed to assess use of Fitbit and health outcomes.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-11-01 16:14:54 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Included in this study were:</P>
<P>
<B>Primary outcome</B>: submaximal exercise capacity (graded exercise test: 2 years at enrolment, 6 months, 12 months, 24 months)</P>
<P>
<B>Secondary outcomes</B>: Fitbit activity data (2 years); self-reported physical activity (Habitual Activity Estimation Scale, 2 years); FEV<SUB>1</SUB> relative change (% predicted, 2 years); FEV<SUB>1</SUB> from before study (baseline, to each data collection time point, and from one data collection time point to the next); FVC relative change (% predicted, 2 years); FVC from before study (baseline, to each data collection time point, and from one data collection time point to the next); FEF<SUB>25-75</SUB> relative change (% predicted, 2 years; FEF<SUB>25-75</SUB> from before study (baseline, to each data collection time point, and from one data collection time point to the next); incidence of exacerbations requiring IV antibiotics (2 years); body mass index (2 years); HRQoL (CFQ-R, 2 years); overall qualitative assessment of participant&#8217;s satisfaction with the Fitbit (2 years; 6-month time point); overall qualitative assessment of participant's potential barriers to Fitbit use (2 years, 6-month time point); qualitative data obtained by open-ended interview; depression (PHQ9, 2 years: enrolment, 6 months, 12 months, 18 months, 24 months); anxiety (GAD-7, 2 years: enrolment, 6 months, 12 months, 18 months, 24 months).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-08-29 17:50:51 +0100" MODIFIED_BY="Nikki Jahnke">
<P>March 14, 2016</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-08-29 17:50:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Ahmet Uluer, Director, Adult Cystic Fibrosis Program, Boston Children's Hospital.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-08-29 17:47:36 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The aim of this study is to evaluate whether the use of a Fitbit device and an exercise prescription is associated with increased daily activity and in turn increased exercise tolerance in young adult patients with cystic fibrosis (CF). The investigators hypothesize that use of the Fitbit and an exercise prescription will be associated with increased exercise tolerance compared to standard counselling and an exercise prescription alone.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>CES-D scale: Centre for Epidemiological Studies - Depression scale<BR/>CF: cystic fibrosis<BR/>CFQ-R: Cystic Fibrosis Questionnaire-Revised<BR/>FEV<SUB>1</SUB>: forced expiratory volume in 1 second<BR/>FVC: forced vital capacity<BR/>HADS: Hospital Anxiety and Depression Scale<BR/>HAES: Habitual Activity Estimation Scale<BR/>IV: intravenous<BR/>MST: modified shuttle test<BR/>PSQI: Pittsburgh Sleep Quality Index<BR/>RCT: randomised controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-11-02 10:10:31 +0000" MODIFIED_BY="Nikki Jahnke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-11-01 16:13:19 +0000" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 11:41:59 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Beaudoin-2017">
<DESCRIPTION>
<P>Randomly assigned open-label study with two parallel arms. Randomisation was conducted in blocks by gender with a ratio of 2:2. No details given for generation of sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:18:25 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Cerny-1989">
<DESCRIPTION>
<P>Described as randomised but no details of the method.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-09-26 12:46:56 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Douglas-2015">
<DESCRIPTION>
<P>Described as randomised but no details of the method.</P>
<P>Randomised by minimisation to one of the two groups (after baseline testing) by an independent blinded medical statistician using the SiMin software package (Wade 2006).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 11:45:48 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-Hebestreit-2010">
<DESCRIPTION>
<P>40 folded paper tickets were put into a bag with a 3:2 ratio, i.e. 24 tickets for the intervention group and 16 for the control group. Participants drew a ticket at random and the drawn ticket was then destroyed. Principal investigator was aware of the number of lots in the bag.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-17 12:58:30 +0000" MODIFIED_BY="Thomas Radtke" RESULT="YES" STUDY_ID="STD-Hommerding-2015">
<DESCRIPTION>
<P>Participants were allocated to the intervention or control group in blocks of 6. A computer-based program was used for randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-29 10:08:34 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Klijn-2004">
<DESCRIPTION>
<P>Described as randomised, but no details of the method.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-15 08:29:35 +0100" MODIFIED_BY="Thomas Radtke" RESULT="NO" STUDY_ID="STD-Kriemler-2013">
<DESCRIPTION>
<P>Participants were randomly assigned by a lot that was drawn from an opaque bag with closed eyes. Investigator was aware of the number of lots in the bag.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:25:30 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1989">
<DESCRIPTION>
<P>Described as randomised, but no details of method.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 16:13:19 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Moorcroft-2004">
<DESCRIPTION>
<P>Randomised to either active or control groups in a ratio of 3:2. A stratified randomisation in blocks (block size not stated) was used to balance the groups for FEV<SUB>1</SUB>, sputum colonisation by <I>Burkholderia cepacia </I>and gender. No details of method reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-13 09:01:18 +0000" MODIFIED_BY="Thomas Radtke" RESULT="YES" STUDY_ID="STD-Rovedder-2014">
<DESCRIPTION>
<P>Participants were randomly allocated in blocks of 6 to the exercise or control group. A computer programme was used to generate randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-10 09:26:07 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Santana_x002d_Sosa-2012">
<DESCRIPTION>
<P>Participants were randomly assigned to exercise or control group with a block on gender based on the randomisation sequence. No details about how randomisation sequence was generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-10 09:40:58 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Santana_x002d_Sosa-2014">
<DESCRIPTION>
<P>Randomisation to intervention or control group with block on gender. No details given for sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:30:37 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Schneiderman_x002d_Walker-2000">
<DESCRIPTION>
<P>Computer-generated randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-10 09:53:20 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Selvadurai-2002">
<DESCRIPTION>
<P>Random allocation in sets of 6. No details given for generation of sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-10 09:54:47 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Turchetta-1991">
<DESCRIPTION>
<P>Described as randomised, but no details given for sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-08-10 16:39:38 +0100" MODIFIED_BY="Nikki Jahnke" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-08 16:05:52 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Beaudoin-2017">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:18:45 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Cerny-1989">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-10 16:39:38 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Douglas-2015">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-26 12:58:29 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-Hebestreit-2010">
<DESCRIPTION>
<P>Participants drew a folded paper ticket from an opaque bag with closed eyes. In case that all lots have been drawn out by 1 study group, allocation concealment would no longer exist.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-11 09:06:35 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Hommerding-2015">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-09 19:57:55 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Klijn-2004">
<DESCRIPTION>
<P>Allocation concealed in opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-13 14:12:24 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Kriemler-2013">
<DESCRIPTION>
<P>Participants drew a lot from an opaque bag with closed eyes. In case that all lots have been drawn out by one study group, allocation concealment would no longer exist.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:25:35 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1989">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:26:57 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Moorcroft-2004">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-26 13:31:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rovedder-2014">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-26 13:33:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santana_x002d_Sosa-2012">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-22 16:53:42 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Santana_x002d_Sosa-2014">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:30:42 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Schneiderman_x002d_Walker-2000">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:32:38 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Selvadurai-2002">
<DESCRIPTION>
<P>Concealed information inside opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:26:31 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Turchetta-1991">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-03-10 17:10:14 +0000" MODIFIED_BY="Thomas Radtke" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-10-26 11:44:37 +0100" MODIFIED_BY="Tracey Remmington" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-08-11 15:04:03 +0100" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Beaudoin-2017">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-12 13:10:32 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Cerny-1989">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Unclear whether personnel was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-10-26 11:44:37 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Douglas-2015">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Investigators confirmed that lung function (spirometry and multiple inert gas washout tests), and cycle ergometer cardiopulmonary exercise tests were performed by clinicians who were not made aware of the randomised grouping of the children.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-10 16:56:04 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Hebestreit-2010">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Unclear whether personnel was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-13 14:11:28 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Hommerding-2015">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Unclear whether personnel was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-13 14:11:48 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Klijn-2004">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. The primary researcher was blinded but their role in the study is unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-10 16:55:12 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Kriemler-2013">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Unclear whether personnel was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-10 16:54:58 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1989">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Unclear whether personnel was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-14 16:30:24 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Moorcroft-2004">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Unclear whether personnel was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-05-08 13:02:26 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Rovedder-2014">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. 1 researcher was blinded to the randomisation and intervention and was responsible for database entries.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-14 16:32:09 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Santana_x002d_Sosa-2012">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Personnel involved in training not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-06-26 13:03:14 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Santana_x002d_Sosa-2014">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Personnel involved in training not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-14 16:33:03 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Schneiderman_x002d_Walker-2000">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Unclear whether personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-14 16:33:13 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Selvadurai-2002">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Unclear whether personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-14 16:33:30 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Turchetta-1991">
<DESCRIPTION>
<P>Not possible to blind participants to intervention. Unclear whether personnel blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-11-01 16:19:40 +0000" MODIFIED_BY="Nikki Jahnke" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-09-14 16:44:14 +0100" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Beaudoin-2017">
<DESCRIPTION>
<P>Unclear whether outcome assessors blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-10 16:45:10 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Cerny-1989">
<DESCRIPTION>
<P>Unclear whether outcome assessors blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-09-26 12:47:05 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Douglas-2015">
<DESCRIPTION>
<P>Investigators confirmed blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-01 16:19:40 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Hebestreit-2010">
<DESCRIPTION>
<P>Outcome assessors were not blinded with respect to the participants' group allocation for VO<SUB>2</SUB> peak and skinfold measurements.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-11 09:49:44 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Hommerding-2015">
<DESCRIPTION>
<P>Unclear whether outcome assessors blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-10 16:58:01 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Klijn-2004">
<DESCRIPTION>
<P>The primary researcher was blinded, but it is unclear whether this researcher was responsible for outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-11-01 16:13:09 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Kriemler-2013">
<DESCRIPTION>
<P>Outcome assessors were blinded for pulmonary function testing (primary outcome FEV<SUB>1</SUB>). Outcome assessors were not involved in supervision and delivery of the intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-10 16:53:55 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1989">
<DESCRIPTION>
<P>Unclear whether outcome assessors blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-10 16:54:27 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Moorcroft-2004">
<DESCRIPTION>
<P>Unclear whether outcome assessors blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-13 09:04:00 +0000" MODIFIED_BY="Thomas Radtke" RESULT="YES" STUDY_ID="STD-Rovedder-2014">
<DESCRIPTION>
<P>Outcome assessors were blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-12 12:54:10 +0000" MODIFIED_BY="Thomas Radtke" RESULT="YES" STUDY_ID="STD-Santana_x002d_Sosa-2012">
<DESCRIPTION>
<P>Outcome assessors were blinded to participants group assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-13 09:02:22 +0000" MODIFIED_BY="Thomas Radtke" RESULT="YES" STUDY_ID="STD-Santana_x002d_Sosa-2014">
<DESCRIPTION>
<P>Outcome assessors were blinded to participants group assignment. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-13 09:19:20 +0000" MODIFIED_BY="Thomas Radtke" RESULT="YES" STUDY_ID="STD-Schneiderman_x002d_Walker-2000">
<DESCRIPTION>
<P>Pulmonary function assessors were blinded to group assignment (primary outcome measure). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-10 17:09:26 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Selvadurai-2002">
<DESCRIPTION>
<P>Unclear whether outcome assessors blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-10 17:10:03 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Turchetta-1991">
<DESCRIPTION>
<P>Unclear whether outcome assessors blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-11-01 16:13:12 +0000" MODIFIED_BY="Nikki Jahnke" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-29 12:59:41 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Beaudoin-2017">
<DESCRIPTION>
<P>At screening,1 participant could not be randomized due to an adverse event during cardiopulmonary exercise testing.</P>
<P>There were 3 dropouts <B>
<I>post-randomisation</I>
</B> (18%).</P>
<UL>
<LI>2 participants dropped out due to a pulmonary exacerbation; group allocation for these 2 participants was not reported.</LI>
<LI>1 patient was excluded due to non-compliance with the exercise program, but the criteria for the decision of "non-compliance" were not reported in the publication.</LI>
</UL>
<P>The study was registered as crossover study but results for the second study part were not presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-09 13:26:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerny-1989">
<DESCRIPTION>
<P>There were no dropouts.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-09-26 12:47:05 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Douglas-2015">
<DESCRIPTION>
<P>4 participants dropped out: 1 from the control group at 6 months (social concerns); 3 from the intervention group at 12 months (1 due to moving to a new area and changing hospitals; 2 because they no longer wished to exercise).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-26 12:59:05 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Hebestreit-2010">
<DESCRIPTION>
<P>5 participants dropped out during the first 12 months of the study: 3 gave no reason, 1 joined another study and 1 moved away.</P>
<P>At 18 and 24 months, dropout rate was 13% and 26% respectively. Dropouts were balanced between groups. Reasons for drop out were not recorded.</P>
<P>Intention-to-treat was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-12 15:01:36 +0000" MODIFIED_BY="Thomas Radtke" RESULT="YES" STUDY_ID="STD-Hommerding-2015">
<DESCRIPTION>
<P>No drop outs were reported during the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-26 13:00:16 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Klijn-2004">
<DESCRIPTION>
<P>Clear description and details about dropouts.<BR/>3 participants dropped out: 1 participant from the training group withdrew for practical reasons; 2 from the control group did not complete assessments due to pulmonary exacerbations.</P>
<P>Intention-to-treat analysis was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-01 16:13:12 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Kriemler-2013">
<DESCRIPTION>
<P>Clear description and details about excluded participants and drop-outs.</P>
<P>3 participants were excluded at baseline due to FEV<SUB>1</SUB> below 35% predicted. 8 participants dropped out at different time points (exacerbation n = 1; non-compliance n = 2; death n = 2; unclear reasons n = 3). 2 of the participants that dropped out for unclear reasons were in the control group and one was in the aerobic training group.</P>
<P>Dropout rate was 21%.</P>
<P>Intention-to-treat analysis was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-03 13:21:09 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1989">
<DESCRIPTION>
<P>No details of dropouts or whether intention-to-treat analysis had been used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-13 14:14:06 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Moorcroft-2004">
<DESCRIPTION>
<P>3 participants dropped out at the start of programme: 1 from training group due to failure to attend on initial assessment; and 2 in the control group were withdrawn due to ill health. A further 6 participants dropped out during the 1-year period. Reasons for dropout were not clearly reported.</P>
<P>After 1 year, overall dropout rate was 18% and balanced among the groups (19% in the intervention and 15% in the control group).</P>
<P>Intentition-to-treat analysis was not performed.</P>
<P>Missing data were treated by omission and only data for those who completed study presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-10 09:14:13 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Rovedder-2014">
<DESCRIPTION>
<P>2 participants in the exercise group could not be assessed at the 3-month visit due to submission to the lung transplant programme. </P>
<P>Intention-to-treat analysis was used and imputations for missing data were performed for these 2 participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-26 13:02:38 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-Santana_x002d_Sosa-2012">
<DESCRIPTION>
<P>Clear description of missing outcome data. 5 participants could not be assessed at different time points (1 post-intervention and 4 after detraining) due to hospitalisations (n = 3), relocation (n = 1) and parents who declined further evaluation (n = 1).</P>
<P>Dropout rate was unbalanced with 28% in the control group and 9% in the intervention group after the detraining period.</P>
<P>Intention-to-treat analysis was used and missing outcome data (at post-training or detraining visit) were replaced by baseline data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-26 13:03:23 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-Santana_x002d_Sosa-2014">
<DESCRIPTION>
<P>Clear description of missing outcome data. 3 participants of the control group could not be assessed at different time points (1 for post-intervention and detraining phase and 2 after detraining phase) due to hospitalisation for lung transplantation preparation (n = 1), infection with <I>Burkholderia cepacia</I> (n = 1) and refusal (n = 1).</P>
<P>Unbalanced distribution of dropouts. Dropout rate in the control group was 30% versus none in the intervention group.</P>
<P>Intention-to-treat analysis was reported, but it is not clear how missing data were handled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-10 09:45:33 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Schneiderman_x002d_Walker-2000">
<DESCRIPTION>
<P>Clear description and details about 7 dropouts were recorded. </P>
<P>Intention-to-treat analysis was reported to yield similar results for pulmonary function. </P>
<P>Results were only reported for 65 participants who completed the 2-year follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-03 13:33:17 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Selvadurai-2002">
<DESCRIPTION>
<P>Stated no dropouts.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-03 13:21:18 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Turchetta-1991">
<DESCRIPTION>
<P>No details of dropouts or whether intention-to-treat analysis had been used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-11-02 10:10:31 +0000" MODIFIED_BY="Nikki Jahnke" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 16:24:10 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Beaudoin-2017">
<DESCRIPTION>
<P>Heart rate and SaO<SUB>2</SUB> were measured during cardiopulmonary exercise testing, but results were not reported. The second study phase was not reported in the original publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 12:47:30 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Cerny-1989">
<DESCRIPTION>
<P>All outcomes detailed in methods were reported in results. Data reported for all time points.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 11:44:58 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Douglas-2015">
<DESCRIPTION>
<P>This is an abstract so unable to assess if all outcome used in methods were reported in results. Unable to assess if data were reported for all time points.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-26 12:59:17 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Hebestreit-2010">
<DESCRIPTION>
<P>Anaerobic capacity (PP, MP) was only reported for 18 - 24 months follow up (non-significant) and results for HRQoL are only presented for the scale 'physical functioning'. No effects were observed for all other HRQoL scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 16:24:48 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Hommerding-2015">
<DESCRIPTION>
<P>Blood pressure was measured prior to and after cardiopulmonary exercise testing but not reported. HR at rest and SaO<SUB>2</SUB> at peak exercise were measured but results were not reported at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-13 14:12:17 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Klijn-2004">
<DESCRIPTION>
<P>Results for HRQoL are only presented for the scale 'physical functioning' which was significantly higher in the training group after the 12-week training period. No change in this HRQoL scale was observed in the control group after 12-weeks. No significant effects were observed for any other HRQoL scales. Data were not reported in detail. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-13 14:12:24 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Kriemler-2013">
<DESCRIPTION>
<P>All outcome detailed in methods were reported in results except HRQoL (secondary outcome) which was mentioned to be reported separately. In the meantime published as Hebestreit et al. BMC Pulm Med. 2014, 27;14:26. HRQoL data were pooled from two intervention studies (<LINK REF="STD-Hebestreit-2010" TYPE="STUDY">Hebestreit 2010</LINK>; <LINK REF="STD-Kriemler-2013" TYPE="STUDY">Kriemler 2013</LINK>) and results were presented for baseline and 6-month follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 12:47:34 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1989">
<DESCRIPTION>
<P>This is an abstract so unable to assess if all outcome used in methods were reported in results. Unable to assess if data were reported for all time points.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 12:47:38 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Moorcroft-2004">
<DESCRIPTION>
<P>All outcome detailed in methods were reported in results. Data reported for all time points.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 12:47:42 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Rovedder-2014">
<DESCRIPTION>
<P>All outcome detailed in methods were reported in results. Data reported for all time points.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 12:47:46 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Santana_x002d_Sosa-2012">
<DESCRIPTION>
<P>All outcomes detailed in methods were reported in results. Data reported for all time points.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 12:47:50 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Santana_x002d_Sosa-2014">
<DESCRIPTION>
<P>All outcome detailed in methods were reported in results. Data reported for all time points.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 12:47:55 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Schneiderman_x002d_Walker-2000">
<DESCRIPTION>
<P>All outcome detailed in methods were reported in results. Data reported for all time points.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-02 10:10:31 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Selvadurai-2002">
<DESCRIPTION>
<P>Did not report on all secondary outcomes detailed in methods (e.g. VE, VCO<SUB>2</SUB>, RQ) in results. Data reported for all time points.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 12:48:05 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Turchetta-1991">
<DESCRIPTION>
<P>This is an abstract so unable to assess if all outcome used in methods were reported in results. Data were reported for all time points.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-11-01 16:20:24 +0000" MODIFIED_BY="Nikki Jahnke" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-10-26 11:42:48 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-Beaudoin-2017">
<DESCRIPTION>
<P>
<I>Sample size</I>
</P>
<P>Information on sample size and recruitment goals differ between the information provided under Clinicaltrials.gov and the final publication. This study aimed to recruit 24 participants (12 exercise group, 12 control group), see Clinicaltrials.gov, NCT02127957. The recruitment goal was not achieved (N = 18 were recruited <I>
<B>but only 17 randomised</B>
</I>), but no information was provided in the final paper. According to the power calculation provided in the original publication, 18 participants (9 per group) were required for the analysis. Finally, 14 participants completed the study so the study is likely to be underpowered.</P>
<P>
<I>Statistical analyses</I>
</P>
<P>The authors reported pre-post within-group changes and no between-group differences as would be appropriate for a RCT. We received raw data from the authors and calculated between-group differences for plasma glucose and plasma insulin values during the oral glucose tolerance test. Our results differ compared to the results reported in the original publication. The initial power analysis, aiming to demonstrate a difference of 1.5 mmol/L in plasma glucose levels 120 minutes after ingestion of the glucose solution after exercise training required a study sample of 18 participants (9 per group). Finally, only 14 participants completed the study that reduces the statistical power to observe a difference between the interventions in the study.</P>
<P>
<I>Control intervention</I>
</P>
<P>In the original publication, no information was provided on the control intervention. We noticed discrepancies between the registered (clinicaltrials.gov) and published trial design (cross-over versus parallel-group design).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 16:12:13 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Cerny-1989">
<DESCRIPTION>
<P>Stated the inclusion criteria but not the exclusion criteria.</P>
<P>Pulmonary function values FEV<SUB>1</SUB> and FEF<SUB>25-75</SUB> were significantly lower in the control compared to the training group at admission.</P>
<P>Clearly described statistical analysis methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-09-26 12:48:08 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Douglas-2015">
<DESCRIPTION>
<P>None identified based on limited information available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-11 10:13:02 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Hebestreit-2010">
<DESCRIPTION>
<P>Financial support (max 200 Euro) was offered for intervention group participants to foster the realisation of the exercise training plan.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 16:19:47 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Hommerding-2015">
<DESCRIPTION>
<P>No validity criteria for maximal performance during cardiopulmonary exercise testing were reported in the methods. The mean (SD) peak heart rate reached during the exercise test was 157.1 (38.5) beats per min in the training group and 167.7 (20.8) beats per min in the control group, indicative of a submaximal effort. This likely underestimates the true VO<SUB>2</SUB> peak of the study participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-23 08:50:45 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Klijn-2004">
<DESCRIPTION>
<P>Clearly stated inclusion criteria but exclusion criteria were not reported. Described statistical methods used in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-16 09:45:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kriemler-2013">
<DESCRIPTION>
<P>Clearly stated inclusion and exclusion criteria and described statistical methods used in analysis. Due to the deterioration of physical health in the control group, the results of this study should be interpreted with caution.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:26:06 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1989">
<DESCRIPTION>
<P>Do not state inclusion or exclusion criteria, nor do they describe the methods of statistical analysis used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:29:53 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Moorcroft-2004">
<DESCRIPTION>
<P>Clearly stated inclusion and exclusion criteria and described method of statistical analysis used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-05 08:43:38 +0000" MODIFIED_BY="Thomas Radtke" RESULT="UNKNOWN" STUDY_ID="STD-Rovedder-2014">
<DESCRIPTION>
<P>Clearly stated inclusion and exclusion criteria and described method of statistical analysis used. Baseline between-group differences existed in BMI which could possibly impact on HRQoL (primary outcome).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 16:20:01 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Santana_x002d_Sosa-2012">
<DESCRIPTION>
<P>Some raw data were made available, but there were inconsistencies between raw data and data reported in the original publication. There were significant between-group differences in primary (VO<SUB>2</SUB> peak) and secondary (strength measures) outcome measures at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-01 16:20:24 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Santana_x002d_Sosa-2014">
<DESCRIPTION>
<P>Some raw data were made available, but there were inconsistencies between raw data and data reported in the original publication. Significant between-group differences in primary outcomes (VO<SUB>2</SUB> peak and strength measures) existed at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:32:07 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Schneiderman_x002d_Walker-2000">
<DESCRIPTION>
<P>Groups similar at baseline.<BR/>Stated the inclusion criteria but not the exclusion criteria.<BR/>Described statistical methods used in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:33:54 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Selvadurai-2002">
<DESCRIPTION>
<P>Clearly stated inclusion and exclusion criteria.<BR/>Described statistical methods used to analyse data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-03 13:26:16 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Turchetta-1991">
<DESCRIPTION>
<P>Do not state inclusion or exclusion criteria, nor do they describe the methods of statistical analysis used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-11-01 16:35:21 +0000" MODIFIED_BY="Nikki Jahnke">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-11-01 16:35:21 +0000" MODIFIED_BY="Nikki Jahnke" NO="1">
<TITLE MODIFIED="2017-09-14 11:14:59 +0100" MODIFIED_BY="[Empty name]">Summary of findings - Aerobic training versus no physical training</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Aerobic training compared with no physical training for cystic fibrosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: adults and children with cystic fibrosis</P>
<P>
<B>Settings</B>: Outpatients</P>
<P>
<B>Intervention</B>: Aerobic training</P>
<P>
<B>Comparison</B>: No physical training</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>No physical training</P>
</TH>
<TH VALIGN="TOP">
<P>Aerobic training</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Exercise capacity:</B> change in VO<SUB>2</SUB> peak during maximal exercise (mL/min per kg body weight)</P>
<P/>
<P>Follow-up: from hospital discharge up to 3 years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Short-term improvements in exercise tolerance during aerobic training were significantly greater than with no physical training at hospital discharge and 1 month after hospital discharge.</P>
<P/>
<P>One study showed no difference between groups at 3 months and 1 study showed a significant improvement in exercise tolerance following aerobic training at 6 months compared to no physical training.</P>
<P/>
<P>No significant longer-term differences between groups were observed.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>170</P>
<P>(4 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2,3</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pulmonary function: </B>change in FEV<SUB>1</SUB> (% predicted)</P>
<P/>
<P>Follow-up: from hospital discharge up to 3 years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>There were no short-term differences between groups at hospital discharge or one month after hospital discharge.</P>
<P/>
<P>Two studies showed a significant improvement in pulmonary function during and following aerobic training at 3 months, 6 months and 18 months post-training compared to no physical training.</P>
<P/>
<P>However, 1 study showed no significant differences in annual change of pulmonary function between groups were observed over 36 months.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>187</P>
<P>(5 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>HRQoL: </B>CFQ Quality of Well-being Scale and perceived 'positive effects.'</P>
<P/>
<P>Follow-up: one month after hospital discharge up to three years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No significant differences between the groups were shown according to the CFQ.</P>
<P/>
<P>A significant improvement in HRQoL according to the Quality of Well-being Scale was observed in the aerobic exercise group compared to the no physical training group at 1 month after hospital discharge, MD 0.10 (95% CI 0.03 to 0.17).</P>
<P/>
<P>Positive effects were reported by 43 out of 49 participants (not reported by treatment group).</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>143</P>
<P>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,4</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>CF-related mortality</B>
</P>
<P>Follow-up: NA</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Outcome not reported.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pulmonary exacerbations: </B>number of hospitalisations and number of days in hospital</P>
<P/>
<P>Follow-up: up to three years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>There were no between-group differences reported for the mean number of hospitalisations or mean number of days in hospital at year 1, 2 and 3.</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,5</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetic control</B>
</P>
<P>Follow-up:NA</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Outcome not reported.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P/>
<P>Follow-up: up to two years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>One study reported that no adverse effects occurred. In the other study, 1 participant in the aerobic training group injured her ankle and missed 2 days of aerobic training. One participant from the control group developed haemoptysis and withdrew from the study.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
<P>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CFQ</B>: Cystic Fibrosis Questionnaire; <B>CI</B>: confidence interval; <B>FEV<SUB>1</SUB>
</B>: forced expiratory volume in 1 second; <B>HRQoL</B>: health-related quality of life;<B> MD</B>: mean difference; <B>NA</B>: not applicable; <B>VO<SUB>2</SUB> peak</B>: peak oxygen consumption.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. Downgraded once due to risk of bias: Methodological details of the studies relating to randomisation and allocation concealment were unclear; one study used an inadequate method of randomisation and allocation concealment which may have introduced bias.<BR/>2. Downgraded once due to applicability: the no physical training group of one study deteriorated more than expected, this should be taken into account when interpreting results.<BR/>3. Downgraded once due to applicability: in one study, the method of measuring VO<SUB>2</SUB> was not validated and likely underestimates the true VO<SUB>2</SUB> peak of the study participants.<BR/>4. Downgraded once due to imprecision and applicability: very limited numerical data reported and unclear if the measures and questionnaires used were validated in this population.<BR/>5. Downgraded once due to imprecision: very limited numerical data reported.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-11-01 16:22:23 +0000" MODIFIED_BY="Nikki Jahnke" NO="2">
<TITLE MODIFIED="2017-06-05 14:58:28 +0100" MODIFIED_BY="[Empty name]">Summary of findings - Anaerobic training versus no physical training</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Anaerobic training compared with no physical training for cystic fibrosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>adults and children with cystic fibrosis</P>
<P>
<B>Settings</B>: outpatients</P>
<P>
<B>Intervention</B>: anaerobic training</P>
<P>
<B>Comparison</B>: no physical training</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>No physical training</P>
</TH>
<TH VALIGN="TOP">
<P>Anaerobic training</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Exercise capacity: </B>change in VO<SUB>2</SUB> peak during maximal exercise (mL/min per kg BW)</P>
<P/>
<P>Follow-up: from hospital discharge up to 3 years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>One study showed a significant improvement in exercise capacity following anaerobic training at 6 months compared to no physical training.</P>
<P/>
<P>No significant differences between groups were observed at any other time points.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>86</P>
<P>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pulmonary function:</B> change in FEV<SUB>1</SUB> (% predicted)</P>
<P/>
<P>Follow-up: from hospital discharge up to 3 years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Two studies showed a significant improvement in pulmonary function during and following anaerobic training at hospital discharge, 1 month after discharge, 3 months, 6 months and 18 months post-training compared to no physical training.</P>
<P/>
<P>The second study showed no significant differences in lung function at any time point.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>86</P>
<P>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>HRQoL: </B>Quality of Well-being Scale or HRQoL scale physical function</P>
<P/>
<P>Follow-up: up to 2 years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No significant differences between groups were observed according to the Quality of Well-being Scale or HRQoL scale physical function.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>64</P>
<P>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,3</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>CF-related mortality</B>
</P>
<P>Follow-up: NA</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Outcome not reported.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pulmonary exacerbations</B>
</P>
<P>Follow-up: NA</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Outcome not reported.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetic control</B>
</P>
<P>Follow-up: NA</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Outcome not reported.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P/>
<P>Follow-up: 2 years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>One study reported that no adverse effects occurred.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate<SUP>1</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>FEV<SUB>1</SUB>
</B>: forced expiratory volume in 1 second; <B>HRQoL</B>: health-related quality of life; <B>NA: </B>not applicable; <B>VO<SUB>2</SUB> peak</B>: peak oxygen consumption.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. Downgraded once due to risk of bias: methodological details of the studies relating to randomisation and allocation concealment were unclear; one study used an inadequate method of randomisation and allocation concealment which may have introduced bias.<BR/>2. Downgraded once due to applicability: the no physical training group of one study deteriorated more than expected, this should be taken into account when interpreting results.<BR/>3. Downgraded once due to applicability: unclear if the measures and questionnaires used were validated in this population.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2017-11-01 16:22:43 +0000" MODIFIED_BY="Nikki Jahnke" NO="3">
<TITLE MODIFIED="2017-06-05 14:58:57 +0100" MODIFIED_BY="[Empty name]">Summary of findings - Combined aerobic and anaerobic training versus no training</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Combined aerobic and anaerobic training compared with no physical training for cystic fibrosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: adults and children with cystic fibrosis</P>
<P>
<B>Settings</B>: outpatients</P>
<P>
<B>Intervention</B>: combined aerobic and anaerobic training</P>
<P>
<B>Comparison</B>: no physical training</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>No physical training</P>
</TH>
<TH VALIGN="TOP">
<P>Combined aerobic and anaerobic training</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Exercise capacity</B>: change in VO<SUB>2</SUB> peak during maximal exercise (mL/min per kg body weight)</P>
<P/>
<P>Follow-up: 12 weeks to two years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>A significantly higher VO<SUB>2</SUB> peak was found in the combined training compared to the no physical training group after 12 to 18 months in 1 study.</P>
<P/>
<P>No significant difference between groups was found at any other time point.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
<P>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Two additional studies recruiting 42 participants showed significant group x time interactions for VO<SUB>2</SUB> peak; however, these results are not included in this review due to concerns over inconsistencies in the data provided to us by the original trial authors.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pulmonary function</B>: change in FEV<SUB>1</SUB> (% predicted) or mL</P>
<P/>
<P>Follow-up: 12 weeks to two years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No significant differences in pulmonary function were observed between treatment groups at any time point.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
<P>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>1,2</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>HRQoL</B>: CFQ,</P>
<P>Medical Outcomes Study-36 Item Short-Form Health Survey, SF-36</P>
<P/>
<P>Follow-up: 12 weeks to 2 years</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Two studies showed no significant differences in any HRQoL scale.</P>
<P/>
<P>One study showed a significant improvement in subjective health perception in the combined training group after 3 to 6 months and after 12 to 18 months (but not between 6 and 12 months).</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>93</P>
<P>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2,3</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>CF-related mortality</B>
</P>
<P>Follow-up: NA</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Outcome not reported.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pulmonary exacerbations</B>
</P>
<P>Follow-up: NA</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Outcome not reported.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetic control</B>
</P>
<P/>
<P>Follow-up: 12 weeks</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Significant differences in some of the parameters were observed in the no physical training group compared to the combined training group and vice versa.</P>
<P/>
<P>Also no significant differences were observed for some parameters.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
<P>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low<SUP>1,2,3</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>The study reported a range of metabolic parameters (HbA1c(%), Glucose AUC, Total Insulin AUC, Insulin Sensitivity Index) Plasma Glucose and Plasma Insulin.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P>Follow-up: NA</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Outcome not reported.</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>AUC</B>: area under the curve; <B>CFQ</B>: Cystic Fibrosis Questionnaire; <B>CI</B>: confidence interval; <B>FEV<SUB>1</SUB>
</B>: forced expiratory volume in 1 second; <B>HRQoL</B>: health-related quality of life; <B>NA</B>: not applicable; <B>VO<SUB>2</SUB> peak</B>: peak oxygen consumption.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. Downgraded once due to risk of bias: methodological details of the studies relating to randomisation and allocation concealment were unclear; one study used an inadequate method of randomisation and allocation concealment which may have introduced bias.<BR/>2. Downgraded once due to risk of bias: one study had many methodological inadequacies including early termination and low statistical power. These inadequacies are likely to have impacted on results.<BR/>3. Downgraded once due to imprecision: wide CIs around effect estimates due to small numbers of participants analysed.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2017-11-01 16:36:37 +0000" MODIFIED_BY="Nikki Jahnke">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-11-01 16:36:11 +0000" MODIFIED_BY="Nikki Jahnke" NO="1">
<TITLE MODIFIED="2015-01-23 12:14:05 +0000" MODIFIED_BY="Thomas Radtke">Study results for Santana-Sosa 2012</TITLE>
<TABLE COLS="7" ROWS="37">
<TR>
<TH>
<P>Variable</P>
</TH>
<TH ALIGN="CENTER">
<P>Group</P>
</TH>
<TH ALIGN="CENTER">
<P>Pre-training</P>
</TH>
<TH ALIGN="CENTER">
<P>Post-training</P>
</TH>
<TH ALIGN="CENTER">
<P>Detraining</P>
</TH>
<TH ALIGN="CENTER">
<P>P value (group x time)</P>
</TH>
<TH ALIGN="CENTER">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Age (mean (SE)) years</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>11 (3)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>10 (2)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Sex (% boys)</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>55</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>64</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>VO<SUB>2</SUB> peak (mean (95% CI)) ml/min per kg body weight</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>3.9 (1.8 to 6.1)</P>
</TD>
<TD ALIGN="CENTER">
<P>-3.4 (-5.7 to 1.7)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.036</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P>Significantly higher in controls at baseline (P = 0.023).</P>
<P>Data were presented in a figure in the original publication.</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>-2.2 (-5.3 to 0.1)</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.7 (-4.4 to 5.9)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Leg press (mean (95% CI)) kg</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>24.9 (14.3 to 34.4)</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.0 (-4.1 to 3.3)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P>Data are reported in a figure in the original publication.</P>
<P>Significantly higher in controls at baseline (P = 0.014).</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Bench press (mean (95% CI)) kg</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>10.5 (7.0 to 14.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.2 (-3.6 to 3.0)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P>Significantly higher in controls at baseline (P = 0.007).</P>
<P>Data presented in a figure in the original publication.</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Seated row (mean (95% CI)) kg</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>12.7 (9.2 to 16.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.2 (-3.6 to 3.2)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P>Significantly higher in controls at baseline (P = 0.009).</P>
<P>Data presented in a figure in the original publication.</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Oxygen saturation at peak exercise (mean (SE))</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>94.9 (0.9)%</P>
</TD>
<TD ALIGN="CENTER">
<P>95.6 (0.8)%</P>
</TD>
<TD ALIGN="CENTER">
<P>94.5 (1.2)%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>n.a.</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>95.7 (0.5)%</P>
</TD>
<TD ALIGN="CENTER">
<P>96.4 (0.4)%</P>
</TD>
<TD ALIGN="CENTER">
<P>96.1 (0.5)%</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>FEV<SUB>1</SUB> (mean (SE)) litres</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>1.87 (0.24)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.94 (0.23)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.90 (0.25)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.769</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>1.77 (0.17)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.87 (0.15)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.79 (0.19)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>FVC (mean (SE)) litres</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>2.41 (0.24)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.49 (0.25)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.56 (0.29)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.920</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>2.29 (0.19)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.36 (0.20)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.40 (0.24)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>PI<SUB>max</SUB> (mean (SE)) cm H<SUB>2</SUB>O</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>64.0 (5.5)</P>
</TD>
<TD ALIGN="CENTER">
<P>69.8 (6.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>75.2 (6.2)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.797</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>61.5 (6.9)</P>
</TD>
<TD ALIGN="CENTER">
<P>72.2 (7.2)</P>
</TD>
<TD ALIGN="CENTER">
<P>76.4 (7.5)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>HRQoL score - children's report (median (range))</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>696 (495 - 741)</P>
</TD>
<TD ALIGN="CENTER">
<P>719 (550 - 734)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.257</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P>HRQoL was assessed before and after the intervention.</P>
<P>P value for comparison pre versus post-training.</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>649 (578 - 768)</P>
</TD>
<TD ALIGN="CENTER">
<P>638 (461 - 791)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>HRQoL score - parents' report (median (range))</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>896 (688-1011)</P>
</TD>
<TD ALIGN="CENTER">
<P>889 (811 - 973)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.143</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P>HRQoL was assessed before and after the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>911 (842 - 1028)</P>
</TD>
<TD ALIGN="CENTER">
<P>978 (684 - 1059)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Weight (mean (SE)) kg</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>39.9 (3.5)</P>
</TD>
<TD ALIGN="CENTER">
<P>40.5 (3.4)</P>
</TD>
<TD ALIGN="CENTER">
<P>41.4 (3.4)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.723</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>34.0 (2.6)</P>
</TD>
<TD ALIGN="CENTER">
<P>35.1 (2.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>36.2 (3.0)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>BMI (mean (SE)) kg/m²</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>18.4 (1.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>18.3 (0.7)</P>
</TD>
<TD ALIGN="CENTER">
<P>18.5 (0.7)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.959</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>17.2 (0.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>17.1 (0.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>17.4 (0.9)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Fat-free mass (mean (SE)) %</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>78.1 (2.7)</P>
</TD>
<TD ALIGN="CENTER">
<P>79.4 (2.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>78.8 (2.9)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.115</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>81.1 (2.5)</P>
</TD>
<TD ALIGN="CENTER">
<P>80.9 (2.1)</P>
</TD>
<TD ALIGN="CENTER">
<P>81.1 (2.2)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Body fat (mean (SE)) %</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>21.9 (2.7)</P>
</TD>
<TD ALIGN="CENTER">
<P>20.6 (2.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>21.2 (2.9)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.115</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>18.9 (2.5)</P>
</TD>
<TD ALIGN="CENTER">
<P>19.1 (2.1)</P>
</TD>
<TD ALIGN="CENTER">
<P>18.9 (2.2)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Compliance with physical training (mean (SE)) %</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>95.1 (7.4)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>-</P>
<P>-</P>
</TD>
<TD ROWSPAN="2">
<P>73% of children completed all training sessions.</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Adverse effects</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>-</P>
</TD>
<TD ROWSPAN="2">
<P>No adverse effects occurred during training or maximal exercise testing.</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>BMI: body mass index<BR/>CI: confidence interval<BR/>FEV<SUB>1</SUB>: forced expiratory volume in one second<BR/>FVC: forced vital capacity<BR/>HRQoL: health-related quality of life<BR/>n.a.: not applicable<BR/>PI<SUB>max</SUB>: maximum inspiratory mouth pressure<BR/>SE: standard error<BR/>VO<SUB>2</SUB> peak: peak oxygen consumption</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2017-11-01 16:36:37 +0000" MODIFIED_BY="Nikki Jahnke" NO="2">
<TITLE MODIFIED="2015-01-23 12:14:38 +0000" MODIFIED_BY="Thomas Radtke">Study results for Santana-Sosa 2014</TITLE>
<TABLE COLS="7" ROWS="33">
<TR>
<TH>
<P>Variable</P>
</TH>
<TH ALIGN="CENTER">
<P>Group</P>
</TH>
<TH ALIGN="CENTER">
<P>Pre-training</P>
</TH>
<TH ALIGN="CENTER">
<P>Post-training</P>
</TH>
<TH ALIGN="CENTER">
<P>Detraining</P>
</TH>
<TH ALIGN="CENTER">
<P>P value (group x time)</P>
</TH>
<TH ALIGN="CENTER">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Age (mean (SE)) years</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>11 (1)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>10 (1)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Sex (% boys)</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>60</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>60</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>VO<SUB>2</SUB> peak (mean (95% CI) ml/min per kg body weight</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>6.9 (3.4 to 10.5)</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.5 (-2.7 to -0.4)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P>Significantly higher in controls at baseline (P = 0.034).</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.a.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Leg press (mean (SE)) kg</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>62.5 (6.5)</P>
</TD>
<TD ALIGN="CENTER">
<P>89.5 (9.3)</P>
</TD>
<TD ALIGN="CENTER">
<P>88.6 (9.2)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
<P>Significantly higher in controls at baseline (P = 0.046).</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>45.2 (4.7)</P>
</TD>
<TD ALIGN="CENTER">
<P>43.9 (5.1)</P>
</TD>
<TD ALIGN="CENTER">
<P>43.9 (5.4)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Bench press (mean (SE)) kg</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>26.4 (2.7)</P>
</TD>
<TD ALIGN="CENTER">
<P>38.4 (3.2)</P>
</TD>
<TD ALIGN="CENTER">
<P>35.9 (2.9)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>23.2 (2.9)</P>
</TD>
<TD ALIGN="CENTER">
<P>21.6 (3.2)</P>
</TD>
<TD ALIGN="CENTER">
<P>21.7 (3.6)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Lateral row (mean (SE)) kg</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>30.5 (3.6)</P>
</TD>
<TD ALIGN="CENTER">
<P>43.0 (4.2)</P>
</TD>
<TD ALIGN="CENTER">
<P>35.9 (2.9)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>23.2 (3.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>22.0 (3.1)</P>
</TD>
<TD ALIGN="CENTER">
<P>21.7 (3.6)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Oxygen saturation at peak exercise (mean (SE)) %</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>94.7 (0.7)</P>
</TD>
<TD ALIGN="CENTER">
<P>94.5 (0.7)</P>
</TD>
<TD ALIGN="CENTER">
<P>93.1 (0.8)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>n.a.</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>96.4 (0.4)</P>
</TD>
<TD ALIGN="CENTER">
<P>96.2 (0.5)</P>
</TD>
<TD ALIGN="CENTER">
<P>96.1 (0.6)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>FEV<SUB>1</SUB> (mean (SE)) L</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>1.65 (0.19)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.74 (0.23)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.69 (0.24)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.486</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>1.57 (0.26)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.55 (0.26)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.59 (0.26)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>FVC (mean (SE)) L</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>2.23 (0.27)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.34 (0.29)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.28 (0.28)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.156</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>1.90 (0.33)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.85 (0.32)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.92 (0.32)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>PI<SUB>max</SUB> (mean (SE)) cm H<SUB>2</SUB>O</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>68.3 (6.3)</P>
</TD>
<TD ALIGN="CENTER">
<P>107.6 (8.4)</P>
</TD>
<TD ALIGN="CENTER">
<P>103.2 (8.1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>69.5 (9.7)</P>
</TD>
<TD ALIGN="CENTER">
<P>71.8 (10.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>66.7 (9.4)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>HRQoL score (median (min - max))</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>629 (505 - 701)</P>
</TD>
<TD ALIGN="CENTER">
<P>688 (609 - 791)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.071</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P>HRQoL was assessed before and after the intervention.</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>636 (626 - 745)</P>
</TD>
<TD ALIGN="CENTER">
<P>638 (626 - 737)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Weight (mean (SE)) kg</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>36.4 (3.1)</P>
</TD>
<TD ALIGN="CENTER">
<P>37.8 (3.2)</P>
</TD>
<TD ALIGN="CENTER">
<P>38.3 (3.1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.342</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>31.5 (4.6)</P>
</TD>
<TD ALIGN="CENTER">
<P>32.4 (4.7)</P>
</TD>
<TD ALIGN="CENTER">
<P>32.7 (4.5)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Fat-free mass (mean (SE)) % of total</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>81.6 (1.3)</P>
</TD>
<TD ALIGN="CENTER">
<P>82.6 (1.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>82.5 (1.0)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.001</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>82.9 (1.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>82.8 (1.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>82.5 (1.9)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Body fat (mean (SE)) % of total</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>18.4 (1.3)</P>
</TD>
<TD ALIGN="CENTER">
<P>17.4 (1.2)</P>
</TD>
<TD ALIGN="CENTER">
<P>17.5 (1.1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2">
<P>0.023</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>17.1 (1.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>17.2 (1.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>17.5 (1.9)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Compliance with physical training (mean (SE)) %</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>97.5 (1.7)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
<TD ROWSPAN="2">
<P>70% of children completed all training sessions.</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Adverse effects</P>
</TD>
<TD>
<P>Intervention</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ROWSPAN="2">
<P/>
</TD>
<TD ROWSPAN="2">
<P>No adverse effects occurred during training or exercise testing.</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI: confidence interval<BR/>FEV<SUB>1</SUB>: forced expiratory volume in one second<BR/>FVC: forced vital capacity<BR/>HRQoL: health-related quality of life<BR/>n.a.: not applicable<BR/>PI<SUB>max</SUB>: maximum inspiratory mouth pressure<BR/>SE: standard error<BR/>VO<SUB>2</SUB> peak: peak oxygen consumption</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2017-10-26 12:08:11 +0100" MODIFIED_BY="Tracey Remmington" NO="3">
<TITLE MODIFIED="2015-03-09 13:59:30 +0000" MODIFIED_BY="Nikki Jahnke">HRQoL results for Rovedder 2014</TITLE>
<TABLE COLS="4" ROWS="21">
<TR>
<TH>
<P>
<B>Health-related quality of life</B>
</P>
</TH>
<TH>
<P>
<B>Exercise group (n = 19)</B>
</P>
</TH>
<TH>
<P>
<B>Control group (n = 22)</B>
</P>
</TH>
<TH>
<P>
<B>P value</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>HRQoL scale - physical (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>6.1 (-4 to 8)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.4 (-10 to 13)</P>
</TD>
<TD>
<P>0.742</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - body image (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>3.3 (-11 to 22)</P>
</TD>
<TD ALIGN="CENTER">
<P>3.0 (-2 to 11)</P>
</TD>
<TD>
<P>0.915</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - digestive (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.0 (-4 to 0)</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.5 (0 to 0)</P>
</TD>
<TD>
<P>0.953</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - respiratory (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>3.8 (0 to 11)</P>
</TD>
<TD ALIGN="CENTER">
<P>-4.7 (-1 to 7)</P>
</TD>
<TD>
<P>0.925</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - emotional (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>1.2 (-6 to 6)</P>
</TD>
<TD ALIGN="CENTER">
<P>-4.3 (-13 to 6)</P>
</TD>
<TD>
<P>0.458</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - social (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.1 (-11 to 5)</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.7 (-5 to 11)</P>
</TD>
<TD>
<P>0.822</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - food (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.3 (-11 to 6)</P>
</TD>
<TD ALIGN="CENTER">
<P>-2.0 (-11 to 0)</P>
</TD>
<TD>
<P>0.913</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - treatment (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>-2.0 (-11 to 0)</P>
</TD>
<TD ALIGN="CENTER">
<P>-2.5 (-11 to 11)</P>
</TD>
<TD>
<P>0.850</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - vitality (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.2 (-16 to 8)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.6 (-8 to 10)</P>
</TD>
<TD>
<P>0.579</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - health (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>1.7 (-11 to 16)</P>
</TD>
<TD ALIGN="CENTER">
<P>-3.0 (-11 to 0)</P>
</TD>
<TD>
<P>0.382</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - weight (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>4.6 (0 to 33)</P>
</TD>
<TD ALIGN="CENTER">
<P>12.1 (0 to 11)</P>
</TD>
<TD>
<P>0.410</P>
</TD>
</TR>
<TR>
<TD>
<P>HRQoL scale - social role (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>0.8 (-8 to 8)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.8 (-2 to 0)</P>
</TD>
<TD>
<P>0.935</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 - functional capacity (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>2.8 (-10 to 15)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.0 (-11 to 10)</P>
</TD>
<TD>
<P>0.916</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 - physical aspects (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>11.8 (-25 to 50)</P>
</TD>
<TD ALIGN="CENTER">
<P>6.8 (-6 to 31)</P>
</TD>
<TD>
<P>0.705</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 - pain (mean (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>-7.2 (-28 to 11)</P>
</TD>
<TD ALIGN="CENTER">
<P>8.0 (7 to 17)</P>
</TD>
<TD>
<P>0.100</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 - general health (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>3.7 (-5 to 10)</P>
</TD>
<TD ALIGN="CENTER">
<P>-3.5 (-11 to 5)</P>
</TD>
<TD>
<P>0.197</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 - vitality (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>1.2 (-15 to 20)</P>
</TD>
<TD ALIGN="CENTER">
<P>7.5 (-1 to 21)</P>
</TD>
<TD>
<P>0.416</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 - social aspects (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>15.2 (0 to 33)</P>
</TD>
<TD ALIGN="CENTER">
<P>21.2 (0 to 66)</P>
</TD>
<TD>
<P>0.989</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 - emotional aspects (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>4.7 (-12 to 37)</P>
</TD>
<TD ALIGN="CENTER">
<P>4.5 (-12 to 25)</P>
</TD>
<TD>
<P>0.914</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 - mental health (median (interquartile range))</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.8 (-12 to 12)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.9 (-9 to 13)</P>
</TD>
<TD>
<P>0.752</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Pre-post changes in HRQoL measured by the CFQ and the SF-36</P>
<P>CFQ: Cystic Fibrosis Questionnaire<BR/>HRQoL: health-related quality of life<BR/>SF-36: Medical Outcomes Study-36 Item Short-Form Health Survey</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-10-30 09:19:24 +0000" MODIFIED_BY="Nikki Jahnke">
<COMPARISON ID="CMP-001" MODIFIED="2017-10-26 12:46:48 +0100" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Aerobic training versus no physical training</NAME>
<CONT_OUTCOME CHI2="15.277512726023728" CI_END="8.717363579486005" CI_START="4.355102470072957" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="6.536233024779481" ESTIMABLE="YES" I2="60.72659137910849" I2_Q="55.76215143518622" ID="CMP-001.01" MODIFIED="2017-09-14 09:56:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01820474188465393" P_Q="0.045700815729160627" P_Z="4.267941074938738E-9" Q="11.302538803790148" RANDOM="NO" SCALE="25.67" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="116" TOTAL_2="96" UNITS="" WEIGHT="600.0" Z="5.873459200085713">
<NAME>Change in VO<SUB>2 </SUB>peak during maximal exercise (ml/min per kg BW)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.205950323469416" CI_START="4.8540496765305825" DF="0" EFFECT_SIZE="8.53" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" MODIFIED="2015-05-15 09:14:10 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="1.0" P_Z="5.413919152593217E-6" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.00000000000001" Z="4.548073645442384">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="12.205950323469416" CI_START="4.8540496765305825" EFFECT_SIZE="8.53" ESTIMABLE="YES" MEAN_1="7.31" MEAN_2="-1.22" MODIFIED="2015-05-15 09:13:46 +0100" MODIFIED_BY="Thomas Radtke" ORDER="72" SD_1="6.29" SD_2="6.15" SE="1.8755193220206312" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.689384700783494" CI_START="1.1306152992165064" DF="0" EFFECT_SIZE="4.91" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" MODIFIED="2017-09-14 09:56:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.010887356738680453" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="2.5462936234294067">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="8.689384700783494" CI_START="1.1306152992165064" EFFECT_SIZE="4.91" ESTIMABLE="YES" MEAN_1="7.56" MEAN_2="2.65" MODIFIED="2015-05-15 09:13:49 +0100" MODIFIED_BY="Thomas Radtke" ORDER="195" SD_1="6.75" SD_2="6.02" SE="1.928292933234895" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.9749739222335796" CI_END="7.29048687451078" CI_START="-2.7135471503294046" DF="1" EFFECT_SIZE="2.2884698620906874" ESTIMABLE="YES" I2="74.84260225188875" ID="CMP-001.01.03" MODIFIED="2017-09-14 09:56:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04618124149791847" P_Z="0.36987797903376085" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="27" WEIGHT="100.0" Z="0.8967019700784646">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="4.86472079879335" CI_START="-7.264720798793348" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.3" MODIFIED="2015-05-15 09:13:37 +0100" MODIFIED_BY="Thomas Radtke" ORDER="206" SD_1="4.6" SD_2="11.9" SE="3.094302164035203" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="68.02502417882047"/>
<CONT_DATA CI_END="18.555859805087678" CI_START="0.8641401949123235" EFFECT_SIZE="9.71" ESTIMABLE="YES" MEAN_1="7.26" MEAN_2="-2.45" MODIFIED="2015-05-15 09:13:40 +0100" MODIFIED_BY="Thomas Radtke" ORDER="135" SD_1="12.1" SD_2="10.3" SE="4.513276710624629" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="31.97497582117953"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="27.710224639527507" CI_START="8.94977536047249" DF="0" EFFECT_SIZE="18.33" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" MODIFIED="2017-09-14 09:56:42 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.2814995060451758E-4" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="3.82998715033213">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="27.710224639527507" CI_START="8.94977536047249" EFFECT_SIZE="18.33" ESTIMABLE="YES" MEAN_1="6.85" MEAN_2="-11.48" MODIFIED="2015-05-15 09:13:46 +0100" MODIFIED_BY="Thomas Radtke" ORDER="73" SD_1="12.6" SD_2="11.1" SE="4.7859168400631455" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.34473819187457" CI_START="-1.3247381918745713" DF="0" EFFECT_SIZE="9.51" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.05" MODIFIED="2015-05-15 09:13:53 +0100" MODIFIED_BY="Thomas Radtke" NO="5" P_CHI2="1.0" P_Z="0.08537360769944818" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="8" WEIGHT="100.0" Z="1.7203237552112043">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="20.34473819187457" CI_START="-1.3247381918745713" EFFECT_SIZE="9.51" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="-9.35" MODIFIED="2015-05-15 09:13:53 +0100" MODIFIED_BY="Thomas Radtke" ORDER="59" SD_1="13.1" SD_2="12.1" SE="5.528029227749899" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="15.422984544152712" CI_START="-9.70298454415271" DF="0" EFFECT_SIZE="2.8600000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.06" MODIFIED="2015-05-15 09:13:54 +0100" MODIFIED_BY="Thomas Radtke" NO="6" P_CHI2="1.0" P_Z="0.6554589192222469" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="7" WEIGHT="100.0" Z="0.4461915061730747">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="15.422984544152712" CI_START="-9.70298454415271" EFFECT_SIZE="2.8600000000000003" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-7.36" MODIFIED="2015-05-15 08:53:25 +0100" MODIFIED_BY="Thomas Radtke" ORDER="60" SD_1="13.8" SD_2="12.9" SE="6.4098037735631515" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="33.278100171825734" CI_END="5.089107990490868" CI_START="1.9721255226813952" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="3.5306167565861317" ESTIMABLE="YES" I2="78.96514535428193" I2_Q="74.61520312487131" ID="CMP-001.02" MODIFIED="2017-09-14 10:15:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.3497531518312798E-5" P_Q="6.091422619290965E-4" P_Z="8.991044870171988E-6" Q="23.636194646405187" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="147" TOTAL_2="132" UNITS="" WEIGHT="700.0" Z="4.440115886173421">
<NAME>Change in FEV<SUB>1</SUB>(% predicted)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.3691205913299465" CI_START="-2.309120591329946" DF="0" EFFECT_SIZE="2.0300000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2015-01-20 11:15:20 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="1.0" P_Z="0.3591724434541278" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.9169431466288945">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="6.3691205913299465" CI_START="-2.309120591329946" EFFECT_SIZE="2.0300000000000002" ESTIMABLE="YES" MEAN_1="6.54" MEAN_2="4.51" MODIFIED="2014-08-15 11:29:12 +0100" MODIFIED_BY="Thomas Radtke" ORDER="76" SD_1="7.76" SD_2="6.9" SE="2.2138777169154005" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.500926673319761E-33" CI_END="5.994834171150694" CI_START="-2.934834171150693" DF="0" EFFECT_SIZE="1.53" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.02" MODIFIED="2017-09-14 10:07:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.501815239853463" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.00000000000001" Z="0.6716363433433936">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="5.994834171150694" CI_START="-2.934834171150693" EFFECT_SIZE="1.5300000000000002" ESTIMABLE="YES" MEAN_1="6.25" MEAN_2="4.72" MODIFIED="2015-02-17 15:18:02 +0000" MODIFIED_BY="Thomas Radtke" ORDER="196" SD_1="7.94" SD_2="7.15" SE="2.278018477058117" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.641905525420539" CI_END="11.938756373574547" CI_START="2.48844461226334" DF="1" EFFECT_SIZE="7.2136004929189435" ESTIMABLE="YES" I2="89.62860611563207" ID="CMP-001.02.03" MODIFIED="2017-09-14 10:07:04 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0019018992045702898" P_Z="0.0027701588860894032" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="27" WEIGHT="100.0" Z="2.992154655227976">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="5.091566798071817" CI_START="-10.691566798071817" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="1.0" MODIFIED="2015-03-11 13:53:48 +0000" MODIFIED_BY="Thomas Radtke" ORDER="207" SD_1="8.6" SD_2="14.2" SE="4.026383576596044" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="35.851374164516685"/>
<CONT_DATA CI_END="18.709598567274163" CI_START="6.910401432725836" EFFECT_SIZE="12.809999999999999" ESTIMABLE="YES" MEAN_1="4.89" MEAN_2="-7.92" MODIFIED="2015-05-15 08:55:30 +0100" MODIFIED_BY="Thomas Radtke" ORDER="141" SD_1="8.0" SD_2="6.7" SE="3.010054579476686" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="10" WEIGHT="64.14862583548332"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="25.75179282108781" CI_START="8.588207178912194" DF="0" EFFECT_SIZE="17.17" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" MODIFIED="2017-09-14 10:07:01 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="8.803856967102925E-5" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="3.9213929205863787">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="25.75179282108781" CI_START="8.588207178912194" EFFECT_SIZE="17.17" ESTIMABLE="YES" MEAN_1="6.17" MEAN_2="-11.0" MODIFIED="2015-05-15 08:56:05 +0100" MODIFIED_BY="Thomas Radtke" ORDER="77" SD_1="11.6" SD_2="10.1" SE="4.378546181858388" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="27.772727233973452" CI_START="6.0672727660265515" DF="0" EFFECT_SIZE="16.92" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.05" MODIFIED="2015-06-01 13:21:03 +0100" MODIFIED_BY="Nikki Jahnke" NO="5" P_CHI2="1.0" P_Z="0.0022454186661692373" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="8" WEIGHT="100.0" Z="3.055691892320423">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="27.772727233973452" CI_START="6.0672727660265515" EFFECT_SIZE="16.92" ESTIMABLE="YES" MEAN_1="1.09" MEAN_2="-15.83" MODIFIED="2015-05-15 08:56:14 +0100" MODIFIED_BY="Thomas Radtke" ORDER="65" SD_1="13.1" SD_2="12.4" SE="5.537207479105931" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="23.626951321759122" CI_START="1.2730486782408796" DF="0" EFFECT_SIZE="12.450000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.06" MODIFIED="2015-06-01 13:21:06 +0100" MODIFIED_BY="Nikki Jahnke" NO="6" P_CHI2="1.0" P_Z="0.029020877436288756" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="100.0" Z="2.1832028166767716">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="23.626951321759122" CI_START="1.2730486782408796" EFFECT_SIZE="12.450000000000001" ESTIMABLE="YES" MEAN_1="0.31" MEAN_2="-12.14" MODIFIED="2015-05-15 08:56:22 +0100" MODIFIED_BY="Thomas Radtke" ORDER="66" SD_1="13.2" SD_2="12.0" SE="5.702630971753301" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.0791400657566905" CI_START="-0.05914006575669006" DF="0" EFFECT_SIZE="2.0100000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.07" MODIFIED="2015-06-01 13:21:06 +0100" MODIFIED_BY="Nikki Jahnke" NO="7" P_CHI2="1.0" P_Z="0.056917427765531436" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="35" WEIGHT="100.0" Z="1.9039443844923147">
<NAME>Annual rate of change over 36 months</NAME>
<CONT_DATA CI_END="4.0791400657566905" CI_START="-0.05914006575669006" EFFECT_SIZE="2.0100000000000002" ESTIMABLE="YES" MEAN_1="-1.46" MEAN_2="-3.47" MODIFIED="2014-08-19 10:18:04 +0100" MODIFIED_BY="Thomas Radtke" ORDER="174" SD_1="3.55" SD_2="4.93" SE="1.0557031058110267" STUDY_ID="STD-Schneiderman_x002d_Walker-2000" TOTAL_1="30" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2017-09-14 10:16:08 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in health-related quality of life</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" MODIFIED="2015-03-11 12:16:00 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="0.17091416515631952" CI_START="0.02908583484368045" EFFECT_SIZE="0.09999999999999999" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="-0.01" ORDER="37" SD_1="0.12" SD_2="0.12" SE="0.036181361349331635" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2017-09-14 11:31:01 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in mean power during WAnT (W per kg BW)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.01" MODIFIED="2015-05-15 08:58:13 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="1.0857335419959302" CI_START="-0.52573354199593" EFFECT_SIZE="0.28" ESTIMABLE="YES" MEAN_1="0.86" MEAN_2="0.58" MODIFIED="2015-05-15 08:58:13 +0100" MODIFIED_BY="Thomas Radtke" ORDER="137" SD_1="1.2" SD_2="0.7" SE="0.4110960958218893" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" MODIFIED="2015-05-15 08:58:27 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.739229237849371" CI_START="-0.9192292378493709" EFFECT_SIZE="-0.08999999999999997" ESTIMABLE="YES" MEAN_1="-0.42" MEAN_2="-0.33" MODIFIED="2015-05-15 08:58:27 +0100" MODIFIED_BY="Thomas Radtke" ORDER="138" SD_1="1.3" SD_2="0.7" SE="0.4230839160261236" STUDY_ID="STD-Kriemler-2013" TOTAL_1="13" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.03" MODIFIED="2015-05-15 08:58:39 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="1.1110759350638313" CI_START="-0.6510759350638313" EFFECT_SIZE="0.22999999999999998" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.51" MODIFIED="2015-05-15 08:58:39 +0100" MODIFIED_BY="Thomas Radtke" ORDER="139" SD_1="1.1" SD_2="0.9" SE="0.44953679864203927" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.04" MODIFIED="2015-05-15 08:58:50 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="1.2817889582673292" CI_START="-0.7217889582673291" EFFECT_SIZE="0.28" ESTIMABLE="YES" MEAN_1="-1.13" MEAN_2="-1.41" MODIFIED="2015-05-15 08:58:50 +0100" MODIFIED_BY="Thomas Radtke" ORDER="140" SD_1="1.2" SD_2="0.9" SE="0.5111262075065218" STUDY_ID="STD-Kriemler-2013" TOTAL_1="9" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2017-09-14 11:33:36 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in strength (Newton metres)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.01" MODIFIED="2015-03-10 11:09:59 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="11.773417724782767" CI_START="4.48658227521723" EFFECT_SIZE="8.129999999999999" ESTIMABLE="YES" MEAN_1="1.83" MEAN_2="-6.3" MODIFIED="2015-02-17 15:47:19 +0000" MODIFIED_BY="Thomas Radtke" ORDER="32" SD_1="6.23" SD_2="6.1" SE="1.858920752381974" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" MODIFIED="2015-03-10 11:10:05 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="9.785236097567747" CI_START="2.474763902432254" EFFECT_SIZE="6.130000000000001" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="-4.23" MODIFIED="2015-02-17 15:47:45 +0000" MODIFIED_BY="Thomas Radtke" ORDER="193" SD_1="6.12" SD_2="6.25" SE="1.8649506452158215" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2017-09-14 11:34:03 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="49" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in peak work capacity during maximal exercise (W per kg BW)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" MODIFIED="2015-05-15 08:59:33 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.8742423673268649" CI_START="0.16575763267313515" EFFECT_SIZE="0.52" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="-0.19" MODIFIED="2015-05-15 08:59:33 +0100" MODIFIED_BY="Thomas Radtke" ORDER="136" SD_1="0.5" SD_2="0.4" SE="0.1807392228230128" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" MODIFIED="2015-05-15 08:59:38 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="1.0960989733711413" CI_START="0.5239010266288588" EFFECT_SIZE="0.81" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="-0.35" MODIFIED="2015-05-15 08:59:38 +0100" MODIFIED_BY="Thomas Radtke" ORDER="74" SD_1="0.4" SD_2="0.3" SE="0.1459715462262845" STUDY_ID="STD-Kriemler-2013" TOTAL_1="13" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.03" MODIFIED="2015-05-15 08:59:41 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="0.6078388287434315" CI_START="-0.10783882874343148" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="-0.21" MODIFIED="2015-05-15 08:59:41 +0100" MODIFIED_BY="Thomas Radtke" ORDER="62" SD_1="0.4" SD_2="0.4" SE="0.18257418583505539" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.04" MODIFIED="2015-05-15 08:59:49 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="0.7226374036269975" CI_START="-0.46263740362699746" EFFECT_SIZE="0.13" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.23" MODIFIED="2015-05-15 08:59:49 +0100" MODIFIED_BY="Thomas Radtke" ORDER="63" SD_1="0.6" SD_2="0.6" SE="0.30237157840738177" STUDY_ID="STD-Kriemler-2013" TOTAL_1="9" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2017-09-14 11:36:32 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Annual rate of change in peak work capacity during maximal exercise over 36 month (%)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.5525179753077207" CI_START="-1.9125179753077204" EFFECT_SIZE="0.8200000000000001" ESTIMABLE="YES" MEAN_1="-1.68" MEAN_2="-2.5" ORDER="30" SD_1="5.16" SD_2="6.08" SE="1.3941674422905082" STUDY_ID="STD-Schneiderman_x002d_Walker-2000" TOTAL_1="30" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2017-09-14 11:36:50 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in treadmill speed (km/h)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.01" MODIFIED="2015-03-11 13:55:39 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.8268753186483698" CI_START="-2.02687531864837" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="0.1" MODIFIED="2015-03-11 13:55:39 +0000" MODIFIED_BY="Thomas Radtke" ORDER="221" SD_1="2.6" SD_2="1.5" SE="0.7280109889280518" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2017-09-14 11:35:50 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in treadmill exercise time (min)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.01" MODIFIED="2015-03-11 13:55:26 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="1.057125049684759" CI_START="-2.057125049684759" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.2" MODIFIED="2015-03-11 13:55:26 +0000" MODIFIED_BY="Thomas Radtke" ORDER="220" SD_1="1.7" SD_2="2.8" SE="0.7944661544636343" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2017-09-14 11:35:29 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="60.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="64" TOTAL_2="69" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in heart rate (beats per min)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aerobic Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.01" MODIFIED="2015-03-11 13:53:29 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At rest at 3 months</NAME>
<CONT_DATA CI_END="19.35362781613323" CI_START="-5.35362781613323" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="-4.0" MODIFIED="2015-03-11 13:53:29 +0000" MODIFIED_BY="Thomas Radtke" ORDER="218" SD_1="20.4" SD_2="16.1" SE="6.302987153629898" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.02" MODIFIED="2015-03-11 12:45:46 +0000" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At maximal exercise at 3 months</NAME>
<CONT_DATA CI_END="25.033533083413406" CI_START="-17.033533083413406" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="6.5" MODIFIED="2015-03-11 12:41:18 +0000" MODIFIED_BY="Thomas Radtke" ORDER="213" SD_1="37.8" SD_2="23.0" SE="10.731591625827429" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.03" MODIFIED="2015-03-11 14:19:58 +0000" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>At maximal exercise - annual rate of change over 36 months</NAME>
<CONT_DATA CI_END="3.0472774244514653" CI_START="-0.8472774244514651" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="0.51" MEAN_2="-0.59" MODIFIED="2015-03-11 14:19:58 +0000" MODIFIED_BY="Thomas Radtke" ORDER="439" SD_1="3.68" SD_2="4.33" SE="0.9935271463207186" STUDY_ID="STD-Schneiderman_x002d_Walker-2000" TOTAL_1="30" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2017-09-14 11:37:40 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="30.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="56" TOTAL_2="56" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in oxygen saturation (%)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.01" MODIFIED="2015-03-11 13:04:07 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>During maximal exercise at hospital discharge</NAME>
<CONT_DATA CI_END="0.9150321417094031" CI_START="0.3249678582905967" EFFECT_SIZE="0.6199999999999999" ESTIMABLE="YES" MEAN_1="-1.28" MEAN_2="-1.9" MODIFIED="2015-03-11 11:32:06 +0000" MODIFIED_BY="Thomas Radtke" ORDER="28" SD_1="0.43" SD_2="0.56" SE="0.15052936892543897" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.02" MODIFIED="2015-03-11 13:55:02 +0000" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>During maximal exercise at 3 months</NAME>
<CONT_DATA CI_END="24.400533764955696" CI_START="-5.200533764955697" EFFECT_SIZE="9.6" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-10.6" MODIFIED="2015-03-11 13:55:02 +0000" MODIFIED_BY="Thomas Radtke" ORDER="208" SD_1="2.9" SD_2="31.0" SE="7.551431496548109" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.03" MODIFIED="2015-03-11 13:04:58 +0000" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At rest at 3 months</NAME>
<CONT_DATA CI_END="1.134918437494005" CI_START="-2.534918437494005" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.9" MODIFIED="2015-03-11 13:04:58 +0000" MODIFIED_BY="Thomas Radtke" ORDER="219" SD_1="1.1" SD_2="3.7" SE="0.9362000791686007" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2017-09-14 11:38:57 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.36" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Annual rate of change in peak VE over 36 months (L/min)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.775124709636496" CI_START="-1.5951247096364964" EFFECT_SIZE="2.09" ESTIMABLE="YES" MEAN_1="3.93" MEAN_2="1.84" ORDER="29" SD_1="8.31" SD_2="6.57" SE="1.8802002173020982" STUDY_ID="STD-Schneiderman_x002d_Walker-2000" TOTAL_1="30" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="32.41515835455831" CI_END="3.26113296759919" CI_START="0.9503320944092317" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="2.105732531004211" ESTIMABLE="YES" I2="78.40516488170837" I2_Q="77.1391041739147" ID="CMP-001.13" MODIFIED="2017-09-14 11:34:34 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="3.401376556166902E-5" P_Q="2.0035877141344471E-4" P_Z="3.541839573676041E-4" Q="26.24569065729145" RANDOM="NO" SCALE="25.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="147" TOTAL_2="132" UNITS="" WEIGHT="700.0" Z="3.5720602062481173">
<NAME>Change in FVC (% predicted)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.6746777040642296" CI_START="-2.5546777040642294" DF="0" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" MODIFIED="2015-01-20 11:16:22 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="1.0" P_Z="0.9641264099592939" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.04497603620117708">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="2.6746777040642296" CI_START="-2.5546777040642294" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" MEAN_1="2.34" MEAN_2="2.28" MODIFIED="2014-08-15 11:33:32 +0100" MODIFIED_BY="Thomas Radtke" ORDER="79" SD_1="4.62" SD_2="4.22" SE="1.3340437501344278" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.169467697266856" CI_END="9.079176666562077" CI_START="0.6925074770401372" DF="1" EFFECT_SIZE="4.8858420718011075" ESTIMABLE="YES" I2="83.79114618846272" ID="CMP-001.13.02" MODIFIED="2015-05-15 10:08:05 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.012997447420629471" P_Z="0.022392586395126767" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="27" WEIGHT="100.0" Z="2.283641879387541">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="5.01640482318747" CI_START="-8.216404823187471" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="2.0" MODIFIED="2015-03-11 11:34:26 +0000" MODIFIED_BY="Thomas Radtke" ORDER="209" SD_1="6.7" SD_2="12.2" SE="3.3757787772514325" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="40.167508562720414"/>
<CONT_DATA CI_END="14.661144373451481" CI_START="3.81885562654852" EFFECT_SIZE="9.24" ESTIMABLE="YES" MEAN_1="3.67" MEAN_2="-5.57" MODIFIED="2015-05-15 10:08:05 +0100" MODIFIED_BY="Thomas Radtke" ORDER="142" SD_1="7.3" SD_2="6.2" SE="2.765940811266317" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="10" WEIGHT="59.832491437279586"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.117336756282" CI_START="5.902663243717997" DF="0" EFFECT_SIZE="12.51" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.03" MODIFIED="2015-05-15 10:08:28 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="1.0" P_Z="2.065257222323663E-4" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="99.99999999999999" Z="3.710897499402344">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="19.117336756282" CI_START="5.902663243717997" EFFECT_SIZE="12.51" ESTIMABLE="YES" MEAN_1="4.66" MEAN_2="-7.85" MODIFIED="2015-05-15 10:08:28 +0100" MODIFIED_BY="Thomas Radtke" ORDER="78" SD_1="8.9" SD_2="7.8" SE="3.37115212748797" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.419278794203549" CI_START="-2.6392787942035487" DF="0" EFFECT_SIZE="-0.10999999999999988" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.04" MODIFIED="2015-06-01 13:42:44 +0100" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="1.0" P_Z="0.9320704922275889" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.00000000000001" Z="0.08524012409920802">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="2.419278794203549" CI_START="-2.6392787942035487" EFFECT_SIZE="-0.10999999999999988" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.31" MODIFIED="2015-02-17 15:16:47 +0000" MODIFIED_BY="Thomas Radtke" ORDER="194" SD_1="4.27" SD_2="4.29" SE="1.290472077116813" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="24.165430462971397" CI_START="6.014569537028603" DF="0" EFFECT_SIZE="15.09" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.05" MODIFIED="2015-06-01 13:42:47 +0100" MODIFIED_BY="Nikki Jahnke" NO="5" P_CHI2="1.0" P_Z="0.0011184785569217685" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="8" WEIGHT="100.0" Z="3.2588929690312405">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="24.165430462971397" CI_START="6.014569537028603" EFFECT_SIZE="15.09" ESTIMABLE="YES" MEAN_1="-0.67" MEAN_2="-15.76" MODIFIED="2015-05-15 10:09:01 +0100" MODIFIED_BY="Thomas Radtke" ORDER="80" SD_1="10.9" SD_2="10.4" SE="4.630406749591948" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.14103022427486" CI_START="-0.9410302242748578" DF="0" EFFECT_SIZE="9.100000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.06" MODIFIED="2015-06-01 13:42:50 +0100" MODIFIED_BY="Nikki Jahnke" NO="6" P_CHI2="1.0" P_Z="0.07568692415029102" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="100.0" Z="1.7762791128937716">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="19.14103022427486" CI_START="-0.9410302242748578" EFFECT_SIZE="9.100000000000001" ESTIMABLE="YES" MEAN_1="-3.29" MEAN_2="-12.39" MODIFIED="2015-05-15 10:09:10 +0100" MODIFIED_BY="Thomas Radtke" ORDER="81" SD_1="12.1" SD_2="10.6" SE="5.123068741812209" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.873336988433793" CI_START="0.4666630115662067" DF="0" EFFECT_SIZE="2.17" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.07" MODIFIED="2015-06-01 13:42:50 +0100" MODIFIED_BY="Nikki Jahnke" NO="7" P_CHI2="1.0" P_Z="0.012527189538301177" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="35" WEIGHT="100.0" Z="2.496935060608667">
<NAME>Annual rate of change over 36 months</NAME>
<CONT_DATA CI_END="3.873336988433793" CI_START="0.4666630115662067" EFFECT_SIZE="2.17" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="-2.42" MODIFIED="2014-08-19 10:19:11 +0100" MODIFIED_BY="Thomas Radtke" ORDER="175" SD_1="2.81" SD_2="4.15" SE="0.8690654531764348" STUDY_ID="STD-Schneiderman_x002d_Walker-2000" TOTAL_1="30" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2017-09-14 11:37:59 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="30.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="47" TOTAL_2="52" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in FEF<SUB>25-75</SUB> (% predicted)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.01" MODIFIED="2015-03-11 11:35:35 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Annual rate of change</NAME>
<CONT_DATA CI_END="3.8049002957199693" CI_START="-2.204900295719969" EFFECT_SIZE="0.8000000000000003" ESTIMABLE="YES" MEAN_1="-3.07" MEAN_2="-3.87" ORDER="36" SD_1="5.34" SD_2="7.0" SE="1.5331405675932002" STUDY_ID="STD-Schneiderman_x002d_Walker-2000" TOTAL_1="30" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.02" MODIFIED="2015-03-11 13:56:11 +0000" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="5.2871908828639125" CI_START="-23.28719088286391" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="-3.8" MEAN_2="5.2" MODIFIED="2015-03-11 13:56:11 +0000" MODIFIED_BY="Thomas Radtke" ORDER="210" SD_1="13.8" SD_2="26.7" SE="7.289517050088395" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2017-09-14 11:38:18 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="14.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="54" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in RV/TLC (%)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aerobic Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.01" MODIFIED="2015-05-15 10:11:18 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="1.6693650831895583" CI_START="-9.529365083189557" EFFECT_SIZE="-3.9299999999999997" ESTIMABLE="YES" MEAN_1="-1.26" MEAN_2="2.67" MODIFIED="2015-05-15 10:11:18 +0100" MODIFIED_BY="Thomas Radtke" ORDER="143" SD_1="6.9" SD_2="6.9" SE="2.8568714156773467" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.02" MODIFIED="2015-05-15 10:11:16 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="6.138741897060612" CI_START="-7.598741897060611" EFFECT_SIZE="-0.73" ESTIMABLE="YES" MEAN_1="1.02" MEAN_2="1.75" MODIFIED="2015-05-15 10:11:16 +0100" MODIFIED_BY="Thomas Radtke" ORDER="69" SD_1="8.5" SD_2="8.2" SE="3.5045245480225" STUDY_ID="STD-Kriemler-2013" TOTAL_1="13" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.03" MODIFIED="2015-05-15 10:11:14 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="10.395966919437505" CI_START="-4.015966919437506" EFFECT_SIZE="3.19" ESTIMABLE="YES" MEAN_1="3.05" MEAN_2="-0.14" MODIFIED="2015-05-15 10:11:14 +0100" MODIFIED_BY="Thomas Radtke" ORDER="70" SD_1="7.8" SD_2="8.7" SE="3.676581292450909" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.04" MODIFIED="2015-05-15 10:11:13 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="4.856969461426582" CI_START="-8.816969461426583" EFFECT_SIZE="-1.9800000000000002" ESTIMABLE="YES" MEAN_1="1.41" MEAN_2="3.39" MODIFIED="2015-05-15 10:11:13 +0100" MODIFIED_BY="Thomas Radtke" ORDER="71" SD_1="7.4" SD_2="7.8" SE="3.488313823802746" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2017-09-14 11:38:38 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in FEV<SUB>1</SUB>/FVC (% predicted)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.16.01" MODIFIED="2015-03-11 13:54:24 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="5.864320049945563" CI_START="-8.664320049945564" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="1.0" MODIFIED="2015-03-11 13:54:24 +0000" MODIFIED_BY="Thomas Radtke" ORDER="211" SD_1="7.7" SD_2="13.2" SE="3.706353844889801" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2017-09-14 11:39:16 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="53" TOTAL_2="33" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in total physical activity (counts per min)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.01" MODIFIED="2015-05-15 10:40:22 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="212.099724855713" CI_START="29.900275144287008" EFFECT_SIZE="121.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-121.0" MODIFIED="2015-05-15 10:40:22 +0100" MODIFIED_BY="Thomas Radtke" ORDER="104" SD_1="93.0" SD_2="116.0" SE="46.48030554351814" STUDY_ID="STD-Kriemler-2013" TOTAL_1="13" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.02" MODIFIED="2015-05-15 10:40:26 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="203.5087150813817" CI_START="-375.5087150813817" EFFECT_SIZE="-86.0" ESTIMABLE="YES" MEAN_1="-133.0" MEAN_2="-47.0" MODIFIED="2015-05-15 10:40:26 +0100" MODIFIED_BY="Thomas Radtke" ORDER="177" SD_1="539.0" SD_2="98.0" SE="147.71124233148643" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.03" MODIFIED="2015-05-15 10:40:35 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="269.67473919840455" CI_START="-309.67473919840455" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="-118.0" MEAN_2="-98.0" MODIFIED="2015-05-15 10:40:35 +0100" MODIFIED_BY="Thomas Radtke" ORDER="178" SD_1="522.0" SD_2="138.0" SE="147.79595007016553" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.04" MODIFIED="2015-05-15 10:40:39 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="336.46028551290453" CI_START="-362.46028551290453" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="-96.0" MEAN_2="-83.0" MODIFIED="2015-05-15 10:40:39 +0100" MODIFIED_BY="Thomas Radtke" ORDER="179" SD_1="589.0" SD_2="142.0" SE="178.29934032941557" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2017-09-14 11:37:18 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="53" TOTAL_2="33" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in moderate-to-vigorous physical activity (hours per week)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.18.01" MODIFIED="2015-05-15 10:43:05 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="1.297158973966042" CI_START="-2.297158973966042" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.3" MODIFIED="2015-05-15 10:43:05 +0100" MODIFIED_BY="Thomas Radtke" ORDER="105" SD_1="2.5" SD_2="1.8" SE="0.9169346927503784" STUDY_ID="STD-Kriemler-2013" TOTAL_1="13" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.18.02" MODIFIED="2015-05-15 10:43:14 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="1.8768749302276184" CI_START="-2.2768749302276188" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.6" MODIFIED="2015-05-15 10:43:14 +0100" MODIFIED_BY="Thomas Radtke" ORDER="180" SD_1="2.6" SD_2="2.4" SE="1.0596495377515827" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.18.03" MODIFIED="2015-05-15 10:43:19 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="2.187311661539419" CI_START="-1.0873116615394187" EFFECT_SIZE="0.55" ESTIMABLE="YES" MEAN_1="0.15" MEAN_2="-0.4" MODIFIED="2015-05-15 10:43:19 +0100" MODIFIED_BY="Thomas Radtke" ORDER="181" SD_1="2.3" SD_2="1.6" SE="0.8353784428970757" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.18.04" MODIFIED="2015-05-15 10:43:24 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="3.4530453705222017" CI_START="-1.0530453705222014" EFFECT_SIZE="1.2000000000000002" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="-0.8" MODIFIED="2015-05-15 10:43:24 +0100" MODIFIED_BY="Thomas Radtke" ORDER="182" SD_1="3.6" SD_2="1.3" SE="1.14953406710222" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2017-09-14 11:35:00 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in total physical activity (MJ/day)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.19.01" MODIFIED="2015-03-10 11:10:53 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="2.5983025982254127" CI_START="-0.19830259822541052" EFFECT_SIZE="1.200000000000001" ESTIMABLE="YES" MEAN_1="12.82" MEAN_2="11.62" ORDER="41" SD_1="2.44" SD_2="2.29" SE="0.7134328024673127" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.20" MODIFIED="2017-09-14 11:39:33 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in body weight (kg)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.20.01" MODIFIED="2015-02-12 13:07:55 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="0.13091602399234964" CI_START="-0.5909160239923497" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.03" ORDER="38" SD_1="0.64" SD_2="0.58" SE="0.184144212260638" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.20.02" MODIFIED="2015-03-10 11:11:31 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="0.5269598133529596" CI_START="-0.3269598133529594" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.0" MODIFIED="2015-02-17 15:21:15 +0000" MODIFIED_BY="Thomas Radtke" ORDER="198" SD_1="0.78" SD_2="0.66" SE="0.21784064233871847" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.21" MODIFIED="2017-09-14 11:40:38 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in BMI (kg/m<SUP>2</SUP>)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.21.01" MODIFIED="2015-05-15 10:44:57 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.7338565226131931" CI_START="-0.13385652261319314" EFFECT_SIZE="0.3" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.3" MODIFIED="2015-05-15 10:44:57 +0100" MODIFIED_BY="Thomas Radtke" ORDER="144" SD_1="0.6" SD_2="0.5" SE="0.22135943621178655" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.21.02" MODIFIED="2015-05-15 10:45:05 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.8000759730296092" CI_START="-7.597302960915542E-5" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.4" MODIFIED="2015-05-15 10:45:05 +0100" MODIFIED_BY="Thomas Radtke" ORDER="82" SD_1="0.5" SD_2="0.5" SE="0.2041241452319315" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.21.03" MODIFIED="2015-05-15 10:45:10 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="0.9867134276034215" CI_START="0.013286572396578433" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="-0.4" MODIFIED="2015-05-15 10:45:10 +0100" MODIFIED_BY="Thomas Radtke" ORDER="83" SD_1="0.5" SD_2="0.6" SE="0.24832774042918898" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.21.04" MODIFIED="2015-05-15 10:45:18 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="1.170600745759848" CI_START="-0.3706007457598478" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.4" MODIFIED="2015-05-15 10:45:18 +0100" MODIFIED_BY="Thomas Radtke" ORDER="84" SD_1="0.8" SD_2="0.9" SE="0.3931708704028483" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.22" MODIFIED="2017-10-26 12:46:48 +0100" MODIFIED_BY="Nikki Jahnke" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in BMI z score</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.22.01" MODIFIED="2015-03-11 12:28:02 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.35598978127597847" CI_START="-0.15598978127597848" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.1" MODIFIED="2015-03-11 12:28:02 +0000" MODIFIED_BY="Thomas Radtke" ORDER="215" SD_1="0.5" SD_2="0.2" SE="0.13060943124220303" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.23" MODIFIED="2017-09-14 11:42:48 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="101" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in fat-free mass (kg)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.23.01" MODIFIED="2015-01-20 11:21:05 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="0.21441280601585966" CI_START="-0.19441280601585964" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.6" MODIFIED="2014-08-15 11:43:42 +0100" MODIFIED_BY="Thomas Radtke" ORDER="90" SD_1="0.37" SD_2="0.32" SE="0.10429416439702044" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.23.02" MODIFIED="2015-05-15 10:47:02 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.4463320500961005" CI_START="-1.0463320500961004" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.0" MODIFIED="2015-05-15 10:47:02 +0100" MODIFIED_BY="Thomas Radtke" ORDER="146" SD_1="1.2" SD_2="0.7" SE="0.3807886552931954" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.23.03" MODIFIED="2015-05-15 10:47:08 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="1.5468000385416887" CI_START="-0.9468000385416889" EFFECT_SIZE="0.29999999999999993" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.7" MODIFIED="2015-05-15 10:47:08 +0100" MODIFIED_BY="Thomas Radtke" ORDER="88" SD_1="1.1" SD_2="1.8" SE="0.6361341577581467" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.23.04" MODIFIED="2015-03-10 11:11:17 +0000" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="0.2679954436267852" CI_START="-0.1879954436267853" EFFECT_SIZE="0.039999999999999925" ESTIMABLE="YES" MEAN_1="0.69" MEAN_2="0.65" MODIFIED="2015-02-17 15:20:36 +0000" MODIFIED_BY="Thomas Radtke" ORDER="197" SD_1="0.41" SD_2="0.36" SE="0.11632634345589214" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.23.05" MODIFIED="2015-05-15 10:47:17 +0100" MODIFIED_BY="Thomas Radtke" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="2.1871010513647877" CI_START="-0.3871010513647879" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-1.2" MODIFIED="2015-05-15 10:47:17 +0100" MODIFIED_BY="Thomas Radtke" ORDER="89" SD_1="1.5" SD_2="1.5" SE="0.6566962768281849" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.23.06" MODIFIED="2015-05-15 10:47:21 +0100" MODIFIED_BY="Thomas Radtke" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="1.75243590060201" CI_START="-0.75243590060201" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-1.2" MODIFIED="2015-05-15 10:47:21 +0100" MODIFIED_BY="Thomas Radtke" ORDER="91" SD_1="1.4" SD_2="1.4" SE="0.6390096504226938" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.24" MODIFIED="2017-09-14 11:42:31 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in body fat (%)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aerobic Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.24.01" MODIFIED="2015-05-15 10:50:00 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="2.8421698594175737" CI_START="0.3578301405824267" EFFECT_SIZE="1.6" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-1.0" MODIFIED="2015-05-15 10:50:00 +0100" MODIFIED_BY="Thomas Radtke" ORDER="220" SD_1="1.3" SD_2="1.7" SE="0.6337717780610514" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.24.02" MODIFIED="2015-05-15 10:50:01 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="3.198117860639533" CI_START="-0.3981178606395326" EFFECT_SIZE="1.4000000000000001" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="-0.3" MODIFIED="2015-05-15 10:50:01 +0100" MODIFIED_BY="Thomas Radtke" ORDER="85" SD_1="1.3" SD_2="2.7" SE="0.9174239296348591" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.24.03" MODIFIED="2015-05-15 10:50:02 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="3.6557331181416584" CI_START="-1.6557331181416584" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.2" MODIFIED="2015-05-15 10:50:02 +0100" MODIFIED_BY="Thomas Radtke" ORDER="86" SD_1="1.8" SD_2="3.6" SE="1.354990774876346" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.24.04" MODIFIED="2015-05-15 10:49:01 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="4.036592255068084" CI_START="-1.636592255068084" EFFECT_SIZE="1.2" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="0.1" MODIFIED="2015-05-15 10:48:40 +0100" MODIFIED_BY="Thomas Radtke" ORDER="87" SD_1="2.6" SD_2="3.5" SE="1.4472675403439867" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.25" MODIFIED="2017-09-14 11:40:56 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Annual rate of change of ideal weight for height (%)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.801869532499399" CI_START="-0.7618695324993989" EFFECT_SIZE="0.52" ESTIMABLE="YES" MEAN_1="0.48" MEAN_2="-0.04" ORDER="40" SD_1="2.52" SD_2="2.75" SE="0.6540270855029083" STUDY_ID="STD-Schneiderman_x002d_Walker-2000" TOTAL_1="30" TOTAL_2="35" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.26" MODIFIED="2017-09-14 11:43:07 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in triceps skinfold thickness (mm)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.26.01" MODIFIED="2015-03-11 13:40:00 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="1.1696501563735908" CI_START="-0.3896501563735909" EFFECT_SIZE="0.39" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.09" MODIFIED="2015-03-11 13:40:00 +0000" MODIFIED_BY="Thomas Radtke" ORDER="216" SD_1="1.3" SD_2="1.0" SE="0.3977880014752168" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.27" MODIFIED="2017-09-14 11:43:24 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in arm muscle circumference (cm)</NAME>
<GROUP_LABEL_1>Aerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.27.01" MODIFIED="2015-03-11 13:40:15 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.3725879422371758" CI_START="-0.05258794223717578" EFFECT_SIZE="0.16" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="-0.1" MODIFIED="2015-03-11 13:40:15 +0000" MODIFIED_BY="Thomas Radtke" ORDER="217" SD_1="0.4" SD_2="0.2" SE="0.1084652289093281" STUDY_ID="STD-Hommerding-2015" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-09-14 13:50:09 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Anaerobic training versus no physical training</NAME>
<CONT_OUTCOME CHI2="13.695882081331826" CI_END="4.868922563929383" CI_START="0.4393719421241724" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="2.6541472530267773" ESTIMABLE="YES" I2="56.19121160382725" I2_Q="61.54775110036248" ID="CMP-002.01" MODIFIED="2017-09-14 13:29:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.033224168835853884" P_Q="0.02334940870179414" P_Z="0.018834733290540497" Q="13.003140630474629" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="88" UNITS="" WEIGHT="600.0" Z="2.348785901662583">
<NAME>Change in VO<SUB>2</SUB> peak during maximal exercise (ml/min per kg BW)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.508356680210086" CI_START="-1.6083566802100855" DF="0" EFFECT_SIZE="1.95" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="0.28279061881685863" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="1.0740715766659623">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="5.508356680210086" CI_START="-1.6083566802100855" EFFECT_SIZE="1.95" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="-1.22" ORDER="42" SD_1="5.89" SD_2="6.15" SE="1.8155214627809229" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.226123584044786" CI_START="-4.026123584044786" DF="0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" MODIFIED="2017-09-14 11:43:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8288280543806208" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="99.99999999999999" Z="0.2162048743362241">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="3.226123584044786" CI_START="-4.026123584044786" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.25" MEAN_2="2.65" MODIFIED="2015-02-17 15:22:36 +0000" MODIFIED_BY="Thomas Radtke" ORDER="199" SD_1="6.25" SD_2="6.02" SE="1.850097049051506" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6927414508571963" CI_END="11.336528064277564" CI_START="-0.24854906985845027" DF="1" EFFECT_SIZE="5.543989497209557" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" MODIFIED="2017-09-14 11:43:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.40523387665340005" P_Z="0.060673834296514184" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="19" WEIGHT="100.0" Z="1.8758648940164204">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="10.852391902660104" CI_START="-2.9523919026601035" EFFECT_SIZE="3.95" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="-2.45" MODIFIED="2015-05-15 12:18:24 +0100" MODIFIED_BY="Thomas Radtke" ORDER="43" SD_1="2.6" SD_2="10.3" SE="3.521693233704951" STUDY_ID="STD-Klijn-2004" TOTAL_1="11" TOTAL_2="9" WEIGHT="70.42691099796741"/>
<CONT_DATA CI_END="19.99174077840688" CI_START="-1.311740778406877" EFFECT_SIZE="9.34" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="-1.84" MODIFIED="2015-05-15 12:17:14 +0100" MODIFIED_BY="Thomas Radtke" ORDER="149" SD_1="12.8" SD_2="12.1" SE="5.434661484816276" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="29.573089002032596"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="29.424164784187504" CI_START="5.975835215812497" DF="0" EFFECT_SIZE="17.7" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.04" MODIFIED="2017-09-14 11:43:37 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0030867678198780286" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="10" WEIGHT="100.0" Z="2.9589623794052726">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="29.424164784187504" CI_START="5.975835215812497" EFFECT_SIZE="17.7" ESTIMABLE="YES" MEAN_1="6.22" MEAN_2="-11.48" MODIFIED="2015-05-15 12:18:32 +0100" MODIFIED_BY="Thomas Radtke" ORDER="92" SD_1="13.7" SD_2="11.1" SE="5.981826644094594" STUDY_ID="STD-Kriemler-2013" TOTAL_1="8" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.617934323285867E-32" CI_END="24.204199387066804" CI_START="-1.0241993870668082" DF="0" EFFECT_SIZE="11.589999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-002.01.05" MODIFIED="2015-05-15 12:18:38 +0100" MODIFIED_BY="Thomas Radtke" NO="5" P_CHI2="0.0" P_Z="0.07173025505224871" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.8008263452779778">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="24.204199387066808" CI_START="-1.0241993870668065" EFFECT_SIZE="11.59" ESTIMABLE="YES" MEAN_1="2.24" MEAN_2="-9.35" MODIFIED="2015-05-15 12:18:38 +0100" MODIFIED_BY="Thomas Radtke" ORDER="150" SD_1="13.6" SD_2="12.1" SE="6.4359342756122055" STUDY_ID="STD-Kriemler-2013" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="22.779185589049128" CI_START="-4.259185589049126" DF="0" EFFECT_SIZE="9.26" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.06" MODIFIED="2015-05-15 12:18:48 +0100" MODIFIED_BY="Thomas Radtke" NO="6" P_CHI2="1.0" P_Z="0.17943968641513525" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="7" WEIGHT="100.0" Z="1.34248223587834">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="22.779185589049128" CI_START="-4.259185589049126" EFFECT_SIZE="9.26" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="-7.36" MODIFIED="2015-05-15 12:18:48 +0100" MODIFIED_BY="Thomas Radtke" ORDER="151" SD_1="13.8" SD_2="12.9" SE="6.897670414194718" STUDY_ID="STD-Kriemler-2013" TOTAL_1="8" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2017-09-14 13:34:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="88" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in FEV<SUB>1</SUB> (% predicted)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" MODIFIED="2015-03-10 11:17:27 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="9.817061613171136" CI_START="1.3429383868288642" EFFECT_SIZE="5.58" ESTIMABLE="YES" MEAN_1="10.09" MEAN_2="4.51" MODIFIED="2015-02-17 14:54:10 +0000" MODIFIED_BY="Thomas Radtke" ORDER="193" SD_1="7.43" SD_2="6.9" SE="2.161805852858796" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.02" MODIFIED="2017-09-14 11:43:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="9.504615981969902" CI_START="0.6553840180300998" EFFECT_SIZE="5.080000000000001" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="4.72" MODIFIED="2015-02-17 15:23:49 +0000" MODIFIED_BY="Thomas Radtke" ORDER="200" SD_1="7.81" SD_2="7.15" SE="2.2574986157249355" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.03" MODIFIED="2017-09-14 11:43:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="17.055423147046803" CI_START="5.164576852953198" EFFECT_SIZE="11.11" ESTIMABLE="YES" MEAN_1="3.19" MEAN_2="-7.92" MODIFIED="2015-05-15 12:21:28 +0100" MODIFIED_BY="Thomas Radtke" ORDER="194" SD_1="7.2" SD_2="6.7" SE="3.033434896734603" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.04" MODIFIED="2017-09-14 11:43:45 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="28.44980726136893" CI_START="10.570192738631066" EFFECT_SIZE="19.509999999999998" ESTIMABLE="YES" MEAN_1="8.51" MEAN_2="-11.0" MODIFIED="2015-05-15 12:21:34 +0100" MODIFIED_BY="Thomas Radtke" ORDER="97" SD_1="10.8" SD_2="10.1" SE="4.561209967063165" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.05" MODIFIED="2015-05-15 12:21:41 +0100" MODIFIED_BY="Thomas Radtke" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="27.230961661002105" CI_START="4.949038338997896" EFFECT_SIZE="16.09" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="-15.83" MODIFIED="2015-05-15 12:21:41 +0100" MODIFIED_BY="Thomas Radtke" ORDER="156" SD_1="12.0" SD_2="12.4" SE="5.684268562524918" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.06" MODIFIED="2015-05-15 12:21:48 +0100" MODIFIED_BY="Thomas Radtke" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="27.74923044277905" CI_START="6.270769557220953" EFFECT_SIZE="17.01" ESTIMABLE="YES" MEAN_1="4.87" MEAN_2="-12.14" MODIFIED="2015-05-15 12:21:48 +0100" MODIFIED_BY="Thomas Radtke" ORDER="157" SD_1="11.5" SD_2="12.0" SE="5.47929988892078" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2017-09-14 13:46:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in HRQoL</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.01" MODIFIED="2015-02-12 14:16:54 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>1 month after discharge</NAME>
<CONT_DATA CI_END="0.09527271294866593" CI_START="-0.035272712948665935" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="-0.01" ORDER="53" SD_1="0.1" SD_2="0.12" SE="0.033303016516389464" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2017-09-14 13:34:47 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="40.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="11" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in HRQoL physical function (CF questionnaire)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.01" MODIFIED="2015-02-17 16:33:25 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="14.1470739145443" CI_START="-11.547073914544278" EFFECT_SIZE="1.3000000000000114" ESTIMABLE="YES" MEAN_1="88.4" MEAN_2="87.1" MODIFIED="2015-02-17 16:33:25 +0000" MODIFIED_BY="Thomas Radtke" ORDER="52" SD_1="9.0" SD_2="17.9" SE="6.554749993306188" STUDY_ID="STD-Klijn-2004" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2017-09-14 13:37:10 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="11" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in peak power during WAnT (W)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.01" MODIFIED="2015-02-12 14:23:00 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="108.09756601413119" CI_START="32.50243398586884" EFFECT_SIZE="70.30000000000001" ESTIMABLE="YES" MEAN_1="66.9" MEAN_2="-3.4" ORDER="46" SD_1="23.8" SD_2="53.7" SE="19.284826819407677" STUDY_ID="STD-Klijn-2004" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2017-09-14 13:37:23 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="11" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in mean power during WAnT (W)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.01" MODIFIED="2015-02-12 14:23:10 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="64.04162631061669" CI_START="22.558373689383323" EFFECT_SIZE="43.300000000000004" ESTIMABLE="YES" MEAN_1="36.6" MEAN_2="-6.7" ORDER="47" SD_1="11.8" SD_2="29.9" SE="10.582656862179093" STUDY_ID="STD-Klijn-2004" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2017-09-14 13:37:40 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="45" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in mean power during WAnT (W per kg BW)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.01" MODIFIED="2015-05-15 12:23:49 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.03897679527085662" CI_START="-1.2989767952708566" EFFECT_SIZE="-0.63" ESTIMABLE="YES" MEAN_1="-0.05" MEAN_2="0.58" MODIFIED="2015-05-15 12:23:49 +0100" MODIFIED_BY="Thomas Radtke" ORDER="95" SD_1="0.9" SD_2="0.7" SE="0.3413209633175202" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.02" MODIFIED="2015-05-15 12:23:59 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.941665443103008" CI_START="-0.34166544310300795" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="-0.33" MODIFIED="2015-05-15 12:23:59 +0100" MODIFIED_BY="Thomas Radtke" ORDER="152" SD_1="0.8" SD_2="0.7" SE="0.3273863439146755" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.03" MODIFIED="2015-05-15 12:24:07 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="0.6696455113096329" CI_START="-0.969645511309633" EFFECT_SIZE="-0.15000000000000002" ESTIMABLE="YES" MEAN_1="-0.66" MEAN_2="-0.51" MODIFIED="2015-05-15 12:24:07 +0100" MODIFIED_BY="Thomas Radtke" ORDER="153" SD_1="0.9" SD_2="0.9" SE="0.41819416977806334" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.04" MODIFIED="2015-05-15 12:24:12 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="1.1360626538666194" CI_START="-0.9360626538666197" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.31" MEAN_2="-1.41" MODIFIED="2015-05-15 12:24:12 +0100" MODIFIED_BY="Thomas Radtke" ORDER="154" SD_1="1.4" SD_2="0.9" SE="0.5286131082198191" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2017-09-14 13:37:50 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="58.43" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in lower limb strength (Newton metres)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.08.01" MODIFIED="2015-03-10 11:17:56 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="28.506160233826066" CI_START="20.733839766173936" EFFECT_SIZE="24.62" ESTIMABLE="YES" MEAN_1="18.32" MEAN_2="-6.3" ORDER="49" SD_1="7.02" SD_2="6.1" SE="1.9827712470635177" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.08.02" MODIFIED="2015-03-10 11:18:04 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="23.217205473102286" CI_START="15.242794526897717" EFFECT_SIZE="19.23" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="-4.23" MODIFIED="2015-02-17 15:25:39 +0000" MODIFIED_BY="Thomas Radtke" ORDER="201" SD_1="7.21" SD_2="6.25" SE="2.0343258879004167" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2017-09-14 13:47:14 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="11" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in peak work capacity during maximal exercise (W)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.09.01" MODIFIED="2015-02-12 14:23:26 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="21.894859788695875" CI_START="4.105140211304125" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="-2.0" ORDER="48" SD_1="14.0" SD_2="5.0" SE="4.538277161650619" STUDY_ID="STD-Klijn-2004" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.10" MODIFIED="2017-09-14 13:47:27 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="35" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in peak work capacity during maximal exercise (W per kg body weight)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.10.01" MODIFIED="2015-05-15 12:26:33 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-0.15745203869275776" CI_START="-0.8425479613072422" EFFECT_SIZE="-0.49999999999999994" ESTIMABLE="YES" MEAN_1="-0.69" MEAN_2="-0.19" MODIFIED="2015-05-15 12:26:33 +0100" MODIFIED_BY="Thomas Radtke" ORDER="168" SD_1="0.4" SD_2="0.4" SE="0.17477257950106062" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.10.02" MODIFIED="2015-05-15 12:26:31 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="0.6107472261732251" CI_START="0.009252773826774918" EFFECT_SIZE="0.31" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="-0.35" MODIFIED="2015-05-15 12:26:31 +0100" MODIFIED_BY="Thomas Radtke" ORDER="169" SD_1="0.4" SD_2="0.3" SE="0.1534452819263419" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.10.03" MODIFIED="2015-05-15 12:26:30 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="0.4642868939153924" CI_START="-0.26428689391539245" EFFECT_SIZE="0.09999999999999999" ESTIMABLE="YES" MEAN_1="-0.11" MEAN_2="-0.21" MODIFIED="2015-05-15 12:26:30 +0100" MODIFIED_BY="Thomas Radtke" ORDER="170" SD_1="0.4" SD_2="0.4" SE="0.18586407545691705" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.10.04" MODIFIED="2015-05-15 12:26:24 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="0.7874777518294327" CI_START="-0.7874777518294327" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.23" MEAN_2="-0.23" MODIFIED="2015-05-15 12:26:24 +0100" MODIFIED_BY="Thomas Radtke" ORDER="171" SD_1="1.1" SD_2="0.6" SE="0.40178174601214955" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.11" MODIFIED="2017-09-14 13:48:27 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="11" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in lactate during maximal exercise (mmol/L)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.11.01" MODIFIED="2015-02-12 14:37:06 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="5.467391586202671" CI_START="1.3326084137973293" EFFECT_SIZE="3.4000000000000004" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="-1.6" ORDER="44" SD_1="1.4" SD_2="2.9" SE="1.0548110080134083" STUDY_ID="STD-Klijn-2004" TOTAL_1="11" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.12" MODIFIED="2017-09-14 13:39:10 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in peak oxygen saturation during maximal exercise (%)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.12.01" MODIFIED="2015-03-11 12:42:14 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="0.61756935112016" CI_START="0.042430648879839716" EFFECT_SIZE="0.32999999999999985" ESTIMABLE="YES" MEAN_1="-1.57" MEAN_2="-1.9" ORDER="45" SD_1="0.4" SD_2="0.56" SE="0.14672175274059648" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.13" MODIFIED="2017-09-14 13:49:24 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="25.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="88" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in FVC (% predicted)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.13.01" MODIFIED="2015-03-10 11:18:17 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="2.652023920853388" CI_START="-2.3120239208533873" EFFECT_SIZE="0.17000000000000037" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="2.28" MODIFIED="2015-02-17 15:28:53 +0000" MODIFIED_BY="Thomas Radtke" ORDER="202" SD_1="4.18" SD_2="4.22" SE="1.2663620048282904" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.13.02" MODIFIED="2015-05-15 12:33:09 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="12.845284890916359" CI_START="1.8947151090836414" EFFECT_SIZE="7.37" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="-5.57" MODIFIED="2015-05-15 12:33:09 +0100" MODIFIED_BY="Thomas Radtke" ORDER="204" SD_1="6.6" SD_2="6.2" SE="2.793564031841762" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.13.03" MODIFIED="2015-05-15 12:33:17 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="20.936903831804457" CI_START="7.163096168195543" EFFECT_SIZE="14.05" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="-7.85" MODIFIED="2015-05-15 12:33:17 +0100" MODIFIED_BY="Thomas Radtke" ORDER="98" SD_1="8.3" SD_2="7.8" SE="3.5137910115325974" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.13.04" MODIFIED="2015-03-10 11:18:21 +0000" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="2.5367913588900217" CI_START="-2.4167913588900216" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" MEAN_1="2.37" MEAN_2="2.31" MODIFIED="2015-02-17 15:30:04 +0000" MODIFIED_BY="Thomas Radtke" ORDER="203" SD_1="4.09" SD_2="4.29" SE="1.263692281300389" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.13.05" MODIFIED="2015-05-15 12:33:22 +0100" MODIFIED_BY="Thomas Radtke" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="22.94245233481806" CI_START="4.37754766518194" EFFECT_SIZE="13.66" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-15.76" MODIFIED="2015-05-15 12:33:22 +0100" MODIFIED_BY="Thomas Radtke" ORDER="158" SD_1="9.9" SD_2="10.4" SE="4.736032094485847" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.13.06" MODIFIED="2015-05-15 12:33:27 +0100" MODIFIED_BY="Thomas Radtke" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="23.131921127321167" CI_START="4.128078872678834" EFFECT_SIZE="13.63" ESTIMABLE="YES" MEAN_1="1.24" MEAN_2="-12.39" MODIFIED="2015-05-15 12:33:27 +0100" MODIFIED_BY="Thomas Radtke" ORDER="159" SD_1="10.2" SD_2="10.6" SE="4.848008025795937" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.14" MODIFIED="2017-09-14 13:47:47 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="30.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in RV/TLC (%)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Anaerobic Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.14.01" MODIFIED="2015-05-15 12:34:59 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="-1.9746470757982673" CI_START="-10.865352924201733" EFFECT_SIZE="-6.42" ESTIMABLE="YES" MEAN_1="-4.27" MEAN_2="2.15" MODIFIED="2015-05-15 12:34:59 +0100" MODIFIED_BY="Thomas Radtke" ORDER="279" SD_1="4.7" SD_2="5.6" SE="2.268078882707085" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.14.02" MODIFIED="2015-05-15 12:35:04 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="-8.364264192063821" CI_START="-21.355735807936178" EFFECT_SIZE="-14.86" ESTIMABLE="YES" MEAN_1="-6.37" MEAN_2="8.49" MODIFIED="2015-05-15 12:35:04 +0100" MODIFIED_BY="Thomas Radtke" ORDER="280" SD_1="7.8" SD_2="7.0" SE="3.3142118218363774" STUDY_ID="STD-Kriemler-2013" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.14.03" MODIFIED="2015-05-15 12:35:08 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="-0.24995723760483557" CI_START="-13.470042762395165" EFFECT_SIZE="-6.86" ESTIMABLE="YES" MEAN_1="1.08" MEAN_2="7.94" MODIFIED="2015-05-15 12:35:08 +0100" MODIFIED_BY="Thomas Radtke" ORDER="281" SD_1="7.2" SD_2="7.3" SE="3.3725327682214257" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.14.04" MODIFIED="2015-05-15 12:35:13 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="1.0736620597801148" CI_START="-10.613662059780115" EFFECT_SIZE="-4.77" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="4.59" MODIFIED="2015-05-15 12:35:13 +0100" MODIFIED_BY="Thomas Radtke" ORDER="282" SD_1="6.3" SD_2="6.5" SE="2.9815150206198555" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.15" MODIFIED="2017-09-14 13:50:09 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="53" TOTAL_2="33" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in total physical activity (counts per min)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.15.01" MODIFIED="2015-05-15 12:36:57 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="115.58809837879193" CI_START="-81.58809837879193" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="-104.0" MEAN_2="-121.0" MODIFIED="2015-05-15 12:36:57 +0100" MODIFIED_BY="Thomas Radtke" ORDER="102" SD_1="116.0" SD_2="116.0" SE="50.30097448547129" STUDY_ID="STD-Kriemler-2013" TOTAL_1="13" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.15.02" MODIFIED="2015-05-15 12:37:02 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="92.95164012676652" CI_START="-58.95164012676652" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="-30.0" MEAN_2="-47.0" MODIFIED="2015-05-15 12:37:02 +0100" MODIFIED_BY="Thomas Radtke" ORDER="187" SD_1="78.0" SD_2="98.0" SE="38.7515488681748" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.15.03" MODIFIED="2015-05-15 12:37:06 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="118.0433717834748" CI_START="-98.0433717834748" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="-88.0" MEAN_2="-98.0" MODIFIED="2015-05-15 12:37:06 +0100" MODIFIED_BY="Thomas Radtke" ORDER="188" SD_1="96.0" SD_2="138.0" SE="55.12518221544229" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.15.04" MODIFIED="2015-05-15 12:37:10 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="244.89605596123994" CI_START="-34.89605596123994" EFFECT_SIZE="105.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="-83.0" MODIFIED="2015-05-15 12:37:10 +0100" MODIFIED_BY="Thomas Radtke" ORDER="189" SD_1="163.0" SD_2="142.0" SE="71.37685032210906" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.16" MODIFIED="2017-09-14 13:49:58 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="53" TOTAL_2="32" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in moderate to vigorous physical activity (hours per week)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.16.01" MODIFIED="2015-05-15 12:38:26 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.12981531967090887" CI_START="-2.929815319670909" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="0.3" MODIFIED="2015-05-15 12:38:26 +0100" MODIFIED_BY="Thomas Radtke" ORDER="103" SD_1="1.8" SD_2="1.8" SE="0.780532362705589" STUDY_ID="STD-Kriemler-2013" TOTAL_1="13" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.16.02" MODIFIED="2015-05-15 12:38:34 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="1.9779122108809923" CI_START="-1.5779122108809924" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.6" MODIFIED="2015-05-15 12:38:34 +0100" MODIFIED_BY="Thomas Radtke" ORDER="190" SD_1="1.2" SD_2="2.4" SE="0.9071147352221454" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.16.03" MODIFIED="2015-05-15 12:38:39 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="0.35543469441162046" CI_START="-2.5554346944116206" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.4" MODIFIED="2015-05-15 12:38:39 +0100" MODIFIED_BY="Thomas Radtke" ORDER="191" SD_1="1.8" SD_2="1.6" SE="0.7425823667638302" STUDY_ID="STD-Kriemler-2013" TOTAL_1="14" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.16.04" MODIFIED="2015-05-15 12:38:44 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="3.051546061665587" CI_START="-0.8515460616655868" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.8" MODIFIED="2015-05-15 12:38:44 +0100" MODIFIED_BY="Thomas Radtke" ORDER="192" SD_1="3.0" SD_2="1.3" SE="0.9957050624700928" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="7" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.17" MODIFIED="2017-09-14 13:47:57 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in physical activity (MJ/day)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.17.01" MODIFIED="2015-03-10 11:18:31 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="2.1639312175951044" CI_START="-0.8639312175951037" EFFECT_SIZE="0.6500000000000004" ESTIMABLE="YES" MEAN_1="12.27" MEAN_2="11.62" MODIFIED="2015-01-21 13:57:35 +0000" MODIFIED_BY="Thomas Radtke" ORDER="56" SD_1="2.2" SD_2="2.29" SE="0.7724280800753485" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="18" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.18" MODIFIED="2017-09-14 13:48:48 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in weight (kg)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.18.01" MODIFIED="2015-02-16 08:38:13 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="2.109867295573648" CI_START="1.3501327044263514" EFFECT_SIZE="1.7299999999999998" ESTIMABLE="YES" MEAN_1="2.76" MEAN_2="1.03" ORDER="54" SD_1="0.7" SD_2="0.58" SE="0.19381340604725042" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.18.02" MODIFIED="2015-03-10 11:18:43 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="2.0612316792184546" CI_START="1.2387683207815452" EFFECT_SIZE="1.65" ESTIMABLE="YES" MEAN_1="2.65" MEAN_2="1.0" MODIFIED="2015-02-17 15:33:20 +0000" MODIFIED_BY="Thomas Radtke" ORDER="205" SD_1="0.73" SD_2="0.66" SE="0.20981593665097814" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.19" MODIFIED="2017-09-14 13:48:17 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in BMI (kg/m<SUP>2</SUP>)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.19.01" MODIFIED="2015-05-15 12:40:02 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="0.9338565226131932" CI_START="0.06614347738680687" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-0.3" MODIFIED="2015-05-15 12:40:02 +0100" MODIFIED_BY="Thomas Radtke" ORDER="100" SD_1="0.6" SD_2="0.5" SE="0.22135943621178655" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.19.02" MODIFIED="2015-05-15 12:40:07 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="1.1338565226131931" CI_START="0.2661434773868068" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.4" MODIFIED="2015-05-15 12:40:07 +0100" MODIFIED_BY="Thomas Radtke" ORDER="160" SD_1="0.6" SD_2="0.5" SE="0.22135943621178655" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.19.03" MODIFIED="2015-05-15 12:40:12 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="1.7549525949594957" CI_START="0.44504740504050433" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="-0.4" MODIFIED="2015-05-15 12:40:12 +0100" MODIFIED_BY="Thomas Radtke" ORDER="161" SD_1="1.0" SD_2="0.6" SE="0.334165627596057" STUDY_ID="STD-Kriemler-2013" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.19.04" MODIFIED="2015-05-15 12:40:20 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="2.2643407884023" CI_START="0.33565921159769996" EFFECT_SIZE="1.3" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="-0.4" MODIFIED="2015-05-15 12:40:20 +0100" MODIFIED_BY="Thomas Radtke" ORDER="162" SD_1="1.3" SD_2="0.9" SE="0.49201964730418374" STUDY_ID="STD-Kriemler-2013" TOTAL_1="12" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.20" MODIFIED="2017-09-14 13:49:05 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="88" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in fat-free mass (kg)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Anaerobic Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.20.01" MODIFIED="2015-03-10 11:18:52 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At hospital discharge</NAME>
<CONT_DATA CI_END="2.0341539965005504" CI_START="1.5658460034994492" EFFECT_SIZE="1.7999999999999998" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="0.6" MODIFIED="2015-02-17 15:33:54 +0000" MODIFIED_BY="Thomas Radtke" ORDER="206" SD_1="0.46" SD_2="0.32" SE="0.11946852000726917" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.20.02" MODIFIED="2015-05-15 13:20:30 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="1.7403094332208477" CI_START="-0.34030943322084783" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.0" MODIFIED="2015-05-15 13:20:30 +0100" MODIFIED_BY="Thomas Radtke" ORDER="222" SD_1="1.6" SD_2="0.7" SE="0.5307798721949362" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.20.03" MODIFIED="2015-05-15 12:47:39 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="2.924915996998217" CI_START="0.07508400300178297" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="-0.7" MODIFIED="2015-05-15 12:47:39 +0100" MODIFIED_BY="Thomas Radtke" ORDER="99" SD_1="1.5" SD_2="1.8" SE="0.7270113166557001" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.20.04" MODIFIED="2015-03-10 11:19:04 +0000" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 1 month after discharge</NAME>
<CONT_DATA CI_END="1.9573892145673302" CI_START="1.4626107854326698" EFFECT_SIZE="1.71" ESTIMABLE="YES" MEAN_1="2.36" MEAN_2="0.65" MODIFIED="2015-02-17 15:35:13 +0000" MODIFIED_BY="Thomas Radtke" ORDER="207" SD_1="0.47" SD_2="0.36" SE="0.12622130637027246" STUDY_ID="STD-Selvadurai-2002" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.20.05" MODIFIED="2015-05-15 12:47:41 +0100" MODIFIED_BY="Thomas Radtke" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="3.8550367517656734" CI_START="0.1449632482343266" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="-1.2" MODIFIED="2015-05-15 12:47:41 +0100" MODIFIED_BY="Thomas Radtke" ORDER="163" SD_1="2.6" SD_2="1.5" SE="0.9464647138406453" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.20.06" MODIFIED="2015-05-15 12:47:43 +0100" MODIFIED_BY="Thomas Radtke" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="5.37811883136739" CI_START="1.0218811686326101" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="-1.2" MODIFIED="2015-05-15 12:47:43 +0100" MODIFIED_BY="Thomas Radtke" ORDER="164" SD_1="3.3" SD_2="1.4" SE="1.1113055385446433" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.21" MODIFIED="2017-09-14 13:49:45 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in body fat (%)</NAME>
<GROUP_LABEL_1>Anaerobic Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Anaerobic Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.21.01" MODIFIED="2015-05-15 12:46:19 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="2.655828835555779" CI_START="-0.25582883555577896" EFFECT_SIZE="1.2" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-1.0" MODIFIED="2015-05-15 12:46:19 +0100" MODIFIED_BY="Thomas Radtke" ORDER="221" SD_1="1.7" SD_2="1.7" SE="0.7427834628795075" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.21.02" MODIFIED="2015-05-15 12:46:24 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="2.454030570271459" CI_START="-0.8540305702714586" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="-0.3" MODIFIED="2015-05-15 12:46:24 +0100" MODIFIED_BY="Thomas Radtke" ORDER="165" SD_1="2.5" SD_2="1.2" SE="0.8439086551172575" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.21.03" MODIFIED="2015-05-15 12:46:30 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="3.538015537244889" CI_START="-0.13801553724488902" EFFECT_SIZE="1.7000000000000002" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="0.5" MODIFIED="2015-05-15 12:46:30 +0100" MODIFIED_BY="Thomas Radtke" ORDER="166" SD_1="1.9" SD_2="2.1" SE="0.9377802611389399" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.21.04" MODIFIED="2015-05-15 12:46:34 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months off training</NAME>
<CONT_DATA CI_END="3.8549840066234498" CI_START="-1.6549840066234496" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="0.7" MODIFIED="2015-05-15 12:46:34 +0100" MODIFIED_BY="Thomas Radtke" ORDER="167" SD_1="2.6" SD_2="3.3" SE="1.4056299137914838" STUDY_ID="STD-Kriemler-2013" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-10-30 09:19:24 +0000" MODIFIED_BY="Nikki Jahnke" NO="3">
<NAME>Combined aerobic and anaerobic training versus no physical training</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:19:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Change in VO<SUB>2</SUB> peak during maximal exercise (ml/min per kg BW)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-22 10:42:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<IV_DATA CI_END="0.6726830760068068" CI_START="-4.931016476006807" EFFECT_SIZE="-2.1291667" ESTIMABLE="YES" ESTIMATE="-2.1291667" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-06-22 10:42:03 +0100" MODIFIED_BY="[Empty name]" ORDER="243" SE="1.42954146" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 13:39:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<IV_DATA CI_END="3.999963984540054" CI_START="0.08003601545994576" EFFECT_SIZE="2.04" ESTIMABLE="YES" ESTIMATE="2.04" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-18 14:00:52 +0100" MODIFIED_BY="Thomas Radtke" ORDER="109" SE="1.0" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 13:39:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<IV_DATA CI_END="3.012757501757264" CI_START="-1.6127575017572642" EFFECT_SIZE="0.7" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-18 14:01:59 +0100" MODIFIED_BY="Thomas Radtke" ORDER="147" SE="1.18" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 13:39:09 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<IV_DATA CI_END="6.140755700984267" CI_START="1.3192442990157334" EFFECT_SIZE="3.73" ESTIMABLE="YES" ESTIMATE="3.73" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-18 14:02:06 +0100" MODIFIED_BY="Thomas Radtke" ORDER="148" SE="1.23" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2017-09-14 14:48:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="87" TOTAL_2="66" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in FEV<SUB>1</SUB> (% predicted)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" MODIFIED="2017-06-22 10:44:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="4.122064686881278" CI_START="-5.622064686881278" EFFECT_SIZE="-0.75" ESTIMABLE="YES" MEAN_1="-1.25" MEAN_2="-0.5" MODIFIED="2017-06-22 10:44:01 +0100" MODIFIED_BY="[Empty name]" ORDER="242" SD_1="4.0620192" SD_2="4.96990946" SE="2.485792966254228" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.02" MODIFIED="2017-06-05 13:38:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="3.8557411076699983" CI_START="-11.85574110767" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-2.0" MODIFIED="2014-10-13 13:28:43 +0100" MODIFIED_BY="Thomas Radtke" ORDER="248" SD_1="16.1" SD_2="7.3" SE="4.0081048272494195" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.03" MODIFIED="2017-06-05 13:38:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<CONT_DATA CI_END="9.312016482921194" CI_START="-5.312016482921194" EFFECT_SIZE="1.9999999999999996" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-4.1" MODIFIED="2014-10-20 16:02:55 +0100" MODIFIED_BY="Thomas Radtke" ORDER="205" SD_1="8.4" SD_2="11.8" SE="3.730689206841272" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="22" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.04" MODIFIED="2017-06-05 13:38:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="6.487884963475823" CI_START="-8.687884963475822" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-4.9" MODIFIED="2014-10-20 16:03:54 +0100" MODIFIED_BY="Thomas Radtke" ORDER="206" SD_1="12.5" SD_2="8.7" SE="3.8714410179616006" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="18" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.05" MODIFIED="2017-06-05 13:38:34 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<CONT_DATA CI_END="11.573400105574441" CI_START="-4.373400105574442" EFFECT_SIZE="3.5999999999999996" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-9.1" MODIFIED="2014-10-20 16:04:09 +0100" MODIFIED_BY="Thomas Radtke" ORDER="207" SD_1="10.1" SD_2="12.2" SE="4.068136031308536" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="20" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:48:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="564.35" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Annual change in FEV<SUB>1</SUB> (mL)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-03-11 12:42:44 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<IV_DATA CI_END="287.9830743324286" CI_START="-73.98307433242863" EFFECT_SIZE="107.0" ESTIMABLE="YES" ESTIMATE="107.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="71" SE="92.34" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:30:55 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Change in subjective health perception (CFQ-R)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 09:54:34 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<IV_DATA CI_END="18.92583432888425" CI_START="0.8941656711157506" EFFECT_SIZE="9.91" ESTIMABLE="YES" ESTIMATE="9.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 10:00:17 +0100" MODIFIED_BY="Thomas Radtke" ORDER="240" SE="4.6" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-20 12:07:07 +0000" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<IV_DATA CI_END="10.841358336263763" CI_START="-15.461358336263764" EFFECT_SIZE="-2.31" ESTIMABLE="YES" ESTIMATE="-2.31" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 10:00:22 +0100" MODIFIED_BY="Thomas Radtke" ORDER="239" SE="6.71" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 09:54:39 +0000" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<IV_DATA CI_END="19.14103000702906" CI_START="0.638969992970944" EFFECT_SIZE="9.89" ESTIMABLE="YES" ESTIMATE="9.89" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 10:00:29 +0100" MODIFIED_BY="Thomas Radtke" ORDER="238" SE="4.72" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2017-09-14 14:31:21 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.78" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="96" TOTAL_2="72" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Quality of Life: CFQ-R</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.01" MODIFIED="2017-06-22 10:57:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Physical Functioning at 12 weeks</NAME>
<CONT_DATA CI_END="4.268057233953382" CI_START="-4.351390573953381" EFFECT_SIZE="-0.041666669999999906" ESTIMABLE="YES" MEAN_1="1.625" MEAN_2="1.66666667" MODIFIED="2017-06-22 10:57:49 +0100" MODIFIED_BY="[Empty name]" ORDER="246" SD_1="1.76776695" SD_2="5.16397779" SE="2.1988791314268696" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.02" MODIFIED="2017-06-22 10:58:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Vitality at 12 weeks</NAME>
<CONT_DATA CI_END="1.5268635205255328" CI_START="-0.7768635205255328" EFFECT_SIZE="0.375" ESTIMABLE="YES" MEAN_1="0.375" MEAN_2="0.0" MODIFIED="2017-06-22 10:58:20 +0100" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="1.30247018" SD_2="0.89442719" SE="0.5876962687127341" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.03" MODIFIED="2017-06-22 11:03:58 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Emotional state at 12 weeks</NAME>
<CONT_DATA CI_END="0.4469179798514493" CI_START="-2.780251319851449" EFFECT_SIZE="-1.16666667" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="0.16666667" MODIFIED="2017-06-22 11:03:58 +0100" MODIFIED_BY="[Empty name]" ORDER="248" SD_1="1.41421356" SD_2="1.60208198" SE="0.8232726022412651" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.04" MODIFIED="2017-06-22 11:04:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Eating disturbances at 12 weeks</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.125" MEAN_2="0.0" MODIFIED="2017-06-22 11:04:33 +0100" MODIFIED_BY="[Empty name]" ORDER="249" SD_1="0.35355339" SD_2="0.0" SE="0.0" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.05" MODIFIED="2017-06-22 11:05:39 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Treatment burden at 12 weeks</NAME>
<CONT_DATA CI_END="1.1702187894139737" CI_START="-2.1702187894139735" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="0.0" MODIFIED="2017-06-22 11:05:39 +0100" MODIFIED_BY="[Empty name]" ORDER="245" SD_1="1.77281052" SD_2="1.41421356" SE="0.852168102367414" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.06" MODIFIED="2017-06-22 11:06:10 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Health perception at 12 weeks</NAME>
<CONT_DATA CI_END="0.9345467448253999" CI_START="-1.9345467448254" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.5" MODIFIED="2017-06-22 11:06:10 +0100" MODIFIED_BY="[Empty name]" ORDER="250" SD_1="1.51185789" SD_2="1.22474487" SE="0.7319250537973766" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.07" MODIFIED="2017-06-22 11:06:41 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Social limitations at 12 weeks</NAME>
<CONT_DATA CI_END="0.5294925040571423" CI_START="-3.279492504057142" EFFECT_SIZE="-1.375" ESTIMABLE="YES" MEAN_1="-0.875" MEAN_2="0.5" MODIFIED="2017-06-22 11:06:41 +0100" MODIFIED_BY="[Empty name]" ORDER="252" SD_1="2.35660167" SD_2="1.22474487" SE="0.971697704182085" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.08" MODIFIED="2017-06-22 11:31:00 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Body image at 12 weeks</NAME>
<CONT_DATA CI_END="0.7963182485924846" CI_START="-1.8796515885924845" EFFECT_SIZE="-0.54166667" ESTIMABLE="YES" MEAN_1="-0.375" MEAN_2="0.16666667" MODIFIED="2017-06-22 11:31:00 +0100" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="0.91612538" SD_2="1.47196014" SE="0.6826579106281232" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.09" MODIFIED="2017-06-22 11:31:34 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Role limitations at 12 weeks</NAME>
<CONT_DATA CI_END="2.2097735633098123" CI_START="-1.1264401633098127" EFFECT_SIZE="0.5416667" ESTIMABLE="YES" MEAN_1="-0.125" MEAN_2="-0.6666667" MODIFIED="2017-06-22 11:31:34 +0100" MODIFIED_BY="[Empty name]" ORDER="251" SD_1="1.95940953" SD_2="1.21106014" SE="0.8510905692490406" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.10" MODIFIED="2017-06-22 11:32:00 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Weight problems at 12 weeks</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.25" MEAN_2="0.0" MODIFIED="2017-06-22 11:32:00 +0100" MODIFIED_BY="[Empty name]" ORDER="255" SD_1="0.88640526" SD_2="0.0" SE="0.0" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.11" MODIFIED="2017-06-22 11:33:37 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Respiratory symptoms at 12 weeks</NAME>
<CONT_DATA CI_END="2.3455736049932097" CI_START="-3.5122402649932094" EFFECT_SIZE="-0.58333333" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.83333333" MODIFIED="2017-06-22 11:33:37 +0100" MODIFIED_BY="[Empty name]" ORDER="254" SD_1="3.10529502" SD_2="2.4832774" SE="1.494367732313478" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.12" MODIFIED="2017-06-22 11:34:00 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Digestion symptoms at 12 weeks</NAME>
<CONT_DATA CI_END="3.1596306126901696" CI_START="-0.49296401269016954" EFFECT_SIZE="1.3333333" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="-0.8333333" MODIFIED="2017-06-22 11:34:00 +0100" MODIFIED_BY="[Empty name]" ORDER="256" SD_1="0.9258201" SD_2="2.13697606" SE="0.931801465279857" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2017-09-14 14:32:13 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="39" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in peak power during WAnT (W per kg body weight)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.01" MODIFIED="2015-02-16 09:33:31 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<CONT_DATA CI_END="0.10040556645453053" CI_START="-0.9804055664545306" EFFECT_SIZE="-0.44" ESTIMABLE="YES" MEAN_1="-0.26" MEAN_2="0.18" MODIFIED="2014-10-21 09:16:18 +0100" MODIFIED_BY="Thomas Radtke" ORDER="267" SD_1="0.95" SD_2="0.7" SE="0.2757221922020918" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="22" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.02" MODIFIED="2015-01-20 12:03:21 +0000" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="1.3733148038495187" CI_START="-2.2333148038495185" EFFECT_SIZE="-0.42999999999999994" ESTIMABLE="YES" MEAN_1="0.16" MEAN_2="0.59" MODIFIED="2014-10-21 09:17:24 +0100" MODIFIED_BY="Thomas Radtke" ORDER="268" SD_1="2.39" SD_2="2.52" SE="0.920075479995467" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="18" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.03" MODIFIED="2015-02-16 09:33:38 +0000" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<CONT_DATA CI_END="1.4026272234125994" CI_START="-0.6626272234125993" EFFECT_SIZE="0.37" ESTIMABLE="YES" MEAN_1="0.72" MEAN_2="0.35" MODIFIED="2014-10-21 09:17:52 +0100" MODIFIED_BY="Thomas Radtke" ORDER="269" SD_1="1.96" SD_2="0.99" SE="0.5268603053718491" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="19" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2017-09-14 14:32:32 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="39" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in mean power during WAnT (W per kg body weight)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.07.01" MODIFIED="2015-02-16 09:35:47 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<CONT_DATA CI_END="0.14309003939714315" CI_START="-0.5830900393971432" EFFECT_SIZE="-0.22000000000000003" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.06" MODIFIED="2014-10-21 09:19:16 +0100" MODIFIED_BY="Thomas Radtke" ORDER="270" SD_1="0.65" SD_2="0.46" SE="0.1852534241757252" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="22" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.07.02" MODIFIED="2015-01-20 12:03:56 +0000" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="0.7817900200556579" CI_START="-0.9417900200556578" EFFECT_SIZE="-0.07999999999999999" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="-0.14" MODIFIED="2014-10-21 09:19:47 +0100" MODIFIED_BY="Thomas Radtke" ORDER="271" SD_1="0.84" SD_2="1.36" SE="0.439696865275764" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="18" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.07.03" MODIFIED="2015-02-16 09:35:54 +0000" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<CONT_DATA CI_END="0.6769284835093505" CI_START="-0.3369284835093505" EFFECT_SIZE="0.16999999999999998" ESTIMABLE="YES" MEAN_1="-0.18" MEAN_2="-0.35" MODIFIED="2014-10-21 09:20:11 +0100" MODIFIED_BY="Thomas Radtke" ORDER="272" SD_1="0.67" SD_2="0.75" SE="0.2586417339848781" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="19" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2017-09-14 14:02:05 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="76" TOTAL_2="88" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in muscle strength (all limbs) (1RM test)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.08.01" MODIFIED="2015-02-16 09:44:11 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Right upper limb at 3 months</NAME>
<CONT_DATA CI_END="1.851904709541666" CI_START="0.1480952904583338" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.0" MODIFIED="2014-08-15 16:25:55 +0100" MODIFIED_BY="Thomas Radtke" ORDER="139" SD_1="1.7" SD_2="0.9" SE="0.4346532468256467" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.08.02" MODIFIED="2015-02-16 09:44:48 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Left upper limb at 3 months</NAME>
<CONT_DATA CI_END="2.473858861134943" CI_START="0.32614113886505725" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="-0.2" MODIFIED="2015-02-16 09:44:48 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="138" SD_1="2.2" SD_2="1.0" SE="0.5478972417888309" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.08.03" MODIFIED="2015-02-16 09:44:34 +0000" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Right lower limb at 3 months</NAME>
<CONT_DATA CI_END="2.7114442720883183" CI_START="-0.5114442720883183" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="1.0" MODIFIED="2015-02-16 09:44:34 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="141" SD_1="2.0" SD_2="3.2" SE="0.8221805527036135" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.08.04" MODIFIED="2015-02-16 09:45:27 +0000" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Left lower limb at 3 months</NAME>
<CONT_DATA CI_END="3.048735106986646" CI_START="0.15126489301335377" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="0.8" MODIFIED="2015-02-16 09:45:02 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="140" SD_1="1.9" SD_2="2.8" SE="0.739164147103765" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.09" MODIFIED="2017-09-14 14:33:06 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in muscular strength - leg press (kg; 1 RM test)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.09.01" MODIFIED="2017-06-22 11:48:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="45.85297107859739" CI_START="-7.32797107859739" EFFECT_SIZE="19.262500000000003" ESTIMABLE="YES" MEAN_1="33.2625" MEAN_2="14.0" MODIFIED="2017-06-22 11:48:43 +0100" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="32.9724533" SD_2="16.9989411" SE="13.566816170266206" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2017-09-14 14:33:51 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Muscular Strength - Chest press (kg; 1 RM test)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.10.01" MODIFIED="2017-06-22 11:53:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="11.91138493984761" CI_START="-5.636384939847611" EFFECT_SIZE="3.1374999999999997" ESTIMABLE="YES" MEAN_1="6.7875" MEAN_2="3.65" MODIFIED="2017-06-22 11:53:29 +0100" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="8.17232918" SD_2="8.37538059" SE="4.476554165818809" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.11" MODIFIED="2017-09-14 14:34:18 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="17.14" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Muscular Strength - Latpull down (kg; 1 RM test)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.11.01" MODIFIED="2017-06-22 11:59:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="6.703439427144227" CI_START="-2.8034394271442267" EFFECT_SIZE="1.9500000000000002" ESTIMABLE="YES" MEAN_1="2.85" MEAN_2="0.9" MODIFIED="2017-06-22 11:59:18 +0100" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="6.295349758" SD_2="2.35966099" SE="2.4252687624052025" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.12" MODIFIED="2017-10-30 09:13:22 +0000" MODIFIED_BY="Nikki Jahnke" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.373579630067805" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="5" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Muscular Strength - Biceps curl (kg; RM test)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.12.01" MODIFIED="2017-06-22 12:15:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="1.0296232188124153" CI_START="-3.204623218812415" EFFECT_SIZE="-1.0875" ESTIMABLE="YES" MEAN_1="1.2125" MEAN_2="2.3" MODIFIED="2017-06-22 12:15:36 +0100" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="1.99959817" SD_2="1.82619824" SE="1.0801847562057327" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.13" MODIFIED="2017-09-14 14:34:36 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="4" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Muscular Endurance - Number of push ups</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.13.01" MODIFIED="2017-06-22 12:16:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="15.729022465563611" CI_START="-1.3718796055636115" EFFECT_SIZE="7.17857143" ESTIMABLE="YES" MEAN_1="9.42857143" MEAN_2="2.25" MODIFIED="2017-06-22 12:16:48 +0100" MODIFIED_BY="[Empty name]" ORDER="234" SD_1="10.517559" SD_2="3.59397644" SE="4.362555181119897" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="4" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.14" MODIFIED="2017-09-14 14:01:30 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Muscular Endurance - Number of sit ups</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.14.01" MODIFIED="2017-06-22 12:17:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="14.407802239126465" CI_START="-2.2649450991264644" EFFECT_SIZE="6.07142857" ESTIMABLE="YES" MEAN_1="4.57142857" MEAN_2="-1.5" MODIFIED="2017-06-22 12:17:57 +0100" MODIFIED_BY="[Empty name]" ORDER="235" SD_1="9.18072515" SD_2="6.024948133" SE="4.253330027940675" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.15" MODIFIED="2017-10-30 09:13:31 +0000" MODIFIED_BY="Nikki Jahnke" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="26.12264425643743" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Muscular Endurance - Flexibility (cm)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.15.01" MODIFIED="2017-06-22 12:19:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="11.714779541733481" CI_START="-15.638588941733481" EFFECT_SIZE="-1.9619047" ESTIMABLE="YES" MEAN_1="-3.4285714" MEAN_2="-1.4666667" MODIFIED="2017-06-22 12:19:36 +0100" MODIFIED_BY="[Empty name]" ORDER="236" SD_1="18.3312769" SD_2="2.03141986" SE="6.9780283462417785" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.16" MODIFIED="2017-09-14 14:35:09 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="91.88" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="5" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Muscular Endurance - hand grip strength (kg)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.16.01" MODIFIED="2017-06-22 12:20:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="6.630125463363593" CI_START="-18.480125463363592" EFFECT_SIZE="-5.925" ESTIMABLE="YES" MEAN_1="-6.125" MEAN_2="-0.2" MODIFIED="2017-06-22 12:20:19 +0100" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="15.1510254" SD_2="7.85493475" SE="6.405793964785486" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:22:09 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Change in peak work capacity during maximal exercise (W per kg BW)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.17.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-23 07:10:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<IV_DATA CI_END="0.465596038299406" CI_START="0.03440396170059404" EFFECT_SIZE="0.25" ESTIMABLE="YES" ESTIMATE="0.25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 08:07:23 +0100" MODIFIED_BY="Thomas Radtke" ORDER="194" SE="0.11" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.17.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-23 07:10:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<IV_DATA CI_END="0.40559603829940594" CI_START="-0.02559603829940596" EFFECT_SIZE="0.19" ESTIMABLE="YES" ESTIMATE="0.19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 08:07:42 +0100" MODIFIED_BY="Thomas Radtke" ORDER="196" SE="0.11" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.17.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-23 07:10:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<IV_DATA CI_END="0.585596038299406" CI_START="0.15440396170059403" EFFECT_SIZE="0.37" ESTIMABLE="YES" ESTIMATE="0.37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 08:08:06 +0100" MODIFIED_BY="Thomas Radtke" ORDER="197" SE="0.11" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.18" MODIFIED="2017-09-14 14:01:12 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="38" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in functional exercise capacity</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.18.01" MODIFIED="2015-02-16 10:11:45 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>6MWT distance (m) at 3 months</NAME>
<CONT_DATA CI_END="22.986808059050617" CI_START="-24.586808059050618" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="-7.0" MEAN_2="-6.2" MODIFIED="2014-08-15 16:22:49 +0100" MODIFIED_BY="Thomas Radtke" ORDER="132" SD_1="39.8" SD_2="37.5" SE="12.136349569011433" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.18.02" MODIFIED="2015-02-16 10:12:53 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>6MWT distance (% predicted) at 3 months</NAME>
<CONT_DATA CI_END="6.814433433244402" CI_START="-3.0144334332444016" EFFECT_SIZE="1.9000000000000001" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-3.1" MODIFIED="2015-02-16 10:12:53 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="133" SD_1="5.9" SD_2="9.9" SE="2.5074100708017215" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.19" MODIFIED="2017-09-14 14:22:30 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in peak heart rate during 6MWT (beats/min)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.19.01" MODIFIED="2015-03-11 12:44:21 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="18.56726502017615" CI_START="-9.167265020176153" EFFECT_SIZE="4.699999999999999" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-5.1" MODIFIED="2014-08-28 10:54:47 +0100" MODIFIED_BY="Thomas Radtke" ORDER="142" SD_1="20.7" SD_2="24.6" SE="7.075265224034405" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:23:12 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="21.56" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Annual change in peak heart rate (beat/min)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.20.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 10:20:05 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load bicycle ergometry (at 1 year)</NAME>
<IV_DATA CI_END="-0.7913361384385942" CI_START="-15.608663861561404" EFFECT_SIZE="-8.2" ESTIMABLE="YES" ESTIMATE="-8.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="57" SE="3.78" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.20.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 10:20:15 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load arm ergometry (at 1 year)</NAME>
<IV_DATA CI_END="7.400238290584843" CI_START="-10.200238290584844" EFFECT_SIZE="-1.4" ESTIMABLE="YES" ESTIMATE="-1.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-16 10:19:01 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="58" SE="4.49" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:23:32 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Annual change in VE (L/min)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.21.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 10:25:25 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load bicycle ergometry (at 1 year)</NAME>
<IV_DATA CI_END="1.1063337315537" CI_START="-6.1063337315537005" EFFECT_SIZE="-2.5" ESTIMABLE="YES" ESTIMATE="-2.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="59" SE="1.84" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.21.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 10:25:58 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load arm ergometry (at 1 year)</NAME>
<IV_DATA CI_END="-0.20325690442671407" CI_START="-6.396743095573285" EFFECT_SIZE="-3.3" ESTIMABLE="YES" ESTIMATE="-3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-16 10:25:58 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="60" SE="1.58" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.22" MODIFIED="2017-10-30 09:16:04 +0000" MODIFIED_BY="Nikki Jahnke" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="22.718733944303175" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in peak ventilation (VE) during maximal exercise</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.22.01" MODIFIED="2017-06-22 12:28:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="3.8705665522439814" CI_START="-17.34889989224398" EFFECT_SIZE="-6.73916667" ESTIMABLE="YES" MEAN_1="-0.8125" MEAN_2="5.92666667" MODIFIED="2017-06-22 12:28:30 +0100" MODIFIED_BY="[Empty name]" ORDER="244" SD_1="10.6988274" SD_2="9.48522992" SE="5.413228664369449" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.23" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:50:14 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.07" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Annual change in lactate (mmol/l)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.23.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 10:29:32 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load bicycle ergometry (at 1 year)</NAME>
<IV_DATA CI_END="-0.12441296556558046" CI_START="-1.5355870344344194" EFFECT_SIZE="-0.83" ESTIMABLE="YES" ESTIMATE="-0.83" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="61" SE="0.36" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.23.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 10:29:50 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load arm ergometry (at 1 year)</NAME>
<IV_DATA CI_END="0.5031848735068227" CI_START="-1.1431848735068229" EFFECT_SIZE="-0.32" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-16 10:29:50 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="62" SE="0.42" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.24" MODIFIED="2017-09-14 14:52:09 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="22" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in RR during 6MWT (breaths/min)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.24.01" MODIFIED="2015-02-16 09:57:20 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<CONT_DATA CI_END="3.562155502932299" CI_START="-5.562155502932299" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.7" MODIFIED="2014-08-20 15:30:31 +0100" MODIFIED_BY="Thomas Radtke" ORDER="135" SD_1="5.0" SD_2="9.5" SE="2.3276731301789213" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:52:28 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Annual change in RR (breaths/min)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.25.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 10:35:26 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load bicycle ergometry (at 1 year)</NAME>
<IV_DATA CI_END="3.296324727688713" CI_START="-4.896324727688713" EFFECT_SIZE="-0.8" ESTIMABLE="YES" ESTIMATE="-0.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="65" SE="2.09" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.25.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 10:35:57 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load arm ergometry (at 1 year)</NAME>
<IV_DATA CI_END="6.105915363669128" CI_START="-3.105915363669128" EFFECT_SIZE="1.5" ESTIMABLE="YES" ESTIMATE="1.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-16 10:35:57 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="66" SE="2.35" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.26" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:52:47 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.12" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Annual change in RER</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.26.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 10:33:45 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load bicycle ergometry (at 1 year)</NAME>
<IV_DATA CI_END="0.05919927969080109" CI_START="-0.019199279690801086" EFFECT_SIZE="0.02" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="63" SE="0.02" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.26.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 10:34:00 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load arm ergometry (at 1 year)</NAME>
<IV_DATA CI_END="0.03919927969080109" CI_START="-0.03919927969080109" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-16 10:34:00 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="64" SE="0.02" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.27" MODIFIED="2017-09-14 13:59:50 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="38" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in oxygen saturation (%)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.27.01" MODIFIED="2015-02-16 10:45:58 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At rest (at 3 months)</NAME>
<CONT_DATA CI_END="1.954383959847255" CI_START="-0.15438395984725506" EFFECT_SIZE="0.9" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-1.0" MODIFIED="2014-08-20 15:34:04 +0100" MODIFIED_BY="Thomas Radtke" ORDER="274" SD_1="1.3" SD_2="2.1" SE="0.5379608850795735" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.27.02" MODIFIED="2015-02-16 10:46:00 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>During 6MWT (at 3 months)</NAME>
<CONT_DATA CI_END="5.313689982227545" CI_START="-0.11368998222754456" EFFECT_SIZE="2.6" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="-1.3" MODIFIED="2015-02-16 10:46:00 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="134" SD_1="5.4" SD_2="2.9" SE="1.3845611468541181" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.28" MODIFIED="2017-09-14 14:53:21 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="38" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Borg breathlessness score</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.28.01" MODIFIED="2015-02-16 11:18:24 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At rest (at 3 months)</NAME>
<CONT_DATA CI_END="0.379605922293623" CI_START="-0.379605922293623" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.1" MODIFIED="2014-08-20 15:36:00 +0100" MODIFIED_BY="Thomas Radtke" ORDER="275" SD_1="0.4" SD_2="0.8" SE="0.19368004988250093" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.28.02" MODIFIED="2015-02-16 11:18:46 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>During 6MWT (at 3 months)</NAME>
<CONT_DATA CI_END="1.1072137042449959" CI_START="-1.307213704244996" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.3" MODIFIED="2015-02-16 11:18:46 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="136" SD_1="2.1" SD_2="1.8" SE="0.6159366772896562" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.29" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:54:48 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Annual change in Borg breathlessness score</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.29.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 11:19:54 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load bicycle ergometry (at 1 year)</NAME>
<IV_DATA CI_END="0.9995816321154277" CI_START="-0.9995816321154277" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67" SE="0.51" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.29.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 11:20:09 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load arm ergometry (at 1 year)</NAME>
<IV_DATA CI_END="0.0995816321154277" CI_START="-1.8995816321154277" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-16 11:20:09 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="68" SE="0.51" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.30" MODIFIED="2017-09-14 14:55:06 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="38" TOTAL_2="44" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Borg fatigue score</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.30.01" MODIFIED="2015-02-16 11:20:56 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At rest (at 3 months)</NAME>
<CONT_DATA CI_END="0.5404152543419615" CI_START="-0.5004152543419614" EFFECT_SIZE="0.02" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.0" MODIFIED="2014-08-20 15:37:15 +0100" MODIFIED_BY="Thomas Radtke" ORDER="276" SD_1="0.8" SD_2="0.9" SE="0.26552286595413516" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.30.02" MODIFIED="2015-02-16 11:21:13 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>During 6MWT (at 3 months)</NAME>
<CONT_DATA CI_END="0.6720815826766846" CI_START="-1.8720815826766848" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.3" MODIFIED="2015-02-16 11:21:13 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="137" SD_1="2.6" SD_2="1.2" SE="0.6490331417876563" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.31" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:55:24 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.52" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Annual change in Borg muscle effort</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.31.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 11:22:04 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load bicycle ergometry (at 1 year)</NAME>
<IV_DATA CI_END="0.895578030569433" CI_START="-1.495578030569433" EFFECT_SIZE="-0.3" ESTIMABLE="YES" ESTIMATE="-0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="69" SE="0.61" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.31.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 11:22:18 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Constant load arm ergometry (at 1 year)</NAME>
<IV_DATA CI_END="1.593576229796436" CI_START="-0.9935762297964359" EFFECT_SIZE="0.3" ESTIMABLE="YES" ESTIMATE="0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-02-16 11:22:18 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="70" SE="0.66" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.32" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 13:58:29 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Change in FVC (% predicted)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.32.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-22 12:30:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<IV_DATA CI_END="10.943018485631354" CI_START="-4.359685145631353" EFFECT_SIZE="3.29166667" ESTIMABLE="YES" ESTIMATE="3.29166667" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-06-22 12:30:21 +0100" MODIFIED_BY="[Empty name]" ORDER="241" SE="3.90382266" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.32.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 13:38:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<IV_DATA CI_END="5.127845133522233" CI_START="-11.727845133522234" EFFECT_SIZE="-3.3" ESTIMABLE="YES" ESTIMATE="-3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-26 15:03:46 +0100" MODIFIED_BY="Thomas Radtke" ORDER="706" SE="4.3" STUDY_ID="STD-Rovedder-2014" TOTAL_1="19" TOTAL_2="22" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.32.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 13:38:07 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<IV_DATA CI_END="5.301911762123133" CI_START="-4.301911762123133" EFFECT_SIZE="0.5" ESTIMABLE="YES" ESTIMATE="0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-26 15:03:51 +0100" MODIFIED_BY="Thomas Radtke" ORDER="707" SE="2.45" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.32.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 13:38:07 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<IV_DATA CI_END="9.785469984189596" CI_START="-4.365469984189596" EFFECT_SIZE="2.71" ESTIMABLE="YES" ESTIMATE="2.71" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-26 15:03:58 +0100" MODIFIED_BY="Thomas Radtke" ORDER="704" SE="3.61" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.32.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 13:38:05 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<IV_DATA CI_END="11.685096635629955" CI_START="0.43490336437004373" EFFECT_SIZE="6.06" ESTIMABLE="YES" ESTIMATE="6.06" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-26 15:04:02 +0100" MODIFIED_BY="Thomas Radtke" ORDER="705" SE="2.87" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.33" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 13:58:54 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="533.66" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Annual change in FVC (mL)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.33.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 11:46:34 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>At 1 year</NAME>
<IV_DATA CI_END="422.9905413036214" CI_START="3.009458696378573" EFFECT_SIZE="213.0" ESTIMABLE="YES" ESTIMATE="213.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="72" SE="107.14" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.34" MODIFIED="2017-09-14 14:55:46 +0100" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="30.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="60" TOTAL_2="38" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in RV/TLC (%)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.34.01" MODIFIED="2015-02-16 11:46:58 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<CONT_DATA CI_END="4.933565783347145" CI_START="-6.733565783347146" EFFECT_SIZE="-0.9000000000000001" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.6" MODIFIED="2014-10-20 16:14:15 +0100" MODIFIED_BY="Thomas Radtke" ORDER="276" SD_1="10.8" SD_2="6.8" SE="2.976363764518924" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="22" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.34.02" MODIFIED="2015-01-20 12:06:40 +0000" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="6.932196007827186" CI_START="-11.332196007827186" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="3.7" MODIFIED="2014-10-20 16:14:25 +0100" MODIFIED_BY="Thomas Radtke" ORDER="277" SD_1="12.2" SD_2="12.7" SE="4.659369294467033" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="18" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.34.03" MODIFIED="2015-02-16 11:47:05 +0000" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<CONT_DATA CI_END="3.883680375682524" CI_START="-13.683680375682524" EFFECT_SIZE="-4.8999999999999995" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="7.1" MODIFIED="2014-10-20 16:14:37 +0100" MODIFIED_BY="Thomas Radtke" ORDER="278" SD_1="11.2" SD_2="13.4" SE="4.481551928998223" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="20" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.35" MODIFIED="2017-09-14 14:02:56 +0100" MODIFIED_BY="[Empty name]" NO="35" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="396.7" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Total Energy Expenditure (k/cal)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.35.01" MODIFIED="2017-06-22 12:33:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="142.37146607350937" CI_START="-360.2047994735094" EFFECT_SIZE="-108.91666670000001" ESTIMABLE="YES" MEAN_1="-57.75" MEAN_2="51.1666667" MODIFIED="2017-06-22 12:33:53 +0100" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="224.277093" SD_2="246.784454" SE="128.21058690651364" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.36" MODIFIED="2017-10-30 09:19:24 +0000" MODIFIED_BY="Nikki Jahnke" NO="36" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in the Number of Steps</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.36.01" MODIFIED="2017-06-22 12:34:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="2039.5568928824005" CI_START="-2260.7235588824005" EFFECT_SIZE="-110.583333" ESTIMABLE="YES" MEAN_1="-181.25" MEAN_2="-70.666667" MODIFIED="2017-06-22 12:34:50 +0100" MODIFIED_BY="[Empty name]" ORDER="239" SD_1="2216.17597" SD_2="1880.76534" SE="1097.0304775202158" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.37" MODIFIED="2017-09-14 14:57:54 +0100" MODIFIED_BY="[Empty name]" NO="37" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Physical Activity (%)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.37.01" MODIFIED="2017-06-22 12:35:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="37.79942266898096" CI_START="1.917243931019037" EFFECT_SIZE="19.858333299999998" ESTIMABLE="YES" MEAN_1="10.775" MEAN_2="-9.0833333" MODIFIED="2017-06-22 12:35:29 +0100" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="7.86833618" SD_2="21.3615933" SE="9.153785227941933" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.38" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:58:13 +0100" MODIFIED_BY="[Empty name]" NO="38" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Change in vigorous physical activity (hours per week)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.38.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 12:03:04 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<IV_DATA CI_END="2.755168666549847" CI_START="-0.6551686665498471" EFFECT_SIZE="1.05" ESTIMABLE="YES" ESTIMATE="1.05" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 09:52:31 +0100" MODIFIED_BY="Thomas Radtke" ORDER="230" SE="0.87" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.38.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-20 12:07:41 +0000" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<IV_DATA CI_END="5.999927969080108" CI_START="-1.8399279690801085" EFFECT_SIZE="2.08" ESTIMABLE="YES" ESTIMATE="2.08" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 09:52:37 +0100" MODIFIED_BY="Thomas Radtke" ORDER="231" SE="2.0" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.38.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-02-16 12:03:48 +0000" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<IV_DATA CI_END="3.2371704673228443" CI_START="0.022829532677155484" EFFECT_SIZE="1.63" ESTIMABLE="YES" ESTIMATE="1.63" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 09:52:43 +0100" MODIFIED_BY="Thomas Radtke" ORDER="232" SE="0.82" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.39" MODIFIED="2017-09-14 13:59:26 +0100" MODIFIED_BY="[Empty name]" NO="39" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="69" TOTAL_2="46" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in body weight (kg)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.39.01" MODIFIED="2017-06-22 12:36:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="1.2218133243333023" CI_START="-1.7559799843333022" EFFECT_SIZE="-0.26708333" ESTIMABLE="YES" MEAN_1="-0.19375" MEAN_2="0.07333333" MODIFIED="2017-06-22 12:36:30 +0100" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="1.01557777" SD_2="1.6397886" SE="0.7596551090109456" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.39.02" MODIFIED="2017-06-05 11:45:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<CONT_DATA CI_END="2.6155723536304643" CI_START="-0.4155723536304641" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="0.0" MODIFIED="2014-10-20 15:03:52 +0100" MODIFIED_BY="Thomas Radtke" ORDER="263" SD_1="1.8" SD_2="2.6" SE="0.7732654097652332" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="22" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.39.03" MODIFIED="2017-06-05 11:45:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="2.9172942824546073" CI_START="-2.517294282454607" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.3" MODIFIED="2014-10-20 15:06:06 +0100" MODIFIED_BY="Thomas Radtke" ORDER="261" SD_1="4.0" SD_2="3.6" SE="1.386400109332762" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="19" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.39.04" MODIFIED="2017-06-05 11:45:06 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<CONT_DATA CI_END="3.7818046864263883" CI_START="-3.7818046864263883" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.8" MODIFIED="2014-10-20 15:07:00 +0100" MODIFIED_BY="Thomas Radtke" ORDER="262" SD_1="6.0" SD_2="5.0" SE="1.9295276424754644" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="20" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.40" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:02:33 +0100" MODIFIED_BY="[Empty name]" NO="40" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Change in BMI (kg/m<SUP>2</SUP>)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.40.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-22 12:36:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<IV_DATA CI_END="0.8041888085886889" CI_START="-0.6091888085886888" EFFECT_SIZE="0.0975" ESTIMABLE="YES" ESTIMATE="0.0975" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-06-22 12:36:50 +0100" MODIFIED_BY="[Empty name]" ORDER="226" SE="0.36056214" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.40.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 12:02:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<IV_DATA CI_END="0.9683895555166158" CI_START="-0.16838955551661572" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-20 15:12:39 +0100" MODIFIED_BY="Thomas Radtke" ORDER="268" SE="0.29" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.40.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 12:02:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Annual change</NAME>
<IV_DATA CI_END="1.1671884750528174" CI_START="-0.08718847505281735" EFFECT_SIZE="0.54" ESTIMABLE="YES" ESTIMATE="0.54" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 13:06:26 +0100" MODIFIED_BY="Thomas Radtke" ORDER="257" SE="0.32" STUDY_ID="STD-Moorcroft-2004" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.40.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 12:02:19 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<IV_DATA CI_END="0.7839855938160217" CI_START="-0.7839855938160217" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-20 15:14:31 +0100" MODIFIED_BY="Thomas Radtke" ORDER="266" SE="0.4" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.40.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 12:02:16 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<IV_DATA CI_END="0.9191812719608282" CI_START="-1.1191812719608283" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-20 15:14:58 +0100" MODIFIED_BY="Thomas Radtke" ORDER="267" SE="0.52" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.41" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:58:38 +0100" MODIFIED_BY="[Empty name]" NO="41" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Change in sum of four skinfolds (mm)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.41.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-20 12:12:02 +0000" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 3-6 months</NAME>
<IV_DATA CI_END="2.573130850316904" CI_START="-4.953130850316904" EFFECT_SIZE="-1.19" ESTIMABLE="YES" ESTIMATE="-1.19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 09:55:44 +0100" MODIFIED_BY="Thomas Radtke" ORDER="234" SE="1.92" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.41.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-20 12:12:08 +0000" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<IV_DATA CI_END="-0.525294720659657" CI_START="-10.834705279340342" EFFECT_SIZE="-5.68" ESTIMABLE="YES" ESTIMATE="-5.68" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 09:55:51 +0100" MODIFIED_BY="Thomas Radtke" ORDER="233" SE="2.63" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.41.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-01-20 12:12:13 +0000" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12-18 months off training</NAME>
<IV_DATA CI_END="-0.8281152494718258" CI_START="-13.371884750528174" EFFECT_SIZE="-7.1" ESTIMABLE="YES" ESTIMATE="-7.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-20 09:55:58 +0100" MODIFIED_BY="Thomas Radtke" ORDER="235" SE="3.2" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.42" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-09-14 14:03:39 +0100" MODIFIED_BY="[Empty name]" NO="42" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Change in body fat (%)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.42.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-22 12:38:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<IV_DATA CI_END="-0.0456348734145231" CI_START="-2.3793651265854767" EFFECT_SIZE="-1.2125" ESTIMABLE="YES" ESTIMATE="-1.2125" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-06-22 12:38:10 +0100" MODIFIED_BY="[Empty name]" ORDER="227" SE="0.59535029" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.42.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 12:04:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<IV_DATA CI_END="4.9455330112445015" CI_START="-2.345533011244501" EFFECT_SIZE="1.3" ESTIMABLE="YES" ESTIMATE="1.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-20 15:32:56 +0100" MODIFIED_BY="Thomas Radtke" ORDER="269" SE="1.86" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.42.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 12:04:07 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<IV_DATA CI_END="3.7727214862973186" CI_START="-4.772721486297319" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-20 15:33:25 +0100" MODIFIED_BY="Thomas Radtke" ORDER="270" SE="2.18" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.42.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2017-06-05 12:03:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<IV_DATA CI_END="8.295487991919568" CI_START="-3.895487991919568" EFFECT_SIZE="2.2" ESTIMABLE="YES" ESTIMATE="2.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-20 15:33:53 +0100" MODIFIED_BY="Thomas Radtke" ORDER="271" SE="3.11" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.43" MODIFIED="2017-09-14 14:04:01 +0100" MODIFIED_BY="[Empty name]" NO="43" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in fat-mass (kg)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.43.01" MODIFIED="2017-06-22 12:39:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="-0.38667016733442605" CI_START="-1.7984131726655743" EFFECT_SIZE="-1.0925416700000001" ESTIMABLE="YES" MEAN_1="-0.166875" MEAN_2="0.92566667" MODIFIED="2017-06-22 12:39:27 +0100" MODIFIED_BY="[Empty name]" ORDER="229" SD_1="0.78305016" SD_2="0.56422643" SE="0.3601451395196026" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.44" MODIFIED="2017-09-14 14:04:23 +0100" MODIFIED_BY="[Empty name]" NO="44" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="27.76" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="62" TOTAL_2="39" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in fat-free mass (kg)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.44.01" MODIFIED="2017-06-22 12:38:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="1.2593835474298938" CI_START="-1.5505502074298938" EFFECT_SIZE="-0.14558333" ESTIMABLE="YES" MEAN_1="-0.05425" MEAN_2="0.09133333" MODIFIED="2017-06-22 12:38:47 +0100" MODIFIED_BY="[Empty name]" ORDER="228" SD_1="1.23976423" SD_2="1.38936527" SE="0.7168330073981426" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.44.02" MODIFIED="2017-06-05 12:03:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>At 3 - 6 months</NAME>
<CONT_DATA CI_END="6.5572148558897645" CI_START="-4.757214855889764" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.6" MODIFIED="2014-10-20 15:39:44 +0100" MODIFIED_BY="Thomas Radtke" ORDER="275" SD_1="9.2" SD_2="7.3" SE="2.886387148189024" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="20" TOTAL_2="13" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.44.03" MODIFIED="2017-06-05 12:03:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months off training</NAME>
<CONT_DATA CI_END="3.4763387040934335" CI_START="-2.076338704093434" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="1.3" MODIFIED="2014-10-20 15:40:42 +0100" MODIFIED_BY="Thomas Radtke" ORDER="273" SD_1="3.7" SD_2="3.1" SE="1.4165253678092247" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="17" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.44.04" MODIFIED="2017-06-05 12:03:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>At 12 - 18 months off training</NAME>
<CONT_DATA CI_END="4.06053486643834" CI_START="-6.860534866438341" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-0.5" MODIFIED="2014-10-20 15:41:45 +0100" MODIFIED_BY="Thomas Radtke" ORDER="274" SD_1="9.6" SD_2="5.3" SE="2.786038370863109" STUDY_ID="STD-Hebestreit-2010" TOTAL_1="17" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.45" MODIFIED="2017-09-14 15:10:48 +0100" MODIFIED_BY="[Empty name]" NO="45" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="4" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in metabolic parameters (HbA1c (%))</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.45.01" MODIFIED="2017-06-22 12:40:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="4" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="3.9938588992054864E-4" CI_START="-0.005149385889920548" EFFECT_SIZE="-0.002375" ESTIMABLE="YES" MEAN_1="-8.75E-4" MEAN_2="0.0015" MODIFIED="2017-06-22 12:40:56 +0100" MODIFIED_BY="[Empty name]" ORDER="221" SD_1="0.00216712" SD_2="0.00238048" SE="0.0014155290157393454" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="4" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.46" MODIFIED="2017-09-14 15:12:25 +0100" MODIFIED_BY="[Empty name]" NO="46" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="32.44" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in metabolic parameters (Glucose AUC)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.46.01" MODIFIED="2017-06-22 12:40:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="2.330941134472922" CI_START="-13.508441134472921" EFFECT_SIZE="-5.58875" ESTIMABLE="YES" MEAN_1="-5.46375" MEAN_2="0.125" MODIFIED="2017-06-22 12:40:11 +0100" MODIFIED_BY="[Empty name]" ORDER="222" SD_1="5.12236256" SD_2="8.84794835" SE="4.040732991494964" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.47" MODIFIED="2017-09-14 15:11:25 +0100" MODIFIED_BY="[Empty name]" NO="47" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in metabolic parameters (Total Insulin AUC)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.47.01" MODIFIED="2017-06-22 12:42:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="12.849161310567926" CI_START="-52.89725651056793" EFFECT_SIZE="-20.0240476" ESTIMABLE="YES" MEAN_1="-8.2157143" MEAN_2="11.8083333" MODIFIED="2017-06-22 12:42:09 +0100" MODIFIED_BY="[Empty name]" ORDER="224" SD_1="33.5157803" SD_2="29.0755983" SE="16.7723535584672" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.48" MODIFIED="2017-09-14 15:11:48 +0100" MODIFIED_BY="[Empty name]" NO="48" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in metabolic parameters (Insulin Sensitivity Index)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours No Physical Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Combined Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.48.01" MODIFIED="2017-06-22 12:41:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>At 12 weeks</NAME>
<CONT_DATA CI_END="0.04332576802706706" CI_START="0.003135651972932949" EFFECT_SIZE="0.02323071" ESTIMABLE="YES" MEAN_1="0.01586571" MEAN_2="-0.007365" MODIFIED="2017-06-22 12:41:38 +0100" MODIFIED_BY="[Empty name]" ORDER="223" SD_1="0.01688779" SD_2="0.02041611" SE="0.010252769023091397" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.49" MODIFIED="2017-09-29 09:14:52 +0100" MODIFIED_BY="Thomas Radtke" NO="49" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.36" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Plasma Glucose (mmol/L)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.49.01" MODIFIED="2017-09-29 09:14:24 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>After 0 minutes</NAME>
<CONT_DATA CI_END="1.2764182735942482" CI_START="-0.4059922735942481" EFFECT_SIZE="0.435213" ESTIMABLE="YES" MEAN_1="0.00688" MEAN_2="-0.428333" MODIFIED="2017-09-29 09:14:24 +0100" MODIFIED_BY="Thomas Radtke" ORDER="591" SD_1="0.494866" SD_2="0.959988" SE="0.4291942506237706" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.49.02" MODIFIED="2017-09-29 09:14:35 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>After 30 minutes</NAME>
<CONT_DATA CI_END="-0.32819110983845334" CI_START="-3.5827548901615462" EFFECT_SIZE="-1.9554729999999998" ESTIMABLE="YES" MEAN_1="-1.747143" MEAN_2="0.20833" MODIFIED="2017-09-29 09:14:35 +0100" MODIFIED_BY="Thomas Radtke" ORDER="585" SD_1="1.585357" SD_2="1.407727" SE="0.8302611185702076" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.49.03" MODIFIED="2017-09-29 09:14:39 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>After 60 minutes</NAME>
<CONT_DATA CI_END="0.39599639423866995" CI_START="-4.11265639423867" EFFECT_SIZE="-1.85833" ESTIMABLE="YES" MEAN_1="-1.79" MEAN_2="0.06833" MODIFIED="2017-09-29 09:14:39 +0100" MODIFIED_BY="Thomas Radtke" ORDER="592" SD_1="1.662117" SD_2="2.360004" SE="1.150187662641002" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.49.04" MODIFIED="2017-09-29 09:14:48 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>After 90 minutes</NAME>
<CONT_DATA CI_END="1.7094109018360504" CI_START="-5.09131690183605" EFFECT_SIZE="-1.690953" ESTIMABLE="YES" MEAN_1="-2.074286" MEAN_2="-0.383333" MODIFIED="2017-09-29 09:14:48 +0100" MODIFIED_BY="Thomas Radtke" ORDER="593" SD_1="1.144871" SD_2="4.11534" SE="1.7349114211575758" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.49.05" MODIFIED="2017-09-29 09:14:52 +0100" MODIFIED_BY="Thomas Radtke" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>After 120 minutes</NAME>
<CONT_DATA CI_END="-0.06206398063974072" CI_START="-6.4137760193602595" EFFECT_SIZE="-3.23792" ESTIMABLE="YES" MEAN_1="-2.34125" MEAN_2="0.89667" MODIFIED="2017-09-29 09:14:52 +0100" MODIFIED_BY="Thomas Radtke" ORDER="586" SD_1="1.258371" SD_2="3.816525" SE="1.6203644783327684" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.50" MODIFIED="2017-09-29 09:13:14 +0100" MODIFIED_BY="Thomas Radtke" NO="50" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="23.32" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="35" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in Plasma Insulin (µU/mL)</NAME>
<GROUP_LABEL_1>Combined Training</GROUP_LABEL_1>
<GROUP_LABEL_2>No Physical Training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Combined Training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours No Physical Training</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.50.01" MODIFIED="2017-09-29 09:12:44 +0100" MODIFIED_BY="Thomas Radtke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>After 0 minutes</NAME>
<CONT_DATA CI_END="1.2591536791688624" CI_START="-5.459779679168863" EFFECT_SIZE="-2.100313" ESTIMABLE="YES" MEAN_1="-0.377143" MEAN_2="1.72317" MODIFIED="2017-09-29 09:12:44 +0100" MODIFIED_BY="Thomas Radtke" ORDER="587" SD_1="1.371631" SD_2="4.001887" SE="1.7140451078019323" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.50.02" MODIFIED="2017-09-29 09:12:50 +0100" MODIFIED_BY="Thomas Radtke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>After 30 minutes</NAME>
<CONT_DATA CI_END="-8.330331828201967" CI_START="-19.466580171798032" EFFECT_SIZE="-13.898456" ESTIMABLE="YES" MEAN_1="-6.120286" MEAN_2="7.77817" MODIFIED="2017-09-29 09:12:50 +0100" MODIFIED_BY="Thomas Radtke" ORDER="588" SD_1="4.26804" SD_2="5.728133" SE="2.8409318822788" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.50.03" MODIFIED="2017-09-29 09:12:54 +0100" MODIFIED_BY="Thomas Radtke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>After 60 minutes</NAME>
<CONT_DATA CI_END="-2.64862983955914" CI_START="-22.13679816044086" EFFECT_SIZE="-12.392714" ESTIMABLE="YES" MEAN_1="-4.277714" MEAN_2="8.115" MODIFIED="2017-09-29 09:12:54 +0100" MODIFIED_BY="Thomas Radtke" ORDER="589" SD_1="6.741404" SD_2="10.45679" SE="4.971562864063295" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.50.04" MODIFIED="2017-09-29 09:13:09 +0100" MODIFIED_BY="Thomas Radtke" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>After 90 minutes</NAME>
<CONT_DATA CI_END="29.448254454626984" CI_START="-17.05400845462698" EFFECT_SIZE="6.1971229999999995" ESTIMABLE="YES" MEAN_1="3.01829" MEAN_2="-3.178833" MODIFIED="2017-09-29 09:13:09 +0100" MODIFIED_BY="Thomas Radtke" ORDER="590" SD_1="22.92715" SD_2="19.84514" SE="11.863040156874789" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.50.05" MODIFIED="2017-09-29 09:13:14 +0100" MODIFIED_BY="Thomas Radtke" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>After 120 minutes</NAME>
<CONT_DATA CI_END="18.44758259583435" CI_START="-13.98420259583435" EFFECT_SIZE="2.23169" ESTIMABLE="YES" MEAN_1="-1.291143" MEAN_2="-3.522833" MODIFIED="2017-09-29 09:13:14 +0100" MODIFIED_BY="Thomas Radtke" ORDER="584" SD_1="13.68341" SD_2="15.81846" SE="8.273566618439544" STUDY_ID="STD-Beaudoin-2017" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-11-02 10:10:32 +0000" MODIFIED_BY="Nikki Jahnke">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-10-30 10:43:10 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAS1CAYAAACBE13TAAB/q0lEQVR42uy9D4RV2////ybXdSWJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-11-02 10:10:32 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgments about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAYUAAAMXCAIAAABacN5+AAA0SklEQVR42u2dvU4kSdaGU0JCGBgY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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-11-02 10:10:32 +0000" MODIFIED_BY="Nikki Jahnke" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgments about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS MODIFIED="2015-03-13 14:49:09 +0000" MODIFIED_BY="Thomas Radtke">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 unique studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;15 studies (s 30 references (one full-text article is listed twice as it refers to two studies) included in qualitative synthesis&lt;/p&gt;&lt;p&gt;Of those, data from 2 unique studies (both full-text articles) are presented in additional tables due to inconsistencies between raw and published data&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;83 unique studies (123 individual references) identified and assessed for eligibility&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;147 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;147 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;147 records identified through database searching&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;24 records excluded&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;51 unique studies (73 individual references) were excluded with reasons.&lt;/p&gt;&lt;p&gt;12 studies (14 individual references) are awaiting classification.&lt;/p&gt;&lt;p&gt;5 studies (6 individual references) are ongoing.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>